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ABSTRACT
Dysfunctional immunity which is the most common antecedent of immunological
diseases is central to the common disorders like rheumatoid arthritis, psoriasis, thyroid
disease, type-1 diabetes mellitus, multiple sclerosis and other autoimmune conditions
that are leading causes of chronic morbidities and disabilities. The currently employed
therapies suffer from serious side effects. For example, steroid therapy, being
nonselective is seldom used. Myleotoxicity limits azathioprine while cyclosporine-A
(CsA) and FK506 do show myleo-, nephro and neuro-toxicities. Antibody therapies
cause immune mediated toxicity. Therefore, the need of developing less toxic and
specific immune modulatory agents is a top priority.
Recently, Pseudomonas aeruginosa quorum sensing signal molecules (QSSMs), N-(3-
oxododecanoyl)-L-homoserine lactone (3O, C12-HSL) and 2-n-heptyl-3-hydroxy-4-
(1H)-quinolone (PQS) have been found to modulate eukaryotic immune processes via
different targets. The structure activity relationship (SAR) study of 3O, C12-HSL by
Chhabra et.al, showed that L-homoserine lactone ring, 3-oxo or hydroxyl group and 12
to14-carbons long acyl chain, apparently conferring optimum lipophilicity and
flexibility, are important for immune modulation. However, the new analogues
including 3O, C12-HSL negated clinical usefulness as these also participated in
bacterial quorum-sensing (QS) activity thus promoting bacterial growth. Also
analogues with more than 12-carbons alkyl chain could not be explored by in vitro
immune assays due to their limited solubility in the solvents employed.
The present study addresses these issues by making further judicial structural changes
in the 3O, C12-HSL in order to optimize its immune modulatory activity while losing
its intrinsic QS activity. Accordingly, a series of new ring variants, 3-acetoxy, aza,
thia, oxa and fluorine substituted analogues were developed. The later were largely
confined in the 1, 3-dicarbonyl segment of the 3O, C12-HSL structure in order to
modulate the 3-enolic content of the molecule. Also tetramic acid analogue, a non-
enzymatic degradative product of 3O, C12-HSL was synthesized. After purity and
identity characterization the new analogues were evaluated for their immune
modulation (with murine cells proliferation assay), cytotoxicity (with Trypan dye
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exclusion assay) and auto-inducing or QS activity (with a specifically designed lux
bacterial bio-reporter).
The splenocyte proliferation assay demonstrated that immune suppression in 4-aza
analogues increased with increasing alkyl chain (up to C15) yet without any solubility
problems in the standard solvents used. Similar trend was observed when N
4
was alkyl
substituted (n-propyl, being most potent). At least one of the C
2
hydrogens was found
to be essential for activity since, difluoro substitution lost activity. Retention of
immune suppression by N
3
-OH and increased potency by N
3
-NH2 (EC50=0.99 µM)
demonstrated that C
3
=O can be replaced by an appropriate H-bond donor/acceptor
groups. Complete loss of activity with 3-thia substitution (3-thia C12-HSL) and then
regain of potency by 3-sulfoxide/sulfone derivatives further demonstrated the
importance of 3-oxo (suitable H-bond acceptor/donor) in immune suppression.
Insertion of oxygen at C
4
retained activity but additional oxygen(s) in the side chain
yielded analogues that were devoid of immune suppression. Analogue with thiazole
ring instead of HSL ring retained activity. In case of hetero ring altered analogues of
3O, 4-aza C12-HSL, almost all retained immune suppressive activities except their oxa
analogues.
In conclusion, all the above strategies have delivered potent immune modulatory
agents yet gratifyingly devoid of QS activity. Some of the most potent and promising
non-inducing immune modulatory agents are 3O, 4-aza-C15-HSL (EC50 0.65 µM), 3-
NH2-3-aza-C12-HSL (EC50 0.99 µM) and N, N’-dimethyl-2-(3-oxo-4-azadodecanoyl)
aminobenzamide (EC50 0.7 µM) and are worthy of further study to be developed as
therapeutic agents.
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1.0 INTRODUCTION
Many people believe that we as a human beings have special obligation to preserve the
beauty, complexity, and balance of the world around us since we have greater power
than any other species over the fate of the planet. Throughout history the human beings
have always put members of the biological world to use in ingenious ways as food,
fiber, and medicines. This biodiversity is one of the Earth’s greatest treasures.
However, the human species has been profoundly affected by microorganisms. These
have decimated humanity countless times with high rates of mortality. Moreover,
nothing was known until late in the 19
th
century that infectious agents cause diseases.
It was Robert Koch who proved that microorganisms are responsible for infectious
diseases. We now distinguish four broad categories of disease-causing
microorganisms, or pathogens: (i) viruses (ii) bacteria (iii) pathogenic fungi and (iv)
parasites (relatively large and complex eukaryotic organisms). Great microbiologists of
19
th
century coupled with Koch’s discoveries then stimulated the extension of Jenner's
strategy of vaccination to other diseases. In the 1880s, Louis Pasteur devised a vaccine
against cholera in chickens and also developed a rabies vaccine. In 1890, Emil von
Behring and Shibasaburo Kitasato discovered antibodies from the serum of vaccinated
individuals. Those discoveries were metamorphosed into other aspects of the immune
systems.
The immune system is miraculous. Some sort of cut-and-paste, shuffle-and-deal
technique has definitely exists in our immune system that enables it to generate
billions of kinds of antibodies in comparison to only about 30,000 human genes. Until
1960's, the molecular-level details of such things were unknown. However, when
observed they found to be extremely complicated.
1,2
Immune systems are generally characterized by their ability to distinguish between self
and non-self cells, tissues, or molecules, and to eradicate the non-self. The mammalian
immune system is an exceptionally complex and intricate system that can recognize
non-self and provide protection from a wide variety of pathogens. Although there is
intrinsic bond between its components, the immune system can be divided into two
subsystems, the innate and the adaptive immune systems. In general, innate immunity
is a non-specific, inducible response to pathogens. It is immediate in action, yet short-
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lived. On the other hand, the adaptive immune system is much more specific, but
takes longer to activate. It also features immunological memory. Both systems work
together to provide protection against a diverse and rapidly-evolving array of
pathogens.
However, it is now realized that the immune system can be overactive, as well as
underactive, and that balance is the answer. On the one hand, the immune system
needs macrophages, natural killer cells and other “soldiers” to stay alert to attack
invading organisms before these can infect the body. On the other hand, autoimmune
diseases like rheumatoid arthritis, type-1 diabetes, etc. where the body attacks itself,
afflict millions of people. Immune overactivity causes unpleasant side effects, such as
allergies and inflammation, and can lead to immune exhaustion and collapse. The
answer to maintaining health, therefore, is to balance the body’s immune system so
that it is neither overactive nor underactive. Balancing the immune system, however, is
more challenging than simply stimulating it and requires thorough knowledge of the
human immune system.
1.1 IMMUNE SYSTEM
The immune system comprises of a diverse army of cells and organs that work
together in harmony to protect the human body against attacks by “foreign” invaders,
like microbes (germs) e.g. infection-causing organisms such as bacteria, viruses,
parasites, and fungi. Because the human body makes available an ideal environment
for many microbes, thus making it prone to microbial infection. However, it is the
immune system’s job to keep them out or, to seek out and ward them off. The immune
system is astonishingly complex. It can recognize and remember several different
enemies and can generate secretions and cells to wipe out each one of them. The secret
to its success is an active and sophisticated communications network. A large numbers
of cells, organized into sets and subsets, co-operate and pass information among
themselves like clouds of bees swarming around a hive. Once immune cells receive the
alarm, they undergo strategic changes and start generating dominant chemicals. These
substances allow the cells to regulate their own growth and behavior and recruit new
cells to harm foreign invaders.
3
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Immune system cells in particular, white blood corpuscles (WBC’s) or leukocytes
roam in the body to detect localized infections. Organs on the other hand focus where
leukocytes mature and where they effectively interact with antigens to become effector
or memory cells. Effector cells eliminate antigens whereas memory cells more
effectively response to repeated antigen exposure.
4
The organs of the immune system
are situated throughout the body. They can be divided as primary and secondary
lymphoid organs as shown in Fig 1.1.
1.1.1 Primary (Central) Lymphoid Organs
The bone marrow and the thymus are the primary lymphoid organs, where the
lymphocytes (responsible for specific immunity) originate. The bone marrow, the soft
tissue in the hollow center of bones, is the vital source of all blood cells, including
white blood cells destined to become immune cells. Both B-lymphocytes and T-
lymphocytes are produced from stem cells in the bone marrow. B-lymphocytes
however, mature in the bone marrow whereas T-lymphocytes migrate to the thymus
(an organ that lies behind the breastbone) and mature there.
Fig 1.1 Locations of the primary and secondary lymphoid organs in the body
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Lymphocytes can travel throughout the body using the blood vessels as well as
lymphatic vessels that closely parallels the body’s veins and arteries. The exchange of
cells and fluids between blood and lymphatic vessels enables the lymphatic system to
monitor the body for invading microbes. The lymphatic vessels carry a clear fluid
called lymph that bathes the body’s tissues. During haematopoiesis, lymphocytes gain
specific antigen receptors, cytokine receptors, co-receptors and carrier molecules that
take cells to a particular immune organ. Haematopoiesis is regulated by growth factors,
growth factor receptors and apoptosis. After maturation both lymphocytes circulate in
blood until they accumulate in one of the secondary lymphoid organs.
3,4
1.1.2 Secondary (Peripheral) Lymphoid Organs
Peripheral lymphoid tissues are available throughout the body and are responsible for
adaptive immune response. Secondary lymphoid organs comprise of (a) highly
organized lymph nodes and spleen and (b) less organized accumulation of
lymphocytes scattered throughout body such as tonsils and adenoids, the appendix, the
Peyer’s patches in the lining of the small intestines (gut associated lymphoid tissues-
GALT), lymphoid tissues beneath the bronchial mucous membranes (bronchial
associated lymphoid tissue or BALT) and lymphoid tissues aggregate throughout
mucosal membrane (Mucosa associated lymphoid tissues or MALT), and beneath the
skin (Skin associated lymphoid tissues or SALT).
5-7
Small, bean-shaped lymph nodes are laced along the lymphatic vessels, with clusters
in the neck, armpits, abdomen, and groin. Each lymph node contains specialized
compartments where immune cells assemble, and where they can come across
antigens. The spleen is a flattened organ at the upper left of the abdomen. Like the
lymph nodes, the spleen contains specialized compartments where immune cells
accumulate and work. It also serves as a meeting point where immune defenses strike
antigens.
Adaptive immune responses demand antigen-presenting cells such as macrophages,
dendritic cells (DCs), and ever changing population of B-lymphocytes and T-
lymphocytes. Antigen-presenting cells collectively detect antigens in the secondary
lymphoid organs. Lymphatic clusters and M-cells (specialized antigen collecting
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epithelial cells) accumulate at the mucosal membranes of respiratory, digestive and
urogenital systems where pathogen contact is highest. Reticular fibers that support
antigen-presenting cells are present in both peripheral organs (lymph nodes and
spleen). When microorganisms or other antigens enter the tissues, they are carried into
secondary organs, where they encounter the ever changing B-lymphocyte population,
thereby filtered out and phagocytosed by fixed macrophages and dendritic cells and
finally exposed to changing T-lymphocyte population.
3,4
1.1.3 Lymphatic Vessels
Lymphatic vessels regulate the flow of lymph within lymphoid system. Fluid
(lymphocyte) exits the blood circulation through high endothelium venules, and bathes
the tissues, supplying nutrients and washing away waste products. Antigen-presenting
cells, entering through afferent lymphatic vessels, in lymph nodes, activate the
lymphocytes. Antigens in paracortex generally activate T-cells. In germinal centers of
the lymphoid follicles activated B-cells become antibody producing plasma cells.
1
Activated lymphocytes leave the nodes through efferent lymphatics and carried back to
blood stream through fluid in lymphatic vessels.
3-6
1.1.4 Products of Immune Cells
The immune system reserves a huge arsenal of immune cells, not only lymphocytes
but also cell-engulfing phagocytes and their family members as shown in Fig 1.2. To
be effective in their work, most immune cells require the cooperation of other cells of
the immune system. Sometimes immune cells communicate by direct physical contact,
sometimes by releasing chemical messengers. The immune system stores specific cells
needed to recognize millions of enemies. When an antigen appears, those matching
cells multiply into full-scale soldiers. On completeing their task, these lie dormant
leaving behind an army to watch for future attacks. All immune cells begin as
immature stem cells in the bone marrow. They respond to different cytokines and other
signals to grow into specific immune cell types, such as T-cells, B-cells, or phagocytes.
Before maturity, stem cells however, are an interesting possibility for treating some
immune system disorders. It is under investigation whether, a person’s own stem cells
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can be used to regenerate damaged immune responses in autoimmune diseases and
immune deficiency diseases.
8
1.1.4.1 Lymphocytes
B-cells and T-cells are the main types of lymphocytes. These lymphocytes are
responsible for adaptive immunity.
1.1.4.1.1 B-Lymphocytes
B-cells work chiefly by secreting substances called antibodies into the body’s fluids.
Antibodies ambush antigens circulating the bloodstream. The function of attacking
target cells is to deport infected cells to T-cells or other immune cells. Each B-cell is
programmed to make one specific antibody.
Antibodies: Antibodies are plasma glycoproteins. Because of their mobility in an
electric field and in immunity, they are respectively called gamma globulins and
Fig 1.2 Cells of immune system
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immunoglobulin (Ig). Antibodies which are identical with each other at every amino
acid are called monoclonal antibodies (mAb).
Each antibody "monomer" as shown in Fig 1.3 is composed of two identical heavy (H)
polypeptide chains and two identical light (L) chains, covalently bonded via inter chain
disulfide (S-S) linkages between cysteine residues. All antibodies have one of two
kinds of L chain, kappa (N) or lambda (O). Furthermore, each antibody has two
identical N chains or two identical O chains. Five different H chains have been
observed: alpha (D), gamma (J), delta (G), epsilon (H), and mu (P).
When a B-cell encounters its triggering antigen, it gives rise to many large cells known
as plasma cells. Every plasma cell is essentially a factory for producing an antibody.
Each of the plasma cells obtained from a given B-cell manufactures millions of
identical antibody molecules and diffuses them into the bloodstream.
An antigen matches an antibody like a key matches a lock. Some match exactly; others
fit more like a skeleton key. Once antigen and antibody interlock, the antibody marks
the antigen for destruction.
Antibody isotypes (classes) belong to a family of large molecules known as
immunoglobulins and are named IgA, IgG, IgD, IgE, and IgM to correspond to their H
Fig 1.3 Structure of antibody
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chain types. Different types play different roles in the immune defense strategy, as
shown in Table 1.1
9
Table 1.1 Properties of antibody isotypes.
Isotype
% of total Ig
(adult serum)
Biological
half-life (days)
Biological Functions
IgA1 11-14 5.9
Pathogen neutralization in mucosal secretions
IgA2 1-4 4.5
IgD 0.2 2-8 Membrane BCR
IgE 0.004 1-5 Mast cell histamine release
IgG1 45-53 21-24
Pathogen neutralization in tissues
Classical complement activation
Opsonization, NK cell ADCC
Transplacental transfer
IgG2 11-15 21-24 Pathogen neutralization in tissues
IgG3 0.03-0.06 7-8
Pathogen neutralization in tissues, Classical
complement activation
Opsonization, NK cell ADCC, Transplacental
transfer
IgG4 0.015-0.045 21-24
Pathogen neutralization in tissues
Transplacental transfer
IgM 10 5-10
Classical complement activation
Membrane BCR (monomer)
1.1.4.1.2 T-Lymphocytes
In contrast to B-cells, T-cells does not remember free-floating antigens. To a certain
extent, presence of specialized antibody-like receptors on their surfaces makes them to
see fragments of antigens on the surfaces of infected or cancerous cells. There are two
major ways through which T-cells contribute in immune defences: (i) by directing and
regulating immune responses and (ii) directly attacking infected or cancerous cells.
Their active participation in variable immune defences is because they exist in several
forms as shown in Fig 1.4.
Helper T-cells, (TH cells) synchronize by communicating with other cells. Type-1 T-
helper cells (TH1) call in microbe-swallowing cells called phagocytes, Type-2 T-helper
cells (TH2) stimulate nearby B-cells to produce plasma cell and eventually an antibody,
still others activate other T-cells. Third type, Killer T-cells also called cytotoxic T-
lymphocytes (CTLs or TC) directly attacks especially viruses because viruses often
hide from other parts of the immune system while they grow inside infected cells.
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1.1.4.1.3 Natural killer (NK) cells
NK cells (Fig 1.2) are another kind of lethal lymphocyte that has the potential to assail
many types of foreign invaders. Because they are equipped with dedicated potent
chemicals they can recognize cells lacking self-MHC molecules while killer T-cells
look for antigen fragments bound to self-MHC molecules.
1.1.4.2 Phagocytes
These are large white cells that can engulf and digest microbes and other foreign
particles. Monocytes are phagocytes that circulate in the blood. When monocytes
migrate into tissues, they develop into macrophages. Macrophages show many
functions. They scavenge dead cells and debris as well as expel them out of the body.
They also provide monokines, which are vital to the immune responses.
Fig 1.4Different types of T-cells and their
roles in immune defences
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1.1.4.3 Granulocytes
These are another kind of immune cell containing granules containing potent
chemicals capable of destroying microorganisms. Some of these chemicals, such as
histamine, also contribute to inflammation and allergy. The neutrophil, is a also
granule containing phagocyte; it ingests the microbes and sprays its pre-stored
chemicals to kill them. Eosinophils and basophils are granulocytes that “degranulate,”
showering their chemicals onto harmful cells or microbes in proximity.
The mast cell is not a blood cell; however, it is a twin of the basophils. It is located in
the lungs, skin, tongue, and linings of the nose and intestinal tract, and is responsible
for the allergic symptoms. Cell fragments, the blood platelets, too, contain granules.
They not only promote blood clotting and wound repair, but also activate some of the
immune defences.
1.1.4.4 Cytokines
Cytokines are small secreted proteins which mediate and regulate immunity,
inflammation, and haematopoiesis. Cytokines are components of the immune system
that communicate with one another by exchanging chemical messengers.
Cytokine is a general term; other names include lymphokine (cytokines made by
lymphocytes), monokine (cytokines made by monocytes), chemokine (cytokines with
chemotactic activities), and interleukin (cytokines made by one leukocyte and acting
on other leukocytes). Cytokines may act on the cells that secrete them (autocrine
action), on cells in proximity (paracrine action), or in some instances on distant cells
(endocrine action). The various cytokines with their sources, targets and functional
activities are listed in Table 1.2. A diverse range of cytokines with different activities
contributes mutually in their actions and together in harmony. For example; they show
pleiotropy (different cells may secrete the same cytokine or a single cytokine may act
on several different cells) and redundancy (similar functions can be stimulated by
different cytokines) in their activity. They are often produced in a cascade and can act
either synergistically or antagonistically. Although many cell populations make
cytokines, but TH cells and macrophage are the predominant (Fig 1.4).
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Table 1.2 Immune cytokines and their activities.
Cytokine Producing cell Target cell Function**
GM-CSF TH cells progenitor cells
growth and differentiation of
monocytes and DC
IL-1D
IL-1E
monocytes
macrophages
B-cells
DC
TH cells co-stimulation
B-cells maturation and proliferation
NK cells activation
Various
inflammation, acute phase response,
fever
IL-2 TH1 cells
activated T-and B-cells,
NK cells
growth, proliferation,
activation
IL-3
TH cells
NK cells
stem cells growth and differentiation
mast cells growth and histamine release
IL-4 TH2 cells
activated B-cells
proliferation and differentiation
IgG1 and IgE synthesis
macrophages MHC Class II
T-cells Proliferation
IL-5 TH2 cells activated B-cells
proliferation and differentiation
IgA synthesis
IL-6
monocytes
macrophages
TH2 cells
stromal cells
activated B-cells differentiation into plasma cells
plasma cells antibody secretion
stem cells Differentiation
Various acute phase response
IL-7
marrow stroma
thymus stroma
stem cells
differentiation into progenitor B- and
T-cells
IL-8
macrophages
endothelial cells
Neutrophils Chemotaxis
IL-10 TH2 cells
macrophages cytokine production
B-cells Activation
IL-12
macrophages
B-cells
activated TC cells
differentiation into CTL
(with IL-2)
NK cells Activation
IFN-D leukocytes various viral replication
MHC I expression
IFN-E fibroblasts various viral replication
MHC I expression
IFN-J TH1 cells,
TC cells, NK cells
various Viral replication
macrophages MHC expression
activated B-cells Ig class switch to IgG2a
TH2 cells Proliferation
macrophages pathogen elimination
MIP-1D macrophages monocytes, T-cells Chemotaxis
MIP-1E lymphocytes monocytes, T-cells Chemotaxis
TGF-E T-cells, monocytes
monocytes, macrophages Chemotaxis
activated macrophages IL-1 synthesis
activated B-cells IgA synthesis
various Proliferation
TNFD macrophages, mast
cells, NK cells
macrophages CAM and cytokine expression
tumor cells cell death
TNF-E TH1 and TC cells phagocytes phagocytosis, NO production
tumor cells cell death
* CTL: cytotoxic T-lymphocytes; DC: dendritic cells; GM-CSF: Granulocyte-Monocyte Colony
Stimulating Factor; IL: interleukin; IFN: Interferon; TGF: Tumor Growth Factor; TNF: Tumor
Necrosis Factor. ** Italicized activities are inhibited.
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1.2 HOW DOES THE IMMUNE SYSTEM DEFEND THE BODY?
The immune system can be pictured as a huge cellular and molecular army working in
concert to protect the body. The main targets of all immune responses are foreign
agents such as bacteria or other invaders, termed as antigens. Antigen-presenting cells
(macrophages) wander throughout the body, ingesting the antigens they find and
breakdown those into fragments called antigenic peptides. These fragmented peptides
are then fixed to major histocompatibility complex (MHC) molecules and are
displayed on the cell surface. Receptors present on T-lymphocytes make them to
recognize different peptide-MHC combinations. This recognition activates T-cells,
which then divide and secrete lymphokines or chemical signals that further trigger
other components of immune system. Set of cells comprising of B-lymphocytes that
also contain receptor molecule of single specificity on their surface responds to those
signals. However, receptors of B-cells can recognize fragments of antigens free in
solution without MHC molecules. When activated, B-cells are converted to plasma
cells that secrete antibodies (soluble forms of their receptors). Antibodies can
neutralise antigens or precipitate their destruction by complement enzymes or
scavenging cells. Some T-cells and B-cells are stored as memory cells in circulation
that eliminate same antigens if appear in future. It should be noted that antibody
response improves after repeated immunisation this is because genes for antibodies in
B-cells mutate frequently.
3,4
This defence phenomenon is termed as immunity which
can be defined as body’s protective mechanism against foreign agents such as
microorganisms, food, drugs or pollens
1
and is conveniently divided into two types;
Innate and Adaptive
1.2.1 Innate Immunity
This is a non-specific immunity comprising of elements that are unable to recognize
antigens but can distinguish foreign organisms.
6,10
This immunity is devoid of
immunological memory and it responds in the same manner every time the host is
exposed to the same antigens. Innate immunity consists of (a) physical and chemical
barriers and (b) cellular defences. These are summarised in Fig 1.5.
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1.2.1.1 Physical and chemical barriers
The main physical barriers are mucous membrane and skin, which provide mechanical
obstructions to the invading organisms
11
and thus prevent their access to the host.
However, an invading organism can gain access through the damages or cuts.
6
Epithelial layers, in addition produce chemicals such as secretion of HCl and
proteolytic enzymes in the stomach, antibacterial proteins in the gut and respiratory
tract.
3,12
Fig 1.5 Summary of Innate immunity
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1.2.1.2 Cellular defences
Cellular barriers include “professional” and “non-professional” phagocytes.
“Professional phagocytes” are those polymorphonuclear neutrophils such as
monocytes, macrophages and dendritic cells (DCs), which have antigen-presenting
capacity. “Non-professional” phagocytes include endothelial cells and Kupffer cells.
Phagocytes ingest, destroy and digest the invading microorganisms intracellularly, by
producing (for example through enzymatic cascade) oxygen free radicals and nitrous
oxide (NO), which are toxic for intracellular bacteria. Cytokines such as interferon
gamma (IFN-J) and tumour necrosis factor alpha (TNF-D) play an important role in
triggering and activating this mechanism.
7,12,13
Acidification of lysosomal enzymes
13
also involved in killing intracellular bacteria. Kupffer cells, the spleen and the lymph
nodes provide an antibacterial defence if microbial invasion occur through blood or
lymphatic circulation. Macrophages interacting with certain bacterial components
produce a range of cytokines, which non-specifically amplify immunological and
inflammatory responses.
14
Other cells showing innate immune defences are natural killer (NK) cells. These
release perforin, which upon damaging cell membrane lead to the death of the target
cells. Cytokines such as interleukin-12 (IL-12) and IFN-D activate the NK cells thus
enhancing their activity against invading organisms.
15-17
1.2.2 Acquired Immunity
Microbes devise specific system to circumvent inherited eukaryotic immune defences.
To overcome this vertebrates have an adaptive immune power, also known as antigen
specific defence mechanism. Adaptive immunity cannot protect against all infections
but is more specific defence mechanism that enables the body to recognize and
respond to any microbe, even if it had never been exposed to the invader before. The
process of clonal selection operates it. Adaptive immunity retains the immunologic
memory and makes us able to resist infections we have faced before, more efficiently
and forcefully than we do face them for the first time. The body stores the lymphocytes
that are exposed in previous infection by microbes. When the same microbes again
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enter the body, these lymphocytes are rapidly reactivated and form antibodies against
microbes and remove them, thus recurrence of disease is avoided.
3,18
This immunity is
developed throughout life. As shown in Fig 1.6, acquired immunity is divided into two
types, namely humoral and cell mediated immunities.
3,5
1.2.2.1 Humoral immunity
This is mediated by B-lymphocytes and involves production of antibodies, specific in
recognising and eliminating antigens. B-lymphocytes (plasma cells derived from B-
cells) secrete antigen-specific antibodies, immunoglobulins,
19
that specifically bind to
antigens and deactivate them either by neutralising their activity or by eliminating
them via activating complement cascade through type-2 receptors
20
or phagocytose
them by acting as opsonins or killing them via stimulating NK cells.
Fig 1.6 Acquired immunity
(Humoral and cell mediated)
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1.2.2.2 Cell mediated immunity
This is mediated by T-lymphocytes and involves the production of cytotoxic T-
lymphocytes, activated macrophages, activated NK cells and cytokines in response to
antigens. Recent research suggested that, bacteria are capable to down regulate
antibacterial responses of T-helper1 (TH1), whereas parasite helminths down regulate
responses of T-helper2 (TH2).
21
Two major histocompatibility complexes (MHCI and
MHCII) can bind to a range of antigenic peptides or protein fragments in forming
respective complexes (Peptide-MHCI and Peptide-MHCII). Peptide-MHCI complex
activates CD8+ T-cells (T-killer) whereas Peptide-MHCII complex activates CD4+ T-
cells (T-helper). The antigen processing by MHC is shown in Fig 1.6.
MHCII molecules produced by macrophages bind to antigenic peptides (from invading
organisms) and carry them to the cell surface in the form of peptide-MHCII complex.
This complex coupled with B7 on the surface of macrophages activates CD4+ T-cells
containing complementary receptor molecule. B7 provides an additional signal to T-
cells in order to develop immunologic response. B7 is recognised by separate protein,
CD28 on T-cell surface.
Activated TH1 cells release interferon-gamma which enhances the production of other
cytokines (TNF) and chemicals like NO and toxic form of oxygen, which lead to the
destruction of microbes. Whereas, activated TH2 cells secrete IL-4 and IL-10 that
enhance antibodies production by B-cells and thereby destroy microbes.
3,22
The target of T-killer cells are mainly cells infected by viruses. Peptide-MHCI
complexes activate T-killer cells that express CD8+. Activated Tc cells then kill
infected cells directly or indirectly. They destroy infected targets by apoptosis thereby
secreting perforin and other proteins that lyse cellular membranes (Fig 1.6).
Additionally, activated CD8+ cells release potent cytokines (IFN-D and TNF) that
inhibit the replication of viruses and other cytokines that kill the infected cells.
3,21,23
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1.3 DISORDERS OF THE IMMUNE SYSTEM
The immune system helps the body defend itself against various microbes and
pollutants. However, the immune system itself can be futile and in some cases
dysfunctional. This leads to the development of immune disorders. An impaired
immune system is also known as immuno-compromised and can make the body
susceptible to various viral, bacterial, or fungal opportunistic infections. Immune
deficiency can cause various illnesses such as viral infections, chronic illnesses, or
immune system illnesses (like AIDS). The other type of immune disorder involves an
over-active immune response. This leads to several different classes of diseases:
hypersensitivities, autoimmune diseases, etc.
1.3.1 Hypersensitivity
The damage made by immune response to the body gives rise to hypersensitivity.
Many immune responses damage the body during antigen removal, causing swelling
and pain from inflammation or lysis of virus-infected cells by cytotoxic T-cells.
However, hypersensitivity can become life-threatening if the damage is too great. Four
types hypersensitivity are observed depending upon the mechanisms by which immune
responses damage cells.
1.3.1.1 Type-I hypersensitivity
This is usually called "allergy" in which IgE is produced in response to an antigen
called an allergen. This immediate hypersensitivity includes hay fever, skin
inflammation (urticaria), food allergies, asthma, and systemic anaphylaxis. The risk of
developing a Type-I hypersensitivity (atopy) is linked to family history and IgE levels.
1.3.1.2 Type-II hypersensitivity
It is mediated by IgG (or occasionally IgM) and occurs when an antibody binds to a
cell surface antigen. The surface antigen-antibody complexes activate complement or
bind to FcJRI on cells that can perform antibody-dependent cell-mediated cytotoxicity
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(ADCC). Both processes result in lysis of the target cell. Examples are hyper acute
graft rejection, acetylcholine receptor in myasthenia gravis, thyroid hormone receptor
in Graves' disease, and erythrocyte membrane proteins in autoimmune hemolytic
anemia.
1.3.1.3 Type-III hypersensitivity
It is also mediated by IgG (or occasionally IgM) antibody and caused by immune
complex deposition in the tissues, where the classical complement cascade results in
tissue damage. Frequently, deposition and tissue damage are observed in blood vessel
walls, kidney, and joints. Immediately after cell damage, an inflammatory response is
initiated. In this process, a release of cytoplasmic enzymes and influx of inflammatory
cells prolong the hypersensitivity. Examples include serum sickness and occupational
diseases (i.e., Farmer's Lung) in which antibodies are produced to soluble
environmental antigens that are encountered repeatedly. Autoantibodies produced in
Systemic Lupus Erythematosis cause tissue damage and infectious diseases with
persistent pathogens (including malaria, some virus infections, leprosy, and Lyme
disease).
1.3.1.4 Type-IV hypersensitivity
It is also called delayed-type hypersensitivity (DTH) because it occurs 48-72 hours
after antigen contact, is mediated by antigen-specific TH1 cells and activated
macrophages. Examples of DTH include local skin reactions to proteins in insect
venom and injected Mycobacterial proteins used in skin testing. Other include contact
sensitivities to poison ivy, latex, nickel in coins and jewelry, and cleaning products
which come in contact with the skin.
1.3.2 Immunodeficiency Disorders
The missing of one or more of components of the immune system during its response
results with an immunodeficiency disorder. Immunodeficiency disorders can be
inherited, acquired through infection, or produced unintentionally by drugs such as
those used to treat people with cancer or those who have received transplants.
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Temporary immune deficiencies can develop a susceptibility to common virus
infections, including influenza, infectious mononucleosis, and measles. Moreover,
blood transfusions, surgery, malnutrition, smoking, and stress can also depress immune
responses.
Some children are born with poorly functioning immune systems. Some have
disabilities in the B-cells to produce antibodies. Infants born with none of all major
immune defenses are seldom. However, this condition is known as severe combined
immunodeficiency disease or SCID.
1.3.2.1 Acquired immunodeficiency syndrome (AIDS)
This is an immunodeficiency disorder caused by a human immunodeficiency virus
(HIV) that infects immune cells. HIV can destroy or disable vital T-cells, paving the
way for a variety of immunologic flaws. HIV also can lie dormant for long periods in
immune cells. As the HIV abates immune defenses it makes a person vulnerable to
unusual, often life-threatening infections and rare cancers. AIDS is a contagious
disease spread by intimate sexual contact, transfer of the virus from mother to infant
during pregnancy, or direct blood contamination. There is no cure for AIDS, but
several developed antiviral drugs have been developed that can slow the advance of the
disease, at least for a time. Moreover, HIV vaccines are in clinical studies.
1.3.3 Cancers of the Immune System
Like other cells, the immune system cells can also grow uncontrollably, resulting in
cancer. The proliferation of white blood cells, or leukocytes cause leukaemias.
Multiple myeloma is due to the unrestricted growth of antibody-producing plasma
cells. Whereas, Hodgkin’s disease includes cancers of the lymphoid organs called
lymphomas.
1.3.4 Autoimmune Diseases10,24,25
The immune system is a complicated cell and cell component network set to defend
the body and eliminate infections caused by bacteria, viruses, and other invading
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microbes. In an autoimmune disease, the immune system mistakenly attacks self,
targeting the cells, tissues, and organs of a person's own body.
Table 1.3 Human autoimmune diseases
Disease Autoantigen Symptoms Extent*
Type II: antibodies to cell surface molecules
Autoimmune hemolytic
anemia
Rh blood group antigens, I
antigen
Lysis of RBC by
complement and FcR
+
cells, anemia
Organ
specific
Autoimmune thrombo-
cytopenic purpura
Platelet integrin GpIIb:IIIa Abnormal bleeding
Organ
specific
Goodpasture's syndrome
Basement membrane Type IV
collagen
Glomerulonephritis,
pulmonary hemorrhage
Organ
specific
Graves' disease
Thyroid-stimulating hormone
receptor
Thyroid over-activity
Organ
specific
Hashimoto's thyroiditis
Thyroglobulin, thyroid
peroxidase
Thyroid under-activity
Organ
specific
Hypoglycemia Insulin receptor (agonist) Low blood glucose
Organ
specific
Insulin-resistant diabetes Insulin receptor (antagonist)
High blood glucose,
ketoacidosis
Organ
specific
Myasthenia gravis
D chain of nicotinic
acetylcholine receptor
Progressive weakness
Organ
specific
Pemphigus vulgaris Epidermal cadherin Skin blisters
Organ
specific
Pernicious anemia
Intrinsic factor, gastric parietal
cells
Anemia
Organ
specific
Rheumatic fever
Streptococcal cell wall antigens;
antibodies cross-react with heart
muscle
Arthritis, myocarditis,
heart valve scars
Organ
specific
Spontaneous infertility Sperm antigens Infertility
Organ
specific
Type III: Immune complex disease
Ankylosing spondylitis Immune complexes Damage to vertebrae Systemic
Mixed essential
cryoglobulinemia
Rheumatoid factor IgG
complexes
Systemic vasculitis
Systemic
Rheumatoid arthritis
Rheumatoid factor IgG
complexes
Arthritis
Systemic
Systemic lupus
erythematosus (SLE)
DNA, histones, ribosomes,
snRNP, scRNP
Glomerulonephritis,
vasculitis, rash
Systemic
Type IV: T-cell-mediated disease
Experimental autoimmune
encephalomyelitis (EAE),
multiple sclerosis
Myelin basic protein, proteolipid
protein, myelin oligodendrocyte
glycoprotein
Brain invasion by CD4 T-
cells, weakness
Systemic
Hashimoto's thyroiditis Thyroid antigen(s) Thyroid under-activity
Organ
specific
Insulin-dependent (Type I)
diabetes mellitus (IDDM)
Pancreatic E cell antigen(s) E cell destruction Organ
specific
Rheumatoid arthritis Unknown synovial joint antigen
Joint inflammation and
destruction
Systemic
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Autoimmunity is caused by an adaptive immune response against "self" antigen. The
random generation of many diverse T-cell receptors (TCR) and B-cell receptors (BCR)
makes autoimmunity possible. Clonal deletion and anergy of self-specific lymphocytes
greatly reduces but does not eliminate the possibility of low affinity self-specific
responses. Transient autoimmune responses are common but usually cause no long-
term damage. Prolonged autoimmune responses resulting in tissue damage can be
serious, because self-antigens are continually present in the body. Autoimmune
diseases can be caused by antibodies or T-cells and may be organ-specific or systemic.
Table 1.3 summarizes some information about some human autoimmune diseases.
Frequently observed autoimmune diseases are summarised below.
1.3.4.1 Rheumatoid arthritis
In rheumatoid arthritis the immune system predominantly targets the synovium that
covers various joints resulting in the symmetrical inflammation of the synovium
thereby causes pain, swelling, and stiffness of the joints. Sometimes it may associate
with other autoimmune diseases such as Sjogren's syndrome (chronic inflammatory
disease), itching, and scaling.
1.3.4.2 Multiple sclerosis
In multiple sclerosis the immune system targets nerve tissues of the central nervous
system, intermittently damaging the central nervous system and eventually preventing
a person from leading a normal life. Multiple sclerosis is the most common disabling
disease of the nervous system in young adults.
1.3.4.3 Immune-mediated or type-1 diabetes mellitus
Autoimmune destruction of the insulin-producing cells of the pancreas results in Type-
1 diabetes mellitus, which is manifested by fatigue, frequent urination, increased thirst,
and possible sudden confusion. Insulin keeps the blood sugar (glucose) level under
control. High levels of blood glucose are responsible for the symptoms and the
complications of the disease. It is observed that most of the insulin-producing cells are
destroyed before the patient develops symptoms of diabetes.
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1.3.4.4 Inflammatory bowel diseases
Two diseases namely Crohn's disease and Ulcerative colitis are of inflammatory bowel
type. In those, the immune system attack the gut (intestine), resulting in diarrhoea,
nausea, vomiting, abdominal cramps, and uncontrolled pain.
1.3.4.5 Systemic lupus erythematosus
Patients with systemic lupus erythematosus commonly experience profound fatigue,
rashes, and joint pains. In severe cases, the immune system attacks and damages the
kidneys, the brain, or the lungs and the patient needs close monitoring.
1.3.4.6 Psoriasis
This immune system disorder affects the skin, and occasionally the eyes, nails, and
joints. Psoriasis may affect small areas of the skin or cover the entire body, building up
red scales called plaques.
1.3.4.7 Scleroderma
This autoimmune disease results in thickening of the skin and blood vessels. Almost
every patient with scleroderma has Raynaud's disease, which is a spasm of the blood
vessels of the fingers and toes.
1.3.4.8 Autoimmune thyroid diseases
The two main types of autoimmune thyroid diseases are Hashimoto's thyroiditis and
Grave's disease. These destruct the immune system or stimulate the thyroid tissue.
Symptoms include fatigue, nervousness, cold or heat intolerance, weakness, and
changes in hair texture or weight gain or loss.
Scientists searching for ways to prevent and treat autoimmune diseases are studying
disease pathogenesis and investigating new ways of modifying the immune system. To
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this end a large number of immune modulatory drugs have been developed to correct
the dysfunctional immune system.
1.4 MODULATION OF THE IMMUNE SYSTEM
Immune modulation may involve either the immune system’s attenuation as in the case
of organ transplantation or its stimulation, for example to combat viral infections.
Clinically immune suppressants are used to withhold the harmful effects of immune
response, primarily in organ transplantation thus avoiding organ rejection. Other
clinical applications involve autoimmune diseases or hypersensitivity. The immune
modulatory agents can be divided as either immunosuppressants or immunostimulants.
Other agents such as tolerogens and disease modifying anti-rheumatic drugs
(DMARDs) are also responsible for immune modulation to some extent.
1.4.1 Immunosuppressants
Immunosuppressants react differently to different immune reactions. For example, they
can suppress the primary immune response more readily than the secondary (memory).
Immunosuppressants are conveniently differentiated into flour classes; helper T-cell
blockers, Glucocorticostroids (glucocorticoids), cytotoxic drugs and antibody reagents.
1.4.1.1 Helper T-cell blockers
1.4.1.1.1 Ciclosporin
Ciclosporin 1.1 is also known as cyclosporin or cyclosporine. It was discovered by
Borel et al from the fungal species Tolypocladiumv inflaturm Gams.
26,27
It is a cyclic
peptide mainly used as prophylaxis and in the treatment of graft-versus-host disease
(GvHD). This immunosuppressant is a calcineuurin inhibitor. It inhibits antibody
synthesis against T-lymphocyte-dependent antigens and lymphokines (IL-2) synthesis
by activated T-lymphocytes. Unfortunately nephrotoxicity and hypertension are major
side effects.
27,28
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1.4.1.1.2 Tacrolimus
Tacrolimus also termed as FK506 1.2 is a macrolide triene, discovered in Japan from
the soil fungus Streptomyces tsukubaensis and acts in the same way as that of
ciclosporin but binds to a different immunophilin. Its binding forms a complex that
interferes with T-cell actvation through its action on calcineurin.
29-31
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Boxed groups are essential for immune suppression
It is used to prevent rejection of liver transplants and in the treatment of rheumatoid
arthritis and causes few side effects. Its use in dermatological diseases through
systemic route is associated with its side effects where as topical applications have
shown positive therapeutic effects. Major side effects are neurotoxicity, diarrhoea,
upset stomach, vomiting, stomach pain, loss of appetite and insomnia.
32,33
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Recently, SAR of tracolimus has developed the semi-synthetic analogue indolyl-
ascomycin, 1.3. This compound contains 2-(3-indolyl)ethoxy group at C
32
position that
alters its drug-receptors interactions. This drug retains immunosuppression whilst
improving its therapeutic index. It has also shown reduction in nephrotoxicity and
neurotoxicity respectively by 2 and 3 folds.
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Boxed groups are essential for immune suppression
1.4.1.1.3 Sirolimus (Rapamycin)
Sirolimus is also one of the potent compounds of the macrocyclic triene series and is
isolated from Streptomyces hygroscopicus. Like tracolimus, sirolimus 1.4 binds to
immunophilins, with no calcineurin inhibitory activity. It inhibits T-cell proliferation
by acting at tow kinases.
26,35
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Boxed positions are sites for metabolism and are essential for immune suppression
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Its synergism with ciclosporin makes it possible to reduce doses of ciclosporin still
within the therapeutic index and thus abates cyclosporine related side effects. Like
other agents, sirolimus also maintains toxicity like hyperlipidemia, leukopenis and
thrombocytopenia whereas, unlike other structurally related agents, it is devoid of
nephrotoxicity.
26,36
Hepatic metabolism of sirolimus greatly reduces
immunosuppressive effect. This suggests that sites of metabolism shown in 1.4 are
important features for immune suppression.
33
1.4.1.1.4 Pimecrolimus
Pimecrolimus 1.5 is an ascomycin derivative isolated from Streptomyces hygroscopius
var. ascomycetes. It mimics the tracolimus chemically with somewhat different
biological behaviour. Pimecrolimus binds to immunophilin before it can affect T-cell
proliferations induced by calcineurin phosphatase.
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It is choice of drug for dermatitis preferably by topical route at comparatively 3 times
larger doses than that of cyclosporine. It has also been used systemically for graft
rejection as well as for contact and atopic dermatitis. Pimecrolimus at well tolerated
systemic doses have shown exciting results in reduction of psoriasis area and its
severity. A comparatively high lipophilic character lowers its permeation through skin
and also reduces its systemic uptake in blood through topical application. The poor
systemic absorption of topical pimecrolimus however, makes it a choice drug for
treatment of immune mediated skin disorders.
37
To a lesser extent it also shows
spurious effects like burning sensation, pruritus, erythema, etc.
38
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1.4.1.2 Glucocorticoids (Glucocorticostroids)
Hench’s et al first discovered Glucocorticoids in 1949 and in that they showed that
cortisone had beneficial acitivities in patients with rheumatoid arthritis.
39,40
A range of
glucocorticoids is available right from the short acting natural hydrocortisone 1.6
through the intermediate acting synthetic prednisolone 1.7 to the long acting
dexamethasone 1.8.
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Hydrocortisone Prednisolone Dexamethasone
1.6 1.7 1.8
These glucocorticoids show a wide range of immune modulating effects. These effects
include decreasing vasodilatation, delayed macrophage activation,
41
slowing down of
the prostaglandin synthesis and decreased lymphocyte levels.
42
Glucocorticoids also
lower cytokine production.
43
Synthetic derivatives cause more severe side effects than
those of hydrocortisone. They are used in autoimmune diseases such as active chronic
hepatitis, rheumatoid arthritis, myasthenia gravis and inflammatory diseases.
44
1.4.1.3 Cytotoxic agents
Cytotoxic agents are mainly antineoplastic drugs used in prevention of rapid division
of cells and clonal expansion of T- and B-cells.
1.4.1.3.1 Azathioprine
Azathioprin, 1.9 is a prodrug approach of purine analogue, which, upon metabolism is
converted to 6-mercaptopurine 1.10 and inhibits the production of purine nucleotides
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thus inhibiting DNA replication. It also affects cell-mediated immune responses and
antibody production.
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It is used in severe rheumatoid arthritis, systemic lupus erythematosus, Crohn’s
disease, myasthenia gravis etc. Toxicity includes GI disturbances, hair loss and
hepatotoxicity.
44
1.4.1.3.2 Mycophenolate Mofetil
Mycophenolate Mofetil (MMF) 1.11 is a semi-synthetic prodrug of mycophenolic acid
1.12 derived from Penicillium fungi. Mycophenolic acid acts by inhibiting inosine
monophosphate dehydrogenase enzyme involved in the de novo synthesis of xanthine
monphosphate.
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It also prevents T-cell proliferation and antibody formation by B-lymphocytes, which
are vital in a de novo synthesis of purine nucleotides.
43
MMF is mainly used in
prevention of rejection of allogenic kidney, heart and liver transplants. It is usually
given in combination with ciclosporin and corticosteroids. Being more selective in
action, it causes only mild side effects of gastrointestinal tract.
44
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1.4.1.3.3 Cyclophosphamide
Chemically 1.13 is known as prodrug of alkylating agents that is enzymatically
converted to cytotoxic phosphoramide mustard by cytochrome P450 oxidases in liver.
28
The resulting alkylation of nitrogen 7 of guanidine causes DNA cross-linking thus
inhibiting DNA replication and transcription.
26,43
HN P OO N(CH2CH2Cl)2
1.13
It also triggers apoptosis. It is mainly useful in severe rheumatoid arthritis not
adequately controlled by standard disease modifying antirheumatic drugs (DMARDs).
Its toxicity includes myelosuppression, sterility, especially in men and risk of
leukaemia.
44
1.4.1.3.4 Methotrexate
Methotrexate 1.14 is a competitive inhibitor of dihydrofolate reductase enzyme, which
is involved in synthesising thymidine nucleotides by converting dihydrofolate to
tetrahydrofolic acid. The latter is essential in DNA replication and thus proliferation of
lymphocytes.
26
It also inhibits protein synthesis.
43
It is primarily used to treat
rheumatoid arthritis, severe psoriasis, Crohn’s disease, and ulcerative colitis.
Hepatotoxicity, teratogenicity and pulmonary toxicity in rheumatoid arthritic patients,
are common side effects.
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1.4.1.3.5 Leflunomide
Leflunomide 1.15 is completely metabolised by hydrolytic cleavage in the cytoplasm
to its active constituent A177 1726 1.17 (Scheme 1.1). The metabolite of this
isoxazole derivative may be involved in inhibiting dihydroorotate dehydrogenase in de
novo pyrimidine synthesis thus avoiding T-cell proliferation.
26
It also blocks
phosphorylation of tyrosine, and inhibits activity of cyclo-oxygenase-2 (COX-2). It is
mainly used as disease modifying antirheumatic drug (DMARD) and may show
cumulative toxicity.
44
1.15 1.16 1.17
Scheme 1.1 Leflunomide 1.15 and its active metabolite A77 1726 1.17
1.4.1.4 Antibody reagents (cytokines therapy)
Antibodies eliminate invading molecules by phagocytosis. Various antibodies specific
for cytokines, lymphocytes are used as immunosuppressant. These are prepared by
immunising human lymphocytes with specific animal (horses, rabbits or mice) cells.
Polyclonal antibodies such as ALG (Antilymphocyte immunoglobulin) and ATG
(Antithymocyte immunoglobulin) reduce activity of circulating T-cells interacting with
surface proteins.
46
These antibodies therefore, can be made to target different cytokine
receptors.
1.4.1.4.1 Targeting IL-2 receptors
Humanized monoclonal antibodies created by recombinant DNA technology
daclizumab and an achimeric monoclonal antibody containing both murine
47,48
and
human antibody sequences basiliximab bind to the alpha-chain of the IL-2 receptor
and prevent proliferation blocking signal transduction.
49,50
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1.4.1.4.2 Targeting TNF
A significant role of TNF in inflammatory bowel disease and rheumatoid arthritis has
highlighted that targeting the TNF might lead to favourable immune modulation
51
Infliximab is an achimeric IgG antibody to TNF-v that dose dependently neutralises
the cytotoxic effects of the TNF.
52
Etanercept is synthesized by fusion process and
contains two chains of recombinant human TNF-receptor U75 monomers and FC
domain of the human IgG, which binds to and inactivates TNF. It has been
successfully used in rheumatoid arthritis with negligible side effects.
52
1.4.1.4.3 Targeting CD cells
Some antibodies mAbs target CD3 or CD4 protein on T-cells.
49
MuromonabCD3
(also called OKT3) is the first monoclonal antibodies marketed for the treatment of
organ rejection and inhibit T-cell functions by binding to CD3. Alemtuzumab acts
against cluster of CD52 that is located on most immune cells. It is used in the treatment
of B- cell lymphocytic leukaemia. Rituximab selectively targets CD20 on B-cells and
leads to the disappearance of B-cells within the circulation after treatment. It is used
for the treatment of B-cell non Hodgkin’s lymphoma and also has been evaluated in
autoimmune diseases.
43
1.4.2 Immunostimulants
Immunostimulants are agents employed to encourage or excite the immune system and
enable the body to recognise and respond to foreign agents. It can be broadly
categorised as synthetic agents, natural agents such as bacterial derived agents,
intravenous immune globulins (IVIGs) and cytokines (interferons, interleukins and
colony-stimulating factors), and finally endogenous hormones.
Vaccines are used as prophylactic against infections. They stimulate adaptive
immunity. Antisera like Immunoglobulins (IgG), antivenoms provide protection
against poisons from snakes and antitoxins provide protection against poisons from
microbes.
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1.4.2.1 Synthetic agents
1.4.2.1.1 Levamisole and Imuthiol
Both the sulfur containing compounds Levamisole (LMS) 1.18 and Imuthiol 1.19 act
by similar mode of action. Levamisole is primarily used as an antihelmintic. It
increases NK cells and activated T-cells with consistent effect on production of tumor
necrosis factor and no effect on monocyte cytotoxicity.
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It is used in the UK as the drug of choice in the treatment of Ascaris lumbricoides
(roundworm) infections.
44
Common side effects are diarrhoea, metallic taste and
nausea. LMS may cause a temporary loss of hair in some people. Imuthiol is less toxic
than levamisole and has also shown radio and chemo protective and antifungal
properties.
53
Both these drugs have also been evaluated for their activity in the
treatment of rheumatic arthritis.
54,55
1.4.2.1.2 Linomide
Linomide 1.20 (N-methyl-N-phenyl-1,2-dihydro-4-hydroxyl-1-methyl-2-oxo-quinoline
-3-carboxamide) has been shown to be an immunomodulator.
N
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In clinical trials, it has been shown to have potential in the treatment of autoimmune
disease such as rheumatoid arthritis, systemic lupus erythematosis and multiple
sclerosis. Linomode is a quinoline derivative with pleiotropic immunomodulatory
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activity. It has been found to enhance natural killer (NK) cell number and activity after
autologous bone marrow transplant (ABMT) in patients with acute myeloid leukemia
(AML).
1.4.2.1.3 Isoprinosine
Isoprinosine (inosine pranobex (InPx)) 1.21 is a synthetic compound formed from the
p-acetamido benzoate salt of 3-(N-N-dimethylamino)-2-propanol and inosine in a 3:1
molar ratio. It increases natural killer (NK) cell activity, total T-cells, and T-helper
cells. Some of its effect may persist for months after completion of the treatment
period. It is used in therapy of HIV-1 and rhinoviruse infections
56,57
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1.4.2.1.4 Thalidomide
Thalidomide 1.22 is 2-(2,6-dioxo-3-piperidinyl)-isoindoline-1,3-dione available as two
stereo isomers. The (R)-stereoisomer has sedative and antinausea effects, while the (S)-
stereoisomer has teratogenic effect.
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Thalidomide affects variety of cytokines and inflammatory mediators including TNF-
a, ILi1b, IFN-J, IL-6, IL-10, IL-12 and COX-2 and angiogenesis factors. However, its
mechanism of action has not yet been elucidated. It is used in the treatment of
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Waldenstrom's macroglobulinemia (WM), as well as multiple myeloma,
myelodysplastic syndrome, myelofibrosis, chronic lymphocytic leukemia (CLL), and
B-cell lymphomas. Major side effects include neuropathy and teratogenicity
(phocomelia) when used as antiemetic or sedative in pregnant women.
1.4.2.1.5 loxoribine
Loxoribine (7-allyl-8-oxoguanosine) 1.23 is used as primary adjuvant for antibody
responses to a wide variety of antigen types in a variety of
species. It involves the augmentation of CTL-mediated, NK cell-mediated,
macrophage mediated, and LAK cell-mediated cytotoxicities.
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It is an inducer of cytokines. Main side effects noted resemble those of interferon and
are transient. It up-regulates humoral immune responses in immunodeficiency and acts
as a surrogate TH signal
1.4.2.1.6 Azidiridine derivatives
2-Cyanoaziridine-1-carboxamide 1.24 had been successfully used by Bicker against
PIE 2-3 sarcoma in Wister rats. Since it suffered from side effects, the original
structure was thus use as a start point to develop more promising drug candidates.
Eventually, azimexone 1.25 and ciamexone 1.26 were discovered to have anti-tumour
activity with relatively low toxicity.
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Azimexone acts through increasing serum levels, secretion of CSF and increasing
peripheral macrophages.
58
Whereas, ciamexone alters the balance between TH2 and
TH1, lymphocytes and is responsible for delayed hypersensitivity reaction in mice.
However, both these compounds gave disappointing results in clinical trials. Further
research on this lead molecule, let to the development of imexone 1.27 (scheme 1.2).
1.24 1.27
Scheme 1.2 Synthesis of imexone 1.27
Imexone acts by augmenting T-cell function without effecting NK cells at relatively
tolerated doses with only nausea and vomiting side effects. This compound has been
found active against wide range of cancers and also recently it has undergone clinical
trials in USA for the treatment of AIDS.
59
1.4.2.1.7 Bropirimine
Bropirimine 1.28 is a nucleic acid derivative having significant immunostimulatory
effects through induction of IFN-v, TNF-v and IL-2, B-lymphocytes. It also
stimulates IL-2 receptors, macrophages and NK cells. It is currently undergoing
clinical trials for the treatment of bladder cancer as a sole therapeutic agent and also in
combination with BCG vaccine.
60,61
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1.4.2.2 Natural immunostimulants
Among several bacterial derived agents Bacille-Calmette-Guerin (BCG) is most
extensively studied and approved worldwide in intravesical therapy of superficial
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bladder cancer. It is an attenuated live strain of Mycobacterium bovis. It stimulates the
release of TNF-D from macrophages. However, hypersensitivity, chills, fever and
immune complex disease are major side effects.
The Dipeptide Amastatin 1.29 and the tetrapeptide Bestatin 1.30 derived from
Streptomyces olivoreticuli and Streptomyces ME98-M3 respectively possesses a
diverse range of activities including anti-tumour and immunomodulatory activities.
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Bestatin also known as Ubenimex is an orally active non-toxic peptide and is believed
to activate NK cells and macrophages through binding to amino peptidase.
62,63
Another
non toxic tetrapeptide peptide Tuftsin 1.31 derived from the FC portion of the
immunoglobulin molecule is considered to enhance phagocytosis and the bactericidal
and tumourcidal activities of macrophages.
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It enhances IL-1 and TNF release. Aberrant behaviour of thymus, one of the important
organs of the immune system might be due to the disruption in its biochemical
integrity.
64
More recently, immunologists have expressed interest in thymic peptides
owing to their reduced toxicity. Currently, a few thymic peptides such as
thymopentin, thymosin v1, thymulin and thymic humoral factor are under study
although little is known about their roles in the endocrinology of the thymus.
54,55
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Thymopentin 1.32 is a pentapeptide of 32-36 residues of thymopoietin. It promotes T-
cell proliferation and interleukin production. It is licensed in Italy for the treatment of
cancer and immunodeficiency disorders. Currently, it is under clinical trials in the
USA for the HIV combination therapy with zidovudine (AZT).
54,55
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Various derivatives of thymopentin e.g. 1.33 and 1.34 have also been synthesized.
65
N
H
O
OH
O
N
H
N
O
O
OH
O
NH2
H2N
O
NH
NH2HN
H
N
O
OH
O
N
H
H
N
O
O
OH
O
H2N
O
NH
NH2HN
H-Arg-NMeLys-Asp(k)Val-Phe-OH H-Arg-Nle-Asp-Val(k)Val-OH
Thymopentin analogue Thymopentin analogue
1.33 1.34
Thymosin v1 is a 28 residue recombinant peptide that acts by enhancing the
production of IL-2 and displays IL-2 receptors in T-lymphocytes. It is also undergoing
clinical trials in the USA for the treatment of cancer and hepatitis. An octapeptide of
thymus thymic humoral factor 1.35 has shown increased T-cell responses in HIV
patients in clinical trials in Israel.
54,55
H-Leu-Glu-Asp-Gly-Pro-Lys-Phe-Leu-OH
Thymic humoral factor
1.35
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N-Acetyl muramyl dipeptide (MDP) 1.36 derivatives have been found to have
adjuvant activities.
66
Romuritide 1.37 has been widely accepted in the Japanese
Pharmaceutical market for the treatment of cancer patients undergoing chemotherapy
or radiotherapy. It recovers and maintains WBC’s and platelet counts by inducing
cytokines.
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Murabutide 1.38 and Temurtide 1.39 are improved MDPs with reduced side effects.
Among these temurtide has been successfully used as vaccine adjuvant in animal
studies against several antigens including influenza virus haemagglutinin.
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Similar to MDP, Polynucelotides can also be explored for their adjuvants activity.
Poly(I).poly(C) 1.40 and Poly(A).poly(U) 1.41 have been observed to have potential
for increasing antibody-forming cell numbers.
67
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1.4.2.3 Androgenic Steroids
Unlike immunosuppressants, androgenic steroids such as endogenous hormones
provide indispensable elements that improve the immune system by controlling the
production of some lymphokines.
67
Dehydroepiandrosterone (DHEA) 1.42 and
Dihydrotestosterone (DTH) 1.43 have been extensively evaluated for their
immunomodulatory roles.
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DHEA is produced from DHEA sulphate (DHEAS) through the action of a sulfatase
enzyme where as DTH is obtained from testosterone through the action of 5v-
reductase. DHEA has been found to improve T-cells function by accelerating the
secretions of IL-2 and IFN-J, whereas DTH influence T-cell function by decreasing
secretions of IL-4, IL-5 and IFN-J.68,69
1.4.2.4 Intravenous Immunoglobulins
Intravenous immuno-globulins (IVIGs) are semi-purified entities obtained from pooled
plasma from many donors containing variable IgA, normal IgGs (major subclasses)
and antibodies to common pathogens (antigens). IVIGs are mainly used as replacement
therapy in primary immune deficiency diseases.
1.4.2.5 Cytokines as Immunostimulants
Cytokines such as interferons (IFN), interleukins (IL) and colony stimulating factors
(CSF) have been observed as vital immune stimulating agents. IFN-D, IFN-E and IFN-
J modulate immune responses by interfering with viral replications. IFN-D in low dose
acts as immune stimulator and activates NK cells, macrophages and cytotoxic T-cells.
It is used in the prevention of infections in chronic granulomatous disease. Human
recombinant IFN-D (rhlFN-D) is employed in the treatment of hairy cell leukaemia,
AIDS related Kaposi’s sarcoma, human papillomavirus and hepatitis C infections. An
analogue of IFN-E (IFN-E-1b) has been shown to be capabile of reducing the number
or the severity of attacks in relapsing-remitting multiple sclerosis. Major side effects of
IFNs include fever, headache, mylagias and GI disturbances.
Interleukins (ILs) bind to IL-2 receptor in immune cells, induce proliferation and
differentiation of helper T-cells and cytotoxic T-cells. They have been found to elevate
serum IL-1, TNF-D, and IFN-J levels. Human recombinant IL-2 (rhIL-2) is used to
treat metastatic renal cancer. It is highly toxic and may lead to capillary leak syndrome
(oedema, reduce organ perfusion and hypotension), cardiac arrhythmias, myocardial
infraction and changes in mental status.
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Granulocyte-colony-stimulating factor (G-CSF) induces the maturation of neutrophils
and is used after chemotherapy to lower the incidence of infections in patients with
non-myeloid malignancies. Granulocyte-macrophage colony-stimulating factor (GM-
CSF) induces the development of neutrophils, eosinophils and macrophages and is
used in Hodgkin’s disease and acute lymphoblastic leukaemia. Side effects of G-CSF
include bone pain and splenomegaly whereas with short-term therapy whilst GM-CSF
leads to fluid accumulation.
1.4.3 Selective Tolerogens
15-Deoxyspergualine (DSG) derivative LF 15-0195
Selective tolerogens are used along with immunosuppressants especially in the
prevention of immune responses against viral vectors used in gene therapy.
DSG 1.44 a derivative of spergualine, decreases antibody production, inhibits
production of IL-6 and TNF-D, inhibits B-cell development and inhibits the growth of
native CD4+ T-cells after activation and production of IFN-J by TH1 lymphocytes.
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1.4.4 Antirheumatic Drugs as Immune Modulators
Some antirheumatic drugs especially slow acting ones (e.g. Sulfasalazine 1.45,
chloroquine 1.46, and gold compounds) are used as immune modulators. Sulfasalazine
in autoimmune conditions inhibits leukotriene synthesis thus lymphocyte function.
Chloroquine, is mainly an anti-malarial but also possesses anti-inflammatory and
immunomodulating potential. Sodium aurothiomalate 1.47 has been found to modify
cellular and humoral immune responses.
57
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Modulation of the immune system as an approach to treat autoimmune diseases has
been explored for the past 50 years. However, efficacy of this treatment has been
achieved in a limited number of patients. A major obstacle of immune therapy is the
toxicity related to the non-specific nature of immune activation. Therefore, continued
efforts are needed to improve the specificity of the immune responses. To this end it
has been recently shown that active components excreted by certain bacteria can
modulate the host’s immune system. This is quite logical since, in order to survive,
microbes must reproduce and spread to other host. While doing this, they learn and
adopt skills to override the host’s immune responses. Microbes usually subvert
immune responses by modulating the immune system. The development of strategies
for therapeutic intervention therefore, require an extensive understanding of how
microbes can escape the immune system.
1.4.5 Evasion of immune responses by microbes: can it be a better
strategy for immune modulation?70
Pathogens (invaders and parasites) begin the rapport with host species to sustain their
own chances for survival, proliferation, and subsequent dissemination. Their stable
interaction with the host helps them predominate among the host population and
ensures their lifelong persistence with minimal symptoms of disease. At this stage,
pathogens would have sufficient time for reproduction and spread to new hosts. The
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host immune system, however, mobilizes its molecular arsenal to thwart multiplication
and eliminate the infectious agent. Infectious organisms in response have evolved
many ways of evading the host immune system.
Pathogens can evade the innate immune system by circumventing phagocytosis. It
frustrates binding (as seen in capsules, M protein, and fibrin coats) to the components
of macrophages and neutrophils. To avoid destruction in the phagosome, some
pathogens inhibit fusion with the lysosome and drop in pH. Other pathogens avoid
complement-mediated lysis by blocking insertion of the membrane attack complex of
complement (MAC) into their cell walls.
Pathogens have also evolved strategies to avoid adaptative immunity. Some form
sheath of host proteins around their cell walls. Many pathogens employ antigenic
variation, in which multiple antigenic variants of a pathogen occur and immunity to
one variant is not protective against another, (examples: Influenza virus and HIV).
Both are RNA viruses whose error-prone RNA-copying enzymes result in
antigenically distinct mutants. Influenza undergoes small changes each year (antigenic
drift), and the changing serotypes require new vaccines. Occasionally two influenza
viruses from different species co-infect an animal, usually a pig or a fowl, and
exchange RNA; when this happens, large antigenic shifts occur which may result in
pandemics of influenza and may give rise to high mortality rate. The parasite
Trypanosome cruzii undergoes programmed antigen variation. As the host makes
antibodies to one surface antigen, it is quickly replaced by expression of a different
one.
Exogenous pathogens block antibody function by making surface molecules that bind
the IgG Fc regions to inhibit antibody effector functions. Endogenous pathogens
however, remain inside host cell, thereby avoiding antibodies and complements. Viruses
can remain latent in the host cell, do not replicate and therefore do not express and
present viral proteins on Class-I MHC. Other viruses avoid CTL, antigen processing
and presentation. Some of these microbial strategies for immune evasion are
summarised in Table 1.4.
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Table 1.4 Examples of Microbial Evasion of Immune Defenses
Pathogen
Streptococcus pneumoniae Capsule Avoids phagocytosis
Gram positive bacteria, some
Gram negative bacteria
Resist insertion of complement
MAC
Avoid complement-mediated lysis
Mycobacterium tuberculosis
Blocks lysosome fusion with
phagosome
Avoids antibody and complement
opsonization, macrophage killing
Listeria monocytogenes
Escapes phagosome into
cytoplasm
Avoids macrophage killing,
presentation on Class II MHC
Toxoplasma gondii
Escapes phagosome into own
cytoplasmic vesicle
Avoids macrophage killing,
presentation on both Class I and
Class II MHC
Treponema pallidum
Covers membrane with host
proteins
Avoids immune system recognition
Herpes viruses
Persist in host cells without
dividing (latency)
Avoid immune system recognition
Streptococcus pneumoniae
Influenza virus, HIV
Antigenic variation Avoids memory response
Herpes viruses
Infect cells with little Class I
MHC expression (CNS)
Avoid presentation on Class I MHC
Staphylococcus aureus
Cytomegalovirus
Herpes simplex virus
Expresses membrane Fc-binding
protein
Avoids IgG opsonization
Neisseria meningitidis
Neisseria gonorrhoeae
Haemophilus influenzae
Expresses IgA protease Avoids IgA neutralization
Herpes simplex virus
Expresses membrane
complement receptor
Blocks complement function
Vaccinia virus
Expresses complement control
protein on infected cell
Blocks complement-mediated lysis
of infected cell
Vaccinia virus
Expresses soluble cytokine
receptor
Blocks inflammation
Epstein Barr virus (EBV)
Inhibits host cell expression of
LFA-3, ICAM-1
Blocks adhesion of CTL to infected
cells
Herpes simplex virus
Cytomegalovirus
Inhibits host cells Class I
expression
Blocks CTL recognition
Herpes simplex virus Blocks TAP function Blocks CTL recognition
Epstein Barr virus Expresses homolog of IL-10
Inhibits TH1 response, IFN-J
production, cellular immunity
Staphylococcus aureus Secretes superantigens Suppresses immune response
Hepatitis B Virus
HIV
Peptides act as antagonists T-cell activation is blocked
Mycobacterium leprae Stimulates TH2 response Suppresses TH1 response
Measles virus
Suppresses T-and B-cell
immunity
Suppresses immune response to
many pathogens
Pseudomonas aeruginosa Secretes elastase that
inactivates C3a and C5a
Blocks inflammation
Not surprisingly, the immune evasion strategies are interrelated and important for
reasons outlined below.
&RQILGHQWLDO
- 45 -
First, it gives valuable information regarding the host-pathogen relationship i.e. how a
particular pathogen can subvert the immune system in order to survive and reproduce.
Second, the identification of microbial immunomodulatory proteins occasionally
precedes identification of its host counterpart. This offers opportunities to discover
new immunity-associated molecules and to further our understanding of the immune
response.
Lastly, the function and sites of activity of immunomodulatory proteins suggest
potential agents of and targets for immunotherapy, respectively.
Thus, more recently, a strategy for specific immune modulation has been explored
involving the use of selective microbial species. As shown in Table 1.4 the ability of
bacteria to evade or co-exist with the host’s immune system suggests that they can
alter the immune system in a manner that is beneficial to them. How bacteria
manipulate the host responses is of great interest. Lately it has been realised that one
way bacteria did modulate host immune system is by Quorum sensing, a mechanism
where immunomodulatory effect is dependant on bacterial population size. Among
Gram-negative bacteria, Pseudomonas aeruginosa inactivates complement cascades
C3a and C5a thus block inflammation. Pseudomonas aeruginosa, an opportunistic
hospital pathogen has the ability to cause cross infections right from harmless
colonisation to serious septicaemia. It also establishes chronic colonisation in patients
of chronic obstructive pulmonary disease (COPD) and chronic lung infections in cystic
fibrosis (CF). Whether Pseudomonas aeruginosa, in common with other
microorganism has immune modulation through quorum sensing is thus of high
interest to researchers in the field.
1.5 QUORUM SENSING AND IMMUNE MODULATION
1.5.1 Regulators of virulence factor producing genes
Bacteria have evolved multiple integrated sensory systems in order to facilitate
adaptation to environmental challenges at both the individual cell and population
levels. The perception and processing of chemical information form a pivotal
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Fig 1.7 Mechanism of quorum sensing
component of the regulatory mechanisms necessary for such population-dependent
adaptive behaviour. Many bacteria employ self-generated small diffusible signal
molecules (autoinducers) to control gene expression as a function of cell population
density. In this process, termed “quorum-sensing” (QS), the concentration of a signal
molecule which accumulates in the extracellular environment reflects the cell number.
The perception of a threshold concentration of a signal molecule determines when the
population is ‘quorate’ and thus ready to make a collective behavioural adaptation.
71-74
1.5.2 The quorum-sensing paradigm
In Gram negative bacteria, the autoinducers are usually synthesised by enzymes
belonging to the LuxI family of AHL synthases. Once synthesised, AHLs accumulate
extracellularly and diffuse into neighbouring bacterial cells where they usually interact
with members of the LuxR family of transcriptional regulators.
73-75
AHLs bind to, and
activate LuxR homologous proteins and the resulting LuxR protein/AHL complex
activates or represses the relevant target structural gene(s).
73,74,76
LuxR proteins bind to
a region within the promoter/operator of the target genes.
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1.5.3 The diversity of signal molecules
To date a large number of Gram-negative bacteria have luxI luxR-like QS systems
which generate a range of AHLs which control a variety of processes, many of which
are associated with virulence. Many Gram-negative bacteria have been found to utilize
N-acylhomoserine lactones (AHLs) as signalling molecules
77
1.48-1.55 (Table 1.5) in
which the homoserine lactone (HSL) ring is a common structural unit with a side chain
which varies in length and can be 3-oxo or 3-hydroxy substituted, saturated or
unsaturated.
Table 1.5 AHL signalling molecules produced by Gram-negative bacteria
Microorganisms QS system AHL Produced Abbreviations
Serratia liquefaciens,
Pseudomonas
aeruginosa
swrI, sweR
rhlI/R N
H
O
O
O
H
C4-HSL
(1.48)
Vibrio harveyi LuxM
N
H
O
O
O
H
OH 3(OH), C4-HSL
(1.49)
Serratia liquefaciens,
Chromobacterium
violaceum
Pseudomonas
aureofaciens
SurI
CviI
PhzI N
H
O
O
O
H
C6-HSL
(1.50)
Vibrio fischeri
Erwinia stevartii
Erwinia caratovora
Yersinia enterocolitica
LuxI
EsaI
ExpI/carI
YenI
N
H
O
O
O
H
O
3O, C6-HSL
(1.51)
Vibrio fischeri AinS N
H
O
O
O
H
C8-HSL
(1.52)
Aerobacterium
tumefaciens
TarI
N
H
O
O
O
H
O 3O, C8-HSL
(1.53)
Pseudomonas
aeruginosa
LasI N
H
O
O
O
H
O 3O, C12-HSL
(1.54)
Rhodobacter
sphaeroides
CerI N
H
O
O
O
H
OH 3(OH)-'7Z-C14-HSL
(1.55)
Among the vast majority of Gram-negative bacteria have been studied thus far,
Pseudomonas aeruginosa is perhaps the best understood in terms of quorum sensing
versus pathogenisity mechanisms.
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Gram positive bacteria such as B. subtilis and S. aureus make use of oligopeptide
(1.56) mediated QS to sense their environment
78
while the boron containing signaling
molecule, AI-2 has been identified as a second class of signal molecule which is
involved in quorum sensing in V. harveyi (1.57).
79,80
1.56
S. aureus (AIP-I)
1.5.4 Quorum sensing in Pseudomonas aeruginosa
Pseudomonas aeruginosa (family Pseudomonadaceae) is an opportunistic human
pathogen capable of causing a variety of infections ranging from harmless colonisation
to life threatening septicaemia. It is a particular problem in patients suffering from
chronic obstructive pulmonary disease (COPD) and is the main cause of morbidity
and mortality in patients with cystic fibrosis (CF).
81,82
Cystic fibrosis is a genetic
disorder affecting the gene which codes for the cystic fibrosis transmembrane
conductance regulator (CFTR). Patients with abnormalities in CFTR have decreased
salt and fluid secretions, resulting in abnormally viscous mucous which eventually
makes patients susceptible to lung infections.
83
Pseudomonas aeruginosa is also a
common cause of nosocomial infections including ventilator associated pneumonia,
84
bloodstream infections
85
and infections in burn-wound patients.
86
Asp
Phe
Ile
NHS
H-Tyr-Ser-Thr-HN
O
S Me
O
peptide thiolactone
1.57
AI-2 Vibrio harveyi (LuxS)
&RQILGHQWLDO
- 49 -
The potential of Pseudomonas aeruginosa to cause these infections is due to its ability
to synthesize an armoury of virulence factors
87
such as (i) cell-associated factors (e.g.
flagella and pili) that adhere to bacteria surfaces, (ii) extra-cellular virulence factors
(proteases e.g. alkaline protease and elastase)
88,89
that interfere with the host defense
systems and (iii) some secreted exotoxins (toxin A)
89
that cause local tissue damage.
Pyocyanin, a pigment has been observed to disrupt normal Ca
2+
regulated homeostasis
in human airway epithelial cells thus resulted in abnormal mucus secretions and ciliary
beats.
90
Pyocyanin has also been shown to affect IL-8 expression in lung epithelia.
91
.
The expression of many Pseudomonas aeruginosa exoproducts is dependent on the
cell population density and is regulated by AHL mediated quorum signalling.
92-94
Pseudomonas aeruginosa has two quorum sensing circuits rhlI/R and lasI/R.
95
The transcriptional activator RhlR and AHL synthase RhlI direct N-butyryl-L-
homoserine lactone (C4-HSL) 1.48 synthesis.
96,97
A RhlR-C4-HSL complex regulates
the expression of rhlAB (required for the production of rhamnolipid), lasB, aprA, RpoS
(stationary phase sigma factor) and for secondary metabolites (pyocyanin and cyanide)
production.
77,92,97-101
The second QS system in Pseudomonas aeruginosa comprises lasI and lasR. lasI
directs the sythesis of N-(3-oxododecanoyl)-L-homoserine lactone (3O, C12-HSL)
1.54 which, when complexed with LasR, co-ordinates the expression of a number of
virulence genes such as elastase lasA,
102
lasB,
88,103
and alkaline protease aprA as well
as exotoxin toxA
89,92-94,104
LasR-3O, C12-HSL also regulates the transcription of lasI
105
and rsaL,
95
the products of which regulate Pseudomonas aeruginosa negatively
inhibiting lasI gene expression.
106
N
H
O
O
O
H
O
N
H
O
O
O
H
1.48 1.54
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Pseudomonas aeruginosa also produces other acyl homoserine lactones in small
quantities.
107,108
These are N-hexanoyl-L-homoserine lactone (C6-HSL) 1.50, N-(3-
oxohexanoyl)-L-homoserine lactone (3O, C6-HSL) 1.51 and N-(3-oxooctanoyl)-L-
homoserine lactone (3O, C8-HSL) 1.53. The exact role of these signalling molecules is
unknown however.
109
N
H
O
O
O
H
O
N
H
O
O
O
H
O
N
H
O
O
O
H
1.50 1.51 1.53
Furthermore, a class of diketopiperazines (DKP) 1.58 and 1.59 have been identified
from Pseudomonas aeruginosa supernatants that were found to antagonize 3O, C6-
HSL based induction of bioluminescence in a LuxR based biosensor and also C4-HSL
based swarming motility in Serratia liquefaciens.
110
Similar DKP have been isolated
from an antarctic sponge associated strain of Pseudomonas aeruginosa and have
shown to inhibit the growth of many Gram-positive bacteria.
111
1.58 1.59
In addition to various AHLs another autoinducer belonging to 4-quinolone family,
namely 2-n-heptyl-3-hydroxy-4(1H)-quinolone 1.60, termed PQS (Pseudomonas
Quorum Sensing) was also discovered in Pseudomonas aeruginosa.
112,113
N
H
OH
O
1.60
Cyclo('-Ala-L-Val) Cyclo(L-Pro-L-Tyr)
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The las system has been found to regulate the synthesis, and the rhl system bioactivity
of PQS molecule. The transcriptional activator lasR regulates PQS synthesis that in
turn, induces expression of lasB (this codes, rhl and rhlR) and rhlI. This suggests that
there exists a regulatory link between PQS, las and rhl.
112,114
It is now clear that PQS
does not participate in sensing cell density since it is produced substantially in the late
stationary phase of growth in the absence of lasR. It is involved in stimulation of LasR
independent activation of rhl system.
115
In spite of similarities between LasR and RhlR, both respond to structurally different
AHLs for their activation. This in turn indicates that, specific recognition sequences
are a must for targeted genes when expressing quorum sensing systems.
77
Despite there
being high specificity of these systems for their regulatory molecules and gene targets,
there exists a link, in that the las system positively regulates expression of both rhlR
and rhlI.
114
Also 3O, C12-HSL competes with C4-HSL for RhlR binding and given
that this situation can arise in Pseudomonas aeruginosa, 3O, C12-HSL is therefore an
ideal target to examine the antagonistic effects of newly synthesised AHL analogues.
This clarifies that, in Pseudomonas aeruginosa quorum sensing is arranged in
hierarchical manner with las being dominant regulator and exerts transcriptional
control over both rhlR and rhlI (Fig 1.8).
95,116
Fig 1.8 Quorum sensing in Pseudomonas aeruginosa
(adepted from: http://www.avalon.net/~ajp/quorumsensing.jpg)
&RQILGHQWLDO
- 52 -
Recently the biosynthesis of PQS, a 4-hydroxy-2-alkylquinolines (HAQ) family of
secondary metabolite from Pseudomonas species has been carried out.
117-121
The
biosynthesis of HAQ requires the pqsABCDE genes and is regulated by MvfR. The 4-
hydroxy- 2-heptyl-quinoline (HHQ) 1.61, which is congener of HAQ and precursor of
PQS is converted to PQS through PqsH. However, LasR regulates PqsH. PQS induces
the expression of lasB elastase and rhlI.
97,116
N
OH
1.61
In Pseudomonas aeruginosa quorum sensing system, other regulators have also been
identified. Positive regulator such as Vfr;
122
which regulates the expression of lasR and
GacA
123,124
regulate the expression of both lasR, rhlR as well as rhlI. On the other hand
negative regulator such as QscR,
125
a homolog of LasR and RhlR act as repressors for
the expression of lasI and Rsal.
106
It is also known to repress lasI, probably at lower
cell densities.
QS in Pseudomonas aeruginosa represents a very complex network of regulatory
systems. A summary of the QS associated virulence genes and transcription factors
employed by Pseudomonas aeruginosa is shown in Table 1.5.
Table 1.5 Quorum sensing regulation in Pseudomonas aeruginosa
Signaling molecule R
protein
I
protein
Genes
regulated
Virulence
Factors
N
H
O
O
O
H
O
1.54
LasR LasI
lasI, lasR, rhlR,
lasB, lasA,
toxA, aprA,
xcpR, xcpP
Elastase,
Exotoxin A,
Alkaline protease
N
H
O
O
O
H
1.48
RhlR RhlI
rhlI, rhlAB,
lasB, lasA,aprA
Elastase,
Alkaline protease,
Pyocyanin
N
H
OH
O
1.60
NA PqsH rhlI,
lasB
Elastase
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Interestingly, the Pseudomonas aeruginosa quorum-sensing system not only
coordinates virulence gene expression through cell-to-cell intercommunication but also
modulates the host immune response.
1.5.5 Pseudomonas aeruginosa and immune modulation
Quorum sensing signals support bacteria to minimise host immune defence by
delaying tissue damaging virulence factor synthesis until sufficient bacteria are
accumulated over time and alert them to overwhelm host defence mechanisms in
establishing infections.
126
It is clear that upon infection Pseudomonas aeruginosa coordinates virulence gene
expression through cell-to-cell inter-communication. There is also a substantial body
of evidence which suggests that Pseudomonas aeruginosa can modulate the host
immune response to an infection.
92,127,128
Pseudomonas aeruginosa in combination
with fixed immunoglobulins have been found to eliminate in vitro immune suppression
triggered by hydrocortisone
129
whilst 3O, C12-HSL [OdDHL] can modulate the
inflammatory response by inducing the production of cyclooxygenase-2 (COX-2) and
prostaglandin-E2 in human lung fibroblasts
127,130
and has also been shown to down
regulate both human and murine lymphocyte proliferation as well as LPS-induced
secretion of TNF-D and interleukin-12. 3O, C12-HSL [OdDHL] also promotes
immunoglobulinG-1 (IgG-1) production in antigen challenged splenocyte cultures and
can induced apoptosis of leukocytes.
92,128
It is interesting to note that 3O, C12-HSL has
shown its potential in stimulating gamma interferon (IFN-J) in T-cells as well as
accelerating apoptosis in macrophages and neutrophils.
127
C4-HSL was not active in any of the above-mentioned systems, although it has been
found be effective with protein tyrosine kinase (PTK) albeit at very high doses.
However, recently more C4-HSL than 3O, C12-HSL have been isolated from the
sputum of CF patients, suggesting its importance in biofilm formation but it has lacked
immune modulation in vitro.
126
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PQS has been isolated in substantial amounts from the lungs of CF patients infected
with Pseudomonas aeruginosa. This indirectly showed that, the in vitro presence of
PQS might have helped Pseudomonas aeruginosa to develop to a chronic state.
115,131
PQS acts as an immune modulator by a distinctly different mechanism to that of 3O,
C12-HSL. Both PQS and 3O, C12-HSL prevent leukocyte proliferation in the
production of interleukin-2, and 3O, C12-HSL is also capable of down regulating TNF
secretion although this is not the case for PQS.
128
This thus suggested the presence of
two separate targets for PQS and 3O, C12-HSL binding for the same response to be
initiated.
132
The ability of these bacterial pheromones to affect the immune responses of eukaryotic
cells in addition to their role in effecting prokaryotic genes expression, lead to their
investigation as immune modulators. Telford et al, revealed that one of the lead
structures 3O, C12-HSL inhibited lymphocyte proliferation in a ConA mitogen
stimulated murine spleen cell proliferation assay (Appendix-I). This suggested that
3O, C12-HSL exhibits anti-proliferative activity by modulating T-lymphocyte
responses and not by depressing immune responses.
128
These results by Telford et al
led Chhabra et al. to consider 3O, C12-HSL as the lead structure for chemical
modifications to generate synthetic analogues as novel immune modulators. However,
structural modifications made to 3O, C12-HSL.
131
were limited in their activity because
some analogues of 3O, C12-HSL have been found to possess comparable prokaryotic
autoinduction in addition to eukaryotic immune modulation. Additionally, some
analogues have not been evaluated in vitro because they showed no or poor solubility
in a range of solvents and several analogues which were synthesized by replacing the
L-HSL ring by other rings could not confirm that L-HSL ring is essential for immune
modulation.
131
1.6 PROJECT AIMS
The 3O, C12-HSL, of Pseudomonas aeruginosa has sophisticated dual mechanisms in
that it co-operates with bacterial cell-to-cell communication thus inducing a virulence
gene expression. It also mediates the immune modulation in eukaryotes.
92
As
mentioned previously, various analogues of 3O, C12-HSL synthesized to date also
possess comparable prokaryotic autoinduction in addition to eukaryotic immune
&RQILGHQWLDO
- 55 -
modulation.
131
In this research we sought to tackle the above issues to search for new
immune modulating drug candidates devoid of any prokaryotic autoinduction.
Therefore, the principal aim of the research programme was to synthesise and assay
analogues of 3O, C12-HSL that are immune modulatory but non-inducing agents.
This could be achieved by further alterations in 3O, C12-HSL structure through
replacement of, C
1
or C
3
carbonyl functionality by other functional group; C
4
carbon
with hetero atom (nitrogen with or without substitution or oxygen); one or both the C
2
hydrogen by electron withdrawing fluorine and replacement of hetero ring with other
rings as well as insertion of hetero atom(s) in the side chain A, as shown in Fig 1.7.
These analogues will be taken forward to evaluate for their immunological and
microbiological (quorum sensing agonistic/antagonistic) assays. Newly developed
analogues might show promising immune modulation even better than 3O, C12-HSL as
shown in Fig 1.8.
Fig 1.8 Immune modulations by quorum sensing molecules
TH: Helper T-cells type1; M: Monocyte/macrophage
(Adepted from Pritchard et’al )
Fig 1.7Structure of 3O, C12-HSL showing points
where changes can be made.
N
H
O
O
OO
123
4
5
HH H
Insertion of
Hetero atom(s)
A-side chain
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2.0 SEARCH FOR IMMUNE-MODULATORY BUT NON-INDUCING
AGENTS: Design and synthesis of analogues of the Pseudomonas
aeruginosa quorum-sensing molecule N-(3-oxododecanoyl)-
L-homoserine lactone
As already discussed in the previous chapter, the opportunistic pathogen Pseudomonas
aeruginosa can actively monitor the host immune system through quorum sensing
(QS). When a sufficient bacterial cell density is achieved to overwhelm host defense,
the harmony within individual processes such as virulence factor release, biofilm
formation and antimicrobial resistance by quorum sensing is considered to promote
bacterial evasion to host immune responses thereby upregulating virulence factors.
77
Moreover, it is now understood that the immune system has evolved ways of sensing
viral or bacterial products e.g. lipopolysaccharides. Among these toll-like receptors
which activate antigen presenting cells, are perhaps the best studied ones.
133
A recent study by Wu et al. has indicated that the opportunistic pathogen Pseudomonas
aeruginosa elicits production of virulence factor in response to IFN-J and thus actively
monitors the host immune status.
134
The interaction between OprF, an outer membrane
protein of Pseudomonas aeruginosa and host cytokine IFN-J was found to upregulate
production of virulence factors by OprF specifically binding to the cytokine IFN-J.
This exciting new element of bacteria-host interactions exemplifies that Pseudomonas
aeruginosa QS system, both senses and modulates the host immune state.
135
Wu et al., while monitoring expression of the rhl-regulated virulence factors, type-I
Pseudomonas aeruginosa lectin (lecA) and pyocyanin, observed that exogenous IFN-J
substantially enhanced upregulation of lecA. This effect was revoked in mutations of
rhlR or rhlI strains of Pseudomonas aeruginosa PAO1. This suggests the importance
of rhl QS system in mediating the bacterial response to exogenous IFN-J. An extended
examination showed that the major outer-membrane protein OprF specifically binds to
IFN-J and that this activates the rhl QS system in an unknown manner.134 Moreover,
how does the las system transduce the signal(s) responsible for IFN-J enhancement of
the rhl system is still an important unresolved question. Thus the observed activation
of the rhl system by exogenous cytokines that is caused by stimulation of the las
system or by another regulatory pathway (or pathways) remains to be established.
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As already discussed above that the immunomodulatory effects observed with
autoinducer molecules 3O, C12-HSL and C4-HSL suggest that Pseudomonas
aeruginosa not only actively senses but also tailors the host immune response.
134,136
3O, C12-HSL stimulates various host signaling pathways to inhibit or activate immune
cell responses, whereas C4-HSL does not
127,131,136
Therefore, a cyclic network as shown in Fig 2.1 can be proposed, from Wu et al.
research data to exist between the Pseudomonas aeruginosa QS system and T-cells.
The las regulon synthesizes the 3O, C12-HSL (green ovals) which is actively
transported outside of the cellular membrane by the MexAB-OprM efflux pump.
77
The 3O, C12-HSL then stimulates T-cells and produces IFN-J (pink circles).136 IFN-J
then binds to OprF and this interaction then transduces a signal that might upregulate
the rhl QS system by (a) activation of the PQS system; (b) upregulation of the las
system through unknown regulator(s); or (c) activation through a currently unknown
pathway. Two or more pathways may contribute to mediate the observed effect on the
rhl system. Positive regulation is shown by plus symbol (+) and red arrows.
Fig 2.1Current model of QS and proposed mechanisms of
IFN-J mediated QS activation.
Adepted from: Wagner et al., Trends in Microbiology 2006, 14, 55-58.
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2.1 The diverse immunological bioactivity of 3O, C12-HSL
2.1.1 Effect of 3O, C12-HSL on TH1-TH2 balance
In the beginning of research in this field, the long chain AHL, 3O, C12-HSL but not C4-
HSL, was shown to modulate immune system. Here 3O, C12-HSL showed suppression
of IL-12 and TNF-D secretion by bacterial lipopolysaccharide (LPS)-stimulated
macrophages, and also inhibited T-cell proliferation. In contrast, in vitro immune
evaluation in murine and human leukocytes showed that 3O, C12-HSL at high
concentrations (>7u10-5 M) inhibits antibody production by keyhole limpet
hemocyanin-stimulated spleen cells; but at lower concentrations (<7 u10-5 M), it
stimulates antibody production, apparently by increasing the proportion of the
immunoglobulin G1 (IgG1) isotype. It also promotes IgE production by IL-4-
stimulated human peripheral blood mononuclear cells. These data suggest that 3O, C12-
HSL may influence the TH1–TH2 balance in the infected host in a dose dependant
manner.
128
2.1.2 Effect of 3O, C12-HSL on insulitis and diabetes
Demolition of ȕ-cell in the islets of Langerhans leads to loss of insulin production by
the pancreas and symptoms of hyperglycaemia, polyuria, polydipsia and weight loss.
137
This ȕ-cell destruction is preceded insulitis and infiltration of mononuclear cells is
characterized by a TH1-type CD4 T-cell response.
138
The work was therefore taken
forward to evaluate the efficacy of 3O, C12-HSL in vivo for the alleviation of insulitis
and diabetes in non-obese diabetic mice (NOD). In this, groups of 20 mice were
administered with 3O, C12-HSL intraperitoneally (i.p.) at a dose of 30 milligram per
kilogram (mg/kg) from weeks 4-8 of the lifespan. This treatment with 3O, C12-HSL
showed significant reduction in insulitis and also inhibited the infiltration of
mononuclear cells into pancreatic islets, thus resulted in a complete and statistically
significant reversal of the incidence of cumulative diabetes in the NOD mouse. Solvent
controls did not show any protective effect in this model of diabetes.
139
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2.1.3 Effect of 3O, C12-HSL on inflammatory chemokines and cytokines
The immunological effects of 3O, C12-HSL have been further explored by other
groups, who showed the induction of dermal inflammation in vivo by autoinducer. To
determine how 3O, C12-HSL did induce inflammation in the skin of mice, the research
was carried out further in detail to evaluate effect of 3O, C12-HSL on the individual
components of the inflammatory process such as chemokines, cytokines, etc. Induction
of chemokines and cytokines was determined from RNA extracted from skin samples
of mice injected with 3O, C12-HSL. A rise of five-to-six fold was found with the
chemokines macrophage inflammatory protein-1E (MIP-1E), MIP-2, and monocyte
chemotactic protein-1 (MCP-1). Similarly for the chemokines inducible protein-10
(IP-10) and T-cell activation gene-3 (TCA-3) as well as for proinflammatory cytokines
IL-1D and IL-6, a three-to-four fold induction in the mRNA levels was found when
stimulated with 3O, C12-HSL in vivo. Altogether it suggests potency of 3O, C12-HSL
as an inducer of both inflammatory cytokine and chemokine genes. Among these,
chemokines are known to encourage the migration of both activated and naive T-
cells.
127
This known fact then motivated Smith et al. further to determine what effects,
if any, 3O, C12-HSL would have on these cells. Although not substantial, but
significant induction in the production of the inflammatory cytokine IFN-J was
observed when naive T-cells previously activated with antigen and antigen-presenting
cells (APCs) were cultured with 3O, C12-HSL. The IFN-J levels were analogous to
those induced by the cytokine IL-12, a potent stimulator of IFN-J production in T-
cells. It is noteworthy to mention that 3O, C12-HSL did not stimulate T-cells to
produce IL-4, a cytokine generated by TH2 cells. These data suggest that 3O, C12-HSL
potentially activates T-cells through induction of the inflammatory TH1 phenotype. Not
only as an inducer of inflammatory chemokines and cytokines, but 3O, C12-HSL has
also induced additional inflammatory mediators in vivo such as Nuclear Factor-kappa
B (NF-NB), Cox and prostaglandins.130
The chemokines MIP-2, MIP-1E, IP-10, and MCP-1, induced by 3O, C12-HSL, contain
in their promoter regions specific binding sites for NF-NB.140-143 3O, C12-HSL induced
NF-NB was found to regulate the production of the chemokine IL-8. This enabled
Smith et al. to hypothesize that the inflammation stimulated by 3O, C12-HSL is
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mediated through the induction of NF-NB. This hypothesis was supported by model
where mouse keratinocytes were purified and stained with an anti-NF-NB antibody to
visualize the localization of NF-NB in the cell. Cells stimulated with 3O, C12-HSL
showed translocation of NF-NB into the nucleus, where it could then potentially induce
the transcription of multiple genes. Whereas, in cells without stimulation, NF-NB
remain sequestered in an inactive form.
130
2.1.4 Effect of 3O, C12-HSL on Cox enzymes
Cox enzymes available in two isofoms, Cox-1 and Cox-2 are essential in biosynthesis
of prostaglandins (PG) from arachidonic acid. Prostaglandins are involved in both
normal and pathophysiological processes, such as inflammation, edema, platelet
aggregation, fever, and hyperalgesia. Cox-1 favors normal physiological functions
whereas, inflammatory stimulation is thought to induce Cox-2. Moreover, Cox-2 is
identified as an immediate-early gene product due to the rapid induction of mRNA
after stimulation.
94
The skin samples from normal mice (injected with phosphate-
buffered saline (PBS) articulated no Cox-2 mRNA but constitutively expressed Cox-1
mRNA. In contrast, high levels of both Cox-1 and Cox-2 mRNAs were observed in
samples from mice treated with 3O, C12-HSL. Similarly protein extracts from mice
skin injected with 3O, C12-HSL, expressed a significant induction in Cox-2 protein
highlight that Cox-2 is localized to the cells of inflammatory infiltrate as well as
isolated cells, such as fibroblasts, lower in the dermis. Moreover, it demonstrates that
3O, C12-HSL is a potent inducer of Cox-2 expression and not of Cox-1 in vivo.
144
2.1.5 Effect of 3O, C12-HSL on Prostaglandin E2
Prostaglandin E2 (PGE2) is a potent molecule that influences multiple functions in the
body. Its production thus may have profound effects on the pathogenesis of
Pseudomonas aeruginosa because it is anti-inflammatory in the lung and inhibits the
release of mediators from mast cells as well as migration of eosinophils and induces
bronchodilation in asthmatic patients.
145
Moreover, it has been demonstrated that PGE2
is induced by Pseudomonas aeruginosa in mouse pneumonia and thermal injury
models.
146-148
Therefore, it was of interest to see if Pseudomonas aeruginosa quorum
sensing molecule 3O, C12-HSL has any effect on PGE2 production in human lung
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fibroblasts. A novel finding by Smith et al. revealed that the expression of membrane-
associated prostaglandin E synthase (mPGES) in human lung fibroblasts was increased
with 3O, C12-HSL stimulation in sequential manner with Cox-2. This sequential
regulation of these Cox-2 and mPGES enzymes is most likely a method of controlling
the levels of PGE2 production. The sequential induction of both Cox-2 and mPGES
significantly increased the production of PGE2.
144
However, Cox-2 induction was
quicker and short-lived than that of mPGES. Similar sequential expression of Cox-2
and mPGES was induced by stimulation of orbital fibroblasts with IL-1E.149 It was also
demonstrated that 3O, C12-HSL stimulation did not induce cytosolic PGES (cPGES)
and Cox-1. This supports the previous finding that cPGES is functionally associated to
Cox-1 while mPGES is bonded with Cox-2.
150,151
This indicated that 3O, C12-HSL
predominately induces Cox-2 and mPGES for the induction of PGE2.
2.1.6 Effect of 3O, C12-HSL on biochemical signaling events of innate immunity
Because the airways are the main point of entry of Pseudomonas aeruginosa into the
human body, a diverse range of cells including alveolar macrophages, lung fibroblasts,
and bronchial epithelial cells is therefore most likely to be exposed to this pathogen
and eventually to 3O, C12-HSL. Very recently, Kravchenko
152
et al., have
demonstrated that 3O, C12-HSL induce the phosphorylation of mitogen-activated
protein kinase (MAPK) p38 and eukaryotic translation initiation factor 2D (eIF2D) in
these diverse cell types. This phosphorylation event is one of the important innate
immune responses observed when immune cells encounter the pathogen-associated
molecular patterns (PAMPs).
153
Moreover, they have clearly demonstrated that 3O,
C12-HSL mediated signaling events are independent on MyD88, TRIF, TLR2, TLR4,
Nod1, and Nod2, key molecules of pattern recognition receptors (PRRs).
133,153-155
These observations suggested that 3O, C12-HSL might represent a new class of PAMP
that signals through pathways different from those occupied by TLR and Nod1/Nod2
proteins.
152
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2.1.7 Contradictory effects of 3O, C12-HSL
It is noteworthy that in contrast to the findings of Telford et al., findings of Smith et
al., led later authors to postulate that 3O, C12-HSL was in fact encouraging a TH1
environment. However, one cannot deny the effects observed by Smith et al., though
these were at high dose (100 PM) of 3O, C12-HSL than those of Telford et al., which
were at low dose (10 PM).144,156,157 Very recently Prichard et al., found that the doses
used by Smith et al., have in fact been shown to cause programmed cell death
(apoptosis) in eukaryotic cells. This perhaps raises question related to the physiological
relevance of the high doses of 3O, C12-HSL.
158
Moreover, an independent research
conducted by Tateda et al., confirmed the pro-apoptotic effect of high-dose
exposure.
127
Until now, several reports although controversial, have suggested that 3O, C12-HSL
has immune modulatory effect and promoted either humoral (TH2-mediated) or
inflammatory (TH1-mediated) responses. Ritchie et al., have tried to investigate this
phenomenon in detail in order to resolve confliction of previous reports. They studied
a series of experiments using in vivo and in vitro animal models; TH1 biased C57BL/6,
TH2 biased BALB/c and T-cell receptor (TCR) transgenic. Ritchie et al., were the first
to demonstrate a direct effect of 3O, C12-HSL on in vivo antigen-specific immune
response i.e. the production of antibody to the protein antigen OVA (ovalbumin). In
vivo administration of BALB/c mice with 3O, C12-HSL at an equivalent dose of 0.3
mg/kg was found to raise the TH2-associated antibodies, OVA-specific
(immunoglobulinG1) IgG1, while having no significant effect on the levels of TH1-
associated antibodies, OVA-specific IgG2a. The 3O, C12-HSL was also found to
inhibit in vitro cytokines production i.e. inhibition of both IFN-J and IL-4 in
splenocytes of C57BL/6 and BALB/c mice stimulated with ConA and also in TCR
transgenic splenocytes, where IFN-J being more inhibited than IL-4. Interestingly, in
the case of antigen-specific immune responses, in vivo administration of 3O, C12-HSL
in TH1-biased C57BL/6 mice favored the expression of the TH1 cytokine IFN-J over
the TH2 cytokine IL-4, thus temporarily accentuated the TH1 response. Whereas,
mitogen and antigen induced responses in TH2-biased BALB/c mice favored
enhancement in level of TH2 cytokine IL-4 over IFN-J, thus accentuated TH2 response.
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In summary, unlike earlier findings of Telford et al., this effect proposed that action of
3O, C12-HSL on T-cell cytokine production is likely to be a relatively nonspecific, not
promoting either TH1 or TH2 responses but is dependant on the model being used.
159
Further research by Ritchie et al., selected a well-described TCR-transgenic mouse
model to explore the effects of 3O, C12-HSL in a defined in vitro antigen-specific T-
cell response.
160
In this model the transgenic TCR expressed on the majority of CD4 T-
cells recognizes a defined peptide antigen from moth or pigeon cytochrome-c.
161
Using
this model, Ritchie et al., have demonstrated that the effects of 3O, C12-HSL on CD4
+
T-cell was to inhibit the differentiation of both TH1 and TH2 cells, that 3O, C12-HSL
must be present within the first 2 h after antigen or mitogen stimulation. In addition, in
contrast to Telford et al., and Smith et al., they have showed that the cytokine
production was not due to toxicity or death of T-cells. Similarly its site of action was
found likely to be cytoplasmic and did not appear to depend on its insertion into the
cell membrane as explained by Chhabra et al.
131
In summary, recent research has now established that quorum sensing signal molecule
(QSSM) hierarchical cascades is biologically linked to the presence of chemically
diverse and differentially active immune modulating molecules in Pseudomonas
aeruginosa.
162
These findings have played a pivotal role in understanding of bacterial
pathogenesis, and may be useful in the development of better future tactics for disease
management. For example, QSSM inhibitors and conventional antibiotics combination
have been recently recommended.
163,164
In addition, novel therapeutics for a multitude
of immunological diseases through a potentially valuable natural source of chemical
templates has been identified. For example, 3O, C12-HSL has been found to act not
only as a eukaryotic immune modulator but also a prokaryotic autoinducer.
165
Recently, Kravchenko et al., have classified this 3O, C12-HSL as separate type of
PAMP which modulates immune system via mechanism distinct from those by TLR
and Nod1/Nod2 proteins.
152
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2.2 Biological targets for 3O C12-HSL
Since the immune modulatory capabilities of 3O, C12-HSL have been discovered on
various cellular patterns of host immune system, its precise binding target in
mammalian cells has remained to be identified. Smith et al. have observed that 3O,
C12-HSL enhances activation of NF-NB130 and COX-2144 in respiratory epithelial cells.
Ritchie et al., have further narrowed down the possible modes of action in T-cells by
strongly suggesting modulation of some aspect of the TCR-dependent or costimulatory
signal transduction pathways by 3O, C12-HSL. However, researchers were unable to
identify where in the pathway 3O, C12-HSL was bound to lead this activation.
Hooi et al., on the other hand proved that 3O, C12-HSL in eukaryotes mediate
fluctuations in immunological behaviours by targeting specific receptor(s) different
from another class of QSSM namely PQS targets. 3O, C12-HSL and PQS exhibited
aberrant effects on the release of IL-2. Administration of 3O, C12-HSL has inhibited
cell proliferation and IL-2 release in previously activated human T-cells by the T-cell
receptor and CD28, whereas PQS administration has inhibited cell proliferation
without disturbing IL-2 release. In addition, as mentioned by Tateda et al., in human
monocytes, 3O, C12-HSL has found to inhibit release of TNF-D in the presence of
Escherichia coli LPS, whereas PQS unable to inhibit TNF-D.132,166
As discussed by Kravchenko et al., the effects of 3O, C12-HSL imitate the effects of
adaptor proteins, MyD88 and TIR-domain-containing protein inducing INF-ȕ (TRIF).
Whether 3O, C12-HSL requires MyD88 or TRIF for phosphorylation of p38 and eIF2D
as well as induction of cleavage of poly(ADP-ribose) polymerase (PARP) was of
interest. Effects in BMDM of control mice and mice with genetic defects in MyD88 or
TRIF functions were compared. Biochemical analysis of BMDM from the adaptor
protein-deficient mice showed that 3O, C12-HSL induction of PARP cleavage, P-p38,
and P-eIF2D was identical to that of control mice. Thus, neither MyD88 nor TRIF was
expressed in the 3O, C12-HSL mediated biochemical signalling events. Eventually,
these findings suggested that the recognition and transduction of the 3O, C12-HSL
signal did not require Toll-like receptors (TLRs) such as TLR-3, -5, -7, -8, and TLR-9.
These TLRs in specific pattern are essential for MyD88 and TRIF. Other receptors
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TLR-2 and TLR-4 that are able to recognize long-chain fatty acid moieties containing
molecules were also observed unimportant for 3O, C12-HSL mediated biochemical
changes. It is also known that the intracellular proteins Nod1 and Nod2 also participate
in innate immune responses distinct from those intervened by the TLRs.
133,153,167
Examination of BMDM from mice missing both Nod1 and Nod2 revealed that 3O,
C12-HSL induced phosphorylation of p38 and eIF2D and PARP cleavage was similar
as that of control mice. This suggested that initial recognition and signalling events of
3O, C12-HSL in macrophages do not require Nod1 and Nod2 proteins.
152
Mitochondrial stresses activate caspase-9 and caspase-3 proapoptotic signals which
eventually lead to inevitable proteolytic cleavage of PARP.
168,169
Similarly, with local
stress stimuli the endoplasmic reticulum (ER) changes the rates of translation and
transduction processes through phosphorylation of eIF2D.170 Kravchenko et al.,
showed with evidence the ability of 3O, C12-HSL to induce mitochondrial damage
depends on the activation of caspase-9, a biochemical event indicative of
mitochondria-mediated apoptosis
169
as well as its ability to induce ER stress and
phosphorylate eIF2D. Additionally diverse cell types of either human or murine origin
were found to be affected by 3O, C12-HSL in a qualitatively similar manner. Electron
microscopic analysis of 3O, C12-HSL treated BMDM fibroblasts and epithelial cells
showed dramatic morphological alterations including mitochondrial swelling and
distension of the ER. However, less pronounced mitochondrial alterations in
fibroblasts and epithelial cells suggested that macrophages are more sensitive to the
proapoptotic effects of 3O, C12-HSL. In contrast, identical ER distention in
macrophages and non-myeloid cells, suggested that the ER is involved centrally in the
response of different cell types to 3O, C12-HSL. In total, these observations suggested
that 3O, C12-HSL affects signaling pathways in a manner distinct from TLR-specific
PAMPs.
152
Overall, explanation of the binding target(s) of 3O, C12-HSL therefore, demands
analysis of effects of 3O, C12-HSL at proteomics level and/or modification of its
structure into new analogue(s) with high affinity to specific immune receptor(s). This
still raises question: ‘Is the 3O, C12-HSL a good lead molecule to aim at in order to
alleviate aberrant immune system?’
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2.3 Is the 3O, C12-HSL an ideal molecule to aim at in order to combat
dysfunctional immune system?
The first question to address is whether the 3O, C12-HSL is an ideal molecule to select
in the fight to correct abnormal immune behaviours. Consensus is generally positive
with some immune modulatory results of 3O, C12-HSL being brought forward. The
healthy immune system is apt to combat infections and diseases, whereas an
unbalanced immune system hampers good health and quality of life. As mentioned
already 3O, C12-HSL has the potential to modulate immune system. However, it must
be noted that the 3O, C12-HSL is utilised by Pseudomonas aeruginosa not only to co-
ordinate its population density but also to control the expression of numerous virulence
factors. Therefore, while explaining 3O, C12-HSL to target the immune system, care
must be taken to avoid the expression of virulence factors.
A wise approach therefore, is to alter 3O, C12-HSL chemically for its structural
modifications and to generate a series of new synthetic congeners that would
selectively enable eukaryotic immune modulation without promoting prokaryotic
quorum sensing as shown in Fig 2.2.
To this end recently Chhabra et al., have synthesized a series of synthetic analogues
through variations within the structural components of the native autoinducer 3O, C12-
HSL with some success in the improvement of eukaryotic immune modulation.
131,171
Fig. 2.2 New synthetic analogues of 3O, C12-HSL as selective immune
modulators.
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2.4 First generation immune modulatory analogues of 3O, C12-HSL:
SAR studies to date
As mentioned earlier among all QSSMs of Pseudomonas aeruginosa, 3O, C12-HSL
has been thoroughly investigated because of its ability to mediate immune processes of
eukaryotic cells in addition to its role in effecting prokaryotic genes expression.
126
The
preferred anti-proliferative activity observed by Telford et al., prompted Chhabra et al.,
to explore 3O, C12-HSL as a ‘lead structure’ for SAR studies and developed a large
number of immune modulatory analogues of 3O, C12-HSL.
128,131,156,171
The SAR is an approach which can be used to relate the effect of a chemical moiety
(drug or toxic chemical or bioactive component of natural or synthetic origin) on an
animal, plant or the environment to its molecular structure. The SAR may be assessed
by considering a lead molecule, making gradual changes in its structure to obtain a
series of new molecules and finally noting the effect of each change upon their
biological activity. With this principle, synthetic analogues of 3O, C12-HSL were
prepared introducing single or combined structural variations within the structural
components A, B and C (as shown in Fig. 2.3)
131,156
and were subjected to
immunological assays.
Biological screening of analogues synthesised by Chhabra et al., showed that the L-
HSL ring acylated with 3-oxo or hydroxy, substituted 12-14 carbon chain is optimal
for immune suppressive activity. Terminal carbon halogenation (bromide) and/or
hydroxylation as well as unsatutation in acyl chain ‘A’ retained activity. Product
N
H
O
O
O
H
O
A
Side chain
B
Oxoacyl
C
Hetero
ring
Fig 2.33O, C12-HSL structure showing A, B
and C fragment, where changes have
been made.
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formed from the conversion of 3-oxo to hydroxy group was equi-potent to that of
parent compound in immune suppression. Long acyl chains have found to maintain
lipid solubility that is important for immune suppression by these compounds.
However, compounds with more than 12 carbon acyl chain gave solubility problems in
the solvents used for bioassays. Opening of L-HSL ring ‘C’ and its replacement by
other ring such as thiolactone have shown no immune suppression.
131
Interestingly,
replacement of ‘C’ with cyclohexanol, caprolactam have resulted compounds with
agonistic behaviour in prokaryotes and replacement with quinoline ring showed strong
agonism, though this might be due to its structural similarity with the autoinducer
PQS.
172
Tateda et al, in their previous study of the small number of compounds without 3-oxo
functionality and/or with (D)-HSL found no apoptosis activity.
127
Same was
reconfirmed later by Horikawa et al., when activity was measured on the macrophage
P388D1 cell line.
173
This profoundly supported Chhabra et al., research and proved the
significance of the 3-oxo acyl group and of the homoserine lactone moiety to be of (L)-
configuration.
131
Moreover, Horikawa et al, have also synthesized an array of 3O, C12-HSL analogues
containing different acyl side chains as well as Pseudomonas QS agonist (2.1) and an
antagonist (2.2)
172
and subjected them for the induction of apoptosis in macrophages
that is, the P388D1 cells.
N
H
OO
OH
N
H
OO
OH
2.1 2.2
The lack of apoptotic activity in the analogues 2.1 and 2.2 further confirmed the role of
the L-HSL in immune modulation. Analogues with 3-oxo-acyl chains of 12-14 carbons
retained potent apoptosis-inducing activities. The shifting of the 3-oxo group to the 4-
(2.3) or 5- (2.4) position greatly reduced the activity.
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Terminal substitution of acyl chain with hydrophilic functional groups, (such as
hydroxy or succinyl group), reduced the apoptosis inducing ability whereas terminal
lipophilic (phenyl, benzyl, cyclopropyl or cyclopropylethyl groups) substitution gave
potent apoptosis inducing compounds.
173
As discussed previously, Kravchenko et al, have also suggested that the structural
integrity of the homoserine lactone ring motif in 3O, C12-HSL was required for
induction of apoptotic pathways as well as phosphorylation of MAPK p38 and eIF2D.
A variety of structurally highly conserved microbial products also referred as PAMPs
when encounter to key cells of the innate immune system such as macrophages, it
induces several signalling events including the phosphorylation of MAPK p38, and/or
of eIF2D. MyD88- and TRIF-dependent signalling pathways control the activation of
the transcription factor NF-NB and phosphorylation of MAPK including p38. Whereas,
TRIF-dependent signalling attenuate protein synthesis via phosphorylation of the
eukaryotic eIF2D. Both MyD88 and TRIF are known as Toll/interleukin-1 receptor
(TIR) domain-containing adaptors and among these TRIF induces IFN-J. Kravchenko
et al., therefore, decided to determine effects of 3O, C12-HSL and its analogues on the
phosphorylation state of p38 and eIF2D to investigate possible PAMP-like signaling in
macrophages.
152
Bone marrow derived macrophages (BMDM) when exposed to 3O, C12-HSL exhibited
phosphorylation of p38 and eIF2D in time- and dose-dependent manner. The specific
L-stereochemistry of natural analogue was observed to be essential, because unnatural
D-stereoisomer lacked activity. Interestingly, induction of phosphorylation was
retained by other members of the 3-oxo-AHL family (C10 and C14). However, C4-HSL
not containing 3-oxo group has no activity. Additionally, the lactam congener of the
3O, C12-HSL also failed to induce phosphorylation. Taken together, these data have
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suggested the importance of integrity of the homoserine lactone ring motif to induce
distinct cellular events leading to P-p38 and P-eIF2D.152
Moreover, at experimental cell culture pH~7.4, 3O, C12-HSL through two non-
enzymatic reactions is converted into tetramic acid derivative (2.5) and its ring opened
hydrolysed structure (2.6) as shown below.
The product 2.6 was rapidly generated and predominantly distributed in cellular
fractions whereas 3O, C12-HSL predominantly distributed in the supernatant.
Association of 3O, C12-HSL, 2.6 or both with the cells was found to be essential to
induce P-p38 as well as P-eIF2D. However, administration of 2.5 and 2.6 separately
with macrophages has not shown the induction of P-p38 and P-eIF2D. This thus
supports importance of integrity of 3O, C12 HSL structure.
152
As already shown by Li et al., that 3O, C12-HSL on prolonged incubation with
transformed human cells
174
have induced the cleavage of PARP, a biochemical marker
suggestive of apoptosis.
168
Whereas, 2.5, 2.6 or lactam analogue, have not induced the
cleavage of PARP. Thus, induction of apoptotic pathways as well as P-p38 and P-
eIF2D requires structural integrity of the homoserine lactone ring moiety.152
2.4.1 Limitations in the SAR studies and conflicting reports in the immune
modulatory behaviour of 3O C12-HSL
Unfortunately, the analogues including 3O, C12-HSL do suffer from a main drawback
that besides mediating eukaryotic immune responses, these also participate in bacterial
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intercellular communication inducing virulence gene expressions. This later trait
promotes bacterial growth and thus obliviously negates the clinical usefulness of these
analogues. Additionally, synthetic analogues with an alkyl chain more than 12-carbons
possess low solubility in routine solvents employed for in vitro testing and thus, could
not be explored for their immunomodulatory effects. Furthermore, opening of L-HSL
ring and thiolactone ring containing analogues developed by Chhabra et al., as well as
lactam congener of Kravchenko et al, do not strongly convince that the L-HSL ring is
essential for immune modulation. This would have been better supported by
synthesizing a few more other ring variants of 3O, C12-HSL and then correlating their
immune responses.
As explained, the acyl chain which maintains lipophilicity of the molecule was
important for immune suppression. This suggested that 3O, C12-HSL must be acting by
disruption of the association of the TCR molecules possibly by entering within the
lipid bilayer. However, research data of the in vitro investigation of TCR-transgenic
CD4 T-cells model obtained by Ritchie et al., have contradicted this where the effect
of 3O, C12-HSL on activation and cytokine production did not depend on its insertion
in the cell membrane, instead was likely at an intracellular site.
Furthermore, as already discussed earlier, inherent immune modulatory capability of
3O, C12-HSL has been extensively studied by several groups, indicating a range of
contradictory effects on mammalian cells. Chhabra et al., Ritchie et al. and Telford et
al., discovered in vitro suppression of lymphocytes by 3O, C12-HSL. Telford group
further observed more pronounced inhibition of preferably TH1 type responses by 3O,
C12-HSL. Smith et al. however, produce contradictory data to support up-regulation of
proinflammatory cytokines such as IL-8 at higher concentrations of 3O, C12-HSL.
Ritchie et al., revealed that the action of 3O, C12-HSL on T-cell cytokine production
was likely to be a relatively nonspecific and dependant on the model being used.
Recently, Ritchie and group came up with other contradictory results that 3O, C12-HSL
inhibits the differentiation of TH1 and TH2 CD4
+
T-cell within the first 2 h of after
antigen or mitogen stimulation. They also showed that immunosuppressive effect of
3O, C12-HSL does not depend on its insertion in the cell membrane.
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In spite of the contradictory results observed by different groups, what is undoubted is
the immune modulatory potential of 3O, C12-HSL. It would therefore be desirable to
introduce further modifications in the structure of 3O, C12-HSL molecule in order to
improve its immunological profile while losing prokaryotic QS activity and also to
alleviate solubility problem. Based on this, the aim of the current project was to
generate a second generation analogues of 3O, C12-HSL and then carry out a detailed
SAR studies.
2.5 Second-generation immune modulatory analogues of 3O, C12-HSL
and its SAR studies
Being highly amenable to chemical modifications, 3O, C12-HSL provides immense
scope for the generation of potential immune modulatory drug candidates. We
considered introducing further structural changes in 3O, C12-HSL molecule by
applying the following strategies and expected to generate new analogues with better
biological profile.
2.5.1 Strategies for new SAR studies of 3O C12-HSL
To generate synthetic analogues of 3O, C12-HSL, which would retain immunological
modulation in the absence of any deleterious bacterial growth, 3O, C12-HSL molecule
was divided into three regions A, B and C as shown in Fig 2.4.
Fig 2.4Structure of 3O, C12-HSL of which A (alkyl chain)
and B (1,3 diketo) and C (L-HSL) were considered
for SAR studies
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Chhabra and coworkers
13
have already explored the SAR of this molecule by
synthesizing a number of analogues and showed that 3-oxo functionality is important
for its immunomodulatory activity.
131
As the 3-hydroxy compound was equipotent, we
wondered whether the activity was elicited through 3-oxo structure or its enolic form.
We thus, decided to extend investigation of this molecule by modulating its 3-enolic
content (Fig 2.4) by using the following strategies
Strategy-1: Aza (4-aza and 3-Aza) analogues of 3O, C12-HSL
C
3
or C
4
carbon atom may be replaced by heteroatom nitrogen and
nitrogen may be optionally substituted.
Strategy-2: Fluorinated 4-aza analogues of 3O, C12-HSL
One or both the C
2
hydrogen(s) in 4-aza analogues of 3O, C12-HSL may
be replaced by electronegative fluorine(s).
Strategy-3: 1-Thia and 3-thia analogues of 3O, C12-HSL
Here alteration of carbonyl group at C
1
or C
3
position by sulphide,
sulfonyl or sulfone group with or without insertion of hetero atom at C
4
carbon may be performed.
Strategy-4: 4-Oxa analogue of 3O, C12-HSL
C
4
carbon may be replaced by another heteroatom, oxygen.
Strategy-5: Other ring altered analogues of 3O, C12-HSL and its 4-aza analogues
L-Homoserine lactone ring of 3O, C12-HSL may be replaced by other
aromatic or hetero aromatic ring with or without substitution.
Strategy-6: Insertion of hetero atom(s) in the acyl chain of 3O, C12-HSL or its 4-aza
analogues
Hetero atom(s) oxygen may be introduced at C
8
position individually or
C
7
and C
10
positions in combination to increase hydrophilicity.
Strategy-7: 3-Acetoxy analogue of 3O, C12-HSL
C
3
oxo group may be reduced to hydroxyl group and then acetylated.
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Strategy-8: Tetramic acid (TMC) analogue derived from 3O, C12-HSL
3O, C12-HSL may be transformed using strong base to obtain a TMC
derivative via an intramolecular cyclisation.
The purpose of these alterations was to establish the optimal pharmacophores in the
A, B and C regions of the nolecule which could alleviate problems associated with (a)
QSSM activity without losing immunomodulatory activity and (b) solubility of the
molecule so that longer chain length can be accommodated in the A region of the
molecule.
The new 3O, C12-HSL analogues will be screened for activity using established
immunological assays and are expected to have selective human immune modulation
without any prokaryotic autoinduction.
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2.6 4-Aza analogues of 3O, C12-HSL
Introduction of nitrogen in bioactive organic molecules has become increasingly
popular recently in drug design due to its ability to confer electronic and steric effects.
This in turn has effect on the biological potency of a drug molecule. One of the
objectives of synthesizing 4-aza analogues of 3O, C12-HSL as shown in Fig 2.5 was in
part to evaluate its immune modulation compared to 3O, C12-HSL.
The electronegative nitrogen was expected to provide an additional site for receptor
binding and thus may contribute towards selective immune modulation in eukaryotes.
If active, 4-aza analogues will then be N
4
-substituted to see if the activity is retained
and this in turn would be useful information to confirm whether N
4
-H is a site of
interaction with the receptor.
Furthermore, the new C
3
-N
4
amide bond can give rise to keto 2.7 -enol 2.8 form
tautomerism.
175
Also alkyl substituted 4-aza derivatives 2.11-2.13 are expected to exist
Fig 2.5Tautomeric keto-enol forms of 4-aza analogue of 3O, C12-HSL;
preferable enol form may show selective activity.
SELECTIVE
IMMUNE
MODULATION
Where, R= H or alkyl
N N
H
O
O
H
OO
R
HAHA
O
NH
O
OH
HA
HA
N
R
Y
HM
HM
O
Restricted
rotation
Keto form 2.7
Enol form 2.8
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preferably as E-isomer (Fig 2.5) due to the restricted rotation of the N
4
-C
3
. The later
attribute may influence the auto-inducing activity of 3O, C12-HSL.
Moreover, the electronegative N
4
would be expected to improve solubility of new
analogues through hydrogen bonding. This would in turn maintain the hydrophilic-
lipophilic balance and may allow alkyl chains of the larger length to be
accommodated. Various 4-aza analogues 2.8-2.13 of 3O, C12-HSL were consequently
synthesized as outlined in Table 2.1.
Table 2.1 4-Aza analogues of 3O, C12-HSL
N
H
O
OH
R
Comp. R Chemical name Abbreviation
2.8 NH
O O N-(3-Oxo, 4-azadodecanoyl)-
L-HSL 3O, 4-aza C12-HSL
2.9 NH
O O N-(3-Oxo, 4-azatridecanoyl)-
L-HSL 3O, 4-aza C13-HSL
2.10 NH
O O N-(3-Oxo, 4-azapenta
decanoyl)-L-HSL 3O, 4-aza C15-HSL
2.11 N
O O N-(3-Oxo, 4-methyl, 4-
azadodecanoyl)-L-HSL
3O, 4-Me, 4-aza C12-
HSL
2.12 N
O O
N-(3-Oxo, 4-n-propyl, 4-
azadodecanoyl)-L-HSL
3O, 4-Pr
n
, 4-aza C12-
HSL
2.13 N
O O
OH
N-(3-Oxo, 4-(2-hydroxyethyl),
4-azadodecanoyl)-L-HSL
3O, 4-(2-hydroxyEt), 4-
aza C12-HSL
The retro-synthetic approach for the generation of these analogues of 3O, C12-HSL is
shown in Scheme 1.
Scheme 1 Retrosynthesis of 4-aza analogues of 3O, C12-HSL
N N
H
O O
O
OHR1
R N H2N
O O
O
OHR1
R O +
NH O O
R1
R
OX+
R1 = H OR Alkyl
X = OH, Cl
Or
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As seen in Scheme 1, the starting material required for the generation of these
analogues are either primary amines 2.14-2.16 or secondary amines 2.17-1.19 (Table
2.2).
Table 2.2. Amines required as starting materials
R
H
N R1
Comp. R R
1
Chemical name
2.14 -C8H17 H n-Octylamine
2.15 -C9H19 H n-Nonylamine
2.16 -C11H23 H n-Undecylamine
2.17 -C8H17 -CH3 N-Methyloctylamine
2.18 -C8H17 -n-C3H7 N-Propyloctylamine
2.19 -C8H17 -C2H5-OH N-(Hydroxyethyl)octylamine
The primary amines 2.14-2.16 were commercially available but the secondary amines
2.18 and 2.19 except N-methyl octylamine 2.17, needed to be synthesized.
176-179
2.6.1 Synthesis of secondary amines (2.18 and 2.19)
Secondary amines due to their role in physiological activities become core
pharmacophores in many bioactive compounds and thus play exemplary role in drug
discovery.
180
Designing of expedient synthetic routes for these compounds has been
the focus of many research groups over the years. A brief survey of the major
traditional methods of secondary amine syntheses
180
is shown in Fig 2.6.
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From a methodological standpoint, alkylation of primary amines with alcohols using
metal catalyst thorium oxide (ThO2) and transition metal catalysts such as nickel (Ni),
rhodium (Rh) or ruthenium (Ru) are although selective for mono-N-alkylation, have
main drawback that they prefer homogeneous phase reaction conditions where
separation and recycling of catalyst is rather a difficult task. However, cesium
hydroxide promoted N-alkylation of primary amines has been found to give
predominant or exclusive secondary amines.
181
Direct alkylation of primary amine
2.20 with alkyl halides have been somewhat limited due to the concomitant further
alkylation of the desired secondary amine 2.21 to tertiary amines 2.22 and the
quaternary ammonium salt (2.23) as shown in Scheme 2.
However, secondary amine 2.21 can be obtained predominantly using excess of 2.20 in
the reaction. Therefore, by controlling reaction conditions such as appropriate
2.20 2.21 2.22 2.23
Scheme 2 Overalkylation of amine
R NH2
R' X
R N
H
R' R N R'
R'
R N R'
R'
R'XR' X R' X
Fig 2.6 Methods for the synthesis of secondary amines
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3
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proportion in reactants, temperature, time and other reagents, it is possible to obtain
desired secondary amine. Shrivastava et al., (Scheme 3) have observed that selective
amine can be obtained by using inorganic base such as K2CO3 in a polar aprotic
solvent (DMF, DMSO, or MeCN) at appropriate temperature (depending upon nature
of starting material).
182
As mentioned in Scheme 3, here alkylation was strongly dependant on a type of
electrophile (alkyl bromide) used. Long chain alkyl bromide afforded exclusively
mono-N-alkylation 2.26 where as short chain alkyl bromide gave rise exclusively to N,
N-dialkyl product 2.24. Similarly, Maeda et al., obtained selectively a range of
secondary amines by mono alkylation of excess of appropriate primary amines with
alkyl halides in the presence of Na2CO3.
183
The ready availability of n-octylbromide
prompted us to apply the aforementioned methods for the synthesis of N-
propyloctylamine 2.18 and N-(hydroxyethyl)octylamine 2.19 as shown in Scheme 4.
2.24 2.25 2.26
Scheme 3 Selective mono and di-N-alkylation of primary amine
N NH2 HN
Br Br
K2CO3, DMSO
13 h, 80 C, 83%
K2CO3, DMSO
13 h, 80 C, 95%
2.27; < 1% >99%; 2.28
(unsuccessful)
2.18; 57.8 % 2.29; 22.8 %
2.19; 51.0 % 2.30; 33.0 %
Reaction conditions: K2CO3, Acetonitrile (MeCN), rt., 18 h
Scheme 4 Synthesis of secondary amines
N
H
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NH3+Cl-
N
H
N
H
OH
NH2
HO NH2
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5
5
5
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+
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The N-alkylation of commercially available n-propylamine in excess amounts (2 mole
equivalents) with a mole equivalent of n-octylbromide in a polar aprotic solvent,
MeCN using K2CO3 as the base yielded a mixture of 2.18 and 2.29 in a proportion of
2.5:1. Similar alkylation of hydroxyethylamine gave a mixture of 2.19 and 2.30 in a
proportion of 1.5:1. The required products N-Propyloctylamine 2.18 and N-
(hydroxyethyl)octylamine 2.19 were separated from their respective mixtures by
chromatography in methanol-ammonia (9.7:0.3).
Unfortunately, in several attempts using 2.0, 2.5, 3.0 and 5.0 moles of ethylamine
(used as HCl salt) failed to give the expected secondary amine 2.27; instead the tertiary
amine 2.28 was isolated in nearly a quantitative yield. However, the amine 2.27 can be
selectively obtained by a route developed by Phanstiel et al., where they used benzoyl
peroxide (BPO), amines and organoborane as reactants in dichloromethane (DCM)
181
(Scheme 5).
2.6.2 Synthesis of 3-oxo-4-azaalkanoyl-L-homoserine lactones
(compounds 2.8-2.13)
Newly synthesized aforementioned amines 2.18 and 2.19 as well as commercially
available amines 2.14-2.17 were utilized for the synthesis of 4-aza analogues of 3O,
C12-HSL 2.8-2.13 as shown in Scheme 6.
2.31
2.27
Scheme 5 Synthesis of N-ethyloctylamine
179
H2N
H
N
6O
O
B
6 N
6
O
O
B
H
N
B
H
H
N
BPO
DCM
pH 10.5 buffer
Na2CO3
H2O
&RQILGHQWLDO
- 81 -
Amines 2.14-2.18 were readily acylated with ethyl malonyl chloride in the presence of
diisopropylethylamine (DIEA) to yield 4-aza-3-oxo esters 2.32-2.36. However,
acylation of N-(hydroxyethyl)octylamine 2.19 with ethyl malonyl chloride under
similar conditions gave a mixture of the desired N-acylated product 2.37 and N-, O-bis
acylated derivative 2.44 in a proportion of 1:2 as shown in scheme 7.
DIEA, dry DCM
rt
2.19 2.37 (24.0%) 2.44 (48.0%)
Scheme 7 Formation of N-acylated and N-, O-bis acylated products
NH N OEt
O OEt
O O
O O
OH
EtO Cl
O O
5
N
OH
5 OEt
O O
+ 5
2.14-2.19 2.32-2.37
2.8-2.13 2.38-2.43
Reaction conditions: (i) dry DCM, 0 qC to rt., 2 h; (ii) NaOHaq., EtOH, rt., 4 h; (iii) CDI, TEA,
dry DCM, rt., 16 h (for comp 2.11) and EDC, TEA, Water-Dioxane, rt., 16 h. (for comp. 2.8-
2.10 and 2.12-2.13)
Compounds R R
1
Chemical name
2.32 -C8H17 H Ethyl 3-oxo-4-azadodecanoate
2.33 -C9H19 H Ethyl 3-oxo-4-azatridecanoate
2.34 -C11H23 H Ethyl 3-oxo-4-azapentadecanoate
2.35 -C8H17 -CH3 Ethyl 3-oxo-4-methyl-4-azadodecanoate
2.36 -C8H17 -n-C3H7 Ethyl 3-oxo-4-propyl-4-azadodecanoate
2.37 -C8H17 -C2H5-OH Ethyl 3-oxo-4(2-hydroxyethyl)-4-azadodecanoate
2.38 -C8H17 H 3-Oxo-4-azadodecanoic acid
2.39 -C9H19 H 3-Oxo-4-azatridecanoic acid
2.40 -C11H23 H 3-Oxo-4-azapentadecanoic acid
2.41 -C8H17 -CH3 3-Oxo-4-methyl-4-azadodecanoic acid
2.42 -C8H17 -n-C3H7 3-Oxo-4-propyl-4-azadodecanoic acid
2.43 -C8H17 -C2H5-OH 3-Oxo-4(2-hydroxyethyl)-4-azadodecanoic acid
Scheme 6 General synthetic route of N-(3-oxo, 4-azaalkanoyl)-L-HSL
NH NCl OEt
O O
OEt
O O
N N
H
O O
O
OH N OH
O O
ClH
.
H2N O
OH
R1 R1
R1
R1
+
(i)
(ii)
(iii)
R R
R
R
Amine
Ethyl malonyl
chloride
4-aza-3oxo ester
4-aza-3-oxo acidN-(3-oxoalkanoyl)-L-HSL
L-HSL.HCl
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Saponification of esters 2.32-2.37 and 2.44 with NaOH gave the corresponding 4-aza
acids 2.38-2.43. Aza acid 2.41 was coupled to L-homoserine lactone using
1,1’carbonyldiimidazole (CDI) and triethylamine (TEA) in DCM and furnish the
expected product 2.11 in somewhat lower yield. Low product yield was in part due to
lower solubility of the resultant product in DCM. Therefore, other including higher
chain length aza acids 2.38-2.40 and 2.42-2.43 were coupled to L-HSL in the presence
of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) in dioxane-water and
obtained the desired products 2.8-2.10 and 2.12-2.13 respectively in better yields.
Mechanistically, during CDI coupling, the critical formation of imidazolyl mixed
anhydride 2.45 can proceed via two routes to yield the desired amide products. In one
route direct reaction between 2.45 and the free amine takes place while in other route,
2.45 is converted to imidazolide 2.46 before it reacts with the free amine (Scheme 8).
4-Aza-3oxo-acid CDI
TEA
Imidazole L-HSL
imidazolyl mixed anhydride
2.45
Route-2 Route-1
Imidazole
Imidazolide 4-Aza analogues of
2.46 3O,C12-HSL
Scheme 8 Reaction mechanism for the coupling of 4-
aza acid and L-HSLin the presence of CDI
R N
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The formation of an amide using a water soluble carbodiimide (EDC) is
straightforward, as shown in scheme 9. The acid first reacts with the carbodiimide to
produce the activated intermediate the O-acylisourea 2.47. The latter then acylates the
L-HSL to deliver the desired 4-aza analogues.
Final products 2.14-2.19 were easily purified by preparative thin layer chromatography
using an appropriate hexane - ethyl acetate solvent system.
1
HNMR spectrum of 2.11
as shown in Fig 2.5 suggested that due to restricted rotation between C
3
-N
4
bond the
product exists as a mixture of E and Z isomers and consequently N-Me appears as two
singlets at G 2.96 and 3.03. Other analogues were also duly characterised by their
1
HNMR spectra, which displayed N
4
-H and N
4
-CH2- signals at G values as shown in
Table 2.3.
Table 2.3 Analytical characteristics of analogues
Compound Chromatography solvent system Proton(s) G
2.8 Hexane-Ethyl acetate (2:8) N
4
-H s, 7.14
2.9 Hexane-Ethyl acetate (1:4) N
4
-H s, 6.49
2.10 Hexane-Ethyl acetate (1:4) N
4
-H s, 6.48
2.12 Ethyl acetate N
4
-CH2- m, 3.31
2.13 Ethyl acetate N
4
-CH2- m, 3.50
Where: s – singlet, m – multiplet
TEA
EDC.HCl
TEA
O-acylisourea
2.47
Urea
4-Aza analogues of 3O, C12-HSL
Scheme 9 EDC catalysed coupling of acid and L-HSL
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Biologically all 4-aza analogues 2.8-2.13 showed immune suppressive activity in
murine monocyte prolifereation assays in vitro. They were also found to be non-
inducers of quorum sensing with no or partial agonist activities (Chapter 3).
2.7 Fluorinated 4-aza-3O, C12-HSL analogues
Over the last 30 years, introduction of fluorine atoms in established pharmaceutical
drug candidate has become routine and occasionally improved their therapeutic
activity. Being comparatively smaller atom (Van der waals radius 1.47Aq), its covalent
bonded form occupies smaller volume than methyl, amino or hydroxyl groups while
slightly larger volume than hydrogen.
184,185
Therefore, it was of interest to replace
these groups with fluorine atom. This will introduce changes in molecular properties
and consequently will modulate biological behaviour.
Presence of fluorine within the structure modulates its metabolic stability and thus
bioavailability as well. Lipophilic molecules are usually labile to oxidative liver
enzymatic (Cytochrome P450) degradation. Replacing oxidative C-H group of
compound by C-F group can block this degradative site without affecting its target
protein binding. Well known example of this is the discovery of Ezetimibe 2.49, the
potent cholesterol-absorption inhibitor. In this molecule introduction of fluorine blocks
two metabolically labile sites preventing oxidation of phenyl ring to phenol and
dealkylation of the methoxy group of the lead molecule SCH 48461 2.48 (Fig
2.7).
186,187
SCH 48461 2.48 Ezetimib 2.49
Fig 2.7 Development of Ezetimib by optimization of SCH 48461
N
O
OMe
OMe
N
O
OMe
F
F
OH
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Being most electronegative atom, fluorine influences acidity and basicity strongly of
the functional group present in its vicinity in a molecule. The pKa profoundly affects
the pharmacokinetic properties and binding affinity of the molecules. Successive
fluorine incorporation in the earlier 5-hydroxytryptophan (5HT) receptor agonist 2.50
was found to reduce its basicity (Fig 2.8) and thus reduced pKa of the molecules 2.51
and 2.52 that in turn increased their membrane permeability and substantial
bioavailability.
188
Also fluorination of the weak and narrow spectrum first generation antibacterials 2.53
(e.g. Nalidixic acid) resulted in the discovery of novel broad-spectrum fluoroquinolone
antibacterials 2.54 (e.g. Ciprofluoxacin).
184,188
Overall, the fluorine substituents have been found to modulate the molecular
properties. Very recently Welch et al. had synthesized difluoro derivatives 2.55-4.58 of
3-oxo-hexanoyl-L-homoserine lactone (OHHL), one of the quorum sensing signalling
molecules of Erwinia carotovora and tested them to see how they affected protease
and carbapenem production in the Ecc ATTn10 CarI mutant.
189
2.50 2.51 2.52
pKa 9.7 pKa 8.7 pKa 6.7
(very low bioavailability) (medium bioavailability) (substantial bioavailability)
Fig 2.8 Effect of fluorine on the bioavailability of 5HT agonists
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Biological results showed that though the parent compound OHHL substantially
induced carbapenem biosynthesis and exoprotease activity, among fluorinated
analogues, only 2.58 elicited some carbapenem production at high concentration,
displayed tighter binding to EccR, a LuxR homologue and induced 100 fold less
protease activity than OHHL.
189
Kline et al., have synthsized geminal (gem) difluoro analogues of 3O, C12-HSL as
shown in scheme 10 to determine their agonist or antagonist autoinducing activity in
both PAI-1-LasR and PAI-2-RhlR systems of Pseudomonas aeruginosa.
A Reformatsky reaction between decanal and ethyl bromodifluoroacetate gave
hydroxy ester 2.59. Saponification of 2.59 followed by amidation with L-HSL using
EDC, acetic acid (HOAc) and DIEA yielded 2.60 as a mixture of diastereomers.
Oxidation of 2.60 with Dess-Martin periodinane readily produced difluoro analogue
2.61. In autoinducing assays both analogues 2.60 and 2.61 were agonists at LasR with
2.60 being less potent.
190
As mentioned in previous section, 4-aza analogues showed immune modulatory
behaviour, We intended to modulate 4-aza-3O, C12-HSL at C
2
position by replacing
one and both hydrogens with fluorine isostere(s) to generate respectively 4-aza-2-
fluoro-3-oxododecanoyl-L-homoserine lactone (4-aza-2-F-3O, C12-HSL) 2.62 and 4-
2.55 n = 1; X = CH2
2.56 n = 2; X = CH2
2.57 n = 3; X = CH2
2.58 n = 1; X = O
OHHL
N
H
O
OH
OO
N
H
X
OH
OO
F F
n
(i) (ii), (iii) (iv)
Decanal 2.59 2.60 2.61
Reaction conditions: (i) ethyl bromodifluoroacetate, Zn dust, THF, reflux (ii) KOH, THF-EtOH-H2O
(iii) L-HSL, EDC. HOAc, DIEA, DMF (iv) Dess-Martin periodinane, DCM.
Scheme 10 Synthesis of difluoro analogues of 3O, C12-HSL
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aza-2, 2-difluoro-3-oxododecanoyl-L-homoserine lactone (4-aza-2-F2-3O, C12-HSL)
2.63. These new molecules were expected to have better lipid solubility and possibly
with preferred molecular conformations for appropriate protein binding interactions
and also with better pharmacokinetic profile. Moreover, fluorine substitution at C
2
position would eventually shed light on the importance of C
2
hydrogens in immune
modulation.
Commercially available diethyl difluoromalonate 2.64 and dimethyl fluoromalonate
2.65 were used as starting materials for the synthesis of 2.62 and 2.63 respectively.
Diethyl difluoromalonate 2.64 Dimethyl fluoromalonate 2.65
Difluoromalonate 2.64 and monofluoromalonate 2.65 esters were each reacted with n-
octylamine to generate their respective amides, which were then further processed as
shown in Scheme 11 to obtain the desired products 4-aza-2-F-3O, C12-HSL and 4-aza-
2-F2-3O, C12-HSL. Here the formation of the undesired difluorobisamide 2.66 and
monofluorobisamide 2.67 could not be avoided but these could be easily removed via
chromatography.
4-Aza-2-F-3O, C12-HSL 2.62 4-Aza-2-F2-3O, C12-HSL 2.63
N
H
N
H
O
OH
OO
F F
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H
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2.7.1 Synthesis of 4-aza-2-F2-3O, C12-HSL
In the first attempt, direct reaction between diethyl difluoromalonate 2.64 and n-
octylamine in anhydrous ethanol gave mainly undesired bisamide 2.66, the desired
product 2.68 was only isolated in 23 % yield after thin layer chromatography.
Therefore, in the next attempt a n-octylamine was added dropwise to the solution of
diethyl difluoromalonate in dry ethanol over a period of 2 h. With this procedure the
yield of the desired product 2.68 was increased to 50%. However, bisamide was still
produced as a major side product.
Finally, the direct coupling of the ethyl 2, 2-difluoro-3-oxo-4-azadodecanoate 2.68
with L-homoserine lactone in acetonitrile gave 4-aza-2-F2-3O, C12-HSL 2.63. The
product was purified by preparative layer chromatography (PLC) in ethyl acetate-
2.69
2.66 2.67
2.68 2.70
2.63 2.62
Reaction conditions: (i) Diethyl difluoromalonate, ethanol, rt., 2 h; (ii) dimethyl fluoromalonate,
methanol, rt., 2 h; (iii) L-HSL.HCl, TEA, acetonitrile, reflux, 16 h; (iv) NaOHaq., methanol, rt., 3 h;
(v) L-HSL.HCl, DCCI, 1-hydroxy benzotriazole (HOBt), dry DCM, 16 h.
Scheme 11 Synthesis of fluorinated 4-aza analogues of 3O, C12-HSL.
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hexane (1:1) in a low yield of 15%. The
1
H NMR spectrum of the product did not
display C
2
protons signal present at G 3.28 in 4-aza-3O, C12-HSL thus indicating that
replacement of C
2
hydrogens by fluorines has taken place. The molecular ion peak at
m/z 335 due to MH
+
in the mass spectrum (MS) confirmed the structure.
2.7.2 Synthesis of 4-aza-2-F-3O, C12-HSL
As above the dropwise addition of n-octylamine to the dimethyl fluoromalonate 2.65
solution in anhydrous methanol resulted in the formation of methyl 2-fluoro-3-oxo-4-
azadodecanoate 2.69 in a yield of 47% and monofluorobisamide 2.67 as a side product.
Both 2.69 and 2.67 were separated by PLC using diethyl ether - petroleum ether (3:2).
Direct coupling of 2.69 with L-homoserine lactone did not give any product. Therefore,
2.69 was subjected to base saponification to yield 2-fluoro-3-oxo-4-azadodecanoic
acid 2.70 in a quantitative yield. The free amine was generated from L-homoserine
lactone HCl using HOBt and this was coupled to the acid 2.70 using DCCI (1, 3-
dicyclohexylcarbodiimide) as a coupling agent to yield the desired product 2.62.
Purification by PLC in ethyl acetate afforded 2.62 in a highly pure form in 11 % yield.
1
H NMR of 4-aza-2-F-3O, C12-HSL showed C
2
proton signal at G 5.3 as dd with
typical coupling constants JH, NH 10.2 Hz and JH, F 38.0 Hz.
2.8 3-Aza analogues of 3O, C12-HSL
As already seen in 4-aza analogues, how modulation of the 3-enolic content of 3O,
C12-HSL through the N
4
insertion had influenced eukaryotic immune modulation
(chapter 3). Therefore, it was of interest to further modulate 3-enolic content of the
lead molecule 3O, C12-HSL by replacing C
3
=O functional group by N
3
-OH
(hydroxamic acid) and N
3
-NH2 (hydrazine) isosteres. Thus N-(3-hydroxy-3-
azadodecanoyl)-L-HSL (3-OH, 3-aza-C12-HSL) 2.71 and N-(3-amino-3-
azadodecanoyl)-L-HSL (3-amino, 3-aza-C12-HSL) 2.72 structures were elaborated.
3-OH, 3-aza-C12-HSL 2.71 3-NH2, 3-aza-C12-HSL 2.72
N N
H
O O
O
OH
N N
H
N O
O
OH
H HH
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In one study, Li et al. demonstrated that hydrogen bonding between an inhibitor and
S1c subsite of calpain is important for potent inhibition of the enzyme.191 Calpain is
calcium-dependent proteolytic enzyme involved in cell motility and have been
implicated in apoptotic cell death.
192,193
With this report in mind, we envisioned that
N
3
-OH insertion would lower pKa of 2.71 relative to that of 3O, C12-HSL and may
improve the binding affinity through H-bonding to the active site of enzyme (Fig 2.9-
a) whereas, N
3
-NH2 substitution 2.72 may explore the receptor and identify new
binding interactions (Fig 2.9-b). The whole process may render the molecule
metabolically more stable to enzymatic degradation.
194-196
Overall, an increased
strength of hydrogen bonding of 2.71 and new binding interactions of 2.72 with the
enzymes may potentiate selective immune modulation.
Hydroxamic acid motif containing molecules have been investigated as inhibitors of
amino peptidases whereas aza-peptide substrates are reported to function as inhibitors
of serine proteases.
194,195
Compounds with hydroxamic acid motif possess a potential
to target tumors and bacteria. To this end, compound MetAP-I has been observed as
the most potent inhibitor of methionine aminopeptidase (MetAP). MetAP is an
essential enzyme of both bacteria (e.g. Escherichia coli) and human. Eukaryotes
contain two different enzymes, MetAP-1 and MetAP-2 the latter stimulates
angiogenesis.
194,197-201
Receptor Receptor
(a) 2.71 (b) 2.72
Fig 2.9 Proposed hydrogen bonding interactions between the compounds
(a & b) and the active sites of enzyme
N N
H
O O
O
OH
N N
H
N O
O
OH
H HH
H X
X X
MetAP-I
N N
H
N
O
O
OH
S
NH2
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2.8.1 Synthesis of 3-OH, 3-aza-C12-HSL
Synthesis of 3-OH, 3-aza-C12-HSL 2.71 is shown in Scheme 12. Condensation of 1-
nonanal and O-benzylhydroxylamine in methanol at pH # 4.7 gave oxime 2.73 which
was a mixture of E and Z isomers in a proportion of 4:1 as estimated from its proton
nuclear magnetic reaonance (NMR).
202
Attempts to reduce 2.73 by sodium borohydride (a), triacetoxyborohydride-acetic acid
(b) and 1M sodium cyanoborohydride in THF (c) were unsuccessful.
202-204
As shown in
Scheme 12, the reagent (a) did not effect any reduction, while reagents (b) and (c)
A a
+
1-Nonanal O-Benzylhydroxyl b 2.74
amine ( 5%)
B
32% c
58% Oxime 2.73 2.73 (! 95%)
(Recovered)
d
22%
(i) (ii)
O-Benzyl-N-nonyl
hydroxylamine 2.74 2.75 2.76
(iii)
(iv)
2.71 2.77
Reaction conditions: (A) Methanol 0 qC to rt, pH#4.7, 4 h; (a) sodium borohydride, methanol, rt, 2
h; (b) triacetoxyborohydride-acetic acid, dichloroethane (DCE), rt, 6 h; (c) sodium cyanoboro-
hydride (1M solution in THF)-methanolic HCl, methanol, pH#3.4, rt, 6 h; (d) sodium cyanoboro-
hydride-acetic acid, DCE, rt, pH#4.2, 4 h; (B) sodium cyanoborohydride-acetic acid, methanol, 0
qC to rt, pH#4.2, 16 h (i) t-butyl bromoacetate, DIEA, THF, reflux, 18 h; (ii) TFA, ethyl acetate, rt,
3 h; (iii) L-HSL.HCl, EDC.HCl, TEA, dioxane-water, rt, 6 h (iv) H2, Pd/C, ethanol or ethyl acetate
Scheme 12 Attempted synthesis of 3-OH, 3-aza-C12-HSL
O
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N O
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delivered the reduced product, N-nonyl derivative of O-benzylhydroxyamine 2.74 only
in poor yield.
205
Gratifyingly, the reductive amination of 1-nonanal with O-t-butyl-
hydroxylamine in the presence of sodium cyanoborohydride at acidic pH afforded the
desired product 2.74 though substantial amount of the oxime 2.73 was also isolated as
a side product.
202,205,206
The reduced product 2.74 was purified by chromatography in
ethyl acetate-hexane (1:9).
Alkylation of the key interemediate 2.74 with t-butyl bromoacetate gave N, N-
dialkylated O-benzylhyxroxylamine derivative 2.75.
194,207
Deprotection of t-butyl ester
with TFA afforded free acid 2.76, which was then coupled with L-HSL and obtained 3-
3-benzyloxy, 3-aza-C12HSL 2.77. Although Dupont et al.
208
have achieved it
successfully, even after several trials in different reaction conditions, we were not able
to remove benzyl group of 2.77 by catalytic hydrogenation. Thus, an alternative
protecting group strategy as shown in scheme 13 was employed for the synthesis of
2.71. However, it is noteworthy to mention that compound 2.77 was found as non-QS
immunosuppressive agent.
O
H
7
O NH2
H
N O
7
N O
7
N7 O
O O
N7 OH
O O
N7 N
H
O O
O
OH
N N
H
OH O
O
OH
O NH2.HCl +
(i)
O-t-Butylhydroxylamine.HCl Amine 1-Nonanal 2.78 (11%)
(iii) (ii)
2.81 2.80 2.79 (73%)
(iv)
(v)
2.82 2.71
Reaction conditions: (i) O-t-butylhydroxylamine.HCl, NaOMe, Sodium cyanoborohydride-
acetic acid, methanol, 0 qC to rt., 16 h; (ii)benzyl 2-bromoacetate, DIEA, THF, reflux, 16 h;
(iii) H2, Pd/C, EtOH, rt., 8 h; (v) L-HSL.HCl , EDC.HCl, TEA, water-dioxane, rt., 16 h; (vi)
50% v/v TFA/DCM, rt., 6 h.
Scheme 13 Synthesis of 3-OH, 3-aza C12-HSL
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Here free amine obtained by the neutralisation of O-t-butylhydroxlamine.HCl with
sodium methoxide, was used for the reductive amination of 1-nonanal to obtain a
mixture of 2.78 and 2.79 in a proportion of 1:7. The alkylation of purified 2.79 with
benzyl 2-bromoacetate followed by deprotection of benzyl ester 2.80 under catalytic
conditions afforded the free acid 2.81. Water soluble carbodiimide (EDC) mediated
coupling of this acid with L-HSL yielded 2.82. Finally the deprotection of O-t-butyl
group with TFA gave the desired product 2.71. The
1
H NMR spectrum of the product
displayed N
3
-OH proton signal at G 10.38 and m/z 301 of MH+ by MS confirmed final
structure.
2.8.2 Synthesis of 3-amino, 3-aza C12-HSL
The synthesis of 3-amino, 3-aza-C12-HSL 2.72 required the production of a key
compound N-octylcarbazate 2.83. The reductive amination of 1-nonanal with t-butyl
carbazate gave 2.83 in poor yield whereas, direct alkylation of t-butyl carbazate with n-
nonyl bromide gave 2.83 in an increased yield of 25%. The overall synthesis of 2.72 is
shown in scheme 14.
1-Nonanal
(i) 12%
(iii)
(ii) 25%
t-Butyl carbazate 2.83 2.84
n-Octyl (iv)
bromide
(vi) (v)
2.72 2.86 2.85
Reaction conditions: (i) Sodium cyanoborohydride-acetic acid, methanol, 0 qC to rt, pH#4.2, 16 h;
(ii) THF, reflux, 18 h; (iii) benzyl-2-bromoacetate, DIEA, THF, reflux, 16 h; (iv) H2, Pd/C, EtOH,
rt, 16 h; (v) L-HSL.HCl, EDC.HCl, TEA, water-dioxane, rt., 16 h; (vi) 50% v/v TFA/DCM, rt., 6 h
Scheme 14 Synthesis of 3-amino, 3-aza C12-HSL
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Compound 2.83 was further alkylated with benzyl 2-bromoacetate to obtain the
corresponding N, N-dialkylated carbazate derivative 2.84 which upon catalytic
hydrogenation gave deprotected acid 2.85. Product 2.85 was coupled with L-HSL
using EDC and obtained 2.86. Lastly Boc group deprotection by TFA yielded the
desired compound 3-amino, 3-aza C12-HSL 2.72 in a quantitative yield. In the
1
H
NMR spectrum N
3
-NH2 protons appeared as broad singlet at G 8.66 whereas, in MS
MH
+
appeared at m/z 300.
2.9 Thia analogue of 3O, C12-HSL
Although native sulphur has limited success as a medicinal agent, there is hardly a
class of drugs which does not contain compounds having sulphur in their structure.
Sulphur occurs in drug molecules in all its oxidative states and in all its forms of
organic combination such as sulfone, sulfoxide and sulfonamide. Moreover,
introduction of sulfur in the form of sulfone or sulfoxide imparts antibiotic properties
to the otherwise inactive organic compounds. Sulphur-containing dyes have produced
many clinically useful substances (sulfonamides as antibacterial), others, such as the
lactam antibiotics, have been developed from naturally occurring molecules. Thus,
organo-sulphur compounds unquestionably form a major therapeutic resource
however, their potential remains to be further exploited.
Incorporating several defined bioactive structural units to form a more potent
pharmacophore is well known approach in medicinal chemistry. We surmised that the
introduction of sulfur at the C
1
and C
3
position in 3O, C12-HSL structure would alter
the 3-enolic content due to its stereoelectronic properties. Thus, a range of 1-thia and
3-thia analogues as shown in Table 2.4 were elaborated and screened for their
immunological and auto-induction capabilities.
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Table 2.4 Thia analogues of 3O, C12-HSL
N
H
O
OH
R
Comp. R Chemical name Abbreviation
A. 3-Thia analogues of 3O, C12-HSL
2.87 S
O N-(3-Thiadodecanoyl)-
L-HSL
3-Thia C12-HSL
2.88 S
OO N-(3-Oxo, 3-thia
dodecanoyl)-L-HSL
3O, 3-Thia C12-HSL
2.89 S
O O N-(3-Oxo, 3-thia
tetradecanoyl)- L-HSL
3O, 3-Thia C14-HSL
2.90 S
OO
O
N-(3, 3-Dioxo, 3-thia
dodecanoyl)-L-HSL
3, 3-Dioxo, 3-thia
C12-HSL
2.91 S
O O
O
N-(3, 3 Dioxo, 3-thia
tetradecanoyl)-L-HSL
3, 3-Dioxo, 3-thia
C14-HSL
B. 1-or 3-Sulfonamide motif containing analogues of 3O, C12-HSL
2.92 NH
S
OO
O
N-(1, 3-Dioxo, 4-aza, 1-thia
dodecanoyl)-L-HSL
1, 3-Dioxo, 4-aza,
3-thia C12-HSL
2.93 NH
S
OO
O
N-(3, 3-Dioxo, 4-aza, 3-thia
dodecanoyl)-L-HSL
3, 3-Dioxo, 4-aza,
3-thia C12-HSL
2.9.1 3-Thia analogues of 3O, C12-HSL
Reverchon et al., although not in context with the long chain 3O, C12-HSL, were the
first to synthesize 3-thia derivative 2.94 of the shorter chain 3O, C6-HSL 1.51. Among
a range of analogues bearing ramified cycloalkyl or aryl substituent at C
4
, 2.94 was
found as a quorum sensing inhibitor.
209
1.51 2.94 2.95
This exciting bioactivity of 2.94 prompted Persson et al. to synthesize few more 3-thia
analogues of 1.51 with an extended or aryl substituted acyl chains (Scheme 15a) as
well as their corresponding sulfoxide and sulfone derivatives (Scheme 15b).
207
In this
study N-(heptylsulfanylacetyl)-L-HSL 2.95 was found to be most potent quorum
sensing inhibitor.
N
H
O O
O
OH
S N
H
O
O
OH
S N
H
O
O
OH
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The synthetic sequences utilized for the preparation of derivatives, 2.87-2.91 are
outlined in Scheme 16. The key thioether intermediates, 2.96-2.97 were obtained by
alkylating appropriate thiols with t-butyl bromoactetate.
210
Extreme basic conditions
and elevated reaction temperature afforded in situ deprotection of t-butyl group.
211
Alternatively, these thioethers can also be prepared by Mitsunobu reaction of the
appropriate alcohols with thiolacetic acid or by reaction between alkyl bromides and
methyl thioglycolate to give the corresponding thioacetates which can then be easily
hydrolyzed.
212
(i)
(ii) R
1
= (iv)
(iii)
R
2
= Alkyl (C3-C9) or aryl
Reaction conditions: (i) bromoacetyl brmide, TEA, DCM, -78 qC to rt, 70%; (ii) R2SH, TEA,
ethanol, rt; (iii) ) bromoacetyl brmide, TEA, DCM, -20 qC to rt, then R2SH, TEA; (iv) (COCl)2,
dimethyl sulfoxide (DMSO), DCM, -78 qC.
Scheme 15a Synthetic scheme of 3-thia analogues as quorum sensing inhibitors
(i) (ii)
R
2
= Alkyl or aryl
Reaction conditions: (i) 3-chloroperbenzoic acid (m-CPBA), DCM, -10 qC; (ii) m-CPBA, DCM, rt.
Scheme 15b Synthetic scheme of 3-sulfoxide and 3-sulfone analogues
Br N
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Oxidation of 2.96-2.97 to obtain sulfoxides, 2.98-2.99 and sulfones, 2.100-2.101 was
carried out using bromate-bromide/acid
211
and potassium permanganate/acid
213-215
solutions respectively. Oxidation using cerric (III) ammonium nitrate and sodium
bromate was not effective.
216
No attempts were made at this stage to resolve the
enantiomeric mixtures of 2.98 and 2.99. The enantiomeric ratio in these mixtures, as
estimated from their
1
H NMR spectra, was approximately 1:1. Compounds 2.96, 2.98
and 2.100 were coupled to L-HSL using CDI to furnish expected derivatives 2.87, 2.88
and 2.90. Adducts 2.99 and 2.101 were successfully coupled with L-HCL using EDC
to produce desired analogues 2.89 and 2.91. Analogues 2.88 and 2.89 were obtained
as a mixture of their diastereomers. The absolute stereochemical identies of these
analogues 2.88 and 2.89 were not established because their separation by PLC proved
unsuccessful. The diastereomeric ratio in their mixtures, as estimated from
1
H NMR
spectra, were approximately 3:1 and 1:1 respectively.
(ii) or (v)
(i) (iii)
Thiol 2.98-2.99
2.88-2.89
(ii) (iv)
2.96-2.97
(ii) or (v)
2.87 2.100-2.101 2.90-2.91
Reaction conditions: (i) t-butyl bromoacetate, 18% w/v NaOH, 90
0
C, 14 h; (ii) L-HSL.HCl ,
CDI, TEA, dry DCM, rt., 16 h (for compounds 2.87, 2.88 and 2.90); (iii) 0.5 N bromate-
bromide, HCl, acetic acid, 0
0
C, 45 min.; (iv) 4% w/v KMnO4, acetic acid, 50
0
C to rt., 40 min.;
(v) L-HSL.HCl, EDC.HCl, TEA, water-dioxane, rt., 16 h (for compounds 2.89 and 2.91).
3-thia acids R Chemical name
Sulphide 2.96 -C9H19 3-Thiadodecanoic acid
2.97 -C11H23 3-Thiatetradecanoic acid
Sulfoxide 2.98 -C9H19 3-Oxo-3-thiadodecanoic acid
2.99 -C11H23 3-Oxo-3-thiatetradecanoic acid
Sulfone 2.100 -C9H19 3,3,-Dioxo-3-thiadodecanoic acid
2.101 -C11H23 3, 3-Dioxo-3-thiatetradecanoic acid
Scheme 16 Synthesis of 3-thia analogues of 3O, C12-HSL
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2.9.2 Sulfonamide motif containing analogues of 3O, C12-HSL
The sulfonamide moiety, a direct isostere of the amide bond is almost a common
constituent of especially small medicinal molecules because it exhibits ubiquitous
biological activity and provides a relative ease of further derivatization as well. The
motif imparts the tetrahedral SO2NH junction that may alter the conformation and may
provide a hydrolytically stable new analogue. The incorporation of a sulfonamide into
novel 3O, C12-HSL was thus of interest and accordingly new analogues 2.92 and 2.93
with sulfonamide moieties were synthesized.
S N
H
O
OH
O OO
N
H
N
H
S N
H
OOO
O
OH
2.92 2.93
Several sulfonamides with immune modulatory potential have been reported. For
example, N-phenyl-phthalimide sulfonamide, LASSBio 468 2.102, a compound having
a sulfonyl-thiomorpholine moiety, inhibited LPS-induced neutrophil recruitment in
Male BALB/c mice.
217
In HIV-1-infected patients with tuberculosis, daily co-
trimoxazole (sulfamethoxazole 2.103 and trimethoprim) prophylaxis was found to be
well tolerated and has significantly decreased mortality rates.
218
N S
N
S
O
O
O
O
S N
H
ON
H2N
O O
LASSBio 468 2.102 Sulfamethoxazole 2.103
A series of N-acylhomoserine lactone analogues by replacement of the carboxamide
bond by a sulfonamide group, were synthesized by Casting el al. as shown in Schemes
17a and 17b. These compounds were evaluated for their ability to inhibit the action of
3O, C6-HSL, which in turn activates expression of bioluminescence in Vibrio fischeri.
Several compounds displayed antagonist activity.
219
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We aimed to produce new analogues 2.92 and 2.93 as outlined in scheme 18 by
replacing
1
C=O and
3
C=O in our 4-aza analogues with S=O group. Synthesis of methyl
2-(chlorosulfonyl)actetate 2.105 was accomplished in two steps.
220
Firstly,
esterification of sulfoacetic acid to yield methyl ester 2.104 was achieved by refluxing
it in a mixture of methanol-benzene (20:80) with azeotropic distillation of water.
Refluxing 2.104 with phosphoryl chloride (POCl3) afforded sulfonyl chloride 2.105.
The amidation of sulfonyl chloride 2.105 with L-HSL in presence of 1, 8-diazabicyclo
[5.4.0]undec-7-ene (DBU) and DMAP gave the sulfonamide 2.106 while its amidation
with refluxing octylamine in presence DBU and K2CO3 gave sulfonamide 2.108. Acid
hydrolysis of methyl ester, 2.106 was preferred to preserve the integrity of L-HSL ring
and successfully obtained the free acid, 2.107. Attempts to couple 2.107 with
octylamine using CDI or EDC were unsuccessful. However, it was successfully
coupled using DCCI and DMAP and afforded 2.92. Simple saponification of 2.108
yielded 2.109, which was successfully coupled to L-HSL using EDC to furnish 2.93.
(i) (ii) (iii)
Reaction conditions: (i) sodium sulfite, water, 24 h reflux; (ii) thionyl chloride, benzene, 4h reflux;
(iii) L-HSL.HBr, 1,8-diazabicyclo[5.4.0]-undec-7-ene, DMAP, DCM, 24 h, rt.
Scheme 17a Synthetic route for N-alkyl sulfonyl-HSL
(i) (ii) (iii),
(iv)
(v)
(vi)
Reaction conditions: (i) LiCH2SO3C2H5, THF, 1.5 h 60 qC, then 2 h rt ; (ii) ethylene glycol, p-
toluenesulfonic acid, benzene, 24 h, reflux,; (iii) NaI, acetone, 24 h rt; (iii) triphenylphosphine,
sulfuryl chloride, DCM, 16 h, rt; (iv) L-HSL.HBr, 1,8-diazabicyclo[5.4.0]-undec-7-ene, DMAP,
DCM, 24 h, rt; (vi) aqueous 95% TFA, 2 h, rt.
Scheme 17b Synthetic route for 3-oxo-alkyl sulfonyl-HSL
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(i)
Sulfoacetic acid Methyl 2-sulfocetate 2.104
(iii) 2.106
(ii)
(iv)
(vi) 2-(Chlorosulfonyl)acetate
2.105 2.107
(v)
2.108
(vii) 2.92
(viii)
2.109 2.93
Reaction conditions: (i) Methanol-benzene (2:8), distillation, 8 h; (ii) POCl3, reflux, 4 h; (iii) L-
HSL.HCl, DMAP, DBU, dry DCM, 0
0
C to rt., 16 h; (iv) 1.0 M HCl, reflux, 4 h; (v) n-octylamine,
DCCI, DMAP, dry DCM, rt., 16 h.; (vi) n-octylamine, DBU, K2CO3, dry DCM, reflux, 3 h; (vii)
NaOHaq., methanol, rt., 4 h; (viii) L-HSL.HCl , EDC.HCl, TEA, water-dioxane, rt., 16 h
Scheme 18 Synthesis of 1- or 3-sulfonamide motif containing analogues of
3O, C12-HSL.
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2.10 Hetero ring altered analogues of 3O, C12-HSL
In a limited number of analogues examined, it was found that homoserine ring was
essential for immune modulation activity.
131,156
This is borne out from the observation
that the ring opened derivative is devoid of any activity.
221
Thus the analogues with
changes in the hetero ring are relatively less explored. Hence, one of the aims of this
project was to prepare 3O, C12-HSL analogues by introducing structural changes
within the homoserine lactone ring and to evaluate their immune modulation effects in
eukaryotes. The three molecules N-(3-oxododecanoyl)-L-aspartimide (NOdDA) 2.110,
N-(3-oxododecanoyl)-L-glutarimide (NOdDG) 2.111 and N-(3-oxododecanoyl)-2-
aminothiazole (NOdAT) 2.112 as shown below were designed.
N
H
NH
OO
O
O
H7 NH
NH
OO
OH
7 NH
N
S
OO
7
O
2.110 2.111 2.112
Here the designed analogues retain the same acyl side chains as that of 3O, C12-HSL,
but with an aspartimide, glutarimide or thiazole ring instead of the homoserine lactone
ring.
Chemokines signalling orchestrate an inappropriate inflammation in a range of human
diseases including autoimmune diseases, atherosclerosis, osteoporosis, asthma and
cancer. Because chemokines involve in the regulation of human systems both in
inflammation and during host defence, they represent an important target for immune
modulation therapy.
222-224
The modifications in both 2.110 and the higher ring structure 2.111 are the
replacement of the hetero-atom oxygen within the ring of L-HSL with a nitrogen and
incorporation of an additional carbonyl at position 5 and 6 respectively.
Pyrrolidinone based hetero-ring analogues 2.113, but not containing 5-oxo substituent
have been synthesized in the past
131,225
but were found to be inactive as immuno-
modulators. However, the NR58-4 (N-undec-10-enoyl-3-aminoglutarimide) 2.114 has
been found as most potent broad-spectrum chemokine inhibitor in vitro.
226,227
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R N
H
NH
OO
OH
N
H
NH
O
OH
O
3-Acylamino-L-2-pyrrolidinone 2.113 NR58-4 2.114
Therefore, further modifications by incorporation of oxo group next to the nitrogen
within the expanded or non-expanded ring will change the overall chemical properties
of the molecules, which may overcome their inefficacy possibly by making them non-
inducing immune modulators. Probably the additional carbonyl substituent might
increase the molecule’s affinity for the receptor through hydrogen bonding, mapping
larger area within the receptor via the delocalisation of the lone pair of electrons of
nitrogen onto the neighbouring carbonyls. The improved binding to the receptors
might lead to better immune modulation.
Immune modulatory potential of 2-aminothiazole has already been established by Das
et al., by synthesizing a novel aminothiazole based small molecule inhibitors of
Interleukin-2-inducible T-cell kinases (Itk)
228
. Itk is expressed mainly in T, natural
killer and mast cells.
229,230
Itk is implicated in activation of T-cells through TCR and
CD28 engagement.
231,232
Optimization of the 2.115 led to the discovery of 2.116 as a
potent and selective Itk inhibitor (Fig 2.10).
233
Screening of 2-amino-5-thioaryl-
thiazole series led to the identification of 2.117 as a highly potent and selective Itk
inhibitor. It also reduced T-cell proliferation in vitro, IL-2 production in mice in vivo
and lung inflammation in a mouse model of ovalbumin induced allergy/asthma.
234
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Therefore, replacement of pH sensitive L-HSL ring of 3O, C12-HSL with
immunologically active 2-aminothaizaole ring may enhance its immune modulatory
behaviour and may overcome auto-induction.
Chemical synthesis of 2.110-2.112 required the initial formation of 5-decanoyl
Meldrum’s acid 2.118 which was prepared almost in quantitative yield by the N, N’-
dicyclohexylcarbodiimide (DCCI) and 4-dimethylaminopyridine (DMAP) catalysed
acylation of Meldrum’s acid with n-decanoic acid in dry DCM (Scheme 19).
131,235
2.115
Itk IC50 = 1 ȝM
Jurkat IL-2 I50 = 22 ȝM
2.116
Itk IC50 = 96 nM
Jurkat IL-2 I50 = 700 nM
2.117
Itk IC50 = 19 nM
Jurkat IL-2 I50 = 250 nM
Fig 2.10 Itk inhibitory activity of aminothiazoles
N
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N
SH
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O O
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N
N
O
DCCI
DMAP
Acid
R = C9H19 Meldrum’s acid keto form enol form
5-Decanoyl Meldrum’s acid
2.118
Scheme 19 Synthesis of 5-decanoyl Meldrum’s acid
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The reaction mechanism for DMAP catalysed acylation is shown in Scheme 20.
The intermediate N-acylpyridinium cation formed exists in two resonance forms (a &
b). The b form is less favoured because the positive charge on the pyridinium nitrogen
is destabilised by the adjacent carbonyl’s G+ charge. The final product 2.118 exists in
the enolic form rather than the keto form as evidenced by their
1
H NMR, in which the
presence of the H-bonded enolic proton resonates at a downfield G value of 15.3.
Scheme 20 The reaction mechanism for DMAP catalysed acylation
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2.10.1 Retro-synthesis of NOdDA and NOdDG
The retro-synthetic approach to the construction of these molecules is shown in
Scheme 21.
The hetercycles L-aspartimide and L-glutarimide required for the analogues 2.110 and
2.111 respectively were elaborated from L-Asn and L-Gln as shown in Scheme 22.
Commercially available N-Boc-L-Asn 2.119 and N-Boc-L-Gln 2.120 were used for
cyclisation to yield N-Boc-L-aspartimide 2.121 and N-Boc-L-glutarimide 2.122
respectively. Intramolecular cyclisation was achieved by activating COOH group with
the coupling agent 1,1’-carbonyldiimidazole (CDI) in dry tetrahydrofuran (THF). The
product 2.121 was easily purified by chromatography using ethyl acetate. The pure
product was obtained as a white solid in a yield of 57%. The product 2.122 was pure
by TLC and was recrystallised from ethyl acetate as a white solid in a yield of 81%.
CDI, THF TFA
Reflux DCM/MeCN
2 h
n = 1; N-Boc-L-Asn 2.119 N-Boc-aspartimide 2.121 TFA salt 2.123
n = 2; N-Boc-L-Gln 2.120 N-Boc-glutarimide 2.122 TFA salt 2.124
Scheme 22 Synthesis of aspartimide and glutarimide
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Scheme 21 Retro-synthesis of NOdDA and NOdDG.
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Removal of the Boc group from 2.121 and 2.122 was achieved by acidolysis with
trifluroacetic acid (TFA) in DCM and acetonitrile respectively. This resulted in the
formation of the trifluroacetate salts of aspartimide 2.123 and glutarimide 2.124. Along
with the desired product in each reaction other by products from the generated t-butyl
carbocation were expected to be produced are shown in Scheme 23. These are either
isobutene gas by loss of proton or t-butanol via quenching of the t-butyl carbocation
with water. The t-butanol was expected to be produced rather than the isobutene gas
due to the presence of water in DCM and acetonitrile.
2.10.2 Synthesis of NOdDA, NOdDG and NOdAT
The condensation of L-aspartimide TFA salt 2.123 and L-glutarimide TFA salt 2.124
with 2.118 and two molar equivalents of TEA in acetonitrile under reflux conditions
gave the desired products NOdDA 2.110 and NOdDG 2.111. Similar condensation of
2-aminothiazole with 2.118 in acetonitrile gave NOdAT 2.112. The syntheses and
mechanism of their reactions are shown in Scheme 24.
t-Butanol
TFA N-Boc-amide
t-Butyl
carbocation
iso-butene gas
n = 1, 2.123; n = 2, 2.124 carbamic acid
Scheme 23 Removal of Boc by acidolysis
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Condensation of acylated Meldrum’s acid with amines does produce small amounts of
undesirable side products (Scheme 25). This is because amidation could also occur on
the exocyclic carbonyl instead of the endocyclic carbonyls, which is the desired route.
We tried to minimise this problem by leaving both reaction mixtures overnight at room
temperature first to discourage the Schiff’s base formation with the exocyclic carbonyl
and hence increase the chances for the more reactive endocyclic carbonyls to be
favourably attacked by the amine.
The crude NOdDA, NOdDG and NOdAT were successfully purified using PLC in
yields of 58%, 51% and 31% respectively. The pure NOdDA was a pale-yellow solid
whereas NOdDG and NOdDAT were off white solids. These were further
characterised using IR and
1
H NMR. Analogues 2.110-2.112 showed reduction in QS
activity but only 2.112 displayed an equipotent immune modulation behaviour as that
of 3O, C12-HSL whereas, 2.110-2.111 did not.
Undesired path
Amine
Meldrum’s acid
Undesired side product
Desired path
Meldrum’s acid
Desired product
Scheme 25 Amidation of acylated Meldrum’s acid
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2.11 Hetero ring altered analogues of 4-aza 3O, C12-HSL
As discussed previously, the hetero ring moiety of the 3O, C12-HSL was considered to
be essential for immune modulation. However, this statement now stands to be
corrected by looking at immune modulatory profile shown by 2.112. Additionally, on
observing the preservation of immune modulation and loss of QS behaviour by 4-aza
analogues prompted us to use these analogues to investigate the effect of replacement
of L-HSL by other aryl rings on immune modulation. Thus new analogues of 4-aza-
3O, C12-HSL 2.125-2.135 as shown in Table 2.5 were conceived with an expectation
that they may display selective immune modulation.
Table 2.5 Hetero ring altered 4-Aza analogues of 3O, C12-HSL
N
H
N
H
O O
R
Comp. R Chemical name
2.125
N
S 2-(3-Oxo-4-azadodecanoyl)aminothiazole
2.126 OHH
(1R,2S)-2-(3-Oxo-4-azadodecanoyl)aminocyclopentanol
2.127 H OH
(1R,2S)-2-(3-Oxo-4-azadodecanoyl)aminocyclohexanol
2.128 H
N-(3-Oxo-4-azadodecanoyl)cycloheptylamine
2.129 OH
2-(3-Oxo-4-azadodecanoyl)aminophenol
2.130
OH
Cl
2-(3-Oxo-4-azadodecanoyl)amino-4-chlorophenol
2.131
NH2O
2-(3-Oxo-4-azadodecanoyl)aminobenzamide
2.132
NO
N, N-Dimethyl-2-(3-oxo-4-azadodecanoyl)aminobenzamide
2.133
NH2
O
3-(3-Oxo-4-azadodecanoyl)aminobenzamide
2.134 N 2-(3-Oxo-4-azadodecanoyl)aminopyridine
2.135
NH
N
5-(3-Oxo-4-azadodecanoyl)amino-1H-indazole
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2.11.1 Selection of R-group for the hetero-ring replacement
An active component of either existing immune modulatory or antibacterial agents or
both was chosen as R-group. This might either potentiate immune modulation or
restrain QS by the new analogues.
In addition to already mentioned utilization of 2-aminothiazole in Itk inhibitors 2.115-
2.117, recently it has also been explored by Wang et al. who discovered a novel series
of 2-aminothiazole-derived CCR4 antagonists. This led to the invention of a compound
2.136, with adequate potency and pharmacokinetic properties.
236
CCR4 is a G-protein-
coupled receptor from the C-C motif containing family of chemokine receptors that is
involved in the migration of inflammatory cells into inflamed tissue and predominantly
expressed on T-lymphocytes, mainly on those of the TH2 phenotype.
237,238
The 2-
aminocyclohexanol has been used to make QS agonist where as 2-amino
cycloheptanol, cycloheptylamine, 2- and 3-aminobenzamides, 2-aminophenols and 5-
aminoindazole have been used to develop QS antagonists.
172
Moreover,
aminobenzamide derivative CI-994, N-acetyldinaline-[4-(acetylamino)-N-(2-
aminophenyl)benzamide] 2.137 is an antitumor cytostatic agent currently undergoing
clinical trial
239-242
, the 3-aminobenzamide as PARP inhibitor
243
, phenols in analgesic-
antipyretic (e.g. paracetamol) drugs and a 2-aminopyridine containing pyrilamine
2.138 as antihistamine.
244
HN
S
N
N
N N
N OCH3N
H
N
H
O
O
NH2
2.136 CI994 2.137 Pyrilamine 2.138
Synthetic route to 2.125-2.135 analogues was as similar to that of 4-aza-3O, C12-HSL
(Scheme 6). Except coupling of 3-oxo-4-azadodecanoinc acid 2.38 with L-HSL, here
various aryl, heteroaryl and cycloalkyl amines (R-groups as shown in Table 2.5) were
coupled separately with 2.38 as shown in Scheme 26-a to generate the desired
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analogues 2.125-2.135. Moreover, benzyl protected R groups (2.126-a and 2.127-a)
were deprotected by catalytic hydrogenation as shown in Scheme 26-b.
2.12 Oxa analogues of 3O, C12-HSL
Besides showing immune modulatory activity, lower solubility of the acyl chain larger
than 12 carbons containing 3O, C12-HSL analogues (ref. ‘A-part’ in Fig 2.4, page 72)
in the solvents used for their in vitro bioassays have restricted these derivatives to be
studied furher. We therefore, decided to introduce in the ‘A’ side chain a hetero
atom(s) ‘oxygen(s)’ in 3O, C12-HSL at C
4
position to modulate its 3-enolic
content
245,246
and in 4-aza-3O, C12-HSL at C
7
and C
10
or at C
8
position(s) to modulate
its hydrophilic-lipophilic balance. Moreover, introduction of oxygen at C
4
might
provide an additional site for the target proteins to form hydrogen bonding and show
potent biological response whereas; oxygen(s) introduction at C
7
and C
10
or C
8
position(s) might enhance its solubility in appropriate solvents. Thus three types of
analogues 2.139-2.143 as shown in Table 2.6 were developed and evaluated for
immune and microbiological responses.
n-Octylamine
2.32
(i)
2.125-2.135 2.38
Reaction conditions: (i) EDC.HCl, TEA, Dioxane-water/DCM, 8-16 h. rt.
Scheme 26-a Synthesis of hetero ring altered analogues of 4-aza-3O, C12-HSL
(i) n = 1 or 2
Reaction conditions: (i) H2, Pd/C, EtOH, rt., 6 h.
Scheme 26-b Removal of benzyl group of 2.126-a (n=1) and 2.127-a (n=2) by
catalytic hydrogenation
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Table 2.6 Oxa analogues of 3O, C12-HSL
Comp. Structure Chemical name Abbreviation
2.139 O
O O
N
H
O
OH
N-(3-Oxo, 4-oxadodecanoyl)-
L-HSL 3O, 4-oxa C12-HSL
2.140 O NH
O O
N
H
O
OH
N-(3-Oxo, 8-oxa 4-aza
dodecanoyl)-L-HSL
3O, 8-oxa, 4-aza
C12-HSL
2.141 O NH
O O
N
H OHH
(1R,2S)-2-(3-Oxo- 8-oxa-4-azadodecanoyl)
aminocyclopentanol
2.142 O
O N
H
O O
N
H
O
OH
N-(3-Oxo, 7, 10-dioxa, 4-aza
dodecanoyl)-L-HSL
3O, 7, 10-dioxa, 4-aza
C12-HSL
2.143 O
O N
H
O O
N
H OHH
(1R,2S)-2-(3-Oxo- 7, 10-dioxa- 4-azadodecanoyl)
aminocyclopentanol
2.12.1 Synthesis of 3O, 4-oxa C12-HSL
For the preparation of 4-Oxa analogue 2.139 (Scheme 27), esterification of mono-
benzyl malonate with octyl bromide in the presence of tetrabutylammonium fluoride
(TBAF) gave di-ester 2.144. The catalyst TBAF was generated in situ from
tetrabutylammoniun hydrogen sulfate (TBAHSO4) and potassium fluoride dihydrate
(KF.2H2O) in THF.
245,246
However, this reaction gave the desired di-ester 2.144 in a
very low yield of only 10%. Therefore, mono-benzyl malonate was esterified with 1-
octanol in the presence of DCCI and DMAP to furnish di-ester 2.144, in an excellent
yield of 76%. The di-ester 2.144 was then deprotected by catalytic hydrogenation to
afford the free acid 2.145. Compound 2.145 was activated by CDI and coupled with L-
HSL to furnish the desired 3O, 4-oxa C12-HSL 2.139.
(i) 10%
(iii)
(ii) 76%
2.145
Mono-benzyl di-ester 2.144 (iv)
malonate
2.139
Reaction conditions: (i) n-octylbromide, TBAHSO4, KF.2H2O, THF, rt., 18 h; (ii) n-octyl alcohol,
DCCI, DMAP, DCM, rt., 16 h; (iii) H2, Pd/C, EtOH, rt., 6 h; (iv) CDI, TEA, DCM, rt., 16 h.
Scheme 27 synthesis of 3O, 4-oxa C12-HSL
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The identity of the final product 2.139 was confirmed by its
1
H NMR which showed
all protons at the expected G values and the MS which displayed exact mass of m/z 300
for MH
+
.
2.12.2 Synthesis of 8-oxa and 7, 10-dioxa analogues of 3O, 4-aza C12-HSL
The starting amine 3, 5-dioxa-octylamine 2.146 required for the syntheses of 1.242 and
1.243 was prepared by Mitsunobu reaction between di(ethyleneglycol)ethyl ether and
phtahlimide using triphenylphosphine (TPP) to generate N-alkylphtalimide.
247
The
phthalimide derivative was then deprotected by hydrazinolysis to afford 2.146.
248
The
Mitsunobu reaction is reported to proceed via the path as shown in Scheme 28.
Initially, the nucleophilic attack of TPP upon DIAD (I) produces a betaine
intermediate II, which deprotonates the alcohol (ROH) to form the hydrazo anion and
Di(ethyleneglycol)ethyl
ether DIAD
N-alkyl
phthalimide
TPP Hydrazine Methanol
hydrate
Phthalimide
MECHANISM 2.146
I II
VI V III
IV
Scheme 28 synthesis of amine 2.146 by Mitsunobu reaction
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alkoxyphosphonium cation III. The hydrazo anion then deprotonates phthalimide
which in turn attacks cation III to form the desired product V along with
triphenylphosphine oxide (IV) and dihydro-DIAD (VI).
Commercially available 3-butoxypropylamine 2.147 was used as the starting material
for the syntheses of 8-oxa analogues 1.240 and 1.241. The synthetic route used for the
synthesis of 2.140-2.143 is shown in scheme 29. The acylation of amines 2.146-2.147
with ethyl malonyl chloride followed by base hydrolysis afforded 4-aza acids 2.148-
2.149.
The acids 2.148-2.149 were coupled separately with L-HSL and (1R, 2S)-2-
benzyloxycyclopentylamine to generate desired products 2.140, 2.142 and bezyloxy
analogues 2.150-2.151 respectively. Deprotection of benzyl group in 2.150-2.151 was
achieved by catalytic hydrogenation to afford other target products 2.141 and 2.143.
(i), (ii) (iii)
2.146-2.147 2.148-2.149
2.140 or 2.142
(iv)
= 2.140,
2.141, 2.147, 2.148, 2.150 (v)
= 2.142,
2.143, 2.146, 2.149, 2.151
2.150-2.151 2.141 or 2.143
Reaction conditions: (i) ehyl malonyl chloride, DCM, 0 qC to rt., 16 h; (ii) NaOHaq., EtOH,
rt., 6 h; (iii) L-HSL.HCl, EDC.HCl, TEA, water-dioxane, rt., 16 h. (iv) (1S, 2S)-2-benzyloxy
cyclopentylamine, EDC.HCl, TEA, dry DCM, rt., 16 h. (v) H2, Pd/C, EtOH, rt., 8 h.
Scheme 29 synthesis of oxa analogues of 3O, 4-aza C12-HSL
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2.13 Miscellaneous analogues of 3O, C12-HSL
2.13.1 Synthesis of tetramic acid derivative:
Rearranged isomeric product of 3O, C12-HSL
The kauffmaun et al., discovered a previously undescribed nonenzymatically formed
product, the 3-(1-hydroxydecylidene)-5-(2-hydroxyethyl)pyrrolidine-2,4-dione, 2.152
a tetramic acid. The degradation product 2.152 is derived from 3O, C12-HSL via an
unusual intramolecular Claisen-like condensation reaction and showed bactericidal
activity against Gram negative. We considered that 2.152 if displays immune
modulatory activity, it might be a breakthrough in the development of a new set of
immune modulatory drugs.
249
Abstraction of C
2
acidic protons of 3O, C12-HSL by a strong base sodium methoxide
(NaOMe) in methanol at 55°C afforded carbanion 2.153 which underwent
intramolecular Claisen like condensation and yielded a desired product 2.152 as shown
in scheme 30.
NaOMe/
Methanol,
55 qC, 6 h
3O, C12-HSL 2.153
2.152
Scheme 30 synthesis of 3-(1-hydroxydecylidene)-5-(2-hydroxyethyl)
pyrrolidine-2,4-dione
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2.13.2 Synthesis of 3-acetoxy, C12-HSL
Acetylation of hydroxyl groups is a frequently used transformation method in
medicinal chemistry to protect hydroxyl group from conversion by enzymes in vivo or
chemical reactions in vitro to other undesired functional group. Chemically acetyl is
the most convenient group in view of its easy introduction, being stable to the acidic
reaction conditions, and also easily removable by mild alkaline hydrolysis.
250,251
Due
to the importance of acetylation, we designed and synthesized N-(3-acetoxy-
dodecanoyl)-L-HSL 2.154 as shown in scheme 31.
The key intermediate required for the synthesis of 2.154 was the N-(3-hydroxy-
dodecanoyl)-L-HSL 2.155 which was synthesized from 3O, C12-HSL by reduction
method suggested by Chhabra et al.
225
who were able to reduce N-3-oxo analogues to
N-3-hydroxy analogues (e.g. 2.155) as a mixture of diastereomers without the
protection and deprotection of the E-hydroxy moiety using sodium cyanoborohydride
reducing agent. The sodium cyanoborohydride reducing agent was preferred over
sodium borohydride because it required acidic conditions in which both the stability of
the L-HSL ring and the chiral integrity of the molecule are retained.
The N-(3-hydroxyacyl) derivatives have been synthesized by Zhu et al.
252
by coupling
protected E-hydroxy alkanoic acid with L-HSL as shown in scheme 32.
(i) (ii)
3O, C12-HSL (racemic mixture) 2.155 2.154
Reaction conditions: (i) sodium cyanoborohydride, methanol-HCl, rt, pH#4.0, 16 h; (ii) acetic
anhydride, reflux, 2 h.
Scheme 31 synthesis of 3O-Ac,C12-HSL
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Here E-hydroxy alkanoic acid was prepared by the Reformatsky reaction between an
aldehyde and ethyl bromoacetate in the presence of zinc. Prior to saponification and
coupling with L-HSL, the E-hydroxy group was protected with dihydropyran to obtain
the tetrahydropyran (THP) ether.
Alternatively, 2.153 can be obtained from 3O, C12-HSL using suitable reducing agents.
The nature of the reducing agents have been found to determined the enantiomeric
excess of the resulting mixture of E-hydroxy derivatives (Table 2.7).253-256
Table 2.7 List of reducing agents showing yields obtained with their use and
enantiomeric excess
Reagents Stereo-
chemistry
Yield
(%)
Enantiomeric
excess
RuCl3/(R)-(MeO-BIPHEP) 1 mol %
H2 (6 bar), methanol, 80 qC, 23 h.
R 96 99
NaBH4, THF, 0 qC. R/S 74 -
R-BINAP (2 mol %), H2 (1 bar),
50 qC, 48 h.
R 100 97
Zn(BH4)/ZnCl2, toluene, -78 qC, 3 h. R 94 84
DIBAL/BHT, toluene, 78 qC, 3 h S 82 92
Lastly, the desired product 2.154 was obtained by acetylation of the 3-hydroxyl group
of 2.155 by refluxing it with acetic anhydride. Moreover, commonly used reaction
condition for this conversion uses acetic anhydride in the presence of an acid/base
I (ii)
Racemic mixture
(iii)
(v) (iv)
R= Alkyl chain
Reaction conditions: (i) Zinc, ethanol, H3O
+
; (ii) dihydropyran, tosic acid; (iii) NaOHaq,
dioxane; (iv) L-HSL.HCl, EDC.HCl, TEA, water; (v) aqueous perchloric acid.
Scheme 32 General synthesis N-(3-hydroxyacyl)-L-HSL
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catalyst.
257
Various metal salts such as CoCl2,
258
TiCl4-AgClO4,
259
Me3SiCl,
260
LiClO4,
261
Mg(CLO4)2,
262
CuSO4.5H2O
263-265
and some metaltriflates such as
Se(OTf)3,
266
MeSiOTf,
267
In(OTf)3,
268
Cu(OTf)2,
269
and Bi(OTf)3,
270
have been
investigated to meet the demands for more efficient and selective methods. The purity
of the final product was confirmed from its
1
H NMR.
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3.0 BIOLOGICAL ASSAYS
3.1 Immunology
Immune modulation is the means of equilibrating immune system via external stimuli.
Balancing immune system is the only solution to combat disorders due to its
overactivity as well as underactivity. The macrophages, natural killer cells and other
“soldiers” of the immune system attack invading organisms and shield the body from
their infections. Whereas, the immune system when attacks the body itself leads to the
autoimmune diseases like rheumatoid arthritis, type-1 diabetes, etc. Immune
overactivity causes unpleasant side effects, such as allergies and inflammation, and can
lead to immune exhaustion and collapse. Therefore, balancing the body’s immune
system so that it is neither overactive nor underactive is the real answer to maintain
good health. The existing agents used to balance the immune system have been
reviewed in Chapter 1. A number of drugs, which modulate immune system, have
been developed directly or indirectly from the natural resources. For example, the
potent immunosuppressive agents derived from fungi or bacteria such as CsA, FK506,
and rapamycin, which have a degree of selective action on the immune system, has
improved the success rate of transplant surgery indicating the value of natural products
to clinical medicine.
26
The recent observation that the bacterial signal molecules
participating in their cellular communication (QS), also possesses immune modulatory
activity
128
in animals had motivated researchers to study these signal molecules
biologically for better understanding of their mechanism of action and chemically for
the development of novel immuno therapeutic agents.
131
The Pseudomonas aeruginosa quorum sensing signal molecules (QSSMs), 3O, C12-
HSL 1.54 and PQS 1.60 have been observed to modulate immune system apparently
by targeting different receptors. However, details of locations and exact structure of
immunophilin targets are still unknown.
132
N
H
O
O
OH
O
N
H
O
OH
1.54 1.60
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Recently, detailed structure activity relationship (SAR) study using PQS as a lead
molecule has been undertaken with successful development of its novel analogues.
271
However, initial SAR study using 3O, C12-HSL as a lead molecule had delivered its
analogues that though exhibit the desired immune suppressive behaviour
131
but also
have undesired quorum sensing effects (unpublished data). Moreover, some of the
analogues of 3O, C12-HSL suffered with solubility problems in the routine solvents.
The 3O, C12-HSL structure thus demanded further investigations to overcome these
problems of solubility and unwanted quorum sensing behaviour. To address these
issues 3O, C12-HSL was subjected to further structural modifications for the
development of further analogues with improved immunomodulatory and optimum
solubility behaviors as well as with no auto-induction or QS activity.
3.1.1 Structural modifications in 3O, C12-HSL
Biologically active compounds impart their effects by interacting with their target
receptors to which they selectively bind through one or all of the binding interactions
such as ionic bonding, Van der Waal’s interactions, dipole-dipole interactions and/or
hydrogen bonding. The functional group(s) of the active molecule(s) can be perhaps
prone to one or all of these interactions, or even this may not be happening at all in
practice. Importance of these potential interactions can be established by partially
altering the lead structure and comparing their activity. Similar activity to that of lead
molecule reveals that the altered group does not participate in interactions whereas,
enhanced or reduced activity compare to the lead concludes influence of group on
interactions. The SAR studies quite often employed to ascertain biologically important
part(s) of the molecule that eventually confirm final structure of a lead molecule. In
initial SAR studies of 3O, C12-HSL, Chhabra et al, have been successful to ascertain
few functional units amenable for binding to immunophilin targets but none of the
analogues were devoid of molecular interactions responsible for unwanted QS
effect.
131
In order to identify functional units within the structure of 3O, C12-HSL that
are important for selective binding to immunophilin targets, it was essential to carry
out further structural modifications in it. As already discussed, the areas that might
have potential for binding to a selective receptor are as shown in Fig 2.4.
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Further alterations in 3O, C12-HSL structure were achieved by replacing; C
1
or C
3
carbonyl functionality by other functional group; C
4
carbon with hetero atom (nitrogen
with or without substitution or oxygen); one or both the C
2
hydrogen(s) by electron
withdrawing fluorine and replacement of hetero ring with other rings as well as
insertion of hetero atom(s) in positions other than C
4
in the side chain A. Newly
synthesized analogues of the 3O, C12-HSL were evaluated for immunological activity
via inhibition of T-cell proliferation by them (murine leukocyte proliferation assay)
and cytotoxicity effects (dye exclusion assay). Murine leukocyte proliferation assay
and toxicity assay are outlined in Appendix-I and Appendix-II respectively.
128
The
results of the murine splenocyte proliferation assay are expressed as EC50 (PM) and are
an indicator of compound’s pharmacological activity. The term EC50 is a dose (PM) of
compound required to inhibit 50% of a proliferating population of murine splenocytes,
measured using tritiated-thymidine ([
3
H]-thymidine) incorporation as a marker of
proliferation and determined by nonlinear regression analysis. Splenocytes stimulated
with concanavalin A (ConA) are stimulated to incorporate [
3
H]-thymidine into newly
synthesized DNA, indicated as counts per minute (cpm).
All analogues were assayed over a concentration range of 0.3 to 1000 µM in duplicates
(n = 2) and EC50 was assigned from the dose-response curve of murine splenocytes
proliferation (cpm) marked as incorporation of [
3
H]-thymidine into newly synthesized
DNA versus concentrations (µM). The DMSO was used as solvent control for all
Fig 2.4Structure of 3O, C12-HSL of which A (alkyl chain)
and B (1, 3-dicarbonyl) and C (L-HSL) were
considered for SAR studies
N
H
O
O
O
H
O
1
2
3
4
C
Insertion of
hetero atom(s)
S, N
B
Insertion of
hetero atom(s)
N, O
A
Introduction
of F or F2
CH3C(O)-
substitution
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analogues and it was found to display little or no inhibitory effect on cell proliferation.
The results are presented to illustrate stimulations to ConA compared with positive
control (cells + ConA with no compounds or DMSO), negative control (cells only) and
reference standard (cells + ConA with dexamethasone). The effect of 3O, C12-HSL in
the proliferation of murine leukocytes in ConA stimulated assay is shown in Fig 3.1.
Fig- 3.1 Dose-response curves of 3O, C12-HSL and DMSO on ConA stimulated
murine leukocytes proliferation.
3.1.2 SAR studies to develop second generation immune modulatory
analogues of 3O, C12-HSL
New analogues as described in Chapter 2 developed by systematic alterations in the
structure of 3O, C12-HSL within the indicated areas as shown in Fig 2.4.
3.1.2.1 Insertion of N at position 4 in the side chain A of 3O, C12-HSL:
4-Aza analogues
As evidenced from previously reported data, lipophilicity of the alkyl chain A of 3O,
C12-HSL was found to be essential for its immuno suppressive effect with an optimum
length between 9 to 11 carbons.
131,171
However, these analogues also exhibited
unwanted QS effect and analogue(s) with alkyl chain length of 11 or more carbons
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were insoluble in solvent employed for bioassays. Thus insertion of N
4
in alkyl chain
was expected to modulate 3-enolic content of the parent compound which is reported
to be must for immune modulation.
131,171
It would also provide an additional site for
binding interactions with immune specific receptors, thus may display a selective
immune modulation. Whether N
4
-H is, a site of interaction with the receptor was
further confirmed by developing N
4
-substituted analogues. These 4-aza analogues
were obtained via the synthetic methods discussed in chapter 2. The results of
analogues 2.8-2.13 in the proliferation of murine leukocytes in ConA stimulated assay
are shown in Fig 3.2.
Fig- 3.2 Dose-response curves of 4-aza analogues of 3O, C12-HSL on ConA stimulated
murine leukocytes proliferation
From Fig 3.2 it can be deduced that insertion of N
4
in the side chain A is tolerated as it
has retained immune suppression. The dose-response curves were extrapolated and
EC50 obtained from these curves were compared with 3O, C12-HSL as summarised in
Table 3.1
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R X N
H
O
OH
OO
Table 3.1 Immunological results of 4-aza/substituted 4-aza analogues of 3O, C12-HSL
Compound(s) R X EC50 (µM)
1.54 (3O, C12-HSL) CH3(CH2)7- CH2 4.30-4.50
2.8 CH3(CH2)7- NH 15.10
2.9 CH3(CH2)8- NH 2.90
2.10 CH3(CH2)10- NH 0.652
2.11 CH3(CH2)7- NCH3 6.10
2.12 CH3(CH2)7- N(CH2)2CH3 2.90
2.13 CH3(CH2)7- N(CH2)2OH 17.10
The three-fold drop in immune suppressive activity observed with analogue 2.8 as
compared to 3O, C12-HSL However, increased chain length to C9 and C11 (compounds
2.9 and 2.10) enhanced the immune suppression potency when compared to the parent
compound 1.54. Thus, it further confirmed that a longer alkyl chain length (R) is
important for activity. The alkyl substitution on N
4
also contributes towards potency
with optimum level reached with n-propyl substitution (2.12). Insertion of N
4
not only
retains lipophilic character of resultant analogues but also improves their solubility as
evidenced from observation that all analogues were completely soluble in the solvents
employed for their bioassays. However, hydrophilic hydroxylethyl substitution on N
4
(2.13) had slightly reduced potency thus supporting the importance of lipophilicity
131
in immune modulation. These data also support that N
4
may be interacting with an
additional site on the immunophilin receptors in order to elicit selective immune
suppression. Gratifyingly, 4-aza analogues did not show any auto-induction rather they
were found to as QS antagonists (will be discussed in microbiology study).
3.1.2.2 Replacement of C
2
hydrogen(s) of 4-aza 3O, C12-HSL by fluorine(s):
Fluorinated 4-aza analogues
Being most electronegative atom, fluorine greatly influences acidity or basicity of the
nearby functional groups and thus the pKa of the molecule. The pKa has control over
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the pharmacokinetic properties of the molecule and its binding affinity with target
proteins. As discussed before, lipophilicity is a key molecular parameter in medicinal
chemistry as functional groups of substantial lipophilicity within the structure
demonstrate good binding affinity to the target proteins. Moreover, being smallest,
fluorine does not encroach on the spatial requirements of the molecule. Its introduction
in the molecule also imparts metabolic stability.
184
Thus C
2
acidic hydrogens of 3O,
C12-HSL were replaced by fluorine(s) and analogues 2.62 and 2.63 were developed
(Table 3.2).
N
H
N
H
O
OH
OO
R1 R2
Table 3.2 Immunological results of fluorinated 4-aza-3O, C12-HSL analogues
Compound(s) R
1
R
2
EC50 (µM)
1.54 (3O, C12-HSL) H H 4.30-4.50
2.62 F H 21.40
2.63 F F 82.30
Although at higher EC50 compared to 3O, C12-HSL, monofluoro analogue 2.62
retained inhibitory effect on proliferated murine leukocyte cells. Interestingly, distinct
drop in immune suppression activity observed with difluoro analogue 2.63 suggesting
that minimum one hydrogen at C
2
is must for immune modulation. When exposed to
target proteins within the biological system, the C
2
proton(s) of the analogue(s) might
be contributing either via 3-enolic content of the molecule or by binding to the active
site via H-bonding in order to show selective immune modulation. Monofluoro
analogue also did not show QS effect.
3.1.2.3 Insertion of N at position 3 in 3O, C12-HSL: 3-Aza analogues
Carbonyl groups present in a drug molecule are often involved in hydrogen bonding
and ionic bonding interactions with target receptors. Here carbonyl group acts as
hydrogen bond acceptor. Conversion of hydrogen bond acceptor carbonyl group to
hydrogen bond donator hydroxyl group, its bulkier congener benzyloxy group or its
replacement with lone pair containing amino group would alter the nature of bonding
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to the receptor. It had been seen that C
3
=O group of parent compound 3O, C12-HSL
was essential for immune modulation as analogues lacking C
3
=O such as C11-HSL 3.1
and C12-HSL 3.2 were weakly active in murine splenocyte proliferation assay.
131,171
N
H
O
OH
O
N
H
O
OH
O
3.1 3.2
This observation proposes that there exist an interaction between C
3
=O group of the
active molecule and hydrogen donor group of the receptor. We therefore, decided to
further modulate 3-enolic content of the lead molecule 3O, C12-HSL by replacing
C
3
=O functional group with N
3
-OH (hydroxamic acid), more dense N
3
-OBn and N
3
-
NH2 (hydrazine). These replacements resulted in the production of 2.71, 2.77 and 2.72
as shown in Table 3.3.
R Y N
H
O
OH
O
Table 3.3 Immunological results of 3-aza analogues of 3O, C12-HSL
Compound(s) R Y EC50 (µM)
1.54 (3O, C12-HSL) CH3(CH2)8- C=O 4.30-4.50
2.71 CH3(CH2)8- N-OH 13.10
2.77 CH3(CH2)8- N-OBn 1.30
2.72 CH3(CH2)8- N-NH2 0.999
Murine splenocytes proliferation assay showed that activity was reduced by three folds
when free N
3
-OH was inserted to produce analogue 2.71 and newly added functional
group failed to improve the binding affinity through H-bonding to the active sites of
receptors. The hydroxamic acid motif in 2.71 might have lowered its pKa and have
slightly increased its polarity than the parent compound. This was further supported by
potent immune suppression by analogues 2.77 and 2.72 where N
3
was substituted by
lipophilic -OBn and more basic -NH2 groups respectively. Benzyl group would have
balanced appropriate lipophilic content in 2.77. Moreover, through aromatic
interactions, structure in benzyl group might have mapped lager surface of receptor.
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Apart from hydrogen bonding, the N
3
-NH2 substitution would have identified new
binding interactions through its lone pair electrons with receptor.
These results further suggest that by selective modulation of 3-enolic content of parent
compound 3O, C12-HSL, it is possible to discover new active candidates of improved
immune modulatory properties. This denies previous finding that 3-oxo or hydroxyl
group is must for immune modulation.
131
Thus suitably substituted compounds
specifically with hydrogen bonding donating moiety at C
3
can exhibit better immune
modulation. However, further investigations in this direction warranted to support this
hypothesis.
3.1.2.4 Insertion of S in 3O, C12-HSL
Insertion of sulphur as such or its oxidative forms such as sulfone and sulfoxide or
sulphonamide motifs in the medicinal drugs have been achieved successfully to
improve their biological responses. Introduction of sulphur in the form of sulfone or
sufoxide imparts antibiotic properties and its sulphonamide form provides strength
against enzymatic degradation to the otherwise inactive compounds.
210,212,272
It is now
rarely possible to find a class of drugs, which does not possess sulphur in their
structure.
3.1.2.4.1 3-Thia analogues
In order to investigate SAR of 3-thia (2.87-2.91) analogues of 3O, C12-HSL, evaluation
of inhibition of cell proliferation by them was undertaken in the murine leukocytes.
Immune modulatory activity was lost totally in 2.87 where S alone inserted at C
3
in the
parent structure 3O, C12-HSL. Expectedly, introduction of oxo group on S
3
of 2.87
gave rise to compound 2.88 having very high potency of immune suppression
compared to parent compound 3O, C12-HSL. Almost same level of immune
suppression observed when S
3
of 2.87 replaced by sulfone 2.90. These exciting results
are in accordance with the previous statement that 3-oxo group is must for immune
modulation. Around 10 folds further increased immune suppressive potency of
analogues was observed when alkyl chain length A was increased to C11 (2.89 and
2.91). The results of 3-thia analogues are summarised in Table 3.4.
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R Y N
H
O
OH
O
Table 3.4 Immunological results of 3-thia analogues of 3O, C12-HSL
Compound(s) R Y EC50 (µM)
1.54 (3O, C12-HSL) CH3(CH2)8- C=O 4.30-4.50
2.87 CH3(CH2)8- S Inactive
2.88 CH3(CH2)8- S=O 0.547
2.89 CH3(CH2)10- S=O 0.152
2.90 CH3(CH2)8- SO2 0.932
2.91 CH3(CH2)10- SO2 0.450
Moreover, retention of immune modulation by sulfone analogues (2.90-2.91) suggests
that the immunophilin receptors possibly possess considerably bigger size pocket
having more interacting sites to accommodate larger size functional groups like
sulfoxide and sulfone.
3.1.2.4.2 Sulphonamide motif containing analogues: Analogues 2.91 and 2.92
In medicinal chemistry, it is common approach to incorporate several defined bioactive
structural units within single molecule to achieve a more potent pharmacophore.
273
We
successfully employed this concept where active constituents from 4-aza and thia
analogues were utilized in the generation of potent sulphonamide derivatives 2.91 and
2.92 as shown in Table 3.5.
X Y Z N
H
O
OH
Table 3.5 Immunological results of 3O, C12-HSL analogues with sulphonamide motif
Compound(s) X Y Z EC50 (µM)
1.54 (3O, C12-HSL) NH C=O C=O 4.30-4.50
2.91 NH C=O SO2 9.10
2.92 NH SO2 C=O 2.00
&RQILGHQWLDO
- 128 -
Interestingly, slightly less immune suppression was obtained with analogue 2.91 where
C
1
=O was replaced by S
1
=O to generate S
1
(O)NH whereas intense immune
suppression was observed with 2.92 in which S
3
(O)N
4
H was generated by replacing
C
3
=O by S
3
=O followed by insertion of N
4
. This favours our belief that modulation of
3-enolic content of 3O, C12-HSL is more important than modulating C
1
=O function.
Furthermore, in microbiological assay these S containing analogues were found to be
non-quorum sensing.
3.1.2.5 Replacement of L-HSL by other hetero ring
In previous studies, it was found that homoserine ring of 3O, C12-HSL was essential
for immune modulation activity.
131,156
This was further strengthened by the observation
that the ring opened derivative was devoid of any activity.
171,221
However, this finding
was based on immune assays of very few analogues of the altered hetero ring and thus
they were relatively less explored. Hence, one of the aims of this project was to re-
evaluate importance of L-HSL ring of 3O, C12-HSL in eukaryotic immune modulation.
To address this, we synthesized new analogues in which 3-oxo-C12 chain was retained
and other groups replaced the L-HSL ring.
3.1.2.5.1 Hetero ring altered analogues
Introduction of additional heteroatom as well as expansion of active constituents in the
drug molecule can bring about changes in its physiochemical properties.
274
Consequently, a series of hetero ring altered analogues 2.110-2.112 was developed
where the hetero atom O of the L-HSL ring is replaced with N, additional C=O group
is inserted and ring is expanded. A non-chiral thiazole ring replaces the L-HSL. As
shown in Table 3.6 incorporation of N, additional C=O group and ring expansion by
one carbon unit in the hetero ring altered analogues demonstrated complete loss of
immune suppression activity indicating that receptor must be having very specific
pocket to interact with C trait (ref. Fig 2.4) of 3O, C12-HSL. Surprisingly, analogue
with thiazole ring 2.112 retained equipotent immune suppression as that of parent 3O,
C12-HSL.
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N
H
R
OO
Table 3.6 Immunological results of hetero ring altered analogues of 3O, C12-HSL
Compound(s) R EC50 (µM)
1.54 (3O, C12-HSL) O
OH
4.30-4.50
2.110
NH
OH
O Inactive
2.111
H
NH
O
O Inactive
2.112 N
S
12.50
This is not only contradictory to the previous finding that HSL ring and its chirality are
important for immune suppression, but also opened an avenues for the development of
new series of immune modulatory agents. The dose-response effect of 2.112 on the
murine cell proliferation is as shown in Fig 3.3.
Fig- 3.3 Dose-response curves of DMSO, 2.112 and 3O, C12-HSL on ConA stimulated
murine leukocytes proliferation
Moreover, these analogues proved to be non-inducers of QS and very good
antagonists.
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3.1.2.5.2 Hetero ring altered analogues of 3O, 4-aza-C12-HSL
Immunosuppressive results obtained with analogue 2.112 prompted us to further
optimise immunomodulatory potential of existing 3O, 4-aza-C12-HSL 2.8. This will
further explore whether 5-membered ring with a keto or hydroxyl group (or other
hydrogen bond acceptor) adjacent to the amine functionality is essential structural
requirement for binding and activation of immune receptors. Accordingly, types of
cyclic structure that can be constructed are 5- or 6 membered mono or fused rings; (i)
where amino and hydroxyl groups are superimposable with amino and C=O groups in
HSL e.g. 2-aminocyclopentanol, 2-aminocyclohexanol, 2-aminophenols, 2-
aminobenzamides etc., (ii) with amino group but without adjacent hydroxyl (or keto)
group e.g., amino cycloheptanol, 2-aminothiazole, 2-aminopyridine, etc., and (iii) with
more complex structure e.g., 5-aminoindazole. We thus decided to explore immune
modulation of 2.8 by replacing its L-HSL ring by a series of other rings and developed
hetero ring altered analogues of 3O, 4-aza-C12-HSL. Interestingly, all these analogues
when assayed for their inhibitory effects on ConA stimulated proliferative murine
leukocytes showed immune inhibition. Inhibitory effects of few active molecules are
as shown in Fig. 3.4 and Fig 3.5.
Fig- 3.4 Dose-response curves of hetero ring altered 4-aza analogues and 3O, C12-HSL
on ConA stimulated murine leukocytes proliferation.
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Fig- 3.5 Dose-response curves of 2.126 and 3O, C12-HSL on ConA stimulated murine
leukocytes proliferation.
As expected, insertion of thiazole hetero ring 2.125 profoundly increased immune
suppressive potential even more than 2.112 and 3O, C12-HSL. This along with immune
suppression by 2.128 (cycloheptyl) and 2.134 (2-pyridinyl) further indicate that
replacement of L-HSL with other suitable ring without containing keto group (C=O)
retains immune suppression as shown in Table 3.7. As mentioned above, we initially
assumed that since 2-aminocyclopentanol (2.126), 2-aminocyclohexanol (2.127) and 2-
aminophenol (2.129) have hydroxyl group, they would better mimic L-HSL ring
analogy. In fact immunomodulatory activity was retained but at considerably larger
doses than the parent 3O, C12-HSL. This shows the serious participation of ketone in
hydrogen bonding and presumably, hydroxyl substitution seems to maintain less
efficient binding with receptors. The most intriguing observation was that a subtle
structural change from 2-aminophenol (2.129) to 2-amino-4-cholorophenol (2.130)
drastically increased immunosuppressive activity. It is unlikely that such a small
structural difference would completely influence binding to the respective receptors. A
more likely, possible explanation is that 2-aminocyclopentanol (2.126), 2-
aminocyclohexanol (2.127) and 2-aminophenol (2.129) compounds can still bind
immunophilin receptors with similar affinity but are unable to activate them.
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Table 3.7 Immunological results of hetero ring altered 4-aza-3O, C12-HSL
Compound(s) R EC50 (µM)
1.54 (3O, C12-HSL) O
OH
4.30-4.50
2.125 N
S
2.40
2.126
OHH 18.80
2.127
H OH
26.10
2.128
H 2.70
2.129
OH
20.00
2.130
OH
Cl
2.50
2.131
NH2O
12.00
2.132
NO
0.70
2.133
NH2
O
9.40
2.134
N
11.70
2.135 NH
N
6.27
Among these analogues, 2.129-2.133 and 2.130 are aniline derivatives. This set of
molecules also has an ortho- or meta- substituent of a hydroxyl, carboxyamide, or
pyridyl group, which can act as H bond acceptors. The position of these substituents
seems important, and depends on the particular substituent i.e., ortho for hydroxyl or
pyridyl and ortho/meta for carboxyamide. We speculate that the hydroxyl in 2.129 and
2.130, carbonyl group in 2.131, 2.132 and 2.133 as well as the pyridyl group in 2.134
maintains the putative hydrogen bond interaction observed with receptors. In case of
the ortho and meta carboxamide substituents almost similar potency was retained
however, ortho substitution with more lipophilic dimethyl carboxamide group, greatly
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increased (5-folds) immune suppression by 2.132. We therefore, conclude that the
combination of an aniline structure and hydrogen bond acceptor dictates the immune
suppression by this set of molecules. We also identified analogue 2.135 as equipotent
as parent 3O, C12-HSL molecule. To our surprise this does not has obvious structural
connection with the aniline or other analogues discussed above.
3.1.2.6 Insertion of O in 3O, C12-HSL: Oxa analogues
Introduction of hetero atom O in the medicinal compounds has been widely favored to
modify their biological and physical characteristics. Being larger that carbon, oxygen
can provide an additional site(s) not only to interact with target proteins but also to
form hydrogen bonds with solvent molecules or biological fluids. As discussed already
by Chhabra et al., that lipophilicity is must for immune modulation. However, more
lipophilic analogues exhibited solubility issue.
131
We envisioned addressing this issue
by introducing hetero oxygen(s) within the structure of 3O, C12-HSL not to disrupt its
lipophilicity but to maintain proper hydrophilic-lipophilic balance. Moreover, it can
also modulate 3-enolic content of parent structure. Introduction of oxygen was
successfully achieved with the generation of analogues 2.139-2.143 as shown below in
Table 3.8.
R X N
H
R1
OO
Table 3.8 Immunological results of oxa-analogues of 3O, C12-HSL
Compound(s) R X R
1
EC50 (µM)
1.54 (3O, C12-HSL) CH3(CH2)7- CH2 O
OH
4.30-4.50
2.139 CH3(CH2)7- O O
OH
4.80
2.140 CH3(CH2)3O(CH2)3- NH O
OH
200.00
2.141 CH3(CH2)3O(CH2)3- NH
OHH
154.00
2.142 CH3CH2O(CH2)2O(CH2)2- NH O
OH
240.00
2.143 CH3CH2O(CH2)2O(CH2)2- NH
OHH
47.80
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Murine splenocyte proliferation assays of these analogues demonstrated the
importance of lipophilicity in exhibiting biological effects. The oxygen insertion next
to C
3
=O was well tolerated as 4-oxa analogue 2.139 retained equipotent activity as that
of parent compound. Immune suppression activity was profoundly dropped down
when hetero oxygen was positioned 3 carbons away from C
3
=O as can be seen in
analogues 2.140 and 2.141. Moreover, insertion of two additional oxygens also
resulted in almost inactive analogues 2.142 and 2.143. Overall, oxygen introduction
greatly enhanced hydrophobicity of the resultant molecules without enhancing immune
modulation. The dose-response curves of 2.140 and 2.143 are compared with parent
3O, C12-HSL in Fig 3.6. However, these molecules did not show QS behaviour.
Fig- 3.6 Dose-response curves of Oxa analogues and 3O, C12-HSL on ConA
stimulated murine leukocytes proliferation.
3.1.2.7 Miscellaneous analogues: Tetramic acid motif containing analogue of
3O, C12-HSL and 3-acetoxy, C12-HSL
The previously undescribed non-enzymatically formed product tetramic acid 2.152
was discovered by kauffmaun et al. Because this is non-enzymatically degraded
product of parent compound, it was of interest to verify whether immune modulation
by parent 3O, C12-HSL is exhibited via formation of this tetramic acid analogue. We
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therefore considered to verify if 2.152 displays immune modulatory activity.
249
Also
acetylation of hydroxyl groups is a frequently used protection in medicinal chemistry
to protect hydroxyl group from conversion by enzymes in vivo or chemical reactions in
vitro to other undesired functional group.
250,251
It can also modulate 3-keto group of
parent compound. We designed and synthesized 2.152 and 2.154 and checked them for
their immune suppressive behaviors as shown in Table 3.9
Table 3.9 Immunological results of tetramic acid motif containing and 3-O-acetyl
analogues of 3O, C12-HSL
Compound(s) Structure EC50 (µM)
1.54 (3O, C12-HSL) O O
N
H
O
OH
4.30-4.50
2.152 NH
O
O
OH
O H
5.30
2.154 O O
N
H
O
OH
O
0.520
It is noteworthy to mention here that tetramic acid analogue 2.152 demonstrated
equipotent immune suppression behaviour as that of 3O, C12-HSL. Whereas, 3O-
acetylation on the other hand incredibly increased 10 times more immune suppression
than the parent compound once again indicating the importance of C
3
=O functionality.
The both analogues also found to be non-QS.
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3.2 Cytotoxicity assay
It is necessary to assess the cytotoxic effects of all the newly developed analogues of
3O, C12-HSL before further in vitro tests will be carried out. The cytotoxicity data are
useful information (i) for the prediction of influence of compounds on the cell
proliferation in the murine splenocyte assay and (ii) for the exploitation of the
molecules as drug candidate. Ideally, result of the cytotoxicity assay is for a compound
to be non-toxic (NT) but if this is not the case; a large gap also called therapeutic
window exists between the EC50 and the concentration at which the compound is toxic.
If the EC50 and cytotoxicity concentration are very close, there are more possibilities of
toxic effects being observed when compound is used as drug candidate.
The cytotoxicity can be quantitated in vitro by several methods e.g. Trypan blue
exclusion,
51
Cr release, inhibition of colony formation and lactate dehydrogenase
(LDH) release.
275
One of the earliest means of assessing cell damage was the uptake of
trypan blue by dead cells.
276
This technique is still widely used because it is simple,
rapid, involves little manipulation of cells and advantageous over LDH release. We
therefore, employed Trypan blue exclusion assay (see Appendix-II) technique to
measure cytotoxicity. In this murine spleen cells were incubated with 3O, C12-HSL
analogues for 24 h at 37 qC in 5 % CO2/air. The 0.4 % Trypan blue dye which is
incorporated in to dead cells leaving viable cells unstained was then added to cells. The
viable cells were then counted with a counting chamber.
Sometimes, toxicity reports are expressed as ‘cytostatic’ (S), concentration of
compounds sufficient to stop cell growth but do not kill them. The toxicity
concentrations of solvent, parent compound 3O C12-HSL and few analogues required
to kill viable cells were extrapolated from the graph between viable cell counts and
concentration in µM as shown in Fig 3.7 and Fig 3.8
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Fig 3.7 Toxicity analysis of solvent DMSO and 3O, C12-HSL
Fig 3.8 Toxicity analysis of 3O, C12-HSL analogues
The results of analogues using this assay are depicted in Table 3.10 and compared
with their EC50 values.
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Table 3.10 Toxicity data for DMSO, DMSO(eq), 3O, C12-HSL and its analogues.
Compound(s) EC50 (µM) Toxicity (µM)
1.54 (3O, C12-HSL) 4.30-4.50 250
DMSO - 30
DMSO (eq) - 300S
2.8 15.10 200
2.9 2.90 530
2.10 0.652 140
2.11 6.11 !1000
2.12 2.90 200
2.13 17.10 300
2.62 21.40 800
2.63 82.30 !1000
2.71 13.10 400
2.72 0.999 410
2.77 1.30 63
2.87 Not active !1000
2.88 0.547 720
2.89 0.152 45
2.90 0.932 200
2.91 0.450 170
2.92 9.10 220
2.93 2.00 900
2.110 Not active *
2.111 Not active *
2.112 12.50 800
2.125 2.40 600
2.126 18.80 400
2.127 26.10 400
2.128 2.70 78
2.129 21.00 !1000
2.130 2.50 !1000
2.131 12.00 120
2.132 0.70 160
2.133 9.40 700
2.134 11.70 !1000
2.135 6.27 !1000
2.139 4.80 500
2.140 200.00 !1000
2.141 154.00 !1000
2.142 240.30 !1000
2.143 47.80 700
2.152 5.30 52
2.154 0.520 120
S-cytostatic effect; *-activity not performed
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3.3 Microbiology (Quorum-sensing induction and antagonism)
Manipulation of dual biological functional molecules to block one effect over the other
is most widely accepted approach in the medicinal chemistry. For example, celecoxib
3.3 and rofecoxib 3.4 are non-steroidal anti-inflammatory drugs (NSAIDs) but directly
target COX-2, an enzyme responsible for inflammation and pain. Selectivity for COX-
2 reduces the risk of peptic ulceration.
277
Robarge et al. recently synthesized a
ramatroban isostere 3.6 that is a selective and potent antagonist of the chemo-attractant
receptor-homologous molecule expressed on TH
2
cells (CRTH-2). Ramatroban 3.5 is
marketed in Japan for allergic rhinitis as a selective thromboxanetype prostanoid
receptor (TP) antagonist. However, recently ramatroban also identified as a CRTH-2
antagonist.
278
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As noted earlier Pseudomonas aeruginosa signal molecule 3O, C12-HSL has dual
biological function in that it imparts QS activity and also modulates host’s immune
system.
128,131
Developing selective immune modulatory 3O, C12-HSL analogues which
were devoid of QS behaviour was the main objective of our research. Since newly
discovered analogues shared some structural similarities with the parent 3O, C12-HSL
molecule therefore, it was of interest to see if these analogues also exhibited auto-
induction or QS phenomenon in Pseudomonas aeruginosa. In case, no auto-induction
was observed, these analogues could be used as safe immune modulators. To verify
this, we investigated agonist and antagonist activities of these analogues.
Auto-induction or QS activity can be measured by the ability of the compound to
induce bioluminescence in a specifically designed bacterial bio-reporter system. Here
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analogues were tested for their ability to induce bioluminescence in Pseudomonas
aeruginosa reporter strain, PAO1('lasI-PlasB::lux)279 where QS system can be
exogenously activated by the addition of the synthetic 3O, C12-HSL or its analogues.
Values are expressed as a percentage of the bioluminescence measured after exposure
of the bacterial reporter cells to the analogues for 5 h at 37 qC relative to positive
control 3O, C12-HSL (100%).
3.3.1 Screening of analogues for auto-induction (agonist) activity
The ability of the signal molecule to activate LasR was determined by following the
luminescence of the Pseudomonas aeruginosa PAO1 harbouring in to chromosomal
transcriptional fusion 'lasI-PlasB::lux. Since this biosensor strain lacks the ability to
produce natural auto-inducer 3O, C12-HSL due to the disruption of LasI synthase
genes, activation of LasR relies on the addition of exogenous signal molecule 3O, C12-
HSL. Thus, maximum expression of bioluminescence by exogenous addition of a
range of 3O, C12-HSL concentrations was used as a marker to determine its optimal
concentration required for maximum bacterial growth to be observed as shown in Fig.
3.8.
Fig.3.8 Optimum concentration of 3O, C12-HSL (5 µM) required for
maximum growth of Pseudomonas aruginosa
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Screening of individual molecules for their ability to activate LasR was conducted
using 3O, C12-HSL as a positive control and the reporter strain ('lasI-PlasB::lux) as a
control. The results are as shown in Fig 3.9.
Surprisingly, out of 39 new analogues tested only (1R,2S)-2-(3-oxo-8-oxa-4-
azadodecanoyl)aminocyclopentanol 2.141 (Fig 3.9-E) displayed partial auto-inducing
activity whereas, all other analogues showed no auto-induction. Notably, 2.141 also
exhibited very weak immune suppression activity. Non-inducing results are quite
encouraging and possible explaination for this behaviour is that they still bind LasR
but not with appropriate affinity required to activate it. Therefore, we wonder that
A B
C D
E
Fig. 3.9- Auto-inducing (agonist)
reporter screening
'lasI-PlasB::lux was grown for 5 h alone
(sky blue) and in the presence of 5µM 3O,
C12-HSL(black) or 1mM analogue (other
colors). Bioluminescence intensity was
divided by OD495 of cell culture. Positive
control (black) was set to 100 % and all
other values are relative.
The standard deviation (SD) was derived
from5 independent experiments.
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these compounds might act as QS antagonists. Thus these compouns were taken
forward for antagonist assays.
3.3.2 Antagonist assays
Based on the above hypothesis, we extended our efforts to perform competition assay
of new analogues using same reporter strain (('lasI-PlasB::lux). The results were
calculated as % inhibition of relative bioluminescence (QS) by an analogue compared
to the parent 3O, C12-HSL (positive control) and cell culture (control). The
antagonistic activities of analogues are shown below.
3.3.2.1 Antagonistic behavoir of 4-aza, fluorinated 4-aza and 3-aza analogues
As shown in Fig 3.10, 4-aza analogues 2.8, 2.9 and 2.10 showed potent QS inhibition
to about 20 %, 5 % and 15 % respectively at 20-fold excess concentration over 3O,
C12-HSL. The N
4
-alkyl subtituted analogues 2.11 and 2.12 showed lesser inhibitory
acitivity (40 % and 24 % reduction respectiviely) under the same conditions. However,
polar hydroxylethyl substitution at N
4
2.13 exhibited potent inhibition to 20 %. 2-
Monofluoro analogue 2.62 also retained antagonistic behaviour. Since it is non-
immune suppressive, difluoro analogue 2.63 was not assayed.
Fig. 3.10 Antagonist activity of 4-aza and fluoro-4-aza analogues
Black bar (positive control) represents expression of gene proteins in presence of 5 ȝM
3O, C12-HSL. Sky blue bar (control) represents background expression in absence of
3O, C12-HSL or any analogs. Orange, yellow and blue bars; gene proteins expression in
presence of 5 ȝM of 3O, C12-HSL and 1.0 mM, 100 ȝM and 1.0 ȝM of analogues. The
standard deviation (SD) was derived from 5 independent experiments.
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Similarly, the significant activity was exihibited by 3-aza analogues at 100 µM
concentrations as shown in Fig 3.10.
Fig. 3.10 Antagonist activity of 3-aza analogues
3.3.2.2 Antagonistic behavoir of 3-Thia and sulfonamide motifs containing analogues
Among 3-thia analogues, only 2.87 and sulfoxide 2.89 retained inhibition The sulfone
2.90 showed QS inhibition at high magnitude whereas with increased carbon chain in
2.91 inhibitory potential was dropped down to certain extent as shown in Fig 3.11.
Moreover, sulfonamide analogues 2.92 and 2.93 showed partial antagonistic activity,
presumably because of steric hinderence possibly by large atomic size of sulphur.
Fig. 3.11 Antagonist activity of Thia-analogues
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3.3.2.3 Antagonism by hetero ring altered analogues of 3O, C12-HSL and
4-aza 3O, C12-HSL
Replacement of L-HSL ring of parent compound with aspartimide 2.110, glutarimide
2.111 and 2-aminothiazole 2.112 heterocycles gave rise to considerable QS inhibition.
Among these, 2.112 was found to be most potent one. In 2.110 and 2.111 position of
additional carbonyl group and presence of sulphur and nitrogen in 2.112 seems to
maintain putative H bond intractions similar to those osevrved between TraRTrp57 and
the A. tumefaciens autoinducer.
280
Results are shown below in Table 3.12.
Fig. 3.12 Antagonist activity of hetero ring altered analogues
In case of hetero ring altered 4-aza analogues 2.125-2.135 as expected we identified
eight compounds that inhibited more than or almost 50 % QS. As shown in Table 3.13
analogues 2.128, 2.129, 2.131 and 2.132 are most potent antagonists.
Fig. 3.13 Antagonist activity of hetero ring altered 4-aza analogues
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Among these are aniline derivatives 2.129-2.133 and 2.130 with substitution of
hydroxyl, carboxyamide, or pyridyl group, in the ortho or meta position that can act as
H bond acceptors. The position of substituents is also important; carboxyamide
substituent at meta position 2.133 retained considerably lesser activity than ortho
substituted 2.131-2.132. Similarly introduction of an electronegative Cl in the para
position in 2.129 gave rise to 2.130 with 2-fold drop in activity. Possibly hydroxyl,
carbonyl and the pyridyl groups might be involved to maintain putative hydrogen bond
interaction with receptor proteins. We also analyzed structurally dissimilar compound
2.135 and it was observed to possess antagonist activity.
3.3.2.4 Antagonisic behaviour of Oxa-analogues and miscellaneous analogues
The 4-oxa analogue 2.140 was found to be as potent antagonist whereas, compounds
with introduction of oxa additional group in the side chain (2.140, 2.141 and 2.143)
were deprived of activity. However, di-oxa analogue of 4-aza-C12-HSL retained
inhibitory activity.
Fig. 3.14 Antagonist activity of oxa and miscellaneous
(3-O-acetyl and tetramic acid) analogues
As predicted tetramic acid analogue 2.152 was also found to be most potent QS
inhibitor. Acetoxy derivative 2.154 retained weak antagonist behaviour.
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4.0 SUMMARY, DISCUSSION, CONCLUSIONS AND
FUTURE DIRECTIONS
4.1 Summary
In the present study we have successfully developed a number of novel synthetic
analogues of 3O, C12-HSL, which retain immunological modulation in the absence of
any deleterious bacterial growth. For this 3O, C12-HSL molecule was divided in to
three regions A, B and C (Fig 2.4).
Chhabra and coworkers have already explored the SAR of this molecule by
synthesizing a number of analogues and showed that 3-oxo functionality of this
molecule is important for its immunomodulatory activity.
131
We wondered whether the
activity was elicited through 3-oxo structure or its enolic form. We thus, decided to
extend investigation of this molecule to modulate its 3-enolic content (Fig 2.4) by
introducing hetero atom(s) in its structure at C
1
, C
3
and/or C
4
individually or in
combinations. Alternatively, to modulate 3-enolic content 3O, C12-HSL was reduced to
hydroxyl group first and then acetylated. We also replaced C
2
hydrogen(s) by
fluorine(s) and L-HSL ring by other aromatic or hetero aromatic ring with or without
substitution. In order to enhance hydrophilicity we introduced oxygen(s) at C
7
position
individually or C
8
and C
10
positions within the alkyl chain. Finally, 3O, C12-HSL was
transformed using strong base to a tetramic acid derivative via an intra-molecular
Fig 2.4Structure of 3O, C12-HSL of which A (alkyl chain)
and B (1, 3-diketone) and C (L-HSL) were considered
for SAR studies
N
H
O
O
O
H
O
1
2
3
4
C
Insertion of
hetero atom(s)
S, N
B
Insertion of
hetero atom(s)
N, O
A
Introduction
of F or F2
CH3C(O)-
substitution
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cyclisation. The purpose of these alterations was to establish the optimal A and B
regions which could (a) alleviate problems associated with QSSM activity without
losing immunomodulatory activity and solubility of the molecule so that longer chain
length can be accommodated in the A region of the molecule (b) establish importance
of C
3
=O group and L-HSL ring in immune modulation.
Modifications of biologically active lead molecule by introduction of hetero atoms
such as nitrogen, oxygen, sulfur and the electronegative atom fluorine is common for
drug development. These strategies alter molecular properties and thus, biological
activity. We envisioned that presence of nitrogen in 4-Aza
175
compounds (2.8-2.13,
2.125-2.135, 2.140-2.143 and 2.62-2.63) as well as oxygen in 4-oxa
245,246
compound
(2.139) might provide an additional site for target proteins to form hydrogen bonding
and thus would show potent biological response. Also replacing oxidative 2-CH2 group
of 3-oxoamide compound by –CHF or –CF2 in 2.62 and 2.63 might block oxidative
liver enzymatic degradation of 2-CH2 site without affecting its target protein
binding.
184,185
In 3-aza compounds N
3
-substitution with the hydroxyl (compound 2.72)
would be expected to increase the strength of H-bond with the receptor whereas, N
3
-
amino substitution (compound 2.73) would explore receptor to identify new binding
interactions and may render the molecule metabolically more stable to enzymatic
degradation.
191
Replacement of L-HSL of 3O, C12-HSL (compounds 2.110-2.112) and
4-aza-C12-HSL (compounds 2.125-2.135 and 2.140-2.143) by aromatic or hetero-
aromatic ring would not only explore receptor to identify new binding interactions but
also verify the importance of L-HSL ring in immune modulation.
172
These in turn may
result in potentiation of immune modulation. Moreover, insertion of additional
oxygen(s) in the side chain (analogue 2.140-2.143) might improve hydrophilic-
lipophilic balance. The substantial structural alterations planned and availability of
most of starting materials made us to use rather diverse synthetic schemes as
summarized below.
4.1.1 4-aza, fluorinated-4-aza 7,10-dioxa-4aza, 8-oxa-4aza and hetero ring altered
4-aza analogues
As described in Scheme 4.1, malonamic acid derivatives (1), were obtained through
acylation of an appropriate amines with ethyl malonyl chloride whereas, fluoro esters
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(3) were synthesized by direct condensation of n-octylamine with diethyl
difluoromalonate/dimethyl fluoromalonate. Saponification of esters gave
corresponding acids (2 and 4). Acids were coupled to L-HSL using either EDC in
dioxane-water or CDI in dichloromethane or DCCI with HOBt to give final products,
2.8-2.13, 2.125-2.135, 2.140-2.143, and 2.62. Compound 2.63 was obtained by direct
reaction of acid 3 with L-HSL in refluxing acetonitrile.
4.1.2 4-Oxa analogue
For the preparation of 4-Oxa analogue 2.139, mono-benzyl malonate was esterified
with n-octanol in the presence of DCCI and DMAP to furnish di-ester 2.144. Di-ester
2.144 was then deprotected by catalytic hydrogenation to afford the free acid 2.145.
Compound 2.145 was activated by CDI and coupled with L-HSL to furnish 4-oxa
analogue 2.139 (Scheme 4.3).
1 2
2.8-2.13, 2.125-2.135, 2.140-2.143
3 4 2.62
R = n-C8H17/ n-C8H17/ n-C9H19/n-C11H23/
C4H9OC2H6-/C2H5OC2H4OC2H4-
R
1
= H/-CH3/ n-C3H7/-C2H5OH
R
4
= -Me/Et.
R
5
= L-HSL.HCL/NH2-(aromatic/hetero aromatic ring)
2.63
Scheme 4.1 Facile synthesis of fluorinated, hetero ring altered and 4-aza analogues
Reaction conditions: (i) ClCOCH2COOEt, dry DCM 0
0
C to rt., 2 h; (ii) NaOHaq, EtOH, rt., 4 h; (iii) L-
HSL.HCl (or amino-aromatic or hetero aromatic ring with or without substitution), EDC, TEA, Water-
Dioxane, rt., 16 h or L-HSL.HCl , CDI, TEA, dry DCM, rt., 16 h; (iv) EtCOCF2COEt, EtOH, rt., 2 h or
MeCOCH(F)COMe, MeOH, rt., 2 h; (v) L-HSL.HCl , TEA, CH3CN, reflux, 16 h.; (vi) NaOHaq,
MeOH, rt., 3h; (vii) L-HSL.HCl , DCCI, HOBT, dry DCM, rt., 16 h.
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4.1.3 3-aza derivatives:
The introduction of N-OH and N-NH2 motifs to modify the drug candidates is very
much familiar in medicinal chemistry. The syntheses of compounds with a nitrogen
atom at C
3
position (Scheme 4.2), began with the reductive amination of nonyl
aldehyde with O-tert-butylhydroxylamine in the presence of a reducing agent, sodium
cyanoborohydride to obtain N-octyl derivative 2.79.
Alkylation of tert-butyl carbazate with n-octyl bromide gave N-octyl carbazate 2.83.
Compounds 2.79 and 2.83 were further alkylated with benzyl bromoacetate to obtain
corresponding alkylated hydroxylamine and carbazate derivatives 2.80 and 2.84
2.79/2.83 2.80/2.84 2.81/2.85
2.79-2.82: R = O-tert-Bu
2.83-2.86: R = NH-Boc
2.71: R = OH
2.72: R = NH2
2.71/2.72 2.82/2.86
Scheme 4.2 Facile synthesis of 3-aza analogues
Reaction conditions: (i) O-tert-butylhydroxylamine HCl, NaOMe, CH3COOH, Sodium
cyanoborohydride/AcOH, MeOH, 0
0
C to rt., 16 h; (ii) tert-butyl carbazate, THF, reflux, 18 h; (iii)
BrCH2COOCH2Ph, DIPEA, THF, reflux, 16 h; (iv) H2, Pd/C, EtOH, rt., 8 h; (v) L-HSL.HCl , EDC.
HCl, TEA, Water-Dioxane, rt., 16 h; (vi) 50% v/v TFA/DCM, rt., 6 h.
C8H17 O
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N H
R
C8H17 Br
C9H19
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C9H19
N
R
OH
O
C9H19
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H
R O
O
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C9H19
N N
H
R O
O
OH
(i)
(ii)
(iii) (iv)
(v)
(vi)
2.145
2.144 2.139
Scheme 4.3 Facile synthesis of 4-oxa analogue
Reaction conditions: (i) PhCH2OCOCH2COOH, DCCI, DMAP, dry DCM, rt., 16 h; (ii) H2, Pd/C,
EtOH, rt., 8 h; (iii) L-HSL.HCl , CDI, TEA, dry DCM, rt., 16 h.
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respectively. Deprotection of benzyl ester under catalytic hydrogenation conditions
afforded the free acids 2.81 and 2.85. Water soluble carbodiimide (EDC) mediated
coupling of these acids with L-HSL yielded 2.82 and 2.86. Finally the deprotection of
O-tert-butyl and Boc groups with TFA yielded 2.71 and 2.72 respectively.
4.1.4 1-Thia and 3-thia derivatives
Incorporating several defined bioactive structural units to form a more potent
pharmacophore is well known approach in medicinal chemistry. In medicinal drugs
insertion of sulfur, sulfone, sulfoxide and sulfonamide motifs have been achieved
successfully to improve their biological responses. For example, introduction of sulfur
in the form of sulfone or sulfoxide imparts antibiotic properties to the otherwise
inactive organic compounds. We surmised that the introduction of sulfur at the C
1
and
C
3
position in 3O, C12-HSL structure would alter the 3-enolic content due to its
stereoelectronic properties. Thus, a range of thia analogues 2.87-2.93 were elaborated
and screened for their immunological and auto-induction capabilities. The synthetic
sequences utilized for the preparation of derivatives, 2.87-2.91 are outlined in Scheme
4.4.
The key intermediates, 2.96-2.97 were obtained by alkylating appropriate thiols with
tert-butyl bromoactetate. Extreme basic conditions and elevated reaction temperature
afforded in situ deprotection of tert-butyl group. Oxidation of 2.96-2.97 to obtain
monosulfoxides, 2.98-2.99, as a mixture of diastereomers and sulfones, 2.100-2.101
were carried out respectively using bromate-bromide/acid and potassium
permanganate/acid solutions. No attempts were made at this stage to resolve the
enantiomeric mixtures of 2.98 and 2.99. Compounds 2.96, 2.98 and 2.100 were
coupled to L-HSL using CDI to furnish desired derivatives, 2.87, 2.88 and 2.90. Acids
2.99 and 2.101 were successfully coupled with L-HSL using EDC to produce
analogues 2.89 and 2.91. The analogues 2.88 and 2.89 were obtained as a mixture of
their diastereomers. The precise stereochemical identity of these derivatives was not
established as the diastereomers were not separable by PLC.
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As outlined in scheme 4.5, firstly, esterification of sulfoacetic acid to give methyl ester
2.104 was carried out by refluxing it in a mixture of methanol-benzene (1:4) with
azeotropic distillation of water. Refluxing 2.104 with POCl3 afforded sulfonyl chloride
2.105. The amidation of 2.105 with L-HSL in the presence of DBU and DMAP gave
the sulfonamide 2.106 while its amidation with refluxing octylamine in the presence
DBU and potassium carbonate gave sulfonamide 2.108. Acid hydrolysis of methyl
ester, 2.106 delivered the free acid, 2.107 which was successfully coupled with
octylamine using DCCI and DMAP to afford 2.92. Simple saponification of 2.108
yielded 2.109, which was successfully coupled to L-HSL using EDC to furnish 2.93.
(ii) or (v)
(i) (iii)
Thiol 2.98-2.99
2.88-2.89
(ii) (iv)
2.96-2.97 (ii) or (v)
2.87 2.100-2.101 2.90-2.91
Scheme 4.4 Facile synthesis of 3-thia analogues of 3O, C12-HSL
Reaction conditions: (i) t-butyl bromoacetate, 18% w/v NaOH, 90
0
C, 14 h; (ii) L-HSL.HCl ,
CDI, TEA, dry DCM, rt., 16 h (for compounds 2.87, 2.88 and 2.90); (iii) 0.5 N bromate-
bromide, HCl, acetic acid, 0
0
C, 45 min.; (iv) 4% w/v KMnO4, acetic acid, 50
0
C to rt., 40 min.;
(v) L-HSL.HCl, EDC.HCl, TEA, water-dioxane, rt., 16 h (for compounds 2.89 and 2.91).
3-thia acids R Chemical name
Sulphide 2.96 -C9H19 3-Thiadodecanoic acid
2.97 -C11H23 3-Thiatetradecanoic acid
Sulfoxide 2.98 -C9H19 3-Oxo-3-thiadodecanoic acid
2.99 -C11H23 3-Oxo-3-thiatetradecanoic acid
Sulfone 2.100 -C9H19 3,3,-Dioxo-3-thiadodecanoic acid
2.101 -C11H23 3, 3-Dioxo-3-thiatetradecanoic acid
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In another approach to modulate the 3-enolic structure of 3O, C12-HSL 2.155 (3-OH)
and 2.154 (3-OAc) derivatives were synthesized as shown in Scheme 4.6. Acid
catalyzed reduction of 3-oxo of 3O, C12-HSL, using sodium cyanoborohydride gave
the 3-OH derivative albeit as a racemic mixture. Acetylation of 2.155 to obtain 2.154
was achieved in quantitative yield by refluxing it with acetic anhydride.
2.104
2.106 2.107
2.105
2.92
2.108
2.109 2.93
Scheme 4.5 Facile synthesis of sulfonamide motif containing analogue
Reaction conditions: (i) MeOH-Benzene (20:80), distillation, 4 h; (ii) POCl3, reflux, 4 h; (iii) L-
HSL.HCl , DMAP, DBU, dry DCM, 0
0
C to rt., 16 h; (iv) 1.0 M HCl, reflux, 4 h; (v) n-Octylamine,
DCCI, DMAP, dry DCM, rt., 16 h. (vi) n-Octylamine, DBU, K2CO3, dry DCM, reflux, 3 h; (vii)
NaOH/water, MeOH, rt., 4 h; (viii) L-HSL.HCl, EDC.HCl, TEA, Water-Dioxane, rt., 16 h.
HO S O
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Cl S O
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(i)
(ii)
(vi)
(vii)
(viii)
(iii)
(iv)
(v)
(i) (ii)
3O, C12-HSL (racemic mixture) 2.155 2.154
Reaction conditions: (i) sodium cyanoborohydride, methanol-HCl, rt, pH#4.0, 16 h; (ii) acetic
anhydride, reflux, 2 h.
Scheme 4.6 Synthesis of 3-hydroxy and 3-acetoxy derivatives of 3O, C12-HSL
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4.1.5 Hetero ring altered derivatives of 3O, C12-HSL
As shown in Scheme 4.7 acylated Meldrum’s acid 2.118 was synthesized from n-
decanoic acid and Meldrum’s acid using DCCI and DMAP. Condensation of 2.118
with an appropriate amine under reflux yielded corresponding compounds (2.110-
2.112).
4.1.6 Tetramic acid derivative
Treatment of 3O, C12-HSL with a strong base NaOMe in methanol at 55 °C afforded
2.153, which underwent intramolecular Claisen like condensation to yield a 2.152
(Scheme 4.8)
NaOMe/
Methanol,
55 qC, 6 h
3O, C12-HSL 2.153
2.152
Scheme 4.8 Facile synthesis of 3-(1-hydroxydecylidene)-5-(2-hydroxy-
ethyl) pyrrolidine-2,4-dione (Tetramic acid)
N
H
O
O
O
H
O
H H
N
H
O
O
OH
O
OH
NH
O
O
OH
(2.110-2.112)
Acid Meldrum’s acid
Hetero ring altered
analogues
2.118
Scheme 4.7 Facile synthesis of hetero ring altered analogue of 3O, C12-HSL
Reaction conditions: (i) DCCI, DMAP dry DCM, 0
0
C to rt., 16 h; (ii) RNH2, TEA, CH3CN, rt., 16 h.
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All the newly synthesized analogues were analyzed first for their purities and identities
and then taken forward to assay verify them for their immune modulation, cytotoxicity,
non-auto-inducing or non-QS properties.
&RQILGHQWLDO
- 155 -
4.2 Discussion
The present study was undertaken to determine the optimal structural requirements for
the immune modulatory activity without promoting any deleterious auto-inducing
activity of new 3O, C12-HSL analogues. The parent compound 3O, C12-HSL isolated
from the spent culture of the Gram-negative bacterium Pseudomonas aeruginosa and
its synthetic analogues suppress murine and human leucocytes proliferation
13,19
however; these also promote deleterious bacterial growth. Our investigation dealt with
structure alterations on the A, B and C parts (Fig 2.4; page 146) of 3O, C12-HSL
molecule to verify its molecular basis for immunomodulatory activity. Our goal was to
get potent immunomodulatory compounds that were easily accessible but devoid of
auto-induction. A total of 39 compounds were synthesized and characterized. Their
purity was established by chromatography (TLC) and spectroscopic analyses such as
IR, NMR and MS. These compounds were assayed for their ability to modulate murine
leukocyte proliferation stimulated with concanavalin A (ConA), cytotoxicity and also
for their auto-inducing (or QS) activity.
Quantitative and comparative results presented in Table 4.1 are generated from the
types of data and plots as illustrated in Chapter 3. The EC50 is a dose (PM) of
compound required to inhibit 50% of a proliferating population of murine splenocytes,
measured using [
3
H]-thymidine incorporation as a marker of proliferation and
determined by nonlinear regression analysis. Splenocytes stimulated with Con A are
stimulated to incorporate [
3
H]-thymidine into newly synthesized DNA, indicated as
counts per minute (cpm). An auto-inducer (or QS) activity is a measure of the ability
of the compound to induce light production in a specifically designed bacterial bio-
reporter system. Values are expressed as a percentage of the bioluminescence
measured after exposure of the bacteria to the analogues for 5 hours at 37°C relative to
control 3O, C12-HSL (100 %). In this data EC50 for 3O, C12-HSL would be calculated
to be in between 4.30 and 4.50 PM.
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Table 4.1 Quantitative and comparative immune modulatory and quorum-sensing activities of 3O, C12-HSL and various analogues.
X
Y Z
N
H
R4R1
R2 R3
NH
O
O
O
OH
H
I II
R
4
=
a
O
O
b
NH
O
O
NH
O
O
c
N
S
d e
OH OH
f
OH
g
OH
h
Cl
i
O NH2
j
O N
k
O
NH2
l
NH
N
N
m n
No.
Structure Immune modulation activity*
EC50 (ȝM)
Quorum-sensing activity** ± SD
Auto-
induction
Antagonism in presence of 5 ȝM 3O,
C12HSL at variable analogue conc.X Y Z R
1
R
2
R
3
R
4 Inhibition of murine
cells proliferation
Cytotoxicity
Compounds (fold)*** 1 mM 100ȝM
1.54 I CH2 CO CO CH3(CH2)7 H H a 4.4 ± 0.1 250 12.3 100 100
2.8 I NH CO CO CH3(CH2)7 H H a 15.1 200 0.92 20 ± 2 20 ± 2
2.9 I NH CO CO CH3(CH2)8 H H a 2.9 530 0.70 4.8 ± 1.5 3.4 ± 0.4
2.10 I NH CO CO CH3(CH2)10 H H a 0.65 140 0.37 6.1 ± 1.8 14 ± 2
2.11 I NMe CO CO CH3(CH2)7 H H a 6.1 !1000 1.3 70 ± 2 60 ± 2
2.12 I NPr
n
CO CO CH3(CH2)7 H H a 2.9 200 1.9 104 ± 2 101 ± 1
2.13 I N(CH2)2OH CO CO CH3(CH2)7 H H a 17.1 300 0.95 8.5 ± 0.8 16 ± 2
2.62 I NH CO CO CH3(CH2)7 F H a 21.4 800 1.7 37 ± 3 57 ± 2
2.63 I NH CO CO CH3(CH2)7 F F a 82.3 !1000 0.003 2.7± 2.3 6.0 ± 1
2.71 I CH2 NOH CO CH3(CH2)7 H H a 13.1 400 1.1 43 ± 1 69 ± 1
2.72 I CH2 NNH2 CO CH3(CH2)7 H H a 1.0 410 1.1 71 ± 2 55 ± 2
2.77 I CH2 NOBn CO CH3(CH2)7 H H a 1.3 63 **** **** ****
2.87 I CH2 S CO CH3(CH2)7 H H A Not active !1000 0.89 36 ± 2 51 ± 1
2.88 I CH2 SO CO CH3(CH2)7 H H a 0.55 720 NA NA NA
2.89 I CH2 SO CO CH3(CH2)9 H H a 0.15 45 0.90 50 ± 1 63 ± 2
2.90 I CH2 SO2 CO CH3(CH2)7 H H a 0.932 200 1.3 39 ± 1 72 ± 2
2.91 I CH2 SO2 CO CH3(CH2)9 H H a 0.45 170 0.74 67 ± 2 76 ± 1
2.92 I NH CO SO2 CH3(CH2)7 H H a 9.1 220 0.96 77 ± 1 86 ± 2
2.93 I NH SO2 CO CH3(CH2)7 H H a 2.0 900 1.1 77 ± 1 101 ± 2
2.110 I CH2 CO CO CH3(CH2)7 H H b Not active **** 1.4 125 ± 1 82 ± 1
2.111 I CH2 CO CO CH3(CH2)7 H H c Not active **** 1.1 41 ± 2 71 ± 2
2.112 I CH2 CO CO CH3(CH2)7 H H d 12.5 800 0.84 36 ± 2 51 ± 2
2.125 I NH CO CO CH3(CH2)7 H H d 2.4 600 0.91 50 ± 1 64± 1
2.126 I NH CO CO CH3(CH2)7 H H e 18.8 400 1.5 38 ± 1 55 ± 2
2.127 I NH CO CO CH3(CH2)7 H H f 26.1 400 1.2 40 ± 2 45 ± 3
2.128 I NH CO CO CH3(CH2)7 H H g 2.7 78 1.1 14 ± 1 19 ± 4
2.129 I NH CO CO CH3(CH2)7 H H h 20.0 !1000 1.0 15 ± 1 29 ± 2
2.130 I NH CO CO CH3(CH2)7 H H i 2.5 !1000 0.70 57 ± 2 66 ± 1
2.131 I NH CO CO CH3(CH2)7 H H j 12.0 120 0.93 14 ± 1 23 ± 2
2.132 I NH CO CO CH3(CH2)7 H H k 0.70 160 1.5 19 ± 3 37± 4
2.133 I NH CO CO CH3(CH2)7 H H l 9.4 700 0.69 50 ± 1 59 ± 1
2.134 I NH CO CO CH3(CH2)7 H H m 11.7 !1000 1.0 30 ± 1 41 ± 2
2.135 I NH CO CO CH3(CH2)7 H H n 6.3 !1000 1.5 32 ± 3 62 ± 2
2.139 I CH2 O CO CH3(CH2)7 H H a 4.8 500 0.48 33 ± 1 46 ± 4
2.140 I NH CO CO CH3(CH2)3O(CH2)3 H H a 200 !1000 1.2 121 ± 2 118 ± 2
2.141 I NH CO CO CH3(CH2)3O(CH2)3 H H e 154 !1000 3.8 93 ± 3 111 ± 1
2.142 I NH CO CO CH3CH2O(CH2)2O(CH2)2 H H a 240 !1000 1.3 47 ± 2 61 ± 3
2.143 I NH CO CO CH3CH2O(CH2)2O(CH2)2 H H e 48 700 1.1 77 ± 2 89 ± 1
2.152 II - - - - - - - 5.3 52 1.1 17 ± 2 21 ± 1
2.154 I CH2 CHOAc CO CH3(CH2)7 H H a 0.52 120 1.1 59 ± 2 70 ± 2
** Independent observations n=2; * independent readings n=5; SD = standard deviation; *** fold- calculated as ratio of (relative luminescence of cell culture alone)/(relative luminescence of cell culture with analogue); ****-not performed; NA-not available
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Compound activity in the murine splenocyte proliferation assay demonstrated that
introduction of nitrogen at C
4
in the alkyl chain (compounds 2.8-2.10) had retained
immuno-suppressive activity as that of parent compound. Gratifyingly, activity was
increased considerably with the alkyl chain length of 13 and 15 C, (analogues 2.9 and
2.10) as well as when nitrogen at position 4 was substituted with methyl 2.11 (EC50 6.1
µM) and propyl 2.12 (EC50 2.9 µM). The activity although low, was retained when N
4
was substituted with hydrophilic hydroxyethyl 2.13 (EC50 17.1 µM), suggesting that
appropriate lipophilicity is important for activity. The 4-aza analogues also showed no
auto-induction and profound reduction in biosensor activity. Interestingly, with the
insertion of nitrogen we were able to accommodate longer alkyl chains (compounds
2.9-2.11) with no loss of solubility for in vitro testing.
The anti-proliferation activity maintained, albeit slightly less when one of the C
2
-
hydrogens in alkyl chain was replaced with fluorine (compound 2.62). Unfortunately,
replacement of both hydrogens by fluorines (compound 2.63) showed no activity
against murine splenocyte proliferation. It thus appears that minimum of one hydrogen
at C
2
is essential for activity supporting our belief that the immune response is possibly
elicited via 3-enolic tautomer. Moreover, difluoro substitution in compound 2.63,
dramatically improved quorum sensing inhibition activity whereas, it is improved
comparatively less but substantial with monofluoro substitution in monofluoro
compound. The replacement C
3
=O with N
3
-OH (compound 2.71) maintained
equipotent immune suppression whereas, its replacement with N
3
-NH2 (compound
2.72) and N
3
-OBn (compound 2.77) displayed profound increased in the activity. This
demonstrated that suitably substituted compounds specifically with hydrogen bonding
donating entity at C
3
can show potent immune suppression. However, it needs further
investigations to favour this hypothesis. Moreover, compounds 2.71 and 2.72 did not
exhibit auto-induction activity rather were found to have QS antagonist activity.
Among 3-thia compounds, 2.87 showed no activity against splenocyte proliferation.
Substitution of sulfoxide group at C
3
position in 3O, C12-HSL gave compounds 2.88
and 2.89. Surprisingly, compounds 2.88 (EC50 0.55 µM) and 2.89 (EC50 0.15 µM)
showed potent immune suppression, supporting the initial findings of Chhabra et al.
that the presence of a 3-oxo substituent is essential to retain immune suppression. The
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3-sulfoxide derivatives were assayed as mixtures of the diastereoisomers because they
could not be resolved by chromatography. In view of these observations, sulfonyl
derivatives 2.90 and 2.91 were synthesized. As predicted 2.90 (EC50 0.932 µM) and
2.91 (EC50 0.45 µM) also exhibited potent anti-proliferation activity. Furthermore, no
auto-induction was observed with 3-thia analogues 2.87, and 2.89-2.91 as well as they
all exhibited competitive reduction (antagonists) in biosensor activity compared to
parent compound. The C
1
sulfonamide analogues 2.92 (EC50 9.1µM) displayed
immuno-suppression at almost double dose than that of 3O, C12-HSL (EC50 4.5 µM)
whereas C
3
sulphonamide analogue 2.93 (EC50 2.0 µM) displayed at equivalent of half
dose of parent molecule. This suggested that modulation at C
3
=O is more important
than the C
1
=O for better immune suppressive activity. These were also found to be
non-QS. Additionally all thia analogues offered improved in vitro solubility.
Among the ring altered analogues, the replacement of L-HSL by L-aspartimide
(compound 2.110) and L-glutarimide (compound 2.111) units demonstrated complete
loss of immune suppression activity while surprisingly, L-HSL replacement with 2-
aminothiazole ring 2.112 (EC50 12.5 µM) retained immune suppression yet without
deleterious auto-induction. This finding was surprising as the previous reports
emphasized the importance of HSL ring and its chirality. This observation opens door
for the development of a new series of immune modulatory agents via replacement of
HSL ring by other suitable ring(s).
To this end, immune modulatory potential of existing 3O, 4-aza-C12-HSL 2.8 was
successfully metamorphosed by developing analogues 2.125-2.135 where L-HSL ring
was replaced with other 5- or 6 membered mono or fused aromatic rings. As expected
analogue 2.125 (EC50 2.4 µM) exhibited potent immune inhibition. The 2-
aminocyclopentanol (2.126), 2-aminocyclohecanol (2.127) and 2-aminophenol (2.129)
containing compounds retained activity but did not show any improvement over 2.8.
The 2-aminocyclohexane ring analogue 2.128 on the other hand showed potent
activity. Among the aniline derivatives ortho chloro substitution in 2.129 gave
compound more potent 2.130 (EC50 2.5 µM) than 2.8. The ortho and meta
carboxamide substitution (compounds 2.131 and 2.133) also led to retention of
immune suppression whereas, ortho substitution with more bulky N,N-
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dimethylcarboxamide yielded most potent analogue 2.12 (EC50 0.7 µM). Analogues
with 2-aminopyridine (2.134) and 5-aminoindazole (2.135) were also found to retain
equipotent immune suppressive activity. Overall, improvment of immune suppression
by above analogues demonstrated that L-HSL ring can be replaced by other appropriate
ring(s). Moreover, all these hetero-ring altered analogues showed no microbiological
auto-induction.
In case of tetramic acid analogue 2.152 equipotent immune suppression as that of 3O,
C12-HSL was observed whereas, 3-O-acetylation 2.154 on the other hand unbelievably
increased 10 times more immune suppression than the parent compound once again
indicating the importance of C
3
=O functionality. The both analogues also found to be
non-QS.
Insertion of oxygen at C
4
(compound 2.139) retained anti-proliferation activity at
comparatively equivalent dose (EC50 4.8 µM) and only also inhibition in the
bioluminescence activity was observed with this. However, insertion of additional
oxygen(s) in the side chain at 7
th
and 10
th
positions or at 8
th
position resulted in almost
inactive analogues 2.140-2.143, demonstrating that appropriate lipophilicity is must for
immune modulation. Notably analogue 2.141 was found to be partial auto-inducer
(fold 3.8) and almost all of them were inactive as QS antagonists.
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4.3 Conclusions
To investigate structural necessity for the 1, 3-dicarbonyl moiety of the parent
molecule in terms of immunomodulatory activity and alkyl chain towards solubility,
we have synthesized a series of new 3O, C12-HSL analogues. Here we have shown that
introduction of nitrogen and oxygen at C
4
position can be compatible. 4-aza exhibited
equipotent immunomodulation with great degree of reduction in bacterial
bioluminescence. N-Alkylation at this site also retained activity. At least, single
hydrogen at C
2
position also appears to be important for activity since difluoro
analogue showed no activity. The replacement C
3
keto group by hydroxyl aza (N
3
-OH,
2.71), its benzyl substituted dervative (N
3
-OBn, 2.77) and amino aza (N
3
-NH2, 2.72)
group was successfully achieved and these analogues also exhibited potent immune
modulation without detrimental QS effect. Moreover, C
3
=O of 1, 3-dicarbonyl moiety
can be favorably replaced by sulfoxide and sulfones. However, its replacement with
thia group led to inactive compound thus, it is apparent that the 3-oxo substitution is
important for immune suppressive activity. 3-sulfoxide derivatives, even as a mixture
of diastereoisomers, were potent immune suppressive. The replacement 3-keto
function by sulfonamide (compound 2.93) as well as C
1
keto group by sulfone
(compound 2.92) groups also preserved immune suppressive activity. The L-HSL ring
was found not essential for immune modulation as appropriate ring containing hetero
ring altered analogues (compounds 2.110-2.112 and 2.125-2.135) revealed improved
immune suppression. Insertion of O at C
4
can be better tolerated whereas its insertion
at C
8
as well as with additional oxygen at C
7
and C
10
resulted in complete loss of
activity. The simple 3-O-acetylation also was found to be tolerated and yielded potent
analogue 2.154. Moreover structurally unrelated tetramic acid analogue also retained
activity.
All these structural modifications also lowered the lipophilic character of the
compounds and thus showed improved in vitro solubility. The preliminary quorum
sensing cellular assays of all these analogues have exhibited great degrees of reduction
in bacterial bioluminescence compared to 3O, C12-HSL.
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4.4 Future directions
4.4.1 Further biological investigations of active analogues in higher animals
Following, the results of extended SAR and primary biological (immunological and
microbiological) assays in well-established models, a number of active analogues (2.9,
2.10, 2.12, 2.72, 2.88-2.91, 2.93, 2.125, 2.128, 2.130, 2.132 and 2.139) can be selected
as promising candidate and need to be taken further for immunological investigations
in higher animal/human models. For example, inhibition of mitogen-driven
proliferation of human peripheral blood monocyte cells (HPMC) and inhibition TNF-Į
secretion in HPMC stimulated by bacterial lipopolysaccharide (LPS).
131
If successful,
these compounds would establish the basis for further molecular mechanistic studies to
identify molecular targets in eukaryotic cells.
4.4.2 Synthesis of new series of 3-aza analogues of 3O, C12-HSL
In an attempted synthesis of 3-(N-OH) C12-HSL (compound 2.71) as shown in
scheme-12 (page 91), its precursor 3-(N-OBn) C12-HSL (compound 2.77) was first
synthesized. It was just serendipity that when investigated, this compound showed
potent immune suppression with EC50 = 1.3 µM, even more than its congener molecule
2.71 (EC50 = 13.1 µM). These results further suggest that by hydrophobic interacting
site might be available in the immunophilin receptors to interact with aromatic benzene
ring of analogue 2.77. With this logic it would be possible to design and develop a new
series of 3-aza analogues by replacing benzyl group by various hydrophobic 5 or 6
membered heterocyclic mono or fused (substituted or un-substituted) or other aromatic
rings as shown below in Fig 4.1-A. In addition, new analogues would also be obtained
by replacing L-HSL with other rings used in the synthesis of analogues 2.125-2.135 as
shown in Fig 4.1-B. Similar approach could also be applicable for other active
analogues containing L-HSL ring e.g. active analogues from thia series and 3-O-aceyl
analogue 2.154.
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2.71 2.77
Hydrophilic interaction
Hydrophobic interactions Hydrophobic interactions
A. Proposed molecule with B. Proposed molecule with 3-aza
different 3-aza substitutent sunstituent and hetero ring alteration
Fig 4.1 Proposed new 3-aza analogues showing possible interactions with receptor
4.4.3 Synthesis of bivalent ligands
A bivalent ligand is a composite structure that comprises of two pharmacophores
linked through an appropriate spacer.
281,282
It serves as the conceptual basis for the
design of congener with dual function and thus may be with better potency. Thorough
immunological evaluations of 3O, C12-HSL at cellular and molecular levels in
eukaryotic cells have made it clear that there exist(s) specific receptor(s) for its
binding in eukaryotes to mediate fluctuations in immunological behaviours. Similar
studies in PQS showed the presence of an additional target that is different from 3O,
C12-HSL targets in eukaryotes for its binding to mediate immune modulation.
Surprisingly combination of 3O, C12-HSL and PQS exhibited synergism in suppressing
leukocyte proliferation. This demonstrates that both 3O, C12-HSL and PQS have
separate receptors for their binding in eukaryotes in showing their synergistic effects in
immune modulation. However, exact location and structures of these targets have not
yet been identified and need further investigation. It is possible to maximize this
synergistic behaviour by design and synthesis of bivalent ligands by linking these two
structures through an appropriate spacer as shown below in Fig 4.2.
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Fig 4.2 Synergistic behaviour of divalent ligands
Active analogues of newly synthesized compounds would be used to develop their
homo- and/or hetero- bivalent dimers with PQS molecule or its active analogues in
order to synergize immune modulatory effect. The possible combinations of this
approach are shown below in Fig 4.3
Fig 4.3 (A) Hetero-ligands of 3O, C12-HSL; (B) homo-dimer of 3O, 4-aza C12-HSL.
The new dimeric molecules with a spacer of optimal length would be expected to
exhibit a potency that is greater than that derived from the sum of its two monovalent
pharmacophores i.e. 3O, C12-HSL and PQS.
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4.4.4 Isolation and identification of target proteins (immunophillins)
The understanding of immune system really means our ability to understand how drugs
act to modulate immune system. To understand how drugs act within the immune
system, the isolation and the characterization of the target proteins is imperative. This
has been exploited by employing the affinity chromatography, this involves loading
the drug molecule on the biological fluids for participatory targets.
283
In the previous study Harty et al. have developed terminal chain linked affinity matrix
4.1 to isolate targeted proteins responsible for immune activity. Here, 4.1 was treated
with mouse splenocyte and human granulocytes extracts and two proteins of molecular
weight 14 KDa (Kilo Daltons) and 8 KDa were isolated from each extract. These
proteins were identified as calgranulin A and B respectively. Subsequent research has
demonstrated calprotectin as the putative target for the 3O, C12-HSL. How 3O, C12-
HSL interacts with calprotectin to exhibit immunological activity is yet to be
understood.
N
H
O O
O
OH
N
O
N
O
Affi-Gel
4.1
As 3O, C12-HSL has dual activities that are QS and immune modulation. It is thus
possible that it in this form it might not have strong affinity for the appropriate target
proteins. Also, it is understood that lipophilic character of the alkyl side chain is must
for activity. This further suggests that possibly free alkyl chain may be interacting to
hydrophobic pocket in the immunophilin. This raises the possibility, that binding
proteins must be linked to other linkage point in alkyl chain and not terminally.
Therefore, if newly developed selective immune modulatory analogues are presented
to the binding proteins through any linkage except the terminal linkage and then are
treated with mouse splenocyte or human granulocyte extracts, these might target
selectively to putative proteins responsible for immune modulation. Representative
structures of analogue(s) linked Affi-Gel matrices are shown below in Fig 4.4.
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Fig 4.4 Proposed analogue loaded Affi-Gel matrices via 1,3-diaminopropane or
piperazine linker
Isolation of the correct target immunophilins would further facilitate the development
of novel immune modulatory agents for therapeutic intervention.
N N
H
O O
R1
Affi-Gel
R
YX N
H
O O
R1
Affi-Gel
Y
a
O
O
b
NH
O
O
NH
O
O
c
N
S
d e
OH OH
f
OH
g
OH
h
Cl
i
O NH2
j
O N
k
O
NH2
l
NH
N
N
m n
R1=
X= N
R = H, Alkyl
Y =
N
O
N
O
N
H
N
H
O O
&RQILGHQWLDO
- 166 -
5.0 EXPERIMENTAL
5.1 Chemicals and reagents
L-Homoserine obtained from NovaBiochem (Nottingham, U.K.), was used to make L-
homoserine lactone hydrochloride. Carboxylic acids and other starting materials were
purchased from Aldrich Chemical Co. and Lancaster chemicals. The solvents used
were of HPLC grade. Dichloromethane was dried by storing it over anhydrous calcium
chloride and distillation.
5.2 General analytical methods
Melting points were recorded on Kofler Hot Stage melting point apparatus and are
reported uncorrected.
FT-Infrared spectra were taken on Avatar 360 Nicolet FT-IR spectrophotometer
through the range 4000-600 cm
-1
and measured in KBr pellets or as thin films.
1
H NMR spectra were recorded in deuteriochloroform (CDCl3) or DMSO-d6 solvent
as specified on Bruker AMX-250 or Bruker Avance-400 spectrophotometer operating
at 250 and 400 MHz respectively.
13
C NMR spectra were recorded in CDCl3 or DMSO-d6 with a Bruker Avance-400
instrument operating at 100 MHz.
Chemical shifts are referenced to an internal standard Tetramethylsilane (TMS) or
residual protic solvents, on a broad band decoupled mode, and assignments were made
using a DEPT pulse sequence. Chemical shifts are expressed as G units and J values
are in Hz.
Electrospray mass spectra (ES-MS) were recorded using Micromass VG platform
and Micromass LCT spectrometers for low- and high-resolution spectra, respectively.
Thin-layer chromatography (TLC) was performed using Merck silica gel 60 GF254
precoated (0.2 mm) aluminium plates. Preparative thin-layer chromatography
&RQILGHQWLDO
- 167 -
(PLC) was performed using Merck silica gel 60 GF254 coated (1.0 mm) glass plates (20
cm u 20 cm). Flash chromatography was performed using Merck Kieselgel 60 (230-
400 mesh) silica. All products during chromatography were visualized using either UV
light (O=254 nm) or by staining with dilute potassium permanganate or
phosphomolybdic acid solution.
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5.3 Synthesis of analogues of 3O, C12-HSL
5.3.1 Method-A
To a stirred solution of an appropriate acid (1 mmol) in a minimum volume of dioxane
(4-6 mL) was added a solution of L-HSL.HCl (1 mmol) in a minimum amount of water
(about 2 mL). To this was added sequentially TEA (3 mmol) followed by EDC.HCl
(1.5 mmol) and stirring was continued for 16 h at room temperature. Solvents were
removed under reduced pressure and the residue redissolved in warm ethyl acetate (20
mL). Organic solution was sequentially washed with water (3 u 10 mL), saturated
sodium bicarbonate (3 u 10 mL) and brine (1 u 15 mL). The organic layer was dried
over MgSO4, filtered and rotary evaporated to obtain desired products.
5.3.2 Method-B
To a stirred solution of an appropriate acid (1 mmol) in dry DCM (20 ml) was added
sequentially CDI (1 mmol), TEA (1.5 mmol) and L-HSL.HCl (1 mmol). The solution
was stirred at room temperature for 16 h and then filtered to remove the precipitated N,
N’-dicyclohexylurea. The filtrate was evaporated in vacuo. The residue was
redissolved in ethyl acetate (25 mL). Organic solution was washed with saturated
sodium bicarbonate (3 u 10 mL), 1 M HCl (3 u 10 mL) and brine (1 u 15 mL). The
organic layer was dried over MgSO4, filtered and rotary evaporated to obtain product.
5.3.3 Method-C: Synthesis of 3-oxo-4-azaalkanoic acids (Saponification of ethyl
esters of 3-oxo-4-azaalkanoic acids)
To a stirred solution of ethyl or methyl, 3-oxo-4azalkanoates (5 mmol) in ethanol or
methanol (25 mL), was added dropwise NaOH (6 mmol) solution in water (15 mL).
The stirring was continued at room temperature for 4 h. The mixture was rotary
evaporated and the residue redissolved in water (20 mL) and washed with ethyl acetate
(2 u 10 mL). Aqueous layer was acidified with 2 M HCl to pH 2 and the free acid was
extracted with ethyl acetate or DCM (3u15 mL), dried over MgSO4, filtered and
solvent rotary evaporated to afford the title acids.
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5.3.4 Ethyl esters of 3-oxo-4-azaalkanates
5.3.4.1 Method-D
To a stirred solution of an appropriate amine (10 mmol) in dry DCM (25 mL) at 0
0
C,
ethyl malonyl chloride (5 mmol) was added dropwise over a period of 20 min. The
stirring was continued at room temperature overnight. An additional portion of DCM
(15 mL) was added, and the solution was sequentially washed with saturated sodium
bicarbonate (3 u 20 mL), 2 M HCl (3 u 15 mL) and brine (1 u 25 mL) solution. The
organic layer was separated, dried over MgSO4 and rotary evaporated to give the
corresponding ethyl 3-oxo-4-azaalkanoate. Final product was recrystallized from ether.
5.3.4.2 Method-E
To a stirred solution of an appropriate amine (5 mmol) and diisopropylethylamine (5.5
mmol) in dry DCM (20 mL) at 0
0
C, a solution of ethyl malonyl chloride (5.5 mmol) in
DCM (5 mL) was added dropwise over a period of 20 min. The mixture was stirred
overnight at room temperature. The solvent was rotary evaporated and the residue was
redissolved in ethyl acetate (25 mL). The solution was sequentially washed with
saturated sodium bicarbonate (3 u 20 mL), 2 M HCl (3 u 15 mL) and brine (1 u 25 mL)
solution. The organic layer was separated, dried over MgSO4 and rotary evaporated to
give the corresponding ethyl 3-oxo-4-azaalkanoate.
5.3.5 Method-F: N-substituted octylamines
To a solution of appropriate amine (4 mmol) in acetonitrile (20 mL) was added
potassium carbonate (4.4 mmol) and stirred for 10 min. To this suspension was added
n-octylbromide and stirring was continued for 18 h at room temperature. Solvent was
removed by rotary evaporation and the residue was redissolved in ethyl acetate (25
mL). This solution was washed with water (3 u 10 mL) and brine (1 u 15 mL). The
organic layer was dried over MgSO4 and filtered. The solvent was removed under
vacuum to obtain an oily product that was a mixture of the desired product and the
tertiary amine as a side product. The desired product was isolated by column
chromatography in methanol-ammonia (9.6:0.4) solvent system.
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5.4 Synthesis of 4-Aza analogues of 3O, C12-HSL
5.4.1 3O, 4-aza C12-HSL [2.8]
Ethyl 3-oxo-4-azadodecanoate [2.32]
N
H
O
O O
Ethyl 3-oxo-4-azadodecanoate was synthesized as white crystals in 95 % yield from n-
octylamine using Method- D.
TLC-Rf = 0.43 in ethyl acetate-hexane (1:1)
FT-IR (KBr) cm
-1
: 3297m, (QNH); 1731s (QC=O, ester); 1650s(QC=O, amide); 1568s
(GNH, amide).
1
H NMR (CDCl3) į 0.93 (3H, t, J = 6.0 Hz, CH3(CH2)7-), 1.07-1.77 (13H, m,
CH3(CH2)5- and CH3CH2-), 1.43-1.52 (2H, m, CH3(CH2)5CH2-), 3.23 (2H, t, J = 7.5,
CH3(CH2)6CH2-), 3.30 (2H, s, -COCH2CO-), 4.23 (2H, q, J = 7.5 Hz, CH3CH2-), 7.71
(1H, s, broad, -(CH2)7NH-).
3-Oxo-4-azadodecanoic acid [2.38]
N
H
OH
O O
3-Oxo-4-azadodecanoic acid was synthesized as white needles in 85 % yield from
saponification of ethyl, 3-oxo-4-azadodecanoate using Method-C.
mp = 78-80 qC.
FT-IR (KBr) cm
-1
: 3325s, (QNH); 1717s (QC=O, acid); 1623s (QC=O, amide); 1571s
(GNH, amide).
1
H NMR (CDCl3) į 0.9 (3H, t, J = 7.2 Hz, CH3(CH2)7-), 1.23-1.32 (10H, m, CH3
(CH2)5-), 1.53-1.58 (2H, m, CH3(CH2)5CH2-), 3.33 (2H, t, J = 6.8, CH3(CH2)6CH2-),
3.37 (2H, s, -COCH2CO-), 6.69 (1H, s, -(CH2)7NH-), 9.86 (1H, s, -COOH).
13
C NMR (CDCl3) į 168.68, 168.59, 90.71, 40.16, 38.19, 31.76, 29.15, 29.11, 26.82,
22.63, 14.11.
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3O, 4-aza C12-HSL [2.8]
N
H
N
H
O O
O
OH
3O, 4-aza C12-HSL was synthesized as white crystals in 38 % yield from 3-oxo-4-
azadodecanoic acid using Method-A.
TLC-Rf = 0.38 in ethyl acetate-hexane (4:1)
mp = 126-128 qC.
FT-IR (KBr) cm
-1
: 3293s, br. (QNH); 1771s (QC=O, lactone); 1685s (QC=O, 1, 3-
diamide); 1645s (QC=O, amide); 1557s (GNH, amide).
1
H NMR (CDCl3): į 0.90 (3H, t, J = 6.5 Hz, CH3(CH2)7-), 1.27-1.48 (10H, m,
CH3(CH2)5-), 1.51 (2H, s, broad, CH3(CH2)5CH2-) 2.34 (1H, m, ring, 4D-H), 2.66 (1H,
m, ring, 4E-H), 3.22 (2H, t, J = 6.6, CH3(CH2)6CH2-), 3.28 (2H, s, -COCH2CO), 4.23
(1H, m, ring, 3-H), 4.49 (1H, m, ring, 5D-H), 4.60 (1H, m, ring, 5E-H), 7.14 (1H, s, -
(CH2)7NH-), 8.20 (1H, d, J = 6.8 Hz, -NH-HSL).
13
C NMR (CDCl3) į 172.21, 168.13, 167.12, 65.92, 49.28, 42.62, 39.79, 31.81, 29.31,
29.18(3), 26.94, 22.62, 14.11.
(ES-MS/FAB-MS); m/z 299.1960 (M+H
+
) C15H27N2O4, requires m/z 299.1971(' =
3.68 ppm).
5.4.2 3O, 4-aza C13-HSL [2.9]
Ethyl 3-oxo-4-azatridecanoate [2.33]
N
H
O
O O
Ethyl 3-oxo-4-azatridecanoate was synthesized as pink crystals in 66 % yield from n-
nonylamine using Method-D.
TLC-Rf = 0.45 in ethyl acetate-hexane (1:1)
mp = 185-187 qC.
FT-IR (KBr) cm
-1
: 3294m, (QNH); 1744s (QC=O, ester); 1654s(QC=O, amide); 1560s
(GNH, amide).
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1
H NMR (CDCl3) į 0.89 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.21-1.32 (15H, m,
CH3(CH2)6- and CH3CH2-), 1.50-1.55 (2H, m, broad, J = 7.2 Hz, CH3(CH2)6CH2-),
3.29 (2H, t, J = 7.2, CH3(CH2)7CH2-), 3.31 (2H, s, -COCH2CO-), 4.21 (2H, q, J = 7.2
Hz, CH3CH2-), 7.13 (1H, s, -(CH2)7NH-).
3-Oxo-4-azatridecanoic acid [2.39]
N
H
OH
O O
3-Oxo-4-azatridecanoic acid was synthesized as white crystals in 94 % yield from
saponification of ethyl, 3-oxo-4-azatridecanoate using Method-C.
mp = 82-84 qC.
FT-IR (KBr) cm
-1
: 3300s, (QNH and OH); 1708s (QC=O, acid); 1638s(QC=O, amide);
1561s (GNH, amide).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 7.0 Hz, CH3(CH2)8-), 1.24-1.38 (12H, m,
CH3(CH2)6-), 1.53-1.58 (2H, m, broad, CH3(CH2)6CH2-), 3.32 (2H, s, -COCH2CO-),
3.35 (2H, t, J = 7.2, CH3(CH2)7CH2-), 6.30 (1H, s, -NH-), 11.21 (1H, s, -COOH).
13
C NMR (CDCl3) į 168.66, 168.18, 40.14, 38.22, 31.82, 29.43, 29.20, 29.17, 29.14,
26.80, 22.64, 14.08.
3O, 4-aza C13-HSL [2.9]
N
H
N
H
O O
O
OH
3O, 4-aza C13-HSL was synthesized as pinkish white crystals in 31 % yield from 3-
oxo-4-azatridecanoic acid using Method-A.
TLC-Rf = 0.70 in ethyl acetate-hexane (4:1)
mp = 122-124 qC.
FT-IR (KBr) cm
-1
: 3301s, br. (QNH); 1778s (QC=O, lactone); 1679m (QC=O, 1, 3-
diamide); 1642s (QC=O, amide); 1550s (GNH, amide).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.27-1.38 (12H, m,
CH3(CH2)6-), 1.51-1.56 (2H, m, broad, CH3(CH2)6CH2-) 2.26-2.31 (1H, m, ring, 4D-
H), 2.72-2.79 (1H, m, ring, 4E-H), 3.24 (2H, s, -COCH2CO), 3.28 (2H, t, J = 7.0 Hz,
&RQILGHQWLDO
- 173 -
CH3(CH2)7CH2-), 4.26-4.33 (1H, m, ring, 5D-H), 4.48-4.53 (1H, m, ring, 5E-H), 4.55-
4.61 (1H, m, ring, 3-H), 6.49 (1H s, broad, -NH), 7.78 (1H, d, J = 6.0 Hz, -NH-HSL).
13
C NMR (CDCl3) į 174.67, 167.67, 166.73, 65.81, 49.05, 42.46, 39.86, 31.85, 29.56,
29.48, 29.31, 29.25(2), 26.89, 22.67, 14.12.
(ES-MS/FAB-MS); m/z 313.2138 (M+H
+
) C16H29N2O4, requires m/z 313.2127(' = 3.5
ppm).
5.4.3 3O, 4-aza C15-HSL [2.10]
Ethyl 3-oxo-4-azapentadecanoate [2.34]
N
H
O
O O
Ethyl 3-oxo-4-azapentadecanoate was synthesized as pale yellow crystals in 93 %
yield from n-undecylamine using Method- D.
TLC-Rf = 0.41 in ethyl acetate-hexane (1:1)
mp = 196-198 qC.
FT-IR (KBr) cm
-1
: 3292s, (QNH and OH); 1745s (QC=O, ester); 1636s(QC=O, amide);
1548s (GNH, amide).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 6.8 Hz, CH3(CH2)10-), 1.25-1.37 (19H, m,
CH3(CH2)8- and CH3CH2-), 1.50-1.56 (2H, m, broad, J = 7.2 Hz, CH3(CH2)8CH2-),
3.28 (2H, t, J = 7.2, CH3(CH2)9CH2-), 3.31 (2H, s, -COCH2CO-), 4.21 (2H, q, J = 7.2
Hz, CH3CH2-), 7.12 (1H, s, -(CH2)7NH-).
13
C NMR (CDCl3) į 168.13, 166.87, 61.52, 41.05, 39.60, 31.90, 29.57, 29.51(2),
29.36, 29.32, 29.27, 26.90, 22.68, 14.10, 14.05.
3-Oxo-4-azapentadecanoic acid [2.40]
N
H
OH
O O
3-Oxo-4-azapentadecanoic acid was synthesized as white crystals in 87 % yield from
saponification of ethyl, 3-oxo-4-azapentadecanoate using Method-C.
mp = 92-94 qC.
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FT-IR (KBr) cm
-1
: 3317s, (QNH and OH); 1708s (QC=O, acid); 1638s(QC=O, amide);
1553s (GNH, amide).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 7.0 Hz, CH3(CH2)10-), 1.25-1.38 (16H, m,
CH3(CH2)8-), 1.53-1.59 (2H, m, broad, CH3(CH2)8CH2-), 3.31 (2H, s, -COCH2CO-),
3.34 (2H, t, J = 7.2, CH3(CH2)9CH2-), 6.22 (1H, s, -NH-), 12.6 (1H, s, broad, -COOH).
13
C NMR (CDCl3) į 171.68, 166.67, 40.17, 38.10, 31.89, 29.57, 29.54(2), 29.46,
29.30, 29.15, 26.80, 22.67, 14.10.
3O, 4-aza C15-HSL [2.10]
N
H
N
H
O O
O
OH
3O, 4-aza C15-HSL was synthesized as pinkish white crystals in 55 % yield from 3-
oxo-4-azapentadecanoic acid using Method-A.
TLC-Rf = 0.52 in ethyl acetate-hexane (4:1)
mp = 123-125 qC.
FT-IR (KBr) cm
-1
: 3293s, br. (QNH); 1771s (QC=O, lactone); 1686m (QC=O, 1, 3-
diamide); 1644s (QC=O, amide); 1554s (GNH, amide).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 7.0 Hz, CH3(CH2)10-), 1.27-1.33 (16H, m,
CH3(CH2)8-), 1.50-1.58 (2H, m, broad, CH3(CH2)8CH2-) 2.25-2.30 (1H, m, ring, 4D-
H), 2.72-2.78 (1H, m, ring, 4E-H), 3.25 (2H, s, -COCH2CO), 3.27 (2H, t, J = 7.0 Hz,
CH3(CH2)9CH2-), 4.26-4.33 (1H, m, ring, 5D-H), 4.48-4.53 (1H, m, ring, 5E-H), 4.55-
4.62 (1H, m, ring, 3-H), 6.48 (1H s, -NH), 7.75 (1H, d, J = 6.0 Hz, -NH-HSL).
13
C NMR (CDCl3) į 175.17, 167.67, 166.13, 65.78, 54.12, 43.05, 41.46, 32.26,
30.25(2), 29.38, 29.19, 26.82, 22.74, 14.12.
(ES-MS/FAB-MS); m/z 341.2434 (M+H
+
) C18H33N2O4, requires m/z 341.2440 (' =
1.76 ppm).
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5.4.4 3O, 4-Me, 4-aza C12-HSL [2.11]
Ethyl 3-oxo-4-methyl-4-azadodecanoate [2.35]
N O
O O
Ethyl 3-oxo-4-methyl-4-azadodecanoate was synthesized in 97 % yield from N-
methyloctylamine using Method-D. Final product was recrystallized from ether.
TLC-Rf = 0.46 in ethyl acetate-hexane (1:1)
1
H NMR (CDCl3) į 0.87 (3H, t, J = 6.7 Hz, (CH3(CH2)7NCH3-), 1.26-1.32 (13H, m,
CH3(CH2)5- and OCH2CH3), 1.55 (2H, s, broad, CH3(CH2)5CH2-), 2.96 (3H, dd, J =
2.9, 8.6 Hz, -NCH3), 3.24 (1H, J = 7.6 Hz, CH3(CH2)6CH(H)-), 3.39 (1H, quint, J =
2.9, 7.6 Hz, CH3(CH2)6CH(H)-), 3.44 (2H, d, J = 2.9 Hz, -COCH2CO-), 4.2 (2H, 2 u q,
- OCH2CH3).
3-Oxo-4-methyl-4-azadodecanoic acid [2.41]
N OH
O O
Saponification of ethyl, 3-oxo-4-methyl-4azadodecanoate afforded 3-oxo-4-methyl-4-
azadodecanoic acid as white crystals in 93 % yield using Method-C.
FT-IR (KBr) cm
-1
: 3296s, (QOH); 1718s (QC=O, acid); 1649(QC=O, amide).
1
H NMR (CDCl3) į 0.89 (3H, t, J = 6.0 Hz, (CH3(CH2)7-), 1.10-1.45 (10H, m,
CH3(CH2)5-), 1.58 (2H, s, broad, CH3(CH2)5CH2-), 3.03 (3H, s, -NCH3), 3.24 and 3.44,
(2H, t, J = 7.6 Hz, CH3(CH2)6CH2-(Z and E-form)), 3.37 and 3.39 (2H, 2 u s, -
COCH2CO-, (Z and E –isomers)), 10.15 (1H, s, -COOH).
3O, 4-Me, 4-aza C12-HSL [2.11]
N N
H
O O
O
OH
3O, 4-Me, 4-aza C12-HSL was synthesized as a white solid from 3-oxo-4-methyl-4-
azadodecanoic acid using Method-B. The product was purified as crystalline solid in
20 % yield by PLC using ethyl acetate-hexane (1:1).
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TLC-Rf = 0.36 in ethyl acetate-hexane (1:1)
mp = 71-73 qC.
FT-IR (KBr) cm
-1
: 3300s, br. (QNH); 1777s (QC=O, lactone); 1684m (QC=O, 1, 3-
diamide); 1655s and 1640s, (QC=O, amide); 1557s (GNH, amide).
1
H NMR (CDCl3) į 0.88 (3H, t, J = 5.6 Hz, (CH3(CH2)7-), 1.10-1.31 (10H, m,
CH3(CH2)5-), 1.53 (2H, s, broad, CH3(CH2)5CH2-), 2.29 (1H, m, ring, 4D-H), 2.66 (1H,
m, ring, 4E-H), 2.96 and 3.03 (3H, 2 u s, NCH3-(E and Z isomers), 3.30 (2H, t, J = 7.5
Hz, CH3(CH2)6CH2-), 3.38 (2H, dd, J = 4.9, 8.2 Hz, -COCH2CO-), 4.28 (1H, m, ring,
3-H), 4.48 (1H, t, J = 9.1 Hz, ring, 5D-H), 4.6 (1H, m, ring, 5E-H), 8.84 (1H, d, J = 7.4
Hz, -NH-HSL).
13
C NMR (CDCl3) į 174.2, 166.62 (2), 65.88, 53.82, 42.97, 39.76, 31.92, 30.16,
29.72(2), 29.42(2), 26.81, 22.82, 14.02.
(ES-MS/FAB-MS); m/z 313.2134 (M+H
+
) C16H29N2O4, requires m/z 313.2127 (' =
2.24 ppm).
5.4.5 3O, 4-n-Pr, 4-aza C12-HSL [2.12]
N-Propyloctylamine [2.18]
N
H
N-Propyloctylamine was synthesized and purified as colorless oil in 58 % yield from
n-propylamine using Method-F.
TLC-Rf = 0.43 in methanol-ammonia (9.6:0.4)
FT-IR (KBr) cm
-1
: 3386m, br., (QNH); 1460s (GNH); 1131s (QC-N).
1
H NMR (CDCl3) į 0.86-0.94 (6H, m, J = 7.2 Hz, CH3(CH2)7- and CH3(CH2)2-), 1.20-
1.35 (10H, m, CH3(CH2)5-), 1.42 (1H, s, broad, -NH-), 1.47 (2H, m, broad,
CH3(CH2)5CH2-), 1.53 (2H, quint., J = 7.2 Hz, CH3CH2CH2-) 2.57 (2H, t, J = 7.4 Hz,
CH3(CH2)6CH2-), 2.6 (2H, t, J = 7.6 Hz, CH3(CH2)CH2-).
13
C NMR (CDCl3) į 51.99, 50.08, 31.85, 30.14, 29.56, 29.29, 27, 43, 23.19, 22.67,
14.11, 11.82.
(ES-MS/FAB-MS): m/z 172.2132 (M+H
+
) C11H25N, requires m/z 172.2065 (' = 39
ppm).
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N,N-Dioctylpropylamine [2.29]
N
The side product was purified as colorless oil in 23 % yield.
TLC-Rf = 0.70 in methanol-ammonia (9.6:0.4)
1
H NMR (CDCl3) į 0.894 (9H, t (overlap), J = 7.0 Hz, 2CH3(CH2)7- and CH3(CH2)2-),
1.28-1.33 (20H, m, broad, 2CH3(CH2)5-), 1.44-1.52 (6H, m, broad, 2CH3(CH2)5CH2-
and CH3CH2CH2-) 2.39-2.46 (6H, m, 2CH3(CH2)6CH2- and CH3CH2CH2-).
Ethyl 3-oxo-4-n-propyl-4-azadodecanoate [2.36]
N O
O O
Ethyl 3-oxo-4-n-propyl-4-azadodecanoate was synthesized as yellowish oil in 78 %
yield from N-propyloctylamine using Method-E.
TLC-Rf = 0.60 in ethyl acetate-hexane (1:1)
FT-IR (KBr) cm
-1
: 1741s (QC=O, ester); 1649s(QC=O, amide).
1
H NMR (CDCl3) į 0.89-0.96 (6H, m, CH3(CH2)7- and CH3(CH2)2-), 1.24-1.31 (13H,
m, CH3(CH2)5- and CH3CH2O-), 1.52-1.62 (4H, m, broad, CH3(CH2)5CH2- and
CH3CH2CH2-) 3.20 (2H, q, J = 8.0 Hz, CH3(CH2)6CH2-), 3.32 (2H, t, J = 7.8 Hz,
CH3(CH2)CH2-), 3.45 (2H, s, -COCH2CO-), 4.21 (2H, q, J = 7.2 Hz, CH3CH2O-).
13
C NMR (CDCl3) į 167.88, 165.74, 61.40, 50.16, 48.63, 41.27, 31.81, 29.38, 29.25,
27.47, 26.98, 22.64, 20.71, 14.12, 11.32.
(ES-MS/FAB-MS): m/z 286.2413 (M+H
+
) C16H32NO3, requires m/z 286.2382 (' =
10.8 ppm).
3-Oxo-4-propyl-4-azadodecanoic acid [2.42]
N OH
O O
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Saponification of ethyl, 3-oxo-4-propyl-4-azadodecanoate afforded 3-oxo-4-n- propyl-
4-azadodecanoic acid as oil in 55 % yield using Method-C.
FT-IR (KBr) cm
-1
: 3319s, (QOH); 1738s (QC=O, acid); 1629(QC=O, amide).
1
H NMR (CDCl3) į 0.91-0.99 (6H, m, CH3(CH2)7- and CH3(CH2)2-), 1.29-1.35 (10H,
m, CH3(CH2)5-), 1.56-1.67 (4H, m, broad, CH3(CH2)5CH2- and CH3CH2CH2N-) 3.22
(2H, q, J = 7.8 Hz, CH3(CH2)6CH2-), 3.34-3.40 (4H, m, CH3(CH2)CH2- and -
COCH2CO-), 14.20 (1H, s, broad, -COOH).
13
C NMR (CDCl3) į 172.13, 165.71, 88.41, 48.92, 47.19, 31.95, 29.41(2), 27.96,
27.13, 22.85, 21.53, 14.1, 11.58.
(ES-MS/FAB-MS): m/z 256.1906 (M - H
+
) C14H26NO3, requires m/z 256.1913 (' =
2.70 ppm)
3O, 4-n-Pr, 4-aza C12-HSL [2.12]
N N
H
O O
O
OH
3O, 4-Pr, 4-aza C12-HSL was synthesized as yellowish semisolid product in 54 % yield
from 3-oxo-4-n-propyl-4-azadodecanoic acid using Method-A.
TLC-Rf = 0.28 in ethyl acetate
mp = 47-49 qC.
FT-IR (KBr) cm
-1
: 3288m, br. (QNH); 1772s (QC=O, lactone); 1654s and 1632s,
(QC=O, amide); 1552m (GNH, amide).
1
H NMR (CDCl3) į 0.87-0.98 (6H, m, CH3(CH2)7- and CH3(CH2)2N-), 1.24-1.36
(10H, m, CH3(CH2)5-), 1.50-1.67 (4H, m, broad, CH3(CH2)5CH2- and CH3CH2CH2-)
2.23-2.43 (1H, m, ring, 4D-H), 2.68-2.75 (1H, m, ring, 4E-H), 3.23 (2H, m,
CH3(CH2)6CH2-), 3.31 (2H, m, CH3(CH2)CH2-), 3.38 (2H, s, COCH2CO), 4.23 (1H,
m, ring, 5D-H), 4.48 (1H, m, ring, 5E-H), 4.64 (1H, m, ring, 3-H), 8.89 (1H, d, J = 6.8
Hz, -NH-HSL).
13
C NMR (CDCl3) į 174.92, 166.67, 165.69, 65.81, 54.12, 48.71, 46.49, 41.97, 31.97,
30.29, 29.41(2), 27.93, 27.17, 22.80, 21.04, 14.12, 11.53.
(ES-MS/FAB-MS); m/z 341.2449 (M+H
+
) C18H33N2O4, requires m/z 341.2440 (' =
2.64 ppm).
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5.4.6 3O, 4-(2-hydroxyethyl), 4-aza C12-HSL [2.13]
N-(2-Hydroxyethyl)octylamine [2.19]
N
H
OH
N-(2-Hydroxyethyl)octylamine was synthesized and purified as an oil in 51 % yield
from 2-hydroxyethylamine using Method-F.
TLC-Rf = 0.44 in methanol-ammonia (9.6:0.4)
FT-IR (KBr) cm
-1
: 3301s, broad, (QNH and OH); 1467s (GNH); 1121m and 1060m
(QC-N).
1
H NMR (CDCl3) į 0.87 (3H, t, J = 7.2 Hz, CH3(CH2)7-), 1.25-1.29 (10H, m,
CH3(CH2)5-), 1.45-1.50 (2H, m, broad, CH3(CH2)5CH2-), 1.26 (2H, t, J = 7.2 Hz,
CH3(CH2)6CH2-) 2.75 (2H, t, J = 5.2 Hz, -CH2CH2CH2OH), 3.00 (2H s, broad, -NH-
and -OH), 3.65 (2H, t, J = 5.2 Hz, CH2CH2CH2OH).
13
C NMR (CDCl3) į 60.56, 51.24, 49.61, 31.81, 29.90, 29.49, 29.26, 27.30, 22.64,
14.08.
(ES-MS/FAB-MS): m/z 174.1892 (M+H
+
) C10H24NO, requires m/z 174.1858 (' = 19
ppm).
Ethyl 3-oxo-4-(2-hydroxyethyl)-4-azadodecanoate [2.37]
N O
O O
OH
Ethyl 3-oxo-4-(2-hydroxyethyl)-4-azadodecanoate was synthesized as a colorless
viscous oil in 24 % yield from N-(hydroxyethyl)octylamine using Method-E. This
reaction also yielded a compound ethyl, 3-oxo-4-(2-ethoxycarbonylacetyloxyethyl)-4-
azadodecanoate (2.44) in 48 % yield. Column chromatographic separation in ethyl
acetate-hexane (1:1) gave 2.37 and 2.44 in their pure forms.
TLC-Rf = 0.14 in ethyl acetate-hexane (1:1)
FT-IR (KBr) cm
-1
: 3418s, (QOH); 1740s (QC=O, ester); 1633s(QC=O, amide).
1
H NMR (CDCl3) į 0.91 (3H, t, J = 7.2 Hz, CH3(CH2)7-), 1.28-1.32 (13H, m,
CH3(CH2)5- and CH3CH2O- ), 1.59 (2H, m, broad, CH3(CH2)5CH2-), 2.47 (1H, s,
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broad, -OH), 3.29 and 3.38 (2H, t, J = 7.6 Hz, CH3(CH2)6CH2-(Z and E-isomers)), 3.46
and 3.56 (2H, 2 u s, J = 5.6 Hz, COCH2CONH- (E and Z isomers)), 3.48 and 3.61 (2H,
2 u s, COCH2CO- (Z and E isomers)), 3.78 and 3.81 (2H, 2 u t, J = 5.0 Hz, -
CH2CH2OH-(E and Z-isomers)), 4.22 (2H, q, J = 7.2 Hz, CH3CH2-).
(ES-MS/FAB-MS): m/z 288.2189 (M + H
+
) C15H30NO4, requires m/z 288.2175 (' =
4.85 ppm).
Ethyl, 3-oxo-4-(2-ethoxycarbonylacetyloxyethyl)-4-azadodecanoate [2.44]
N OEt
O O
O OEt
O O
TLC-Rf = 0.43 in ethyl acetate-hexane (1:1)
1
H NMR (CDCl3) į 0.87-0.92 (3H, m, J = 6.8 Hz, CH3(CH2)7-), 1.21-1.32 (16H, m,
CH3(CH2)5- and 2CH3CH2O- ), 1.56-1.59 (2H, m, broad, CH3(CH2)5CH2-), 3.28 and
3.37 (2H, t, J = 8.0 Hz, CH3(CH2)6CH2-(Z and E-isomers)), 3.39 and 3.42 (2H, 2 u s,
COCH2CONH- (Z and E isomers)), 3.45 and 3.51 (2H, 2 us, COCH2COO- (Z and E
isomers)), 3.57 and 3.62 (2H, 2 ut, J = 5.8 Hz, -CH2CH2CH2O-(E and Z-isomers)),
4.23 (4H, q, J = 7.2 Hz, 2CH3CH2-), 4.28 and 4.33 (2H, 2 u t, J = 6.0 Hz, -CH2CH2O-
(E and Z-isomers)).
(ES-MS/FAB-MS): m/z 424.2337 (M + Na) C20H35NO7Na, requires m/z 424.2311 (' =
6.12 ppm).
3-Oxo-4-(2-hydroxyethyl)-4-azadodecanoic acid [2.43]
N OH
O O
OH
3-Oxo-4-(2-hydroxyethyl)-4-azadodecanoic acid was synthesized as white crystals in
83 % yield from saponification of ester 2.44 (0.5 mmol) with NaOH (1.2 mmol) using
Method-C.
mp = 68-70 qC.
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FT-IR (KBr) cm
-1
: 3392s, br., (QNH and OH); 1727s (QC=O, acid); 1629(QC=O,
amide).
1
H NMR (CDCl3) į 0.91 (3H, t, J = 7.2 Hz, CH3(CH2)7-), 1.28-1.33 (10H, m,
CH3(CH2)5-), 1.60 (2H, s, broad, CH3(CH2)5CH2-), 2.52 (1H, s, broad, -OH), 3.35 and
3.43 (2H, 2 u t, J = 8.0 Hz, CH3(CH2)6CH2-(Z and E-isomers)), 3.44 and 3.58 (2H, 2 u
s, COCH2CO (Z and E isomers)), 3.47 and 3.62 (2H, 2 u t, -CH2CH2OH (Z and E
isomers)), 3.83 and 3.85 (2H, 2 u t, J = 5.2 Hz, -CH2CH2OH-(E and Z-isomers)), 10.23
(1H, s, broad -COOH).
13
C NMR (CDCl3) į 171.23, 165.27, 60.93, 59.71, 49.47, 35.01, 31.76, 29.21, 28.53,
27.31, 26.91, 22.60, 14.08.
(ES-MS/FAB-MS): m/z 258.1702 (M - H
+
) C13H24NO4, requires m/z 258.1705 (' =
1.16 ppm)
3O, 4-(2-hydroxyethyl), 4-aza C12-HSL [2.13]
N N
H
O O
O
OH
OH
3O, 4-(2-hydroxyethyl), 4-aza C12-HSL was synthesized as white crystals in 44 %
yield from 3-Oxo-4(2-hydroxyethyl)-4-azadodecanoic acid using Method-A.
mp = 54-56 qC.
FT-IR (KBr) cm
-1
: 3309s, br. (QNH and OH); 1775s (QC=O, lactone); 1684m (QC=O,
1, 3-diamide); 1655s and 1637s, (QC=O, amide); 1542s (GNH, amide).
1
H NMR (CDCl3) į 0.85-0.91 (3H, m, CH3(CH2)7-), 1.24-1.30 (10H, m, CH3(CH2)5-),
1.55-1.60 (2H, m, broad, CH3(CH2)5CH2-) 2.25-2.36 (1H, m, ring, 4D-H), 2.40 (1H, s,
broad, -OH), 2.68-2.75 (1H, m, ring, 4E-H), 3.37 (2H, m, CH3(CH2)6CH2-), 3.47 (2H,
s, COCH2CO), 3.56 (2H, m, -CH2CH2OH), 4.29 (1H, m, ring, 5D-H), 4.49 (1H, m,
ring, 5E-H), 4.64 (1H, m, ring, 3-H), 8.43 and 8.59 (1H, 2 u d, J = 6.8 Hz, -NH-HSL
(E and Z isomers).
13
C NMR (CDCl3) į 175.13, 166.6, 165.6, 65.79, 59.27, 54.87, 49.64, 46.51, 40.79,
31.72, 30.3, 29.43(2), 27.85, 27.15, 22.80, 14.1.
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(ES-MS/FAB-MS): m/z 343.2219 (M+H
+
) C17H31N2O5, requires m/z 343.2233 (' =
4.08 ppm); m/z 365.2037 (M+Na) C17H30N2O5Na, requires m/z 365.2052 (' =
4.1ppm).
5.5 Synthesis of fluorinated 4-aza analogues of 3O, C12-HSL
5.5.1 3O, 2-F, 4-Aza C12-HSL [2.62]
Methyl, 2-fluoro-3-oxo 4-azadodecanoate [2.69]
N
H
O
O O
F
To a stirred solution of dimethyl fluoromalonate 2.65 (1 mmol, 0.1501 g) in anhydrous
methanol (10 mL) at room temperature was added dropwise a solution of n-octylamine
(1 mmol, 166 Pl) in methanol (5 mL) over a period of 1 h and stirring was continued
for further 2 h. The solution was rotary evaporated and the residue redissolved in ethyl
acetate (20 mL). The ethyl acetate solution was sequentially washed with 2 M HCl (2 u
10 mL) and brine (1 u 15 mL) solution. The organic layer was separated, dried over
MgSO4, and rotary evaporated to yield a mixture of bisamide 2.67 and methyl, 2-
fluoro-3-oxo 4-azadodecanoate. The PLC separation in petroleum ether b.p. 40-60
0
C-
diethyl ether (3:2) gave the titled product 2.69 in 47 % yield.
TLC-Rf - 0.23 in petroleum ether-diethyl ether (2:3)
mp = 38-40 qC.
FT-IR (KBr) cm
-1
: 3293s, (QNH); 1762s (QC=O, ester); 1668s(QC=O, amide); 1576w
(GNH, amide).
1
H NMR (CDCl3) į 0.88 (3H, t, J = 6.4 Hz, CH3(CH2)7-), 1.26-1.34 (10H, m,
CH3(CH2)5-), 1.50-1.58 (2H, m, broad, CH3(CH2)5CH2-), 3.32-3.38 (2H, m,
CH3(CH2)6CH2-), 3.87 (3H, s, CH3O-), 5.38 (1H, d, J = 31.2, COCF(H)CO), 6.41 (1H,
s, broad, -NH-).
(ES-MS/FAB-MS): m/z 248.1648 (M+H
+
) C12H23FNO3, requires m/z 248.1662 (' =
5.64 ppm).
&RQILGHQWLDO
- 183 -
N
1
, N
3
-dioctylfluoromalonamide [2.67]
N
H
N
H
O O
F
Bisamide N
1
, N
3
-dioctylfluoromalonamide was isolated by PLC as a white solid.
TLC-Rf - 0.08 in petroleum ether-diethyl ether (2:3)
1
H NMR (CDCl3) į 0.89 (6H, t, J = 7.0 Hz, CH3(CH2)7-), 1.3 (20H, m, 2 u
CH3(CH2)5-), 1.53 (4H, s, broad, 2 u CH3(CH2)5CH2-), 3.3 (4H, t, J = 6.7 Hz, 2 u
CH3(CH2)6CH2-), 5.18 (1H, d, J = 38.0 Hz, CF(H)), 6.9 (2H, s, 2 u (-NH-)).
(ES-MS/FAB-MS): m/z 345.2938 (M +H
+
) C19H38FN2O2, requires m/z 345.2917 (' =
6.1 ppm)
2-Fluoro-3-oxo-4-azadodecanoic acid [2.70]
N
H
OH
O O
F
To a stirred solution of methyl, 2-fluoro-3-oxo-4-azadodecanoate 2.69 (0.2 mmol,
0.047 g) in methanol (15 mL), was added dropwise cold NaOH (0.2 mmol, 0.08 g)
solution in water (5 mL). The stirring was continued at room temperature for 2 h. The
mixture was rotary evaporated to remove solvents. The residue was redissolved in
water (15 mL) and washed with ethyl acetate (2 u 5 mL). Aqueous layer was acidified
to pH 2 with 4 M HCl and the free acid was extracted with ethyl acetate (3u10 mL),
dried over MgSO4, filtered and solvent rotary evaporated to give the titled monofluoro
acid 2.70 in a 98 % yield.
FT-IR (KBr) cm
-1
: 3323s, br., (QNH and OH); 1762s (QC=O, acid); 1668s (QC=O,
amide); 1576w (GNH, amide).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 6.4 Hz, CH3(CH2)7-), 1.26-1.33 (10H, m,
CH3(CH2)5-), 1.54-1.62 (2H, m, broad, CH3(CH2)5CH2-), 3.37-3.42 (2H, m,
CH3(CH2)6CH2-), 5.35 (1H, d, J = 47.2, COCF(H)CO), 6.71 (1H, broad s, -NH-), 7.60
(1H, s, broad, -COOH).
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3O, 2-F, 4-Aza C12-HSL [2.62]
N
H
N
H
O O
O
OHF
To a stirred solution of 2-fluoro-3-oxo 4-azadodecanoic acid 2.70 (1 mmol, 0.233 g) in
dry DCM (15 ml) was added sequentially L-HSL HCl (1 mmol, 0.1375 g), HOBt (1.2
mmol, 0.162 g) and finally DCCI (1.1 mmol, 0. 227 g). The stirring was continued for
16 h and solvent was removed under high vacuo. The residue was redissolved in ethyl
acetate (25 mL). The organic solution was washed with saturated sodium bicarbonate
(3 u 10 mL), 1 M KHSO4 (3 u 10 mL) and brine (1 u 15 mL). The organic layer was
dried over MgSO4, filtered and rotary evaporated. The residue was redissolved in cold
acetone (2-4 mL) and left aside. When the remaining DCU crystallized out, this was
carefully removed to obtain oil. The product 2.62 was isolated by PLC in ethyl acetate
as a white solid in 11 % yield.
mp = 53-53 qC.
TLC-Rf = 0.32 in ethyl acetate
FT-IR (KBr) cm
-1
: 3292s, (QNH); 1765s (QC=O, lactone); 1669s (QC=O, 1, 3-
diamide); 1557m (GNH, amide).
1
H NMR (CDCl3) 0.89 (3H, t, J = 6.9 Hz, CH3(CH2)7-), 1.3 (10H, m, CH3(CH2)5-),
1.56 (2H, s, broad, CH3(CH2)5CH2-), 2.27 (1H, m, ring, 4D-H), 2.80 (1H, m, ring, 4E-
H), 3.33 (2H, m, CH3(CH2)6CH2-), 4.28 (1H, m, ring, 3H), 4.53 (1H, m, ring, 5D-H),
4.64 (1H, m, ring, 5E-H), 5.3 (1H, dd, J = 10.2, 38.0 Hz, -COCF(H)CO-), 6.63 (1H, s,
CH3(CH2)6CH2NH-), 7.5 (1H, dd, J = 13.3, 6.4 Hz, -NH-HSL).
13
C NMR (CDCl3) į 174.87, 167.86(2), 106.36, 58.18, 56.12, 41.61, 31.79, 28.87(2),
27.82, 26.12, 22.80, 14.17.
(ES-MS/FAB-MS): m/z 317.1887 (M+H
+
) C15H26FN2O4, requires m/z 317.1877 (' =
3.15 ppm).
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5.5.2 3O, 2-F2, 4-Aza C12-HSL [2.63]
Ethyl 2, 2-difluoro-3-oxo-4-azadodecanoate [2.68]
N
H
O
O O
F F
To a stirred solution of diethyl difluoromalonate 2.64 (2 mmol, 0.3923 g) in ethanol
(30 mL) was added dropwise n-octylamine (2 mmol, 331 Pl) over a period of 2 h at
room temperature. The solution was rotary evaporated and the residue redissolved in
ethyl acetate (30 mL). The ethyl acetate solution was sequentially washed with 2 M
HCl (2 u 15 mL) and brine (1 u 15 mL). The organic layer was dried over MgSO4 and
rotary evaporated to obtain a mixture of ethyl, 2, 2-difluoro-3-oxo-4-azadodecanoate
2.68 and bisamide 2.66. Desired product was isolated as a white solid by PLC in 50 %
yield using petroleum ether b.p. 40-60
0
C-diethyl ether (1:1).
TLC-Rf = 0.46 in petroleum ether-diethyl ether (1:1)
mp = 39-41 qC.
1
H NMR (CDCl3) į 0.88 (3H, t, J = 6.8 Hz, CH3(CH2)7-), 1.26-1.1.36 (13H, m,
CH3(CH2)5- and CH3CH2O-), 1.50-1.60 (2H, s, broad, J = 7.0 Hz, CH3(CH2)5CH2-),
3.36 (2H, q, J = 6.8 Hz, CH3(CH2)6CH2-), 4.38 (2H, q, J = 7.0, CH3 CH2O-), 6.40 (1H,
s, broad, -NH-).
(ES-MS/FAB-MS): m/z 280.1720 (M +H
+
) C13H24F2NO3, requires m/z 280.1724 (' =
1.42 ppm).
N
1
, N
3
-Dioctyldifluoromalonamide [2.66]
N
H
N
H
O O
F F
Bisamide N
1
, N
3
-dioctyldifluoromalonamide was isolated by PLC as a white solid.
TLC-Rf = 0.08 in petroleum ether-diethyl ether (1:1)
1
H NMR (CDCl3) į 0.88 (6H, t, J = 6.5 Hz, 2 u CH3(CH2)7-), 1.28 (20H, m, 2 u
CH3(CH2)5-), 1.56 (4H, s, broad, 2 u CH3(CH2)5CH2-), 3.33 (4H, t, J = 6.71 Hz, 2 u
CH3(CH2)6CH2-), 6.72 (2H, s, 2 u (-NH-)).
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(ES-MS/FAB-MS): m/z 363.2902 (M +H
+
) C19H37F2N2O2, requires m/z 363.2823 (' =
21.7 ppm)
3O, 2-F2, 4-Aza C12-HSL [2.63]
N
H
N
H
O O
O
OHF F
To a stirred solution of ethyl 2, 2-difluoro-3-oxo-4-azadodecanoate 2.68 (0.1 mmol,
0.028 g) in ethanol (5 mL) was added L-HSL HCL (0.11 mmol, 0.014 g) and TEA
(0.15 mmol, 21 Pl). It was then refluxed overnight. The solution was cooled to room
temperature and solvent was rotary evaporated under vacuo. The residue was
redissolved in ethyl acetate (15 mL). The ethyl acetate solution was sequentially
washed with saturated sodium bicarbonate (2 u 10 mL), 2 M HCl (2 u 10 mL) and
brine (1 u 15 mL). The organic layer was dried over MgSO4, filtered and rotary
evaporated to obtain a crude product which was purified by PLC in ethyl acetate-
hexane (1:1) in 15 % yield as white crystals.
TLC-Rf = 0.27 in ethyl acetate-hexane (1:1)
mp = 66-68 qC.
FT-IR (KBr) cm
-1
: 3304s, br. (QNH); 1778m (QC=O, lactone); 1697s (QC=O, 1, 3
diamide); 1550s (GNH, amide).
1
H NMR (CDCl3) į 0.89 (3H, t, J = 6.5 Hz, CH3(CH2)7-), 1.27-1.32 (10H, m,
CH3(CH2)5-), 1.52-1.55 (2H, m, broad, CH3(CH2)6CH2-), 2.26-2.32 (1H, m, ring, 4D-
H), 2.79-2.93 (1H, m, ring, 4E-H), 3.35 (2H, q, J = 6.8 Hz, CH3(CH2)7CH2-), 4.27-4.35
(1H, m, ring, 5D-H), 4.49-4.56 (1H, m, ring, 5E-H), 4.58-4.65 (1H, m, ring, 3-H), 6.6
(1H s, -NH), 7.41 (1H, d, J = 6.0 Hz, -NH-HSL).
13
C NMR (CDCl3) į 173.97, 168.79(2), 137.61, 68.24, 57.23, 43.17, 32.91, 29.97(2),
28.42(2), 27.02, 23.10, 14.10.
(ES-MS/FAB-MS): m/z 335.1769 (M +H
+
) C15H25F2N2O4, requires m/z 335.1782 (' =
3.88 ppm).
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5.6 Synthesis of 3-aza analogues of 3O, C12-HSL
5.6.1 Method-G: N-substituted nonylamine by reductive amination
O-Benzylhydroxylamine (2 mmol, 0.2503 g) was mixed with methanol (20 mL) at 0
qC, whereas O-tert-butylhydroxylamine was released from its hydrochloride salt (2
mmol, 0.252 g) in methanol (20 mL) at 0 qC by adding sodium methoxide (sodium
metal- 2 mmol, 0.051 g). The pH was adjusted below 4.5 with gacial acetic acid. The
1-nonanal (2 mmol, 344 µL) was added and the mixture was allowed to warm to room
temperature. The pH was maintained by the addition of further gacial acetic acid. After
1 h stirring, the reaction mixture was cooled to 0 qC, and first portion of sodium
cyanoborohydride (2.2 mmol, 0.1382 g) was added. The pH was maintained by
addition of glacial acetic acid and the reaction was warmed to room temperature. After
intervals of 1 h at pH 4 second and third portions of sodium cyanoborohydride (1.1
mmol, 0.063 g, each time) were added. The reaction mixture was then stirred for 4 h at
room temperature and solvent was removed to dryness under high vacuo. The residue
was redissolved in ethyl acetate (40 mL) and sequentially washed with water (3 u 10
mL), saturated sodium bicarbonate (3 u 15 mL) and brine (1 u 20 mL). The organic
layer was dried over MgSO4, filtered and rotary evaporated to obtain the title product
as an oil.
5.6.2 Method-H: Benzyl or tert-butyl ester(s) of N-substituted 3-azadodecanoic
acid(s)
To a stirred solution of an appropriate N-substituted nonylamine (4 mmol) in THF (30
mL) containing DIPEA (8 mmol) was added dropwise benzyl 2-bromoacetate or tert-
butyl bromoacetate (8 mmol) and the mixture refluxed overnight. The solution was
cooled to room temperature and rotary evaporated under vacuo. The residue was
redissolved in ethyl acetate (40 mL). The ethyl acetate solution was sequentially
washed with water (3 u 10 mL), saturated sodium bicarbonate (3 u 15 mL), 1 M
KHSO4 (2 u 15 mL) and brine (1 u 20 mL). The organic layer was dried over MgSO4,
filtered and rotary evaporated to obtain the title products as oils.
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5.6.3 Method-I: Removal of benzyl group by catalytic hydrogenation.
An appropriate O-benzyl or benzyl ester product (2 mmol) was dissolved in absolute
ethanol (10 mL). To this was added Pd/C (10 % w/w) and the heterogeneous mixture
was stirred for 16 h under an atmosphere of hydrogen gas. The catalyst was filtered off
using celite as a filter aid. The filtrate was evaporated under vacuo to give the de-
benzylated product.
5.6.4 Method-J: Coupling of L-HSL to N-substituted 3-azadodecanoic acids
To a stirred solution of an appropriate 3-azadodecanoic acid (0.5 mmol) in dioxane (3
mL) was added a solution of L-HSL.HCl (0.5 mmol) in a water (about 1 mL). To this
was added sequentially TEA (1.5 mmol) and EDC.HCl (0.75 mmol) and stirring was
continued for 16 h (6 h for 2.71) at room temperature. Solvent was removed under high
vacuo and residue was extracted with warm ethyl acetate (20 mL). Organic solution
was sequentially washed with saturated sodium bicarbonate (2 u 10 mL) and brine (1 u
15 mL). The organic layer was dried over MgSO4, filtered and rotary evaporated to
obtain desired products.
5.6.5 Method-K: Deprotection of tert-butyl or Boc group
The acid-catalyzed deprotection of the tert-butyl group or Boc group was carried out
by using excess of trifluoroacetic acid (TFA). Solution of TFA (50 % v/v) in DCM (3
mL) was added to O-tert-butyl or N-Boc group containing compound (0.1 mmol). The
mixture was stirred for 2 h. The excess TFA was flushed out under vacuo by
repeatedely dissolving in acetonitrile (3 u 10 mL) and finally under as stream of
nitrogen. The residue was redissolved in ethyl acetate (15 mL) and filtered. The filtrate
was concentrated under vacuo to obtain the deprotected product.
5.6.6 3-BnO, 3-aza C12-HSL [2.77]
N-(Benzyloxy)nonylamine [2.74]
H
N O
Reductive amination (Method-G) of 1-nonanal gave mixture of N-
(benzyloxy)nonylamine and the intermediate oxime 2.73 (32 % yield). The product
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was isolated as an oil by column chromatography using ethyl acetate-hexane (1:9) in
58 % yield.
TLC-Rf = 0.25 in ethyl acetate-hexane (1:9)
1
H NMR (CDCl3) į 0.90 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.25-1.38 (12H, m,
CH3(CH2)6-), 1.49-1.58 (2H, quint, J = 7.2, CH3(CH2)6CH2-), 2.95 (2H, t, J = 7.2 Hz,
CH3(CH2)7CH2-), 4.73 (2H, s, -CH2C6H5), 7.30-7.35 (5H, br, m, -C6H5).
13
C NMR (CDCl3) į 138.02, 128.38(2), 128.36(2), 127.78, 76.20, 52.24, 31.89,
29.54(2), 29.28, 27.33, 27.20, 22.69, 14.13.
(ES-MS/FAB-MS): m/z 250.2159 (M+H
+
) C16H28NO, requires m/z 250.2171 (' = 4.8
ppm).
tert-Butyl 3-benzyloxy-3-azadodecanoate [2.75]
N O
O O
N-Alkylation of N-(benzyloxy)nonylamine 2.74 with tert-butyl bromoacetate gave
desired product tert-butyl, 3-benzyloxy-3-azadodecanoate as a viscous oil in 89 %
yield (Method-H).
TLC-Rf = 0.35 in ethyl acetate-hexane (1:9)
1
H NMR (CDCl3) į 0.90 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.25-1.36 (12H, m,
CH3(CH2)6-), 1.51 (9H, s, -C(CH3)3), 1.61-1.64 (2H, m, CH3(CH2)6CH2-), 2.80 (2H, t,
J = 7.6 Hz, CH3(CH2)7CH2-), 3.47 (2H, s, -COCH2CO-), 4.88 (2H, s, -CH2C6H5), 7.34-
7.35 (5H, m, broad, -C6H5).
13
C NMR (CDCl3) į 168.57, 137.37, 128.79(2), 128.31(2), 127.86, 81.07, 75.34,
61.25, 59.48, 31.91, 29.54(2), 29.30(2), 28.13(3), 27.23, 22.70, 14.15.
(ES-MS/FAB-MS): m/z 364.2867 (M -H
+
) C22H38NO3, requires m/z 364.2852 (' = 4.1
ppm)
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3-Benzyloxy-3-azadodecanoic acid [2.76]
N OH
O O
3-Benzyloxy-3-azadodecanoic acid was synthesized from t-butyl, 3-benzyloxy-3-
azadodecanoate 2.75 by the acid-catalyzed deprotection of the tert-butyl group using
TFA. The desired 3-azadodecanoic acid was obtained in 73 % yield.
1
H NMR (CDCl3) į 0.91 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.23-1.39 (12H, m,
CH3(CH2)6-), 1.57-1.64 (2H, quint, J = 7.2, CH3(CH2)6CH2-), 2.88 (2H, t, J = 7.6 Hz,
CH3(CH2)7CH2-), 3.61 (2H, s, -COCH2CO-), 4.83 (2H, s, -CH2C6H5), 7.31-7.36 (5H,
m, broad, -C6H5), 10.38 (1H, s, broad, COOH).
(ES-MS/FAB-MS): m/z 306.2078 (M-H
+
) C18H28NO3, requires m/z 306.2069 (' = 2.93
ppm)
3-BnO, 3-aza C12-HSL [2.77]
N N
H
OBn O
O
OH
The 3-BnO, 3-aza C12-HSL was obtained from 3-BnO-3-azadodecanoic acid 2.76
using Method-J. The column chromatography in ethyl acetate gave pure solid product
in 27 % yield.
TLC-Rf = 0.48 in ethyl acetate
mp = 82-84 qC.
FT-IR (KBr) cm
-1
: 3403m, 3378m (QNH, amide); 1778s (QC=O, lactone); 1678s
(QC=O, amide); 1664s (QC=C, aromatic); 1519m (GNH, amide).
1
H NMR (CDCl3) į 0.91 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.23-1.37 (12H, m,
CH3(CH2)6-), 1.54-1.59 (2H, m, CH3(CH2)6CH2-), 1.94-2.05 (1H, m, ring, 4D-H),
2.75-2.81 (1H, m, ring, 4E-H), 2.82-2.87 (2H, dt, J = 7.2, 2.0 Hz, CH3(CH2)7CH2-),
3.49 (2H, s, -COCH2CO-), 4.24-4.31 (1H, m, ring, 5D-H), 4.43-4.47 (1H, m, ring, 5E-
H), 4.48-4.55 (1H, m, ring, 3-H), 4.75 (2H, dd, J = 28.4, 11.2 Hz, -CH2C6H5), 7.17
(1H, d, J = 6.4 Hz, -NH-HSL), 7.31-7.36 (5H, m, broad, -C6H5),
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5.6.7 3-OH, 3-aza C12-HSL [2.71]
N-(tert-Butoxy)nonylamine [2.79]
H
N O
This was synthesized using Method-G, the obtained oil was found as a mixture of
desired amine and the intermediate oxime 2.78 (11 % yield). The desired product was
isolated by column chromatography using ethyl acetate-hexane (1:9) in 72 % yield.
TLC-Rf = 0.51 in ethyl acetate-hexane (1:9)
1
H NMR (CDCl3) į 0.89 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.19 (9H, s, -C(CH3)3), 1.92-
1.34 (12H, m, CH3(CH2)6-), 1.45-1.48 (2H, m, CH3(CH2)6CH2-), 2.86 (2H, t, J = 7.2
Hz, CH3(CH2)7CH2-), 4.88 (1H, s, broad, -NH-).
13
C NMR (CDCl3) į 79.10, 42.83, 32.14, 29.52, 28.87(2), 27.38(3), 27.10, 26.92,
22.58, 14.13.
(ES-MS/FAB-MS): m/z 216.2341 (M+H
+
) C13H30NO, requires m/z 216.2327 (' = 6.47
ppm)
Benzyl 3-tert-butoxy-3-azadodecanoate [2.80]
N O
O O
Benzyl, 3-tert-butoxy-3-azadodecanoate was synthesized by N-alkylation of N-(tert-
butyl-oxy)nonylamine 2.79 with benzyl 2- bromoacetate to obtain the title compound
as an oil in 85 % yield (Method-H).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.19 (9H, s, -C(CH3)3), 1.27-
1.35 (12H, m, CH3(CH2)6-), 1.38-1.43 (2H, m, CH3(CH2)6CH2-), 2.86 (1H, t, J = 7.2
Hz, CH3(CH2)7C(H)H-), 2.94 (1H, s, broad, CH3(CH2)7C(H)H-), 3.62 (2H, d, J = 12.8
Hz, -NCH2CO-), 5.17 (2H, s, -CH2C6H5), 7.32-7.39 (5H, m, broad, -C6H5).
(ES-MS/FAB-MS): m/z 364.2878 (M-H
+
) C22H38NO3, requires m/z 364.2852 (' = 7.1
ppm)
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3-t-BuO-3-azadodecanoic acid [2.81]
N OH
O O
3-t-BuO-3-azadodecanoic acid was obtained from its benzyl ester 2.80 by catalytic
hydrogenation in 85 % yield using Method-I.
1
H NMR (CDCl3) į 0.89 (3H, t, J = 7.0 Hz, CH3(CH2)8-), 1.19-1.28 (21H, m, -C(CH3)3
and CH3(CH2)6-), 1.35-1.46 (2H, m, CH3(CH2)6CH2-), 2.86 (2H, t, broad,
CH3(CH2)7CH2-), 3.68 (2H, s, -NCH2CO-), 10.23 (1H, s, -COOH).
13
C NMR (CDCl3) į 171.18, 75.17, 61.21, 59.60, 31.84, 29.49, 29.46, 29.24, 27.23(3),
26.99, 26.81, 22.68, 14.10.
(ES-MS/FAB-MS): m/z 272.2238 (M-H
+
) C15H30NO3, requires m/z 272.2226 (' = 4.40
ppm)
3-t-BuO, 3-aza C12-HSL [2.82]
N N
H
O O
O
OH
The 3-t-BuO, 3-aza C12-HSL was obtained from 3-t-BuO-3-azadodecanoic acid 2.81
using Method-J. The column chromatography in acetone gave pure desired product as
a yellow solid in 55 % yield.
TLC-Rf = 0.47 in acetone
FT-IR (KBr) cm
-1
: 3372m (QNH, amide); 1775s (QC=O, lactone); 1761s (QC=O,
amide); 1519m (GNH, amide); 1368m (GC-H, tert-butyl).
1
H NMR (CDCl3) į 0.89 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.20 (9H, s, -C(CH3)3), 1.23-
1.27 (12H, s, CH3(CH2)6-), 1.38-1.51 (2H, s, broad, CH3(CH2)6CH2-), 2.10-2.21 (1H,
m, ring, 4D-H), 2.79 (2H, s, broad, CH3(CH2)7CH2-), 2.84-2.91 (1H, m, ring, 4E-H),
3.59(2H, s, broad, -NCH2CO-), 4.28-4.34 (1H, m, ring, 5D-H), 4.47-4.52 (1H, m, ring,
5E-H), 4.48-4.55 (1H, m, ring, 3-H), 7.54 (1H, d, J = 5.6 Hz, -NH-HSL).
(ES-MS/FAB-MS): m/z 357.2762 (M +H
+
) C19H37N2O4, requires m/z 357.2753 (' =
2.52 ppm)
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3-OH, 3-aza C12-HSL [2.71]
N N
H
OH O
O
OH
The 3-OH, 3-aza C12-HSL was synthesized as white crystals in 97 % yield from 3-t-
BuO, 3-aza C12-HSL 2.82 using Method-K.
FT-IR (KBr) cm
-1
: 3480 w, broad, (QN-OH); 1769s (QC=O, lactone); 1678s (QC=O,
amide); 1520s (GNH, amide).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.21-1.37 (12H, m,
CH3(CH2)6-), 1.74 (2H, s, broad, CH3(CH2)6CH2-), 1.94 (2H, t, J = 7.2 Hz,
CH3(CH2)7CH2-), 2.33-2.38 (1H, m, ring, 4D-H), 2.76-2.81 (1H, m, ring, 4E-H),
3.89(2H, t, J = 7.2 Hz, -NCH2CO-), 4.28-4.34 (1H, m, ring, 5D-H), 4.50-4.54 (1H, m,
ring, 5E-H), 4.65-4.71 (1H, m, ring, 3-H), 7.13 (1H, s, -N-OH), 10.37 (1H, d, J = 6.8
Hz, -NH-HSL).
13
C NMR (CDCl3) į 175.63, 171.53, 74.23, 59.17, 57.31, 49.03, 31.80(2), 29.34,
29.15, 29.11, 26.51, 22.64(2), 14.08.
(ES-MS/FAB-MS): m/z 301.2140 (M +H
+
) C15H29N2O4, requires m/z 301.2127 (' =
4.31 ppm)
5.6.8 3-NH2, 3-aza-C12-HSL [2.72]
tert-Butyl N
2
-nonyl carbazate [2.83]
H
N N
H
O
O
A THF solution (25 mL) containing n-nonyl bromide (3 mmol, 571 µL) and t-butyl
carbazate (2 mmol, 0.2643 g) was refluxed over 18 h. Solvent was removed to dryness
under high vacuo to obtained yellow a oil that was purified by column chromatography
using ethyl acetate-hexane (1:3) to obtain the desired product as a yellow oil in 25 %
yield.
TLC-Rf = 0.50 in ethyl acetate-hexane (1:3)
FT-IR (KBr) cm
-1
: 3315m, br. (QNH); 1713s (QC=O, Boc); 1458m (GNH); 1367m (GC-
H, tert-butyl).
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1
H NMR (CDCl3) į 0.89 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.20-1.34 (12H, m,
CH3(CH2)6-), 1.42-1.45 (2H, m, CH3(CH2)6CH2-), 1.47 (9H, s, -C(CH3)3), 2.83 (2H, t,
J = 7.2 Hz, CH3(CH2)7CH2-), 3.92 (1H, s, broad -CH2NH-), 6.09 (1H, s, broad, -NH-
Boc).
13
C NMR (CDCl3) į 158.68, 80.37, 52.18, 31.88, 29.57, 29.52, 29.27, 28.37(3), 27.86,
27.09, 22.68, 14.12.
(ES-MS/FAB-MS): m/z 259.2392 (M+H
+
) C14H31N2O2, requires m/z 259.2386 (' =
2.31ppm).
Benzyl, 3-Boc-amino-3-azadodecanoate [2.84]
Benzyl, 3-Boc-amino-3-azadodecanoate was synthesized by N-alkylation of N-(Boc-
amino)nonylamine 2.83 with benzyl 2- bromoacetate to obtain the title product as a
yellow oil in 82 % yield (Method-H).
FT-IR (KBr) cm
-1
: 3364m (QNH); 1739s (QC=O); 1456m (GNH, amide); 1366m (GC-
H, tert-butyl).
1
H NMR (CDCl3) į 0.89 (3H, t, J = 7.0 Hz, CH3(CH2)8-), 1.24-1.31 (12H, m,
CH3(CH2)6-), 1.46 (9H, s, -C(CH3)3), 1.51 (2H, s, broad, CH3(CH2)6CH2-), 2.88 (2H, t,
J = 7.4 Hz, CH3(CH2)7CH2-), 3.77 (2H, s, -NCH2CO-), 5.18 (2H, s, -CH2C6H5), 6.56
(1H, s, broad, NH-Boc), 7.34.-7.40 (5H, m, broad, -C6H5).
13
C NMR (CDCl3) į 168.15, 158.71, 135.21, 128.67(2), 128.50, 128.35(2), 81.73,
75.32, 66.40, 62.52, 31.89, 29.52(2), 29.29, 28.34(3), 27.60, 26.99, 22.68, 14.13.
(ES-MS/FAB-MS): m/z 407.2889 (M+H
+
) C23H39N2O4, requires m/z 407.2910 (' =
5.15 ppm)
3-Boc-NH- 3-azadodecanoic acid [2.85]
N OH
NH O
O
O
N O
NH O
O
O
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3-Boc-NH- 3-azadodecanoic acid was obtained from its benzyl ester 2.84 by catalytic
hydrogenation as white solids in 74 % yield using Method-I.
mp = 76-78 qC.
FT-IR (KBr) cm
-1
: 3342m (QNH); 2578w (QOH); 1724s (QC=O); 1503m (GNH,
amide); 1368w (GC-H, tert-butyl).
1
H NMR (CDCl3) į 0.91 (3H, t, J = 7.2 Hz, CH3(CH2)8-), 1.24-1.35 (12H, m,
CH3(CH2)6-), 1.47 (9H, s, -C(CH3)3), 1.50 (2H, s, broad, CH3(CH2)6CH2-), 2.86 (2H, t,
J = 7.2 Hz, CH3(CH2)7CH2-), 3.58 (2H, s, -NCH2CO-), 5.92 (1H, s, borad, NH-Boc),
10.5 (1H, s, borad, -COOH).
(ES-MS/FAB-MS): m/z 315.2272 (M-H
+
) C16H31N2O4, requires m/z 315.2284 (' =
3.80 ppm)
3-Boc-NH, 3-aza C12-HSL [2.86]
N N
H
NH O
O
OH
O
O
3-Boc-NH, 3-aza C12-HSL was obtained from 3-Boc-amino, 3-azadodecanoic acid 2.85
(Method-J). The desired compound was purified by column chromatography using
acetone solvent in 60 % yield as a yellow solid.
TLC-Rf = 0.62 in acetone
mp = 60-62 qC.
FT-IR (KBr) cm
-1
: 3339w, (QNH, from NH-Boc); 3288m (QNH, amide); 1779s (QC=O,
lactone); 1705s, 1692s (QC=O, Boc); 1661s (QC=O, amide); 1529s (GNH).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.35-1.43 (12H, m,
CH3(CH2)6-), 1.45 (9H, s, -C(CH3)3), 1.47-1.52 (2H, s, broad, CH3(CH2)6CH2-), 2.34-
2.39 (1H, m, ring, 4D-H), 2.52-2.61 (1H, m, ring, 4E-H), 2.75-2.80 (2H, dt, J = 6.8, 2.8
Hz, CH3(CH2)7CH2-), 3.46 (2H, dd, J = 37.6, 8.8 Hz, -NCH2CO-), 4.25-4.28 (1H, m,
ring, 5D-H), 4.47-4.52 (1H, m, ring, 5E-H), 4.61-4.74 (1H, m, ring, 3-H), 5.51 (1H, s,
NH-Boc), 8.75 (1H, d, J = 6.8 Hz, -NH-HSL).
(ES-MS/FAB-MS): m/z 400.2798 (M+H
+
) C20H38N3O5, requires m/z 400.2811 (' =
3.24 ppm)
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3-NH2, 3-aza-C12-HSL [2.72]
N N
H
N O
O
OH
H H
The 3-NH2, 3-aza C12-HSL was synthesized as light yellow crystals in 99 % yield from
3-Boc-amino, 3-aza C12-HSL 2.86 using Method-K.
TLC-Rf = 0.38 in ethyl acetate
mp = 99-101 qC.
FT-IR (KBr) cm
-1
: 3396w, (QNH, from N-NH2); 3287m (QNH, amide); 1778s (QC=O,
lactone); 1704s (QC=O, amide); 1530s (GNH).
1
H NMR (CDCl3) į 0.89 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.26-1.34 (12H, m,
CH3(CH2)6-), 1.69 (2H, s, broad, CH3(CH2)6CH2-), 2.33-2.44 (1H, m, ring, 4D-H),
2.61-2.67 (1H, m, ring, 4E-H), 3.16 (2H, t, J = 7.8, Hz, CH3(CH2)7CH2-), 3.90 (2H, dd,
J = 23.6, 16.0 Hz, -NCH2CO-), 4.28-4.35 (1H, m, ring, 5D-H), 4.49-4.53 (1H, m, ring,
5E-H), 4.62-4.67 (1H, m, ring, 3-H), 5.50 (2H, s, broad, -NH2), 8.66 (1H, d, J = 6.8
Hz, -NH-HSL).
13
C NMR (CDCl3) į 175.63, 171.53, 72.89, 62.37, 57.31, 49.03, 31.80(2), 29.34,
29.15, 29.11, 26.51, 22.64(2), 14.08.
(ES-MS/FAB-MS): m/z 300.2279 (M+H
+
) C15H30N3O3, requires m/z 300.2287 (' =
2.66 ppm)
5.7 Synthesis of thia analogue of 3O, C12-HSL
5.7.1 Method-L: n-Alkylmercaptoacetic acid (3-thia-alkanoic acid)
ref
To an 18 % (w/v) solution of NaOH in water (20 mL) containing n-alkylmercaptan (10
mmol) was added 18 % (w/v) solution of NaOH in water (10 mL) containing tert-butyl
bromoacetate (11 mmol, 1.624 mL). The mixture was heated to 90 qC and stirring was
continued for 14 h. The solution was cooled to room temperature and acidified to pH 2
using 5 M HCl. Alkylmercaptoacetic acid was extracted in ethyl acetate (3 u 15 mL).
Ethyl acetate was washed with brine (1 u 20 mL), dried over MgSO4 and rotary
evaporated under vacuo to the desired white product which was recrystallized from
ether.
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5.7.2 Method-M: Alkylsulfinylacetic acids (3-oxo-3-thiaalkanoic acid)
ref
The alkylmercaptoacetic acid (3 mmol) was dissolved in glacial acetic acid (20 mL)
containing conc. HCl (1.5 mL) and 0.5 N bromate-bromide solution* (30 mL) was
added dropwise (reddish/yellow color of the reaction mixture persists for longer than
15 min). The mixture was poured into stirring ice water to produce crystals of the
alkylsulfinylacetic acid. They were separated by filtration. The filtrate was extracted
with warm chloroform (35 qC, 2 u 10 mL) to furnish some more desired product. The
crude product was washed quickly with warm petroleum ether and dried.
* 0.5 N Bromate-bromide solution: Dissolve potassium bromate (1.4 g) and potassium
bromide (5.96 g) in sufficient water to make 100 mL.
5.7.3 Method-N: Alkylsulfonylacetic acids (3, 3-dioxo-3-thiaalkanoic acid)
ref
The alkylmercaptoacetic acid (3 mmol) was dissolved in glacial acetic acid (20 mL)
and temperature was raised to 50 qC. To this 26 mL of 30 % aqueous KMnO4 solution
(5 mmol, 0.79 g) was added dropwise over a period of 30 min and stirring was
continued further 30 min at 50 qC. The mixture was cooled to room temperature and
was poured into ice water with stirring to produce crystals of the alkylsulfonylacetic
acid. They were extracted with warm chloroform (35 qC, 3 u 15 mL) and the
chloroform extract was washed with 5 % sodium thiosulphate (3 u 15 mL) to remove
black colour MnO2, 1 M HCl (3 u 10 mL) and brine (1 u 15 mL). The organic layer
was dried over MgSO4, filtered and rotary evaporated to obtain the title product as
white crystals.
5.7.4 3-Thia C12-HSL [2.87]
3-Thia-dodecanoic acid or n-nonylmercaptoacetic acid [2.96]
S OH
O
3-Thia-dodecanoic acid was synthesized as white crystals in 97 % yield from n-
nonylmercaptan using Method-L.
mp = 54-56 qC.
FT-IR (KBr) cm
-1
: 3199w, (QOH); 1685s (QC=O).
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1
H NMR (CDCl3) į 0.90 (3H, t, J = 6.4 Hz, CH3(CH2)8-), 1.27-1.32 (10H, m,
CH3(CH2)5-), 1.40 (2H, m, broad, CH3(CH2)5CH2-), 1.59-1.67 (2H, quint, , J = 7.6 Hz,
CH3(CH2)6CH2-), 2.67 (2H, t, J = 7.6 Hz, CH3(CH2)7CH2-), 3.29 (2H, s, -SCH2CO),
10.70 (1H, s, broad, -COOH).
13
C NMR (CDCl3) į 173.68, 44.62, 33.27, 32.12, 30.49, 29.81, 29.38, 29.21, 28.67,
22.77, 14.11.
3-Thia C12-HSL [2.87]
S N
H
O
O
OH
3-Thia C12-HSL was synthesized as a white crystalline product in 34 % yield from 3-
thiadodecanoic acid 2.96 using Method-B.
TLC-Rf = 0.31 in ethyl acetate-acetone (7:3)
mp = 90-92 qC.
FT-IR (KBr) cm
-1
: 3312s, (QNH); 1777s (QC=O, lactone); 1648s (QC=O, amide);
1554s (GNH).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.17-1.34 (10H, m,
CH3(CH2)5-), 1.39 (2H, m, broad , CH3(CH2)5CH2-), 1.58-1.63 (2H, quint, , J = 7.6 Hz,
CH3(CH2)6CH2-), 2.18-2.23 (1H, m, ring, 4D-H), 2.59 (2H, t, J = 6.8 Hz,
CH3(CH2)7CH2-), 2.79-2.82 (1H, m, ring, 4E-H), 3.29 (2H, d, J = 2.0 Hz, -SCH2CO),
4.30-4.35 (1H, m, ring, 5D-H), 4.48-4.53 (1H, m, ring, 5E-H), 4.60-4.62 (1H, m, ring,
3-H), 7.41 (1H, d, J = 8.0 Hz, -NH-HSL).
13
C NMR (CDCl3) į 175.13, 172.11, 66.17, 54.20, 42.23, 32.36, 30.37(2), 29.79(2),
29.13, 28.97, 28.37, 22.82, 14.11.
(ES-MS/FAB-MS): m/z 302.1792 (M+H
+
) C15H28NO3S, requires m/z 302.1790 (' =
0.60 ppm)
5.7.5 3O, 3-thia C12-HSL [2.88]
3-Oxo-3-thiadodecanoic acid or n-nonylsulfoacetic acid [2.98]
S OH
OO
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3-Oxo-3-thiadodecanoic acid was prepared as a white crystalline mixture of
diastereomers (1:1) in 70 % yield from n-nonylmercaptoacetic acid using Method-M.
mp = 69-71 qC.
FT-IR (KBr) cm
-1
: 3398s, br. (QOH); 1726m, 1685s (QC=O); 1049m (QS=O,
sulfoxide).
1
H NMR (CDCl3) į 0.88 (3H, t, J = 7.0 Hz, CH3(CH2)8-), 1.28-1.35 (10H, m,
CH3(CH2)5-), 1.41-1.52 (2H, m, CH3(CH2)5CH2-), 1.75-1.79 (2H, m, CH3(CH2)6CH2-),
2.81-2.91 (1H, m, CH3(CH2)7CH2-), 3.03-3.06 (1H, m, CH3(CH2)7CH2-), 3.45 (1H, d,
J = 14.8 Hz, -S(O)CH2CO), 3.86 (1H, d, J = 14.8 Hz, -S(O)CH2CO), 5.13 (1H, s,
broad, -COOH).
3O, 3-thia C12-HSL [2.88]
S N
H
O
O
OH
O
3O, 3-thia C12-HSL was synthesized as a white crystalline mixture of diastereomers
(3:1) in 50 % yield from 3-oxo-3-thiadodecanoic acid 2.98 using Method-B.
TLC-Rf = 0.21 in ethyl acetate-acetone (7:3)
mp = 132-134 qC.
FT-IR (KBr) cm
-1
: 3317m, (QNH); 1773s (QC=O, lactone); 1649s (QC=O, amide);
1543m (GNH); 1037m (QS=O, sulfoxide).
1
H NMR (CDCl3) į 0.89 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.27-1.36 (10H, m,
CH3(CH2)5-), 1.45-1.51 (2H, m, CH3(CH2)5CH2-), 1.72-1.78 (2H, m, CH3(CH2)6CH2-),
2.21-2.35 (0.3H, m, ring, 4D-H), 2.38-2.51 (0.7H, m, ring, 4D-H), 2.61-2.72 (1H, m,
CH3(CH2)7CH2-), 2.78-2.89 (1H, m, CH3(CH2)7CH2-), 3.02-3.09 (0.3H, m, ring, 4E-
H), 3.11-3.18 (0.7H, m, ring, 4E-H), 3.29 (0.6 H, d, J = 14.4 Hz, -S(O)CH2CO), 3.79
(1.4 H, d, J = 14.4 Hz, -S(O)CH2CO), 4.27-4.32 (1H, m, ring, 5D-H), 4.42-4.59 (0.7H
and 1H, m, ring, 5E-H and 3-H), 4.80-4.87 (0.3H, m, ring, 5E-H), 7.80 (1H, d, J = 6.4
Hz, -NH-HSL).
(ES-MS/FAB-MS): m/z 318.1725 (M+H
+
) C15H28NO4S, requires m/z 318.1739 (' =
4.4 ppm)
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5.7.6 3O, 3-thia C14-HSL [2.89]
3-Oxo-3-thiatetradecanoic acid or n-undecylsulfoacetic acid [2.99]
S OH
OO
3-Oxo-3-thiatetradecanoic acid was prepared as a white crystalline mixture of
diastereomers (1:1) in 86 % yield from n-undecylmercaptoacetic acid using
Method-M.
mp = 81-82 qC.
FT-IR (KBr) cm
-1
: 3404s, br. (QOH); 1711m, 1685s (QC=O); 1034m (QS=O,
sulfoxide).
1
H NMR (CDCl3) į 0.89 (3H, t, J = 7.0 Hz, CH3(CH2)10-), 1.26-1.37 (14H, m,
CH3(CH2)7-), 1.47-1.52 (2H, m, CH3(CH2)7CH2-), 1.78-1.83 (2H, m, CH3(CH2)8CH2-),
2.82-2.90 (1H, m, CH3(CH2)9CH2-), 3.04-3.11 (1H, m, CH3(CH2)7CH2-), 3.45 (1H, d,
J = 14.8 Hz, -S(O)CH2CO), 3.88 (1H, d, J = 14.8 Hz, -S(O)CH2CO), 10.23 (1H, s,
broad, -COOH).
13
C NMR (CDCl3) į 172.93, 51.668, 49.73, 31.87, 29.53, 29.48(2), 29.27, 29.07,
28.58, 22.71, 22.67, 14.10.
3O, 3-thia C14-HSL [2.89]
S N
H
O
O
OH
O
3O, 3-thia C14-HSL was synthesized as off white crystalline mixture of diastereomers
(1:1) in 18 % yield from 3-oxo 3-thiatetradecanoic acid 2.99 using Method-A.
TLC-Rf = 0.22 in ethyl acetate-acetone (7:3)
mp = 114-116 qC.
FT-IR (KBr) cm
-1
: 3316m, (QNH); 1773s (QC=O, lactone); 1648s (QC=O, amide);
1543m (GNH); 1037m (QS=O, sulfoxide).
1
H NMR (CDCl3) į 0.88 (3H, t, J = 6.8 Hz, CH3(CH2)10-), 1.26-1.37 (14H, m,
CH3(CH2)7-), 1.45-1.51 (2H, m, CH3(CH2)7CH2-), 1.73-1.78 (2H, m, CH3(CH2)8CH2-),
2.22-2.34 (0.5H, m, ring, 4D-H), 2.41-2.50 (0.5H, m, ring, 4D-H), 2.64-2.73 (1H, m,
CH3(CH2)9CH2-), 2.79-2.90 (1H, m, CH3(CH2)9CH2-), 3.01-3.11 (0.5H, m, ring, 4E-
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H), 3.12-3.19 (0.5H, m, ring, 4E-H), 3.27 (1H, dd, J = 16.4, 14.4 Hz, -S(O)CH2CO),
3.77 (1H, dd, J = 14.4, 2.4 Hz, -S(O)CH2CO), 4.28-4.33 (1H, m, ring, 5D-H), 4.39-
4.48 (0.5H, m, ring, 5E-H), 4.49-4.54 (1H, m, ring, 3-H), 4.81-4.89 (0.5H, m, ring, 5E-
H), 7.63 (0.5H, d, J = 6.4 Hz, -NH-HSL), 7.70 (0.5H, d, J = 6.4 Hz, -NH-HSL).
(ES-MS/FAB-MS): m/z 346.2037 (M+H
+
) C17H32NO4S, requires m/z 346.2052 (' =
4.33 ppm)
5.7.7 3, 3-Dioxo, 3-thia C12-HSL [2.90]
3, 3-Dioxo-3-thiadodecanoic acid or n-nonylsulfonylacetic acid [2.100]
S OH
OO
O
3, 3-Dioxo-3-thiadodecanoic acid was prepared as a white crystalline solid in 33 %
yield from n-undecylmercaptoacetic acid using Method-N.
mp = 104-106 qC.
FT-IR (KBr) cm
-1
: 3147m, br. (QOH); 1699s, (QC=O); 1321s, 1148s (QS=O, sulfone).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.28-1.35 (10H, m,
CH3(CH2)5-), 1.41-1.51 (2H, m, CH3(CH2)5CH2-), 1.79-1.91 (2H, m, CH3(CH2)6CH2-),
3.28 (2H, m, CH3(CH2)7CH2-), 4.03 (2H, s, -S(O)2CH2CO), 10.12 (1H, s, broad, -
COOH).
3, 3-Dioxo, 3-thia C12-HSL [2.90]
S N
H
O
O
OH
O
O
3, 3-Dioxo, 3-thia C12-HSL was synthesized as white crystals in 32 % yield from 3, 3-
dioxo-3-thiadodecanoic acid 2.100 using Method-B.
TLC-Rf = 0.23 in ethyl acetate-hexane (9:1)
mp = 102-104 qC.
FT-IR (KBr) cm
-1
: 3307s, (QNH); 1778s (QC=O, lactone); 1662s (QC=O, amide);
1557m (GNH); 1327s, 1130s (QS=O, sulfone).
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1
H NMR (CDCl3) į 0.81 (3H, t, J = 7.0 Hz, CH3(CH2)8-), 1.17-1.27 (10H, m,
CH3(CH2)5-), 1.36-1.39 (2H, m, CH3(CH2)5CH2-), 1.75-1.81 (2H, m, CH3(CH2)6CH2-),
2.22-2.33 (1H, m, ring, 4D-H), 2.63-2.71 (1H, m, ring, 4E-H), 3.14 (2H, t, J = 8.0 Hz,
CH3(CH2)7CH2-), 3.85 (2H, s, -S(O)2CH2CO), 4.21-4.31 (1H, m, ring, 5D-H), 4.41-
4.53 (1H, m, ring, 5E-H), 4.56-4.61 (1H, m, ring, 3-H), 7.05 (1H, d, J = 6.8 Hz, -NH-
HSL).
13
C NMR (CDCl3) į 174.73, 167.21, 66.61, 57.42, 52.42, 50.23, 32.07, 30.23, 29.68,
28.88(2), 28.32, 22.94, 20.86, 14.11.
(ES-MS/FAB-MS): m/z 334.1691 (M+H
+
) C15H28NO5S, requires m/z 334.1688 (' =
0.98 ppm)
5.7.8 3, 3-Dioxo, 3-thia C14-HSL [2.91]
3, 3-Dioxo-3-thiatetradecanoic acid or n-undecylsulfonylacetic acid [2.101]
S OH
OO
O
3, 3-Dioxo-3-thiatetradecanoic acid was prepared as a white crystalline solid in 21 %
yield from n-undecylmercaptoacetic acid using Method-N.
mp = 110-112 qC.
FT-IR (KBr) cm
-1
: 3154m, br. (QOH); 1699s, (QC=O); 1321s, 1148s (QS=O, sulfone).
1
H NMR (CDCl3) į 0.83 (3H, t, J = 6.8 Hz, CH3(CH2)10-), 1.15-1.25 (14H, m,
CH3(CH2)7-), 1.37-1.41 (2H, m, CH3(CH2)7CH2-), 1.69-1.82 (2H, m, CH3(CH2)8CH2-),
3.22 (2H, m, CH3(CH2)9CH2-), 3.88 (2H, s, -S(O)2CH2CO), 9.20 (1H, s, broad, -
COOH).
3, 3-Dioxo, 3-thia C14-HSL [2.91]
S N
H
O
O
OH
O
O
3, 3-Dioxo, 3-thia C14-HSL was synthesized as off white crystals in 86 % yield from 3,
3-dioxo-3-thiatetradecanoic acid 2.101 using Method-A.
TLC-Rf = 0.25 in ethyl acetate-hexane (9:1)
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mp = 110-112 qC.
FT-IR (KBr) cm
-1
: 3306s, (QNH); 1777s (QC=O, lactone); 1662s (QC=O, amide);
1556m (GNH); 1328s, 1131s (QS=O, sulfone).
1
H NMR (CDCl3) į 0.91 (3H, t, J = 7.0 Hz, CH3(CH2)10-), 1.21-1.37 (14H, m,
CH3(CH2)7-), 1.41-1.52 (2H, m, CH3(CH2)7CH2-), 1.82-1.91 (2H, m, CH3(CH2)8CH2-),
2.34-2.41 (1H, m, ring, 4D-H), 2.70-2.74 (1H, m, ring, 4E-H), 3.23 (2H, t, J = 8.8 Hz,
CH3(CH2)9CH2-), 3.96 (2H, s, -S(O)2CH2CO), 4.28-4.35 (1H, m, ring, 5D-H), 4.50-
4.55 (1H, m, ring, 5E-H), 4.57-4.63 (1H, m, ring, 3-H), 7.23 (1H, d, J = 6.8 Hz, -NH-
HSL).
13
C NMR (CDCl3) į 175.47, 165.72, 65.66, 55.74, 53.24, 51.02, 31.92, 30.31,
29.72(3), 29.38(2), 28.83, 22.79, 21.08, 14.11.
(ES-MS/FAB-MS): m/z 362.2012 (M+H
+
) C17H32NO5S, requires m/z 362.2001 (' =
3.04 ppm).
5.8 Synthesis of sulphonamide analogues of 3O, C12-HSL
5.8.1 1, 3-Dioxo, 4-aza, 1-thia C12-HSL [2.92]
Methyl 2-sulfoacetate [2.104]
HO S O
OO
O
To a 250 mL long neck round bottom flask containing a 60 mL mixture of methanol-
benzene (2:8) was added sulfacetic acid (30 mmol, 3.84 g). The solution was refluxed
for 8 h to remove traces of water by azeotropic distillation. Solution was cooled to
room temperature and filtered. Solvent was rotary evaporated under vacuo to obtain
the desired product in 98 % yield.
FT-IR (DCM) cm
-1
: 3417s, br. (QOH); 1657s (QC=O); 1203s, 1066s, 640m (QS=O,
sulfonic acid)
1
H NMR (DMSO) į 3.47 (2H, s, -COCH2S(O)2-), 3.55 (3H, s, CH3O-).
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Methyl 2-(chlorosulfonyl)acetate [2.105]
Cl S O
OO
O
Methyl 2-sulfoaceate 2.104 (10 mmol, 1.42 g) was refluxed in phosphorus oxychloride
or POCl3 (3 mL) for 4 h. Excess POCl3 was removed under high vacuo. The residue
was redissolved in DCM (25 mL) and filtered. Solvent was rotary evaporated to obtain
the title product in a 85 % yield.
FT-IR (DCM) cm
-1
: 1751s (QC=O); 1383s, 1169s (QS=O, sulfonyl chloride)
1
H NMR (DMSO) į 3.92 (3H, s, CH3O-), 4.63 (2H, s, -COCH2S(O)2-).
N-(Methoxycarbonylmethylsulfonyl)-L-HSL [2.106]
N
H
SO
O O
O
O
OH
A dry DCM solution (15 mL) containing L-HSL.HCl (2.5 mmol, 0.344 g), 1, 8-
diazabicyclo [5.4.0]undec-7-ene or DBU (2.5 mmol, 374 µL) and DMAP (2.5 mmol,
0.306 g) was stirred at 0 qC for 10 min. To this 2-(chlorosulfonyl)acetate 2.105 (3.5
mmol, 0.618 g) was added and whole mixture was stirred further 16 h at room
temperature. The solvent was removed by rotary evaporation under vacuo and residue
was redissolved in hot ethyl acetate (30 mL). Ethyl acetate solution was quickly
extracted with 1 M HCl (2 u 10 mL) and brine (1 u 15 mL) and then it was dried over
MgSO4. Removal of ethyl acetate under vacuo gave an impure oily product. Desired
compound was isolated by column chromatography in 47 % yield using ethyl acetate-
acetonitrile (1:1) solvent system.
FT-IR (KBr) cm
-1
: 3309s, (QNH, sulfonamide); 1782s (QC=O, lactone); 1756s (QC=O,
ester); 1457w (GNH); 1348s, 1143s (QS=O, sulfonamide).
1
H NMR (CDCl3) 2.29-2.40 (1H, m, ring, 4D-H), 2.71-2.84 (1H, m, ring, 4E-H), 3.84
(3H, s, CH3O-), 4.23 (1H, d, J = 16 Hz, -COC(H)HS(O)2-), 4.27-4.34 (1H, m, ring,
5D-H), 4.80 (1H, d, J = 16 Hz, -COC(H)HS(O)2-), 4.46-4.52 (1H, m, ring, 5E-H),
4.57-4.63 (1H, m, ring, 3-H), 5.65 (1H, d, J = 7.2 Hz, -NH-HSL).
13
C NMR (CDCl3) į 174.71, 164.99, 65.83, 57.23, 53.24, 52.82, 30.46.
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(ES-MS/FAB-MS): m/z 236.0209 (M-H
+
) C7H10NO6S, requires m/z 236.0229 (' =
8.84 ppm)
N-(Carboxymethylsulfonyl)-L-HSL [2.107]
N
H
SHO
O O
O
O
OH
N-(Methoxycarbonylmethylsulfonyl)-L-HSL 2.106 (1 mmol, 0.237 g) was refluxed in
1 M HCl solution (15 mL) for a period of 4 h. Solution was concentrated in vacuo. The
residue was redissolved in ethyl acetate (20 mL), washed with brine (1 u 15 mL) and
dried over MgSO4. Removal of ethyl acetate under vacuo gave the desired product as
white crystals in 77 % yield.
FT-IR (KBr) cm
-1
: 3395s, (QNH, sulfonamide); 2658w (QOH); 1771s (QC=O, lactone);
1636s (QC=O, carboxylate); 1456w (GNH); 1340s, 1143s (QS=O, sulfonamide).
1
H NMR (CDCl3) 2.29-2.40 (1H, m, ring, 4D-H), 2.71-2.84 (1H, m, ring, 4E-H), 4.16
(1H, d, J = 15.6 Hz, -COC(H)HS(O)2-), 4.19-4.26 (1H, m, ring, 5D-H), 4.32 (1H, d, J
= 15.6 Hz, -COC(H)HS(O)2-), 4.38-4.43 (1H, m, ring, 5E-H), 4.45-4.48 (1H, m, ring,
3-H), 6.86 (1H, s, broad, -NH-HSL), 10.56 (1H, s -COOH).
13
C NMR (CDCl3) į 174.87, 166.813, 65.69, 52.51, 49.36, 30.24.
(ES-MS/FAB-MS): m/z 222.0038 (M-H
+
) C6H8NO6S, requires m/z 222.0072 (' = 15.3
ppm)
1, 3-Dioxo, 4-aza, 1-thia C12-HSL [2.92]
N
H
SN
H
O O
O
O
OH
To a stirred solution of N-(carboxymethylsulfonyl)-L-HSL 2.107 (2 mmol) in dry
DCM (15 ml) was added sequentially n-octylamine (2 mmol), DMAP (3 mmol) and
finally DCCI (2.2 mmol). The stirring was continued for 16 h and solvent was
removed under high vacuo. The residue was redissolved in hot ethyl acetate (25 mL).
The organic solution was washed with saturated sodium bicarbonate (3 u 10 mL), 1 M
HCl (3 u 10 mL) and brine (1 u 15 mL). The ethyl acetate solution was dried over
MgSO4, filtered and rotary evaporated to obtain product. The product was kept aside in
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the cold. When the remaining DCU crystallized out this was carefully removed by
passing it through small pipette containing tissue paper plug. A chilled acetone (2-4
mL) was used for rinsing. Final product was isolated as white crystals by PLC using
ethyl acetate in 22 % yield.
TLC-Rf = 0.44 in ethyl acetate
mp = 94-96 qC.
FT-IR (KBr) cm
-1
: 3386s (QNH, amide); 3323w, (QNH, sulfonamide); 1761s (QC=O,
lactone); 1683s (QC=O, amide); 1560m (GNH); 1327s, 1168s (QS=O, sulfonamide).
1
H NMR (CDCl3) į 0.89 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.27-1.33 (10H, m,
CH3(CH2)5-), 1.52-1.57 (2H, m, CH3(CH2)5CH2-), 2.33-2.46 (1H, m, ring, 4D-H),
2.71-2.79 (1H, m, ring, 4E-H), 3.28 (2H, m, CH3(CH2)6CH2-), 4.07 (1H, s, J = 14.2
Hz, -COC(H)HS(O)2-), 4.26 (1H, s, J = 14.2 Hz, -COC(H)HS(O)2-), 4.27-4.34 (1H,
m, ring, 5D-H), 4.45-4.52 (1H, m, ring, 3-H), 4.46-4.51 (1H, m, ring, 5E-H), 6.21 (1H,
d, J = 7.6 Hz, -NH-HSL), 6.69 (1H, t, -CONH-).
(ES-MS/FAB-MS): m/z 335.1638 (M+H
+
) C14H27N2O5S, requires m/z 335.1641 (' =
0.89 ppm)
5.8.2 3, 3-Dioxo-4-aza-3-thia C12-HSL [2.93]
Methyl 3, 3-dioxo-3-thia-4-azadodecanoate [2.108]
N
H
S O
O
O
O
To a dry DCM solution (15 mL) containing 1, 8-diazabicyclo [5.4.0]undec-7-ene or
DBU (1 mmol, 150 µL), n-octylamine (1 mmol, 165 µL) and K2CO3 (1 mmol, 0.138g)
at 0 qC was added 2-(chlorosulfonyl)acetate 2.105 (1 mmol, 0.1765 g). The mixture
was refluxed for 3 h. The solvent was removed by rotary evaporation under vacuo and
residue was redissolved in hot ethyl acetate (20 mL). Ethyl acetate solution was
washed with 1 M HCl (3 u 10 mL) and brine (1 u 15 mL) and then it was dried over
MgSO4. Removal of ethyl acetate under vacuo gave an impure dark brown colored
liquid product. This product was used in the next step without purification.
1
H NMR (CDCl3) į 0.90 (3H, t, J = 7.0 Hz, CH3(CH2)8-), 1.34-1.39 (10H, m,
CH3(CH2)5-), 1.59-1.62 (2H, m, CH3(CH2)5CH2-), 3.16 (2H, dd, J = 13.6, 7.2 Hz,
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CH3(CH2)6CH2-), 3.83 (3H, s, CH3O-), 4.02 (2H, s, -S(O)2CH2CO-), 4.71 (1H, t, -
NHS(O)2-).
(ES-MS/FAB-MS): m/z 266.1382 (M +H
+
) C11H24NO4S, requires m/z 266.1426 (' =
16.53 ppm)
3, 3-Dioxo-3-thia-4-azadodecanoic acid [2.109]
N
H
S OH
O
O
O
To a stirred solution of crude* methyl 3, 3-dioxo-3-thia-4-azadodecanoate 2.108 (2
mmol, 0.530 g) in methanol (10 mL), was added dropwise cold NaOH (2.5 mmol, 0.1
g) solution in water (5 mL). The stirring was continued at room temperature for 4 h.
This mixture was rotary evaporated to remove solvent. The residue was redissolved in
water (20 mL) and washed with ethyl acetate (2 u 10 mL). Aqueous layer was
acidified with 2 M HCl to pH 2 and the free acid was extracted with ethyl acetate (3 u
10 mL), dried over MgSO4, filtered and solvent rotary evaporated to give 3, 3-dioxo-3-
thia-4-azadodecanoic acid in 72 % yield.
(* the product was not purified in the previous step)
1
H NMR (CDCl3) į 0.89 (3H, t, J = 6.8 Hz, CH3(CH2)8-), 1.27-1.35 (10H, m,
CH3(CH2)5-), 1.54-1.62 (2H, m, CH3(CH2)5CH2-), 3.13 (2H, dd, J = 12.8, 6.8 Hz,
CH3(CH2)6CH2-), 3.96 (2H, s, -S(O)2CH2CO-), 5.02 (1H, s, broad, -NHS(O)2-), 9.87
(1H, s, broad, -COOH).
13
C NMR (CDCl3) į 172.15, 54.67, 43.77, 31.73, 29.19, 29.12, 29.07, 26.54, 22.60,
14.06.
(ES-MS/FAB-MS): m/z 250.1098 (M-H
+
) C10H20NO4S, requires m/z 250.1113 (' =
12.79 ppm)
3, 3-Dioxo-4-aza-3-thia C12-HSL [2.93]
N
H
S N
H
O
O
OH
O
O
3, 3-dioxo-3-thia-4-azadodecanoic acid 2.109 (1 mmol, 0.251 g) was coupled with L-
HSL.HCl (1 mmol, 0.1375 g) using Method-A to obtain an impure 3, 3-Dioxo, 4-aza,
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3-thia C12-HSL. Final compound was isolated as white crystals in 64 % yield by PLC
using ethyl acetate.
TLC-Rf = 0.43 in ethyl acetate
mp = 132-134 qC.
FT-IR (KBr) cm
-1
: 3325s (QNH, amide); 3252s, (QNH, sulfonamide); 1773s (QC=O,
lactone); 1671s (QC=O, amide); 1542m (GNH); 1320s, 1147s (QS=O, sulfonamide).
1
H NMR (CDCl3) į 0.89 (3H, t, J = 7.2 Hz, CH3(CH2)8-), 1.28-1.37 (10H, m,
CH3(CH2)5-), 1.54-1.61 (2H, m, CH3(CH2)5CH2-), 2.39-2.49 (1H, m, ring, 4D-H),
2.65-2.74 (1H, m, ring, 4E-H), 3.16 (2H, dd, J = 13.2, 7.2 Hz, CH3(CH2)6CH2-), 4.01
(2H, s, -S(O)2CH2CO-), 4.30-4.36 (1H, m, ring, 5D-H), 4.56-4.61 (1H, m, ring, 5E-H),
4.62-4.66 (1H, m, ring, 3-H), 5.26 (1H, t, J = 6.0 Hz, -NHS(O)2-), 7.01 (1H, d, J = 7.6
Hz, -NH-HSL).
(ES-MS/FAB-MS): m/z 335.1628 (M+H
+
) C14H27N2O5S, requires m/z 335.1641 (' =
3.88 ppm)
5.9 Synthesis of hetero ring altered analogues of 3O, C12-HSL
5.9.1 5-Docecanoyl Meldrum’s acid [2.118]
O
O
O O
O
To a dry dichloromethane solution (40 mL) containing n-decanoic acid (10 mmol,
1.723 g) was added sequentially Meldrum's acid (10 mmol, 1.442 g), DMAP (15
mmol, 1.833 g) and finally DCCI (11mmol, 2.27 g). This solution was stirred at room
temperature for 16 h and then filtered to remove the precipitated N, N’-
dicyclohexylurea (DCU). The filtrate was washed with 2 M HCl (2u20 mL) and dried
over MgSO4. Solvent was rotary evaporated to afford yellow-orange oil contaminated
with small DCU. It was kept aside to allow residual DCU to separate, mixed with
acetone (8 mL) and chilled in a freezer. The solution was then filtered through tissue
paper using pipette and washed with 4 mL chilled acetone. The filtrate after rotary
evaporating gave pure 5-decanoyl Meldrum’s acid as yellow-orange oil in 86 % yield.
TLC: Rf= 0.26 in ethyl acetate
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1
H NMR (CDCl3) į 0.9 (3H, t, J = 6.9 Hz, CH3(CH2)8-), 1.29 (10H, m, CH3-
(CH2)5(CH2)3C(OH)-), 1.38 (2H, quart, J = 7.3 Hz, CH3(CH2)5CH2(CH2)2C(OH)-),
1.71 (2H, quart, J = 7.0 Hz, CH3(CH2)6CH2 CH2C(OH)-), 1.75 (6H, m, (CH3)2COO)),
3.09 (2H, t, J = 7.15 Hz, CH3(CH2)7CH2C(OH)), 15.31 (1H, s, enolic -OH).
5.9.2 N-Boc-L-aspartimide and N-Boc-L-glutarimide
To a stirred dry tetrahydrofuran solution (60 mL) containing Boc-L-asparagine (5
mmol, 1.16 g)/Boc-L-glutamine (5 mmol, 1.23 g) was added 1,1’-carbonyldiimidazole
(5.5 mmol, 0.895 g). This reaction mixture was stirred and refluxed for 7h. The
resulting mixture was then cooled to room temperature and evaporated to dryness in
vacuum. The residue was redissolved in excess ethyl acetate (150 mL), as the desired
product was less soluble in it. The organic solution was sequentially washed with 1 M
potassium hydrogen sulphate (2 u 25 mL) and brine (1u25 mL). After drying over
MgSO4, the organic solvent was rotary evaporated.
5.9.2.1 N-Boc-L-aspartimide [2.121]
NH
O
OH
N
H
O
O
The residue was purified by column chromatography in ethyl acetate. Purification
provided N-Boc-L-aspartimide as a white solid in 57 % yield.
TLC-Rf = 0.74 in ethyl acetate
1
H NMR (CDCl3) G 1.44 (9H, s, -OC(CH3)3), 2.8 (1H dd, ring, 4D-H), 3.1 (1H, dd,
ring, 4E-H), 4.4 (1H, m, ring, 3-H), 5.7 (1H, d, J=8.0 -OCONH-), 9.5 (1H, s, ring,
imide –NH-).
5.9.2.2 N-Boc-L-glutarimide [2.122]
NHN
H
O
O
O
O
H
Recrystallization of crude product from ethyl acetate yielded pure N-Boc-L-glutarimide
in 81 % yield.
TLC: Rf= 0.26 in ethyl acetate-hexane (1:1).
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1
H NMR (CDCl3) G 1.41 (9H, s, -OC(CH3)3), 1.83 (1H m, ring, 4D-H), 2.45 (1H, m,
ring, 4E-H), 2.63 (1H m, ring, 5D-H), 2.73 (1H, m, ring, 5E-H), 4.3 (1H, m, ring, 3H),
5.46 (1H, d, J=8.0, -OCONH-), 8.85 (1H, s, ring, imide –NH-)
5.9.3 L-Aspartimide [2.123] and L-glutarimide [2.124] trifluoroacetates
To a solution of acetonitrile (5 mL) containing Boc-L-aspartimide (1.5 mmol)/Boc-L-
glutaimide (1.5 mmol) was added trifluoroacetic acid (5 mL). The mixture was stirred
at room temperature for about 3 h. The solvent was rotary evaporated. Then the
resulting yellow oil was redissolved in acetonitrile (15 mL) and rotary evaporated to
dryness. This step was done thrice to obtained constant weight product.
Both L-aspartimide trifluoroacetate 2.123 and L-glutarimide trifluoroacetate 2.124 were
obtained as yellow oils with 95 % and 97 % yields respectively. These were utilized
for next step without any further characterization or purification.
5.9.4 Method-O: Synthesis of hetero ring altered analogues of 3O, C12-HSL
To a stirred solution of decanoyl Meldrum's acid (1 mmol, 300 mg) in dry acetonitrile
(30 mL) was added an appropriate amine (1 mmol) and TEA (1.1 mmol, 155 ȝl) was
also added when L-aspartimide/L-glutarimide trifluroacetate salt was used. The mixture
was stirred for 16 h at room temperature and then refluxed for 3 h. Solvent was rotary
evaporated and the residue was redissolved in ethyl acetate. The organic layer was
washed with 1 M potassium hydrogen sulphate (2u20 mL), dried over MgSO4 and
solvent rotary evaporated to obtain the desired product.
5.9.5 N-(3-Oxododecanoyl)-L- aspartimide [2.110]
NH
O
OH
N
H
OO
The product was purified by PLC in ethyl acetate. The product N-(3-oxododecanoyl)-
L-aspartimide appeared as a pale yellow solid in 58 % yield (Method-O).
TLC-Rf = 0.62 in ethyl acetate
mp = 114-115 qC.
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FT-IR (KBr) cm
-1
: 3302m (QNH, amide and imide), 1786 (QC=O, imide), 1719,
1657(QC=O, amide); 1552s (GNH).
1
H NMR (CDCl3 with a drop of DMSO) į 9.4 (1H, s, imide -NH), 8.1 (1H, d, amide -
NH), 4.6 (1H, m, ring 3-H), 3.5 ( 2H, s, OCH2O) 3.1 (1H, dd, ring 4-H), 2.8 (1H, dd,
ring 4-H), 2.5 (2H, t, -CH2CO), 1.6 ( 2H, m, CH2CH2O) 1.2 (12H, m, -CH2(CH2)6-),
0.8 (3H, t, -CH3 ).
13
C NMR (CDCl3) į 206.67, 179.17, 174.73, 166.81, 47.95, 47.36, 41.86, 38.51, 31.29,
29.78, 29.41, 29.25(2), 22.89, 22.21, 14.12.
(ES-MS/FAB-MS); m/z 311.1985 (M+H
+
) C16H27N2O4, requires m/z 311.1971 (' = 4.5
ppm).
5.9.6 N-(3-Oxododecanoyl)-L-glutarimide [2.111]
NHN
H
O
O
O
H
O
The product was purified by PLC in ethyl acetate. The product N-(3-oxododecanoyl)-
L-glutarimide obtained as off-white solids in 51 % yield (Method-O).
TLC-Rf = 0.27 in ethyl acetate
mp = 96-98 qC.
FT-IR (KBr) cm
-1
: 3339s (QNH, amide and imide), 1723 (QC=O, imide), 1703,
1639(QC=O, amide); 1533s (GNH).
1
H NMR (CDCl3 ) į 0.9 (3H, t, J = 7.0 Hz, CH3(CH2)8-), 1.21-1.3 (12H, m,
CH3(CH2)6-), 1.62 (2H, m, broad, CH3(CH2)6CH2-), 1.94 (1H, m, ring, 4D-H), 2.51
(1H, m, ring, 4E-H), 2.57 (2H, quart, J = 7.2, 4.2 Hz, CH3(CH2)7CH2-), 2.75 (1H, m,
ring, 5D-H), 2.82 (1H, m, ring, 5E-H), 3.5 (2H, s, -COCH2CO-), 4.64 (1H, m, ring, 3-
H), 7.85 (1H, d, J = 6.0, -COCH2CONH-), 8.0 (1H, s, ring, 1-NH-).
13
C NMR (CDCl3) į 206.52, 172.77, 169.12, 166.66, 57.45, 47.93, 41.62, 31.91, 29.79,
29.78, 29.51, 29.39, 29.28(2), 23.97, 22.18, 14.12.
(ES-MS/FAB-MS); m/z 325.2113 (M+H
+
) C17H29N2O4, requires m/z 325.2127 (' = 4.3
ppm).
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5.9.7 2-(3-Oxododecanoyl-2-amino)thiazole [2.112]
N
SN
H
OO
The product was purified by PLC in ethyl acetate-hexane (1:1). The product 2-(3-
oxododecanoyl-2-amino)thiazole was obtained as a white solid in 30 % yield
(Method-O).
TLC-Rf = 0.41 in ethyl acetate
mp = 137-139 qC.
FT-IR (KBr) cm
-1
: 3427s (QNH, amide), 1719 (QC=O, amide), 1679 (QC=O, diamide);
1587s (GNH).
1
H NMR (CDCl3 ) į 0.9 (3H, t, J = 7.0 Hz, CH3(CH2)8-), 1.22-1.29 (12H, m,
CH3(CH2)6-), 1.62 (2H, m, broad, CH3(CH2)6CH2-), 2.57 (2H, quart, J = 7.2, 4.2 Hz,
CH3(CH2)7CH2-), 3.34 (2H, s, -COCH2CO-), 7.12 (1H, d, J = 3.6 Hz, ring, 5-H), 7.56
(1H, d, J = 3.6 Hz, ring, 4-H), 8.21 (1H, s, -CH2CONH-)
13
C NMR (CDCl3) į 207.14, 164.4, 162.92, 138.6, 107.95, 47.93, 42.6, 32.17, 29.72,
29.38(2), 29.18, 23.2, 22.79, 14.12.
(ES-MS/FAB-MS); m/z 297.1624 (M+H
+
) C15H25N2O2S, requires m/z 297.1637 (' =
4.3 ppm).
5.10 Synthesis of hetero ring altered analogues of 4-aza 3O, C12-HSL
5.10.1 Method-P
To a stirred solution of 3-oxo-4-azadodecanoic acid 2.38 (1 mmol, 0.215 g) in DCM
(15 mL) was added sequentially TEA (1.5 mmol, 210 µL), EDC.HCl (1.2 mmol, 0.23
g), and an appropriate amine (1.2 mmol). Stirring was continued for 16 h at room
temperature. Solvent was removed under high vacuo and residue redissolved in hot
ethyl acetate/DCM (20 mL). Organic solution was sequentially washed with saturated
sodium bicarbonate (3 u 10 mL) 1 M HCl (3 u 10 mL) and brine (1 u 15 mL). The
organic layer was dried over MgSO4, filtered and rotary evaporated to obtain desired
product.
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5.10.2 Method-Q
To a stirred solution of 3-oxo-4-azadodecanoic acid 2.38 (1 mmol, 0.215 g) in a
minimum volume of dioxane (4-6 mL) was added a solution of appropriate amine (1.2
mmol) in a minimum amount of water (about 2-4 mL). To this was added sequentially
TEA (1.5 mmol, 210 µL) and EDC.HCl (1.2 mmol, 0.23 g) and stirring was continued
for 16 h at room temperature. Solvent was removed under high vacuo and residue
redissolved in hot ethyl acetate/DCM (20 mL). Organic solution was sequentially
washed with water (3 u 10 mL), saturated sodium bicarbonate or1 M KHSO4 (3 u 10
mL) and brine (1 u 15 mL). The organic layer was dried over MgSO4, filtered and
rotary evaporated to obtain desired products.
5.10.3 2-(3-oxo-4-azadodecanoylamino)thiazole [2.125]
N
SN
H
N
H
OO
2-(3-oxo-4-azadodecanoylamino)thiazole was synthesized from 2-aminothiazole (1.2
mmol, 0.12 g) as off-white crystals in 34 % yield using Method-P. The product was
purified by washing it with ether.
TLC-Rf= 0.6 in ethyl acetate
mp = 137-139 qC.
FT-IR (KBr) cm
-1
: 3314s (QNH, amide), 1701 (QC=O, amine), 1637 (QC=O, diamide);
1558s (GNH).
1
H NMR (CDCl3) į 0.89 (3H, t, J = 6.4 Hz, CH3(CH2)7-), 1.23-1.39 (10H, m,
CH3(CH2)5-), 1.52-1.57 (2H, m, CH3(CH2)5CH2-), 3.29-3.34 (2H, dd, J = 13.2, 7.2 Hz,
CH3(CH2)6CH2-), 3.50 (2H, s, -COCH2CO), 6.64 (1H, t, J = 5.8 Hz, -NH-), 7.03 (1H,
d, J = 3.6 Hz, ring, 5-H), 7.61 (1H, d, J = 3.6 Hz, ring, 4-H), 12.05 (1H, s, ring, 2-NH-)
13
C NMR (CDCl3) į 167.12, 164.27, 162.93, 139.11, 109.47, 43.51, 39.76, 32.92,
30.11, 29.53(2), 26.73, 22.91, 14.18.
(ES-MS/FAB-MS): m/z 298.1579 (M+H
+
) C14H24N3O2S, requires m/z 298.1589 (' =
3.35 ppm)
(1S, 2R)-1-O-Benzyl 2-(3-oxo-4-azadodecanoylamino)cyclopentanol [2.126-a]
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N
H
N
H
O
OH
O
(1S, 2R)-O-Benzyl-2-(3-oxo-4-azadodecanoylamino)cyclopentol was synthesized from
(1S,2R)-1-O-benzyl-2-aminocyclopentanol (1.2 mmol, 0.229 g) as pink crystals in 53
% yield using Method-Q.
TLC-Rf= 0.39 in ethyl acetate
mp = 55-57 qC.
FT-IR (KBr) cm
-1
: 3280m (QNH, amide), 1655s (QC=O, amide), 1637s (QC=O,
diamide); 1560s (GNH), 1064s (QC-OPh, ring).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 7.2 Hz, CH3(CH2)7-), 1.24-1.38 (10H, m,
CH3(CH2)5-), 1.48-1.56 (3H, m, sequentially, CH3(CH2)5CH2-, and ring, 4D-H ), 1.70-
1.77 (2H, m, sequentially ring, 5D-H, 4E-H), 1.80-1.85 (1H, m, ring, 3D-H), 1.91-1.98
(1H, m, ring, 5E-H), 2.11-2.20 (1H, m, ring, 3E-H), 3.27 (2H, m, CH3(CH2)6CH2-),
3.35 (2H, s, -COCH2CO), 3.85 (1H, m, ring 2-H), 4.25 (1H, m, ring, 1-H), 4.59 (2H,
dd, J = 20.4, 12.0 Hz, -CH2C6H5), 7.29-7.34 (5H, m, -C6H5), 7.70 (1H, s, broad, -
CH2NH-), 7.78 (1H, broad, ring, 2-NH-).
13
C NMR (CDCl3) į 166.60, 166.35, 137.51, 128.71(2). 127.93, 127.51(2), 79.10,
73.17, 51.03, 43.29, 39.79, 31.89, 30.21, 30.09, 29.41(2), 29.1, 27.4, 23.2, 19.4, 14.10.
(ES-MS/FAB-MS); m/z 389.2814 (M+H
+
) C23H37N2O3, requires m/z 389.2804 (' = 2.5
ppm).
(1S, 2R)-1-O-Benzyl 2-(3-oxo-4-azadodecanoylamino)cyclohexanol [2.127-a]
N
H
N
H
O
H
O
O
(1S, 2R)-1-O-Benzyl 2-(3-oxo-4-azadodecanoylamino)cyclohexanol was synthesized
from (1S,2R)-1-O-benzyl-2-aminocyclohexanol (1.2 mmol, 0.2464 g) as glassy-white
crystals in 56 % yield using Method-Q.
TLC-Rf= 0.4 in ethyl acetate
mp = 77-79 qC.
FT-IR (KBr) cm
-1
: 3284m (QNH, amide), 1661s (QC=O, amide and diamide); 1559s
(GNH), 1101s (QC-OPh, ring).
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1
H NMR (CDCl3) į 0.89 (3H, t, J = 6.8 Hz, CH3(CH2)7-), 1.21-1.35 (10H, m,
CH3(CH2)5-), 1.36-1.44 (4H, m, sequentially, ring, 4D-H, 5D-H, 6D-H, 4E-H), 1.51
(2H, m, CH3(CH2)5CH2-), 1.67 (1H, m, 5E-H), 1.78 (1H, m, ring, 3D-H), 2.06-2.12
(2H, m, sequentially, ring, 5E-H, 3E-H), 3.20 (2H, s, -COCH2CO), 3.24 (2H, t, 8.0 Hz,
CH3(CH2)6CH2-), 3.29 (1H, m, ring 2H), 3.80-3.85 (1H, m, ring, 1H), 4.48 (1H, d, J =
12.0 Hz, -C(H)HC6H5), 4.66 (1H, dd, J = 12.0, 1.6 Hz, -C(H)HC6H5), 7.16 (1H, s,
broad, -CH2NH-), 7.28-7.31 (5H, m, -C6H5), 7.61 (1H, broad, ring, 2-NH-).
13
C NMR (CDCl3) į 166.20, 166.15, 138.71, 128.43(2). 127.67(2), 127.62, 79.42,
70.67, 53.83, 39.89, 31.80(2), 30.88, 30.21(2), 29.22, 29.19, 26.94, 24.02, 23.69,
22.64, 14.10.
(ES-MS/FAB-MS); m/z 403.2944 (M+H
+
) C24H39N2O3, requires m/z 403.2961 (' = 4.2
ppm).
5.10.4 Catalytic hydrogenation
An appropriate (1S, 2R) O-benzyl-2-(3-oxo-4-azadodecanoyl)aminocyclopentanol or
(1S, 2R) O-benzyl-2-(3-oxo-4-azadodecanoyl)aminocycloxexanol (1 mmol) was
dissolved in absolute ethanol (10 mL). To this was added Pd/C (10 % w/w) and the
heterogeneous mixture was stirred for 4 h under atmosphere of hydrogen gas. The
catalyst was filtered off using celite as a filter aid. The filtrate was evaporated under
vacuo to obtain the desired product 2.126 or 2.127 in 98 % yield.
5.10.5 (1S, 2R)-2-(3-oxo-4-azadodecanoylamino)cyclopentanol [2.126]
N
H
N
H
O
OHH
O
mp = 103-105 qC.
FT-IR (KBr) cm
-1
: 3273s (QNH, amide and QOH, ring), 1668 (QC=O, amide), 1633
(QC=O, diamide); 1562s (GNH), 1348m (GOH).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 7.2 Hz, CH3(CH2)7-), 1.25-1.38 (10H, m,
CH3(CH2)5-), 1.08 (2H, s, broad, CH3(CH2)5CH2-), 1.65-1.85 (4H, m, sequentially
ring, 4D-H, 5D-H, 4E-H, 3D-H), 2.00-2.06 (1H, m, ring, 5E-H), 2.12-2.19 (1H, m, ring,
3E-H), 3.27 (2H, t, J = 6.4 Hz, CH3(CH2)6CH2-), 3.36 (1H, s, -COCH2CO), 3.87 (1H,
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m, ring 2-H), 4.04 (1H, m, ring, 1-H), 4.50 (1H, s, broad, ring, 1-OH), 7.55 (1H, s, -
CH2NH-), 8.16 (1H, d, J = 4.4 Hz, ring, 2-NH-).
13
C NMR (CDCl3) į 166.62, 166.35, 75.42, 53.81, 43.89, 39.80, 32.46, 30.88, 30.12,
29.42(2), 28.79, 26.84, 22.84, 19.64, 14.10.
(ES-MS/FAB-MS); m/z 299.2329 (M+H
+
) C16H31N2O3, requires m/z 299.2335 (' = 2.0
ppm).
5.10.6 (1S, 2R)-2-(3-oxo-4-azadodecanoylamino)cyclohexanol [2.127]
N
H
N
H
O
H
O
OH
mp = 102-104 qC.
FT-IR (KBr) cm
-1
: 3279s (QNH, amide and QOH, ring), 1660 (QC=O, amide), 1624
(QC=O, diamide); 1567s (GNH), 1379m (GOH, ring); 1074s (QC-OH, ring).
1
H NMR (CDCl3) į 0.92 (3H, t, J = 7.2 Hz, CH3(CH2)7-), 1.21-1.32 (10H, m,
CH3(CH2)5-), 1.34-1.43 (4H, m, sequentially, ring, 4D-H, 5D-H, 6D-H, 4E-H), 1.47
(2H, m, CH3(CH2)5CH2-), 1.67 (1H, m, 5E-H), 1.78 (1H, m, ring, 3D-H), 2.06-2.12
(2H, m, sequentially, ring, 5E-H, 3E-H), 3.20 (2H, s, -COCH2CO), 3.24 (2H, t, 8.0 Hz,
CH3(CH2)6CH2-), 3.29 (1H, m, ring 2H), 4.21 (1H, s, broad, ring, 1-H), 4.66 (1H, ring
1-OH), 7.16 (1H, s, broad, -CH2NH-), 7.61 (1H, broad, ring, 2-NH-).
13
C NMR (CDCl3) į 166.76, 166.32, 67.21, 62.21, 44.19, 39.71, 32.06, 31.48, 30.23,
29.47(2), 27.69, 26.91, 23.22, 22.83, 21.86, 14.10.
(ES-MS/FAB-MS); m/z 313.2480 (M+H
+
) C17H33N2O3, requires m/z 313.2491 (' =
3.51 ppm).
5.10.7 N-(3-oxo-4-azadodecanoyl)cycloheptylamine [2.128]
N
H
N
H
OO
H
N-(3-oxo-4-azadodecanoyl)cycloheptylamine was synthesized from cycloheptylamine
(1.2 mmol, 153 µL) as off white crystals in 39 % yield using Method-P.
TLC-Rf= 0.34 in ethyl acetate
mp = 53-55 qC.
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FT-IR (KBr) cm
-1
: 3299s (QNH, amide), 1662s (QC=O, amide and diamide); 1552s
(GNH).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 5.2 Hz, CH3(CH2)7-), 1.21-1.39 (10H, m,
CH3(CH2)5-), 1.43-1.61 (8H, m, CH3(CH2)5CH2- and ring, 4-2H, 5-2H, 3D-H, 6D-H),
1.63-1.67 (4H, m, ring, 3E-H, 6E-H, 2D-H, 7D-H), 1.89-1.95 (2H, m, ring, 2E-H, 7E-
H), 3.13 (2H, s, -COCH2CO), 3.24-3.29 (2H, m, CH3(CH2)6CH2-), 3.95 (1H, m, ring,
1-H), 6.72 (1H, s, broad, -CH2NH-), 6.88 (1H, d, ring, 1-NH-) .
13
C NMR (CDCl3) į 167.18, 166.10, 50.69, 43.37, 39.68, 34.82(2), 31.79, 29.36,
29.23, 29.19, 27.97(2), 26.91, 24.00(2), 22.64, 14.09.
(ES-MS/FAB-MS); m/z 311.2687 (M+H
+
) C18H35N2O2, requires m/z 311.2699 (' =
3.85 ppm).
5.10.8 2-(3-Oxo-4-azadodecanoyl)aminophenol [2.129]
N
H
N
H
OO
OH
2-(3-Oxo-4-azadodecanoyl)aminophenol was synthesized from 2-aminophenol (1.2
mmol, 0.1309 g) as a shiny white crystal in 82 % yield using Method-Q.
TLC-Rf= 0.43 in ethyl acetate-hexane (9:1)
mp = 84-86 qC.
FT-IR (KBr) cm
-1
: 3327m, sharp, (QOH, phenol); 3261s (QNH, amide); 3095m, (QCH,
aromatic); 1676s, 1643s, (QC=O, amide and diamide); 1614s, 1601s, 1455s (aromatic
skeletal); 1546s (GNH); 744s (ȖCH, O-disubtituted benzene).
1
H NMR (CDCl3 with a drop of DMSO) į 0.82 (3H, t, J = 6.4 Hz, CH3(CH2)7-), 1.18-
1.31 (10H, m, CH3(CH2)5-), 1.47 (2H, s, broad, CH3(CH2)5CH2-), 3.20 (2H, t, J = 6.4
Hz, CH3(CH2)6CH2-), 3.39 (1H, s, -COCH2CO), 6.78 (1H, t, J = 7.6 Hz, ring 6-H),
6.90 (1H, d, J = 8.0 Hz, ring, 4-H), 6.98 (1H, t, J = 7.6 Hz, ring, 5-H), 7.47 (1H, d, J =
8.0, 1.2, Hz, ring, 3-H), 7.65 (1H, s, -NH-), 8.0 (1H, s, broad, ring, -NH-), 9.97 (1H, s,
ring , 1-OH).
13
C NMR (DMSO) į 166.64, 165.07, 150.1, 128.1. 126.46, 123.16, 121.98, 116.12,
42.31, 40.1, 32.18, 29.99, 29.51, 29.27, 27.21, 23.22, 14.13.
(ES-MS/FAB-MS); m/z 307.2034 (M+H
+
) C17H27N2O3, requires m/z 307.2022 (' = 3.9
ppm).
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5.10.9 2-(3-Oxo-4-azadodecanoyl)amino-4-chlorophenol [2.130]
N
H
N
H
OO
OH
Cl
2-(3-Oxo-4-azadodecanoyl)amino-4-chlorophenol was synthesized from 2-amino-4-
chlorophenol (1.2 mmol, 0.1722 g) as a white solid in 36 % yield using Method-Q.
TLC-Rf= 0.82 in ethyl acetate
mp = 80-82 qC.
FT-IR (KBr) cm
-1
: 3373m, sharp, (QOH, phenol); 3253s (QNH, amide); 3100m, (QCH,
aromatic); 1677s, 1644s, (QC=O, amide and diamide); 1608m, 1598m, 1422s (aromatic
skeletal); 1544s (GNH); 809w (ȖCH, adjacent 2H of benzene).
1
H NMR (DMSO) į 0.85 (3H, t, J = 6.8 Hz, CH3(CH2)7-), 1.21-1.26 (10H, m,
CH3(CH2)5-), 1.39-1.42 (2H, m, CH3(CH2)5CH2-), 3.08 (2H, dd, J = 12.8, 6.8 Hz,
CH3(CH2)6CH2-), 3.35 (1H, s, -COCH2CO), 6.86 (1H, d, J = 8.4 Hz, ring 6-H), 6.93
(1H, dd, J = 8.4, 2.4 Hz, ring, 5-H), 8.15 (1H, d, J = 2.8 Hz, ring, 3-H), 8.21 (1H, t, J =
5.6 Hz, -NH-), 9.97 (1H, s, broad, ring, 2-NH-), 10.27 (1H, s, ring , 1-OH).
13
C NMR (DMSO) į 167.64, 166.07, 145.99, 128.18. 123.56, 122.56, 119.96, 116.25,
43.93, 39.15, 31.68, 29.35, 29.15, 29.12, 26.83, 22.55, 14.41.
(ES-MS/FAB-MS); m/z 341.1625 (M+H
+
) C17H26N2O3Cl, requires m/z 341.1632 (' =
2.05 ppm).
5.10.10 2-(3-Oxo-4-azadodecanoyl)aminobenzamide [2.131]
N
H
N
H
OO
NH2O
2-(3-Oxo-4-azadodecanoyl)aminobenzamide was synthesized from anthranilamide
(1.2 mmol, 0.1634 g) as a white solid in 52 % yield using Method-P.
TLC-Rf= 0.28 in ethyl acetate
mp = 120-121 qC.
FT-IR (KBr) cm
-1
: 3402w, 3306m, (QNH, amides); 3201m, (QCH, aromatic); 1685s
(QC=O, benzamide); 1634s, (QC=O, doamide); 1592m, 1449w (aromatic skeletal);
1521s (GNH); 752s (ȖCH, adjacent 4H of benzene).
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1
H NMR (CDCl3) į 0.89 (3H, t, J = 7.2 Hz, CH3(CH2)7-), 1.26-1.31 (10H, m,
CH3(CH2)5-), 1.52-1.59 (2H, m, CH3(CH2)5CH2-), 3.34 (2H, dd, J = 12.8, 6.8 Hz,
CH3(CH2)6CH2-), 3.46 (1H, s, -COCH2CO), 6.04 (1H, d, ring, 1-N(H)H), 6.26 (3H, s,
ring, 1-N(H)H), 7.14-7.18 (1H, dt, J = 8.0, 1.2 Hz, ring 5-H), 7.50 (1H, s, broad, -NH-)
, 7.52-7.60 (2H, m, ring, 4-H, 3-H), 8.57 (1H, d, J = 8.0 Hz, ring, 6-H), 11.59 (1H, s,
ring , 2-NH-).
13
C NMR (CDCl3) į 167.61, 165.52, 165.01, 138.38. 133.25, 127.37, 124.67, 123.53,
121.81, 44.36, 39.75, 31.80, 29.35, 29.25, 29.19, 26.95, 22.65, 14.11.
(ES-MS/FAB-MS); m/z 334.2123 (M+H
+
) C18H28N3O3, requires m/z 334.2131 (' =
2.39 ppm); m/z 317.1853 (M-NH2), requires m/z 317.1865.
5.10.11 N, N-Dimethyl-2-(3-oxo-4-azadodecanoyl)aminobenzamide [2.132]
N
H
N
H
OO
NO
N, N-Dimethyl-2-(3-oxo-4-azadodecanoyl)aminobenzamide was synthesized from N,
N-dimethyl anthranilamide (1.2 mmol, 0.180 g) as a pink solid in 66 % yield using
Method-P.
TLC-Rf= 0.14 in ethyl acetate-hexane (9:1)
mp = 59-60 qC.
FT-IR (KBr) cm
-1
: 3304m, (QNH, amides); 3160m, (QCH, aromatic); 1685s, 1660w
(QC=O, benzamide, diamide); 1605s, 1484w (aromatic skeletal); 1530m (GNH); 722s
(ȖCH, adjacent 4H of benzene).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 6.8 Hz, CH3(CH2)7-), 1.24-1.34 (10H, m,
CH3(CH2)5-), 1.49-1.55 (2H, m, CH3(CH2)5CH2-), 3.03 (3H, s, ring, -N(CH3)CH3),
3.15 (3H, s, ring, -N(CH3)CH3), 3.28 (2H, dd, J = 13.2, 7.2 Hz, CH3(CH2)6CH2-), 3.36
(1H, s, -COCH2CO), 7.14-7.18 (1H, dt, J = 8.0, 1.2 Hz, ring 5-H), 7.21 (1H, s, broad, -
NH-), 7.27-7.29 (1H, dd, J = 8.0, 1.2 Hz, ring, 4-H), 7.38-7.43 (1H, dt, J = 8.2, 1.2 Hz,
ring, 3-H), 9.71 (1H, s, ring , 2-NH-).
13
C NMR (CDCl3) į 168.76, 166.55, 164.51, 139.98. 130.35, 127.71, 124.31(2),
121.43, 42.43, 39.59, 37.71(2), 31.98, 30.09, 29.45(2), 26.82, 22.86, 14.11.
(ES-MS/FAB-MS); m/z 362.2459 (M+H
+
) C20H32N3O3, requires m/z 362.2444 (' =
4.14 ppm); m/z 317.1866 (M-N(CH2)3), requires m/z 317.1865.
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5.10.12 3-(3-Oxo-4-azadodecanoyl)aminobenzamide [2.133]
N
H
N
H
OO
NH2
O
3-(3-Oxo-4-azadodecanoyl)aminobenzamide was synthesized from 3-aminobenzamide
(1.2 mmol, 0.1634 g) as a pink solid in 33 % yield using Method-Q.
mp = 185-187 qC.
FT-IR (KBr) cm
-1
: 3374m, sharp, 3307m (QNH, amides); 3171w, (QCH, aromatic);
1659s, 1637s (QC=O, benzamide, diamide); 1586s, 1452m (aromatic skeletal); 1541s
(GNH); 791s (ȖCH, adjacent 3H of benzene).
1
H NMR (DMSO) į 0.87 (3H, t, J = 6.8 Hz, CH3(CH2)7-), 1.24-1.27 (10H, m,
CH3(CH2)5-), 1.35-1.41 (2H, m, CH3(CH2)5CH2-), 3.06 (2H, dd, J = 12.8, 6.8 Hz,
CH3(CH2)6CH2-), 3.23 (1H, s, -COCH2CO), 7.34 (1H, s, ring, 1-N(H)H), 7.37 (1H, t, J
= 8.0 Hz, ring 5-H), 7.53-7.55 (1H, dt, J = 8.0, 1.2 Hz, ring, 6-H), 7.74-7.76 (1H, dd, J
= 8.0, 1.2 Hz, ring, 4-H), 7.94 (1H, s, broad, -NH-), 8.02 (1H, t, J = 2.0 Hz, ring, 1-
N(H)H), 8.05 (1H, d, J = 8.0 Hz, ring, 3-H), 10.21 (1H, s, ring, 3-NH-).
13
C NMR (CDCl3) į 168.16, 166.62, 164.15, 138.63. 134.45, 129.17, 125.17, 123.63,
117.28, 42.46, 39.71, 31.90, 30.15, 29.42(2), 26.81, 22.83, 14.10.
(ES-MS/FAB-MS); m/z 334.2146 (M+H
+
) C18H28N3O3, requires m/z 334.2131 (' = 4.4
ppm).
5.10.13 2-(3-Oxo-4-azadodecanoyl)aminopyridine [2.134]
N
H
N
H
OO
N
2-(3-Oxo-4-azadodecanoyl)aminopyridine was synthesized from 2-aminopyridine
(1mmol, 0.0901 g) as purple crystals in 17 % yield using Method-P.
(Note: Here washing of ethyl acetate extract with HCl was excluded to avoid formation
of water soluble pyridinium chloride salt).
TLC-Rf= 0.41 in ethyl acetate
mp = 134-136 qC.
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FT-IR (KBr) cm
-1
: 3306m, (QNH, amides); 3117w, (QCH, aromatic); 1645s (QC=O,
diamide); 1679m, 1578s, 1438s (aromatic skeletal); 1555s (GNH); 778s (ȖCH, adjacent
4H of pyridine).
1
H NMR (CDCl3) į 0.88 (3H, t, J = 6.8 Hz, CH3(CH2)7-), 1.27-1.30 (10H, m,
CH3(CH2)5-), 1.52-1.58 (2H, m, CH3(CH2)5CH2-), 2.86 (1H, s, -NH-), 3.28 (2H, dd, J
= 9.6, 6.8 Hz, CH3(CH2)6CH2-), 3.57 (1H, s, -COCH2CO), 7.16 (1H, s, ring, 2-NH-),
7.23 (1H, t, J = 6.4 Hz, ring 5-H), 7.93 (1H, t, J = 8.0 Hz, ring, 4-H), 8.19 (1H, t, J =
8.8 Hz, ring, 3-H), 8.44 (1H, d, J = 4.8 Hz, ring, 6-H).
13
C NMR (CDCl3) į 167.1, 164.10, 150.16, 146.15, 139.1, 120.21, 116.21, 42.58,
39.76, 31.89, 30.1, 29.37, 29.32, 26.81, 22.76, 14.1.
(ES-MS/FAB-MS); m/z 292.2016 (M+H
+
) C16H26N3O3, requires m/z 292.2025 (' = 3.1
ppm).
5.10.14 5-(3-Oxo-4-azadodecanoyl)amino-1H-indazole [2.135]
N
H
N
H
OO
NH
N
To a stirred solution of 3-oxo-4-azadodecanoic acid 2.38 (1 mmol, 0.215 g) in a
minimum volume of dioxane (4 mL) was added a solution of 5-aminoindazole (1.2
mmol, 0.1598 g) in water (about 2-4 mL). To this was added sequentially TEA (1.5
mmol, 210 µL) and EDC.HCl (1.2 mmol, 0.23 g) and stirred for 16 h at room
temperature. Because product was insoluble in solvent used it was deposited in
reaction mixture as crystals. Solvent was removed under high vacuo and the residue
redissolved in warm ethyl acetate (10 mL). The crystals settled down were then filtered
and collected. Product was sequentially washed with water (1 u 5 mL), 1 M KHSO4 (1
u 5 mL) and finally with methanol (10 mL) to obtained desired product as off-white
crystals in 62 % yield.
mp = 45-47 qC.
FT-IR (KBr) cm
-1
: 3283s, (QNH, amides, ring); 1632s (QC=O, diamide); 1663s,
1597w, (aromatic skeletal); 1565w (GNH); 966m (ȖCH, adjacent 1H of indazole);
816m (ȖCH, adjacent 2H of indazole).
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1
H NMR (DMSO) į 0.85 (3H, t, J = 6.8 Hz, CH3(CH2)7-), 1.24-1.29 (10H, m,
CH3(CH2)5-), 1.40-1.44 (2H, m, CH3(CH2)5CH2-), 3.08 (2H, dd, J = 8.8, 6.8 Hz,
CH3(CH2)6CH2-), 3.23 (1H, s, -COCH2CO), 7.39-7.41 (1H, dd, J = 8.8, 2.0 Hz, ring 7-
H), 7.48 (1H, d, J = 8.8 Hz, ring, 6-H), 8.01 (1H, s, ring, 3-H), 8.05 (1H, t, J = 5.6 Hz,
-NH-), 8.13 (1H, s, ring, 4-H), 10.09 (1H, s, ring, 5-NH-), 12.98 (1H, s, ring, 1-NH-).
13
C NMR (DMSO) į 166.90, 166.00, 137.36, 133.85, 132.48, 123.61, 120.58, 110.60,
109.97, 45.08, 39.16, 31.70, 29.47, 29.18, 29.14, 26.83, 22.56, 14.43.
(ES-MS/FAB-MS); m/z 331.2146 (M+H
+
) C18H27N4O2, requires m/z 331.2134 (' = 3.6
ppm).
5.11 Synthesis of oxa analogues of 3O, C12-HSL
5.11.1 3O, 4-oxa C12-HSL [2.139]
O-Benzyl-O-octanyl malonate [2.144]
O O
OO
To a stirred solution of monobenzyl malonate (2 mmol, 388 g) in a dry DCM (15 ml)
was added sequentially n-octyl alcohol (2 mmol, 318 µL), DMAP (3 mmol, 0.366 g)
and DCCI (2.2 mmol, 0. 454 g). The mixture was stirred for 16 h and solvent rotary
evaporated under vacuo. The residue was redissolved in ethyl acetate (25 mL) and was
washed with saturated sodium bicarbonate (3 u 10 mL), 1 M HCl (3 u 10 mL) and
brine (1 u 15 mL). The organic layer was dried over MgSO4, filtered and rotary
evaporated to get the residue was kept aside in the cold acetone (4-6 mL). When the
remaining DCU separated this was carefully removed. The final product 2.144 was
purified by column chromatography in ether-hexane (3:7) as colorless oil in 76 %
yield.
TLC-Rf= 0.4 in ether-hexane (3:7)
1
H NMR (CDCl3) į 0.90 (3H, t, J = 6.8 Hz, CH3(CH2)7-), 1.25-1.33 (10H, m,
CH3(CH2)5-), 1.61-1.64 (2H, m, CH3(CH2)5CH2-), 3.44 (2H, s, -COCH2CO-), 4.14
(2H, t, J = 6.8 Hz, CH3(CH2)6CH2-), 5.20 (2H, s, -CH2C6H5), 7.35-7.39 (5H, broad, m,
-C6H5).
&RQILGHQWLDO
- 223 -
3-Oxo-4-oxadodecanoic acid [2.145]
O OH
OO
O-Benzyl-O-octanyl malonate 2.144 (1 mmol) was dissolved in absolute ethanol (10
mL). To this was added Pd/C (10 % w/w) and the heterogeneous mixture was stirred
for 6 h under atmosphere of hydrogen gas. The catalyst was filtered off using celite as
a filter aid. The filtrate was evaporated under vacuo and gave the desired product in 94
% yield.
1
H NMR (CDCl3) į 0.89 (3H, t, J = 6.8 Hz, CH3(CH2)7-), 1.25-1.32 (10H, m,
CH3(CH2)5-), 1.63-1.68 (2H, m, CH3(CH2)5CH2-), 3.45 (2H, s, -COCH2CO-), 4.19
(2H, t, J = 6.8 Hz, CH3(CH2)6CH2-), 10.80 (1H, s, -COOH).
3O, 4-oxa C12-HSL [2.139]
O N
H
O O
O
OH
3O, 4-oxa C12-HSL was synthesized from 3-oxo-4-oxadodecanoic acid 2.145 as a
white solid in 55 % yield using Method B.
TLC-Rf= 0.31 in ethyl acetate-hexane (1:1)
mp = 57-59 qC.
FT-IR (KBr) cm
-1
: 3300m (QNH, amide); 1790s (QC=O, lactone); 1737s (QC=O, ȕ-
diketoester); 1650s (QC=O, amide); 1535s (GNH); 1194s, 1165s (QO-C, 2-bands of
ester).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 6.8 Hz, CH3(CH2)7-), 1.26-1.35 (10H, m,
CH3(CH2)5-), 1.63-1.69 (2H, m, broad, CH3(CH2)6CH2-), 2.18-2.31 (1H, m, ring, 4D-
H), 2.75-2.83 (1H, m, ring, 4E-H), 3.40 (2H, s, COCH2CO), 4.17 (2H, t, J = 6.8 Hz,
CH3(CH2)7CH2-), 4.29-4.34 (1H, m, ring, 5D-H), 4.48-4.56 (1H, m, ring, 5E-H), 4.58-
4.65 (1H, m, ring, 3-H), 7.80 (1H, d, J = 5.8 Hz, -NH-HSL).
13
C NMR (DMSO) į 174.97, 168.0, 167.16, 89.15, 66.18, 65.32, 54.2, 32.23, 30.37,
29.47, 29.18, 29.14, 26.32, 23.16, 14.43.
(ES-MS/FAB-MS); m/z 300.1818 (M+H
+
) C15H26NO5, requires m/z 300.1811 (' =
2.33 ppm).
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5.12 Synthesis of 8-oxa analogues of 3O, 4-aza C12-HSL
Ethyl 3-oxo-8-oxa-4-azadodecanoate
O N
H
OO
O
Ethyl 3-oxo-8-oxa-4-azadodecanoate was synthesized as yellow viscous oil in 99 %
yield from 3-butoxypropylamine 2.147 using Method-D.
1
H NMR (CDCl3) į 0.93 (3H, t, J = 7.2 Hz, CH3(CH2)3-), 1.30 (3H, t, J = 7.2 Hz,
CH3CH2CO-), 1.36-1.43 (2H, m, CH3CH2(CH2)2-), 1.54-1.61 (2H, m, CH3CH2
CH2CH2-), 1.78-1.84 (2H, m, -OCH2CH2CH2NH-), 3.29 (2H, s, -COCH2CO-), 3.31-
3.45 (4H, m, -CH2O(CH2)2CH2NH-), 3.49-3.52 (2H, t, J = 5.8 Hz, -OCH2 (CH2)2NH-),
4.21 (2H, q, J = 7.2 Hz, CH3CH2CO-), 7.36 (1H, s, broad, -NH-).
(ES-MS/FAB-MS); m/z 246.1709 (M+H
+
) C12H24NO4, requires m/z 246.1705 (' =
1.62 ppm).
3-Oxo-8-oxa-4-azadodecanoic acid [2.148]
O N
H
OO
OH
Saponification of ethyl, 3-oxo-8-oxa-4-azadodecanoate afforded 3-oxo-8-oxa-4-
azadodecanoic acid as colorless viscous oil in 79 % yield.
FT-IR (CH3CN) cm
-1
: 3319m, br, (QNH and QOH); 1731s (QC=O, acid); 1634s (QC=O,
amide); 1562s (GNH, amide); 1115m (QC-O, ether).
1
H NMR (CDCl3) į 0.96 (3H, t, J = 7.2 Hz, CH3(CH2)3-), 1.34-1.43 (2H, m,
CH3CH2(CH2)2-), 1.54-1.61 (2H, m, CH3CH2CH2CH2-), 1.81-1.87 (2H, m, -OCH2CH2
CH2NH-), 3.28 (2H, s, -COCH2CO-), 3.44-3.53 (4H, m, -CH2O(CH2)2CH2NH-), 3.58-
3.60 (2H, m, -OCH2(CH2)2NH-), 7.20 (1H, s, broad, -NH-), 10.23 (1H, s, -COOH).
13
C NMR (CDCl3) į 169.32, 168.03, 91.21, 71.81, 70.32, 38.13, 31.74, 28.18, 19.40,
13.89.
(ES-MS/FAB-MS); m/z 216.1245 (M-H
+
) C10H18NO4, requires m/z 216.1236 (' = 4.1
ppm).
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5.12.1 3O, 8-oxa-4-aza C12-HSL [2.140]
O N
H
N
H
O
O
OH
O
3O, 8-oxa-4-aza C12-HSL was synthesized from 3-oxo-8-oxa-4-azadodecanoic acid
2.148 using Method-A. Desired compound was purified by column chromatography
using ethyl acetate-methanol (4:1) as a white solid in 68 % yield.
TLC-Rf= 0.56 in ethyl acetate-methanol (4:1)
mp = 83-85 qC.
FT-IR (KBr) cm
-1
: 3282s, (QNH); 1770s (QC=O, lactone); 1684m (QC=O, diamide);
1647s (QC=O, amide); 1556s (GNH, amide); 1118m (QC-O, ether).
1
H NMR (CDCl3) į 0.94 (3H, t, J = 7.4 Hz, CH3(CH2)3-), 1.33-1.43 (2H, m,
CH3CH2(CH2)2-), 1.54-1.61 (2H, quint, J = 9.6, 6.8 Hz, CH3CH2CH2CH2-), 1.77-1.83
(2H, quint, J = 6.0 Hz, -OCH2CH2CH2NH-), 2.24-2.35 (1H, m, ring, 4D-H), 2.68-2.75
(1H, m, ring, 4E-H), 3.23 (2H, s, -COCH2CO-), 3.38-3.45 (4H, m, -
CH2O(CH2)2CH2NH-), 3.52-3.55 (2H, m, -OCH2(CH2)2NH-), 4.25-4.32 (1H, m, ring,
5D-H), 4.47-4.52 (1H, m, ring, 5E-H), 4.56-4.60 (1H, m, ring, 3-H), 7.05 (1H, s, broad,
-NH-), 8.21 (1H, d, J = 6.4 Hz, -NH-HSL).
13
C NMR (CDCl3) į 174.71, 167.41, 167.09, 71.08, 69.86, 65.81, 48.93, 42.24, 38.79,
31.78, 29.48, 28.67, 19.39, 13.93.
(ES-MS/FAB-MS); m/z 323.1574 (M+Na) C14H24N2O5Na, requires m/z 323.1583 (' =
2.78 ppm) and m/z 301.1748 (M+H
+
) C14H25N2O5, requires m/z 301.1763 (' = 4.9
ppm).
5.12.2 (1S, 2R)-2-(3-Oxo, 8-oxa-4-azadodecanoyl)aminocyclopentanol [2.141]
(1S, 2R)-1-O-Benzyl-2-(3-oxo-8-oxa-4-azadodecanoyl)aminocyclopentanol [2.150]
O N
H
N
H
O
OH
O
(1S, 2R)-1-O-Benzyl-2-(3-oxo-8-oxa-4-azadodecanoyl)aminocyclopentanol was
isolated as an oil from 3-oxo-8-oxa-4-azadodecanoic acid 2.148 in 45 % yield using
Method-P.
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TLC-Rf= 0.55 in ethyl acetate-methanol (4:1)
1
H NMR (CDCl3) į 0.94 (3H, t, J = 7.4 Hz, CH3(CH2)3-), 1.34-1.43 (2H, m,
CH3CH2(CH2)2-), 1.44-1.52 (1H, m, ring, 4D-H), 1.54-1.61 (2H, m, CH3CH2CH2CH2-)
, 1.67-1.75 (3H, m, ring, 5D-H, 4E-H, 3D-H), 1.76-1.84 (2H, m, -OCH2CH2CH2NH-),
1.85-1.98 (1H, m, ring, 5E-H), 2.13-2.22 (1H, m, ring, 3E-H), 3.12 (2H, s, -
COCH2CO-), 3.37-3.47 (4H, m, -CH2O(CH2)2CH2NH-), 3.51-3.54 (2H, m, -
OCH2(CH2)2NH-), 3.80-3.84 (1H, m, ring, 2-H), 4.24-4.28 (1H, m, ring, 1-H), 4.62
(2H, dd, J = 12.0, 28.8 Hz, -CH2C6H5), 7.03 (1H, d, J = 4.8 Hz, ring-NH-), 7.31 (1H, s,
broad, -NH-), 7.33-7.51 (5H, m, -C6H5).
13
C NMR (CDCl3) į 166.38, 166.13, 138.66, 128.34(2), 127.64(2), 127.46, 84.75,
71.12, 71.05, 69.69, 55.79, 42.53, 38.57, 31.78, 30.56, 30.47, 28.79, 21.72, 19.38,
13.93.
(ES-MS/FAB-MS); m/z 413.2399 (M+Na) C22H35N2O4Na, requires m/z 413.2416 (' =
4.1 ppm); m/z 391.2575 (M+H
+
) C22H35N2O4, requires m/z 391.2597 (' = 3.9 ppm).
(1S, 2R)-2-(3-Oxo, 8-oxa-4-azadodecanoyl)aminocyclopentanol [2.141]
O N
H
N
H
O
OHH
O
(1S, 2R)-2-(3-Oxo, 8-oxa-4-azadodecanoyl)aminocyclopentanol was synthesized as a
white solid by catalytic hydrogenation of (1S, 2R)-1-O-benzyl-2-(3-oxo-8-oxa-4-
azadodecanoyl)aminocyclopentanol 2.150 in 88 % yield.
mp = 49-51 qC.
FT-IR (KBr) cm
-1
: 3320m (QNH, amide and QOH, ring), 1627 (QC=O, amide,
diamide); 1560s (GNH), 1347m (GOH); 1114m (QC-O, ether).
1
H NMR (CDCl3) į 0.95 (3H, t, J = 7.2 Hz, CH3(CH2)3-), 1.34-1.43 (2H, m,
CH3CH2(CH2)2-), 1.48-1.54 (1H, m, ring, 4D-H), 1.56-1.62 (2H, m, CH3CH2CH2CH2-)
, 1.64-1.76 (3H, m, ring, 5D-H, 4E-H, 3D-H), 1.78-1.84 (2H, m, -OCH2CH2CH2NH-),
2.03-2.08 (1H, m, ring, 5E-H), 2.13-2.18 (1H, m, ring, 3E-H), 3.16 (2H, s, -
COCH2CO-), 3.38-3.46 (4H, m, -CH2O(CH2)2CH2NH-), 3.53-3.56 (2H, m, -
OCH2(CH2)2NH-), 3.82-3.85 (1H, m, ring, 2-H), 3.97-4.03 (1H, m, ring, 1-H), 4.34
(1H, s, broad, ring, -OH-), 6.92 (1H, s, broad, -NH-), 7.77 (1H, s, ring-NH-).
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13
C NMR (CDCl3) į 166.47, 166.22, 74.75, 71.23, 70.25, 53.19, 45.29, 36.67, 32.48,
29.96, 28.97, 19.28(2), 14.13.
(ES-MS/FAB-MS); m/z 301.2119 (M+H
+
) C15H29N2O4, requires m/z 301.2127 (' = 2.6
ppm).
5.13 Synthesis of 7, 10-dioxa analogues of 3O, 4-aza C12-HSL
5.13.1 3O, 7, 10-dioxa, 4-aza C12-HSL [2.142]
N-(3, 6-Dioxaoctyl)phthalimide
NOO
O
O
Diisopropyl azadicarboxylate (14.1 mmol, 2.85 g) was added to a pre-cooled (with a
salt-ice bath) solution of toluene (40 mL) containing triphenylphosphine (13 mmol,
3.41 g), di(ethyleneglycol)ethylether (13 mmol, 1.75 g) and phthalimide (12 mmol,
1.766 g). The reaction mixture was stirred for 50 minutes and then cooling bath was
removed. The reaction mixture was allowed to warm to 15-25 qC and stirred for 1 h.
To this methanol (10 mL) was added and stirred further 16 h at room temperature.
The mixture was filtered and filtrate concentrated under vacuum to obtain more
precipitate. The crude precipitate was washed with methanol (5 mL) and dried to give
white solids in 75 % yield.
mp = 47-49 qC.
1
H NMR (CDCl3) į 1.14 (3H, t, J = 6.8 Hz, CH3-), 1.46 (2H, q, J = 7.2 Hz, CH3CH2-),
1.54 (2H, q, J = 6.4, 5.2 Hz, CH3CH2OCH2-), 3.65 (2H, q, J = 6.4, 5.2 Hz,
CH3CH2OCH2CH2-), 3.75 (2H, t, J = 5.8 Hz, CH3CH2O(CH2)2OCH2-), 3.91 (2H, t, J =
5.8 Hz, CH3CH2O(CH2)2OCH2CH2-), 7.71 (2H, q, J = 5.6, 3.2 Hz, ring, 4’-H, 7’-H),
7.85 (2H, m, ring, 5’-H, 6’-H).
(ES-MS/FAB-MS); m/z 264.1238 (M+H
+
) C14H18NO4, requires m/z 264.1236 (' =
0.76 ppm).
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3, 6-Dioxaoctyl amine [2.146]
NH2
OO
To a solution of N-(3, 6-dioxaoctyl)phthalimide (8 mmol, 2.104 g) in methanol (35
mL) added hydrazine hydrate (16 mmol, 498 µL). After 2 h sodium borohydride (8
mmol, 0.303 g) and a second lot of hydrazine hydrate (16 mmol, 498 µL) were added
and stirred for further 16 h. Suspension was filtered to remove white precipitate and
filtrate was concentrated under vacuo and then under N2 gas. Residue was redissolved
in ethyl acetate (20 mL) heated to 50 qC, sonicated and then cooled to room
temperature. Suspension was kept in liquid nitrogen and filtered. Ethyl acetate rotary
evaporated to get oil. Oil was dissolved in ether (20 mL) filtered and rotary evaporated
under vacuo to obtain desired yellow viscous oil in 80 % yield.
TLC-Rf = 0.2 in methanol-ammonia (9.7:0.3)
FT-IR (CH3CN) cm
-1
: 3398m, 3479m (QNH, primary amine); 1677m (GNH, primary
amine); 1265s (QC-O, ether); 1108s (QC-N).
1
H NMR (CDCl3) į 1.21 (3H, t, J = 7.2 Hz, CH3-), 1.75 (2H, s, -NH2), 2.87 (2H, t, J =
5.2 Hz, -CH2NH2), 3.50-3.55 (4H, m, CH3CH2O(CH2)2OCH2-), 3.57-3.63 (4H, m, -
O(CH2)2O-).
13
C NMR (CDCl3) į 73.24, 70.35, 69.78, 66.66, 65.84, 41.67, 15.15.
Ethyl 3-oxo-7, 10-dioxa-4-aza-dodecanoate
O O N
H
OO
O
Ethyl 3-oxo-7, 10-dioxa-4-azadodecanoate was synthesized as yellowish oil from 3, 6-
dioxaoctyl amine 2.146 using Method-D. Product was purified as colorless oil in 62 %
yield by column chromatography using ethyl acetate-hexane (9:1).
TLC-Rf = 0.2 in ethyl acetate-hexane (9:1)
FT-IR (KBr) cm
-1
: 3379m, br, (QNH); 1738s (QC=O, ester); 1660s (QC=O, amide);
1556s (GNH, amide); 1106s, (QC-O, ether).
1
H NMR (CDCl3) į 1.21 (3H, t, J = 7.2 Hz, CH3CH2OCH2-), 2.27 (3H, t, J = 7.2 Hz,
CH3CH2CO-), 3.29 (2H, s, -COCH2CO-), 3.46-3.51 (2H, m, -CH2NH-), 3.50-3.59 (6H,
m, CH3CH2O(CH2)2O-), 3.61-3.64 (2H, m, -CH2CH2NH-), 4.19 (2H, q, J = 7.2 Hz,
CH3CH2CO-), 7.32 (1H, s, broad, -NH-).
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(ES-MS/FAB-MS); m/z 248.1494 (M+H
+
) C11H22NO5, requires m/z 248.1498 (' = 1.6
ppm).
3-Oxo-7, 10-dioxa-4-azadodecanoic acid [2.149]
O O N
H
OO
OH
Saponification of ethyl, 3-oxo-7, 10-dioxa-4-azadodecanoate afforded 3-oxo-7, 10-
dioxa-4-azadodecanoic acid as a white hygroscopic solid in 89 % yield.
mp = 68-60 qC.
FT-IR (KBr) cm
-1
: 3317m, (QNH and QOH); 2681w, (GOH); 1735s (QC=O, acid);
1639s (QC=O, amide); 1578s (GNH, amide); 1104s, 1093s (QC-O, ether).
1
H NMR (CDCl3) į 1.24 (3H, t, J = 7.2 Hz, CH3CH2OCH2-), 3.34 (2H, s, COCH2CO),
3.52-3.55 (2H, m, -CH2NH-), 3.54-3.64 (6H, m, CH3CH2O(CH2)2O-), 3.65-3.68 (2H,
m, -CH2CH2NH-), 7.17 (1H, s, broad, -NH-), 10.37 (1H, s, -COOH)
13
C NMR (CDCl3) į 169.06, 167.13, 70.32, 69.73, 69.03, 66.76, 39.69, 38.26, 15.14.
(ES-MS/FAB-MS); m/z 218.1037 (M-H
+
) C9H16NO5, requires m/z 218.1028 (' = 4.1
ppm).
3O, 7, 10-dioxa, 4-aza C12-HSL [2.142]
O O N
H
N
H
O
O
OH
O
To a stirred solution of 3-oxo-7, 10-dioxa-4-azadodecanoic acid 2.149 (1 mmol) in a
minimum volume of dioxane (4-6 mL) was added a solution of L-HSL.HCl (1 mmol)
in a minimum amount of water (about 2 mL). To this was added sequentially TEA (3
mmol) and EDC.HCl (1.5 mmol) stirred 16 h at room temperature. Solvent was
removed under vacuo and residue redissolved in warm ethyl acetate (2 u 15 mL).
Solvent was rotary evaporated to obtain crude product that was dissolved in minimum
ethyl acetate (2 mL) and was loaded on small (5 cm length) column containing 2 cm
silica gel. Impurities were eluted with ethyl acetate and desired product with methanol.
Methanol was rotary evaporated to obtain pure desired product as a white semisolid in
58 % yield.
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mp = 44-46 qC.
FT-IR (KBr) cm
-1
: 3457m, 3259s, (QNH, amides); 1773s (QC=O, lactone); 1665s
(QC=O, diamide); 1636s (QC=O, amide); 1567s (GNH, amide); 1116s (QC-O, ether).
1
H NMR (CDCl3) į 1.24 (3H, t, J = 7.2 Hz, CH3CH2OCH2-), 2.27-2.35 (1H, m, ring,
4D-H), 2.66-2.73 (1H, m, ring, 4E-H), 3.27 (2H, s, -COCH2CO-), 3.46-3.51 (2H, m, -
CH2NH-), 3.52-3.60 (6H, m, CH3CH2O(CH2)2O-), 3.62-3.65 (2H, m, -CH2CH2NH-),
4.24-4.31 (1H, m, ring, 5D-H), 4.46-4.51 (1H, m, ring, 5E-H), 4.56-4.63 (1H, m, ring,
3-H), 7.21 (1H, s, broad, -NH-), 8.21 (1H, d, J = 6.8 Hz, -NH-HSL).
13
C NMR (CDCl3) į 174.84, 167.51, 167.53, 70.34, 69.74, 69.33, 66.71, 65.85, 48.94,
42.18, 39.49, 29.37, 15.16.
(ES-MS/FAB-MS); m/z 303.1562 (M+H
+
) C13H23N2O6, requires m/z 303.1556 (' =
1.98 ppm).
5.13.2 (1S, 2R)-2-(3-Oxo, 7, 10-dioxa-4-azadodecanoyl)aminocyclopentanol
[2.143]
(1S, 2R)-1-O-Benzyl-2-(3-oxo-7, 10-dioxa-4-azadodecanoyl)aminocyclopentanol
[2.151]
O O N
H
N
H
O
OH
O
(1S, 2R)-1-O-Benzyl-2-(3-oxo-7, 10-dioxa-4-azadodecanoyl)aminocyclopentanol was
synthesized from 3-oxo-7, 10-dioxa-4-azadodecanoic acid 2.149 (1 mmol, 0.219 g)
and (1S,2R)-1-O-benzyl-2-aminocyclopentanol (1.2 mmol, 0.229 g) as a yellow liquid
using Method-P. The product was purified by column chromatography in 70 % yield
using ethyl acetate-methanol (4:1) solvent system.
TLC-Rf= 0.5 in ethyl acetate-methanol (4:1)
(ES-MS/FAB-MS); m/z 393.2376 (M+H
+
) C21H33N2O5, requires m/z 393.2389 (' = 3.3
ppm).
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(1S, 2R)-2-(3-Oxo, 7, 10-dioxa-4-azadodecanoyl)aminocyclopentanol [2.143]
O O N
H
N
H
O
OHH
O
(1S, 2R)-2-(3-Oxo, 7, 10-dioxa-4-azadodecanoyl)aminocyclopentanol was synthesized
as a colorless liquid in 93 % yield by catalytic hydrogenation of (1S, 2R)-1-O-benzyl-
2-(3-oxo-7, 10-dioxa-4-azadodecanoyl)aminocyclopentanol 2.151.
FT-IR (CH3CN) cm
-1
: 3326m (QNH, amide and QOH, ring), 1657 (QC=O, amide);
1632s (QC=O, diamide); 1553s (GNH), 1338m (GOH); 1109m (QC-O, ether).
1
H NMR (CDCl3) į 1.25 (3H, t, J = 7.2 Hz, CH3CH2OCH2-), 1.45-1.57 (1H, m, ring,
4D-H), 1.62-1.68 (1H, m, ring, 5D-H), 1.69-1.75 (1H, m, ring, 4E-H), 1.77-1.87 (1H,
m, ring, 3D-H), 1.99-2.09 (1H, m, ring, 5E-H), 2.12-2.19 (1H, m, ring, 3E-H), 2.31
(1H, s, broad, ring, -OH), 3.22 (2H, s, -COCH2CO-), 3.47-3.50 (2H, m, -CH2NH-),
3.53-3.61 (6H, m, CH3CH2O(CH2)2O-), 3.63-3.67 (2H, m, -CH2CH2NH-), 3.81-3.89
(1H, m, ring, 2-H), 3.97-4.02 (1H, m, ring, 1-H), 7.06 (1H, s, broad, -NH-), 7.80 (1H,
s, ring, -NH-).
13
C NMR (CDCl3) į 168.53, 167.89, 79.31, 70.39, 69.75, 69.31, 66.74, 60.62, 42.21,
39.49, 32.48, 30.10, 21.21, 15.17.
(ES-MS/FAB-MS); m/z 301.1773 (M-H
+
) C14H25N2O5, requires m/z 301.1763 (' =
3.32 ppm).
5.14 Miscellaneous analogues of 3O, C12-HSL
5.14.1 3-(1-Hydroxydecylidene)-5-(2-hydroxyethyl)pyrrolidine-2,4-dione [2.152]
NH
O
OH
O OH
The Tetramic acid derivative was prepared essentially by the procedure described by
Kaufmann et al. A solution of sodium methoxide in methanol (0.5 M, 1.12 mmol, 2.24
mL) was added to a stirred solution of 3-oxo-C12-HSL (1.12 mmol, 0.333 g) in
methanol (3 mL) under nitrogen. The reaction mixture was stirred for 3 h at 55 qC and
then overnight at 50 qC. The mixture was cooled to room temperature and then passed
&RQILGHQWLDO
- 232 -
through an acidic ion exchange resin (DowexWX2-200). The resin was further eluted
with MeOH (30 mL), the eluants were combined and concentrated in vacuum to obtain
the tetramic acid derivative as a white solid product in 88 % yield.
mp = 84-86 qC.
1
H NMR (CDCl3) į 0.895 (3H, t, J=6.8 Hz, (CH3(CH2)8-), 1.28 (10H, m,
CH3CH2(CH2)5-), 1.38 (2H, m, broad, CH3CH2-), 1.68 (2H, m, CH3(CH2)6CH2-), 1.78
(1H, m, OH CH2CH2- D), 2.13 (1H, m, OHCH2CH2-E), 2.85 (2H, m, CH3(CH2)7CH2-),
3.86 (1H, s, ring H), 3.97 (2H, m, OHCH2CH2-), 6.6 (1H, s, broad -NH- ring).
13
C NMR (CDCl3) į 14.1, 22.6, 25.9, 29.2, 29.4, 31.8, 32.9, 34.0, 61.3, 62.0, 100.5,
175.0, 190.0, 195.3.
(ES-MS/FAB-MS): m/z 298.2023 (M+H
+
) C16H28NO4, requires m/z 298.2018 (' = 1.7
ppm).
5.14.2 3-Acetyloxy, C12-HSL [2.154]
3-Hydroxy, C12-HSL [2.155]
N
H
OH O
O
OH
To a stirred solution of 3O, C12-HSL (2 mmol, 0.594 g) in methanol (20 mL) was
added first portion of sodium cyanoborohydride (2.2 mmol, 0.1382 g). The pH was
maintained by dropwise addition of 3 % HCl in methanol. After intervals of 2 h at
pH=4 second and third portions of sodium cyanoborohydride (1.1 mmol, 0.063 g) were
added, each time pH was maintained below 4 with 3 % HCl in methanol. The reaction
mixture was then stirred for 12 h at room temperature and solvent was removed to
dryness under high vacuo. The residue was extracted with hot ethyl acetate (3 u 15
mL). Ethyl acetate was rotary evaporated to obtain crude product which was purified
in 54 % yield by column chromatography using ethyl acetate solvent.
FT-IR (KBr) cm
-1
: 3297m, (QNH, amide); 1778s (QC=O, ring); 1643s(QC=O, amide);
1547s (GNH, amide).
1
H NMR (CDCl3) į 0.90 (3H, t, J = 7.2 Hz, CH3(CH2)8-), 1.27-1.38 (14H, m,
CH3(CH2)7-), 1.46-1.54 (2H, m, CH3(CH2)7CH2-) 1.55 (1H, s, broad, -C(H)OH), 2.21-
2.25 (1H, m, ring, 4D-H), 3.32-2.40 (1H, m, -C(OH)HC(H)HCO-), 2.44-2.50 (1H, m, -
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C(OH)HC(H)HCO-), 2.79-2.86 (1H, m, ring, 4E-H), 3.40 (1H, s, broad, -C(H)OH ),
4.27-4.34 (1H, m, ring, 3H), 4.47-4.55 (1H, m, ring, 5D-H), 4.56-4.64 (1H, m, ring,
5E-H), 6.64 (0.5H s, -NH-HSL), 6.69 (0.5H s, -NH-HSL).
(ES-MS/FAB-MS): m/z 300.2187 (M+H
+
) C16H30NO4, requires m/z 300.2175 (' =
3.98 ppm).
3-Acetyloxy, C12-HSL [2.154]
N
H
O O
O
OH
O
A solution of 3-hydroxy, C12-HSL 2.155 (2mmol, 0.598 g) in acetic anhydride (5 mL)
was refluxed for 2 h. An excess of acetic anhydride was removed under high vacuum
and residue was redissolved in ethyl acetate (20 mL). Ethyl acetate solution was
washed with saturated sodium bicarbonate (3 u 10 mL) and brine (1 u 15 mL). The
organic layer was dried over MgSO4 and filtered. The solvent was removed under
vacuum to obtain desired product as white solids in 97 % yield.
mp = 65-67 qC.
FT-IR (KBr) cm
-1
: 3284m, (QNH, amide); 1793s (QC=O, ring); 1735s(QC=O, acetoxy);
1645s (QC=O, amide); 1538s (GNH, amide).
1
H NMR (CDCl3) į 0.89 (3H, t, J = 7.2 Hz, CH3(CH2)8-), 1.27-1.39 (14H, m,
CH3(CH2)7-), 1.61 (2H, m, CH3(CH2)7CH2-), 2.09 (1.5H, s, -COCH3), 2.10 (1.5H, s, -
COCH3), 2.11-2.19 (1H, m, ring, 4D-H), 2.53 (1H, d, J = 6.0 Hz, -C(OH)HC(H)HCO-)
, 2.54 (1H, d, J = 6.0 Hz, -C(OH)HC(H)HCO-), 4.26-4.32 (1H, m, ring, 5D-H), 4.46-
4.51 (1H, m, ring, 5E-H), 4.50-4.56 (1H, m, ring, 3H), 5.16-5.21 (1H, m, -
C(H)OCOCH3), 6.25 (1H t, J = 6.4 Hz, -NH-HSL).
(ES-MS/FAB-MS): m/z 342.2292 (M+H
+
) C18H32NO5, requires m/z 342.2280 (' = 3.5
ppm).
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Appendix-I
Immunological Assay
Optimization of cell culture conditions
In the cell culture assays, the number of mouse splenocytes used was initially
optimized to 100 000 cells per well. The optimal dose of ConA, 1 Pg/mL, used in the
cell proliferation assays was determined from ConA titration curves.
Concanavalin A (ConA) mitogen-stimulated proliferation of murine splenocytes
ConA stimulated cell proliferation assay was used to assess the effect of N-
acylhomoserine lactones (AHLs) on T-cell stimulated proliferation. Proliferation was
assessed by the incorporation of [
3
H]-thymidine into DNA. Eight-week-old female
BALB/c mice were obtained from Harlan (Bicester, Oxon, U.K.) and given food and
water ad libitum. Splenocyte suspensions were prepared by removing the spleen and
placing them into RPMI 1640 medium (Sigma, Poole, U.K.). Spleens were forced
through 70 Pm pore size wire gauzes using the plunger from a 5 mL syringe to produce
a single cell suspension. Cells were pelleted by centrifugation, and erythrocytes were
lysed with 0.017 M Tris, 0.144 M ammonium chloride buffer, pH 7.2. Leukocyte
pellets were washed twice with RPMI 1640 medium with 2% (v/v) fetal calf serum
(FCS) and resuspended in complete T-cell culture medium (CTCM) consisting of
RPMI 1640 medium with 5% FCS, 2 mM L-glutamine, and 5 u 10-5M 2-
mercaptoethanol (Sigma, Poole, U.K.). Test compounds were studied using doubling-
down dilutions ranging from 1 mM to 0.1 PM in a final volume of 200 PL of CTCM
containing ConA (Sigma, Poole, U.K.) at 1 Pg/mL and 100 000 spleen cells. Following
incubation for 48 h at 37 °C in 5%CO2/air, 0.25 PCi [3H]-thymidine (Amersham
Pharmacia Biotech, U.K.) in 10 PL of RPMI 1640 medium was added and cells were
incubated for a further 24 h. Cells were collected onto fiberglass filters with a
filtermate harvester (Packard Bioscience, Pangbourne, U.K.). After the addition of 25
PL of MicroScint-O (Packard Bioscience, Pangbourne, U.K.) to each well, these filters
were counted with a Packard Top Count scintillation counter.
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Appendix-II
Cytotoxicity
Trypan blue exclusion assay
Trypan blue exclusion assay is a standard method used to assess cell viability because
only viable cells can exclude the dye added to the medium. The 100 ȝl of murine
splenocyte cells were exposed to a concentration range 0.3-1000 µM of analogues or
physiological saline (control) at 37 qC in 5 % CO2/air for 24 h. Tissues were
thoroughly washed with physiological saline and then stained by 0.4% Trypan blue
dye. The number of viable cells and damaged cells stained in blue were counted in
hemocytometer (counting chamber) in 3 microscopic fields. Cell viability was
determined as the ratio of viable cells to all cells counted in the fields. The experiment
was performed in triplicates.
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Appendix-III
QS-induction and QS-inhibition assays
Strain and culture media
Strain used in this study was Pseudomonas aeruginosa strain, PAO1 ('lasI-PlasB::lux)
which was cultured overnight at 37 °C in Luria-Bertani (LB) broth medium (5 mL)
containing 100 ȝg/ml tetracycline.
QS-induction and -inhibition assays with Pseudomonas aeruginosa PAO1('lasI-
PlasB::lux)
The reporter strain PAO1('lasI-PlasB::lux) was grown overnight as explain above in
LB broth medium media containing 100 ȝg/mL tetracycline at 37º C. Overnight
culture of Pseudomonas aeruginosa (1 mL) was centrifuged, supernatant was
discarded and the residue was diluted to 1 mL with fresh LB medium (40 ȝL of this in
1mL of LB medium is equivalent to an OD495 of 1.0) To the sample tubes (2 mL
capacity) each containing 40ȝL cell culture was added analogue and/or 3O, C12-HSL
and diluted to 1 mL with fresh LB medium as explain below.
QS-induction assay:
To each sample tube containing 40ȝL cell culture added analogues of concentration
1mM and diluted to 1mL with fresh LB medium. Only cell culture was used as control
and 3O, C12-L-HSL (5 ȝM) was added in the positive control. An aliquot of 200-ȝl was
added to separate well in 96 wells plate. The bioluminescence of the PAO1 strain was
determined as a function of cell population density with a combined, automated
luminometer-spectrometer (Anthos Labtech LUCYI) set at 37 qC. The luminescence
and turbidity of the cultures (optical density at O=495 nm) were automatically
determined every 30 min. Luminescence is given in relative light units per unit of
optical density at 495 nm. Experiments were repeated five times with similar results.
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QS-inhibition (Antagonist) assay
To each sample tube containing 40ȝL cell culture and 5 ȝM of 3O, C12-L-HSL,
individual analogues were added in a concentrations range of 1ȝM, 100ȝM and 1 mM.
Only cell culture was used as control and 3O, C12-L-HSL (5 ȝM) was added in the
positive control. An aliquot of 200-ȝl was added to separate well in 96 wells plate. The
bioluminescence of the PAO1 strain was determined as a function of cell population
density with a combined, automated luminometer-spectrometer (Anthos Labtech
LUCYI) set at 37 qC. Experiments were repeated five times with similar results.
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